U.S. patent application number 14/008011 was filed with the patent office on 2015-06-11 for bispecific anti-cxcr7 immunoglobulin single variable domains.
The applicant listed for this patent is Francis Descamps, Maria Gonzalez Pajuelo, Regorius Leurs, David Andre Baptiste Maussang-Detaille, Pascal Gerard Merchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Maarten Van Roy, Peter Vanlandschoot. Invention is credited to Francis Descamps, Maria Gonzalez Pajuelo, Regorius Leurs, David Andre Baptiste Maussang-Detaille, Pascal Gerard Merchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Maarten Van Roy, Peter Vanlandschoot.
Application Number | 20150158948 14/008011 |
Document ID | / |
Family ID | 45952494 |
Filed Date | 2015-06-11 |
United States Patent
Application |
20150158948 |
Kind Code |
A9 |
Descamps; Francis ; et
al. |
June 11, 2015 |
BISPECIFIC ANTI-CXCR7 IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
Abstract
The present invention relates to particular polypeptides,
nucleic acids encoding such polypeptides; to methods for preparing
such polypeptides; to host cells expressing or capable of
expressing such polypeptides; to compositions and in particular to
pharmaceutical compositions that comprise such polypeptides, for
prophylactic, therapeutic or diagnostic purposes. In particular,
the present invention provides immunoglobulin single variable
domains inhibiting CXCR7 mediated tumour growth.
Inventors: |
Descamps; Francis;
(Roeselare, BE) ; Maussang-Detaille; David Andre
Baptiste; (Rotterdam, NL) ; Van Roy; Maarten;
(Zwijnaarde, BE) ; Leurs; Regorius; (Amsterdam,
NL) ; Gonzalez Pajuelo; Maria; (Porto, PT) ;
Merchiers; Pascal Gerard; (Tielen, BE) ; Smit;
Martine; (Amsterdam, NL) ; Stortelers; Catelijne;
(Gent, BE) ; Van Rompaey; Philippe; (Melle,
BE) ; Vanlandschoot; Peter; (Bellem, BE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Descamps; Francis
Maussang-Detaille; David Andre Baptiste
Van Roy; Maarten
Leurs; Regorius
Gonzalez Pajuelo; Maria
Merchiers; Pascal Gerard
Smit; Martine
Stortelers; Catelijne
Van Rompaey; Philippe
Vanlandschoot; Peter |
Roeselare
Rotterdam
Zwijnaarde
Amsterdam
Porto
Tielen
Amsterdam
Gent
Melle
Bellem |
|
BE
NL
BE
NL
PT
BE
NL
BE
BE
BE |
|
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20140227270 A1 |
August 14, 2014 |
|
|
Family ID: |
45952494 |
Appl. No.: |
14/008011 |
Filed: |
March 28, 2012 |
PCT Filed: |
March 28, 2012 |
PCT NO: |
PCT/EP12/55499 PCKC 00 |
371 Date: |
January 31, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61468250 |
Mar 28, 2011 |
|
|
|
61540272 |
Sep 28, 2011 |
|
|
|
61600263 |
Feb 17, 2012 |
|
|
|
Current U.S.
Class: |
424/135.1 ;
435/69.6; 530/387.3; 536/23.53 |
Current CPC
Class: |
A61P 29/00 20180101;
C07K 2317/569 20130101; A61P 25/00 20180101; C07K 16/2866 20130101;
C07K 2317/22 20130101; C07K 2317/31 20130101; C07K 2319/31
20130101; C07K 2317/33 20130101; A61P 35/00 20180101; A61K 2039/507
20130101; C07K 2317/76 20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28 |
Claims
1. A construct comprising at least one immunoglobulin single
variable domain (ISVD) that binds to and/or recognizes amino acid
residue M33, and optionally amino acid residue V32 and/or amino
acid residue M37 in CXCR7 (SEQ ID NO: 1) and at least one ISVD that
binds to and/or recognizes amino acid residue W19, and optionally
S23 and/or D25 of CXCR7 (SEQ ID NO: 1).
2. The construct according to claim 1 for use as a medicament to
reduce tumour growth and/or to treat cancer, preferably head and
neck cancer or GBM.
3. An immunoglobulin single variable domain that can specifically
displace SDF-1 and/or I-TAC on human CXCR7 (SEQ ID NO: 1) with an
average Ki of less than 100 nM and an average SDF-1 and I-TAC
displacement of 50% or more.
4-8. (canceled)
9. An immunoglobulin single variable domain that can bind human
CXCR7 (SEQ ID NO: 1) with a Kd of less than 50 nM.
10. An immunoglobulin single variable domain selected from the
group consisting of immunoglobulin single variable domains that
bind to and/or recognize amino acid residue M33, and optionally
amino acid residue V32 and/or amino acid residue M37 in CXCR7 (SEQ
ID NO: 1); and immunoglobulin single variable domains that bind to
and/or recognize amino acid residue W19, and optionally amino acid
residue S23 and/or amino acid residue D25 of CXCR7 (SEQ ID NO:
1).
11. (canceled)
12. The immunoglobulin single variable domain according to claim 5
for use as a medicament to reduce tumour growth and/or to treat
cancer, preferably head and neck cancer or GBM.
13. The immunoglobulin single variable domain of claim 3, wherein
the immunoglobulin single variable domain is selected from the
group consisting of: immunoglobulin variable domains that comprise
an amino acid sequence with the formula 1
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); wherein FR1 to FR4 refer to
framework regions 1 to 4 and are framework regions of an
immunoglobulin single variable domain; and wherein CDR1 is chosen
from the group consisting of: a) the immunoglobulin single variable
domain of SEQ ID NO: 9, b) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 9, c) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 9, and
wherein CDR2 is chosen from the group consisting of: d) the
immunoglobulin single variable domain of SEQ ID NO: 19; e)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 19; f) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 19; and wherein CDR3 is chosen from
the group consisting of: g) the immunoglobulin single variable
domain of SEQ ID NO: 29; h) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 29; i) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 29;
immunoglobulin single variable domains that comprise an amino acid
sequence with the formula 1 FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1);
wherein FR1 to FR4 refer to framework regions 1 to 4 and are
framework regions of an immunoglobulin single variable domain; and
wherein CDR1 is chosen from the group consisting of: a) the
immunoglobulin single variable domain of SEQ ID NO: 10, b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 10, c) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 10, and wherein CDR2 is chosen from
the group consisting of: d) the immunoglobulin single variable
domain of SEQ ID NO: 20; e) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 20; f) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 20; and
wherein CDR3 is chosen from the group consisting of: g) the
immunoglobulin single variable domain of SEQ ID NO: 30; h)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 30; i) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 30; immunoglobulin single variable
domains that comprise an amino acid sequence with the formula 1
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); wherein FR1 to FR4 refer to
framework regions 1 to 4 and are framework regions of an
immunoglobulin single variable domain; and wherein CDR1 is chosen
from the group consisting of: a) the immunoglobulin single variable
domain of SEQ ID NO: 11, b) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 11, c) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 11, and
wherein CDR2 is chosen from the group consisting of: d) the
immunoglobulin single variable domain of SEQ ID NO: 21; e)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 21; f) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 21; and wherein CDR3 is chosen from
the group consisting of: g) the immunoglobulin single variable
domain of SEQ ID NO: 31; h) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 31; i) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 31;
immunoglobulin single variable domains that comprise an amino acid
sequence with the formula 1 FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1);
wherein FR1 to FR4 refer to framework regions 1 to 4 and are
framework regions of an immunoglobulin single variable domain; and
wherein CDR1 is chosen from the group consisting of: a) the
immunoglobulin single variable domain of SEQ ID NO: 12, b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 12, c) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 12, and wherein CDR2 is chosen from
the group consisting of: d) the immunoglobulin single variable
domain of SEQ ID NO: 22; e) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 22; f) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 22; and
wherein CDR3 is chosen from the group consisting of: g) the
immunoglobulin single variable domain of SEQ ID NO: 32; h)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 32; i) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 32; immunoglobulin single variable
domains that comprise an amino acid sequence with the formula 1
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); wherein FR1 to FR4 refer to
framework regions 1 to 4 and are framework regions of an
immunoglobulin single variable domain; and wherein CDR1 is chosen
from the group consisting of: a) the immunoglobulin single variable
domain of SEQ ID NO: 13, b) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 13, c) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 13, and
wherein CDR2 is chosen from the group consisting of: d) the
immunoglobulin single variable domain of SEQ ID NO: 23; e)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 23; f) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 23; and wherein CDR3 is chosen from
the group consisting of: g) the immunoglobulin single variable
domain of SEQ ID NO: 33; h) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 33; i) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 33;
immunoglobulin single variable domains that comprise an amino acid
sequence with the formula 1 FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1);
wherein FR1 to FR4 refer to framework regions 1 to 4 and are
framework regions of an immunoglobulin single variable domain; and
wherein CDR1 is chosen from the group consisting of: a) the
immunoglobulin single variable domain of SEQ ID NO: 93, b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 93, c) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 93; and wherein CDR2 is chosen from
the group consisting of: d) the immunoglobulin single variable
domain of SEQ ID NO: 95; e) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 95; f) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 95; and
wherein CDR3 is chosen from the group consisting of: g) the
immunoglobulin single variable domain of SEQ ID NO: 97; h)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 97; i) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 97; immunoglobulin single variable
domains that comprise an amino acid sequence with the formula 1
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); wherein FR1 to FR4 refer to
framework regions 1 to 4 and are framework regions of an
immunoglobulin single variable domain; and wherein CDR1 is chosen
from the group consisting of: a) the immunoglobulin single variable
domain of SEQ ID NO: 107, b) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 107, c) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 107, and
wherein CDR2 is chosen from the group consisting of: d) the
immunoglobulin single variable domain of SEQ ID NO: 115; e)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 115; f) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 115; and wherein CDR3 is chosen from
the group consisting of: g) the immunoglobulin single variable
domain of SEQ ID NO: 123; h) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 123; i) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 123;
immunoglobulin single variable domains that comprise an amino acid
sequence with the formula 1 FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1);
wherein FR1 to FR4 refer to framework regions 1 to 4 and are
framework regions of an immunoglobulin single variable domain; and
wherein CDR1 is chosen from the group consisting of: a) the
immunoglobulin single variable domain of SEQ ID NO: 108, b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 108, c) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 108, and wherein CDR2 is chosen from
the group consisting of: d) the immunoglobulin single variable
domain of SEQ ID NO: 116; e) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 116; f) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 116; and
wherein CDR3 is chosen from the group consisting of: g) the
immunoglobulin single variable domain of SEQ ID NO: 124; h)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 124; i) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 124; and immunoglobulin single
variable domains that comprise an amino acid sequence with the
formula 1 FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); wherein FR1 to FR4
refer to framework regions 1 to 4 and are framework regions of an
immunoglobulin single variable domain; and wherein CDR1 is chosen
from the group consisting of: a) the immunoglobulin single variable
domain of SEQ ID NO: 110, b) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 110, c) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 110, and
wherein CDR2 is chosen from the group consisting of: d) the
immunoglobulin single variable domain of SEQ ID NO: 118; e)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 118; f) immunoglobulin single variable domains that have 3,
2, or 1 amino acid difference with the immunoglobulin single
variable domain of SEQ ID NO: 118; and wherein CDR3 is chosen from
the group consisting of: g) the immunoglobulin single variable
domain of SEQ ID NO: 126; h) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 126; i) immunoglobulin single
variable domains that have 3, 2, or 1 amino acid difference with
the immunoglobulin single variable domain of SEQ ID NO: 126.
14-21. (canceled)
22. The immunoglobulin single variable domain according to claim
13, wherein the framework regions (FRs) have a sequence identity of
more than 80% with the FRs of SEQ ID NOs: 4 to 8, 92, 103, 104 or
106 (FR1), 14 to 18, 94, 111, 112 or 114 (FR2), 24 to 28, 96, 119,
120 or 122 (FR3), and/or 34 to 38, 98, 127, 128 or 130 (FR4).
23. A polypeptide comprising an immunoglobulin single variable
domain of claim 3.
24. The polypeptide according to claim 23, wherein the
immunoglobulin single variable domain is selected from the group
consisting of immunoglobulin single variable domains that have an
amino acid sequence with a sequence identity of more than 80% with
the immunoglobulin single variable domains of SEQ ID NOs: 39 to 43,
91 or 99-102.
25. The polypeptide according to claim 23 and additionally
comprising at least one human serum albumin binding immunoglobulin
single variable domain and optionally comprising a linker selected
from the group of linkers with SEQ ID NOs: 49 to 58.
26. The polypeptide according to claim 23 and additionally
comprising ALB8 (SEQ ID NO: 2), and optionally comprising a linker
selected from the group of linkers with SEQ ID NOs: 49 to 58.
27. The polypeptide according to claim 23, wherein the polypeptide
is selected from the group consisting of polypeptides that have an
amino acid sequence with a sequence identity of more than 80% with
the polypeptides of SEQ ID NOs: 44 to 48, 78 to 89 and 131 to
140.
28. A construct chosen from the group consisting of: constructs
comprising at least two ISVDs that bind to and/or recognize amino
acid residue W19, and optionally amino acid residue S23 and/or
amino acid residue D25 of CXCR7 (SEQ ID NO: 1), wherein said at
least two ISVDs can be the same or different; constructs comprising
at least two ISVDs that bind to and/or recognize amino acid residue
M33, and optionally amino acid residue V32 and/or amino acid
residue M37 in CXCR7 (SEQ ID NO: 1), wherein said at least two
ISVDs can be the same or different; constructs comprising at least
one group 1 ISVD and at least one group 2 ISVD; constructs
comprising at least one group 1 ISVD and at least one group 3 ISVD;
constructs comprising at least one group 2 ISVD and at least one
group 3 ISVD; and constructs comprising at least one 01C10-like
sequence and at least one 14G03-like sequence.
29. The construct according to claim 28 for use as a medicament to
reduce tumour growth and/or to treat cancer, preferably head and
neck cancer or GBM.
30. A nucleic acid sequence encoding for an immunoglobulin single
variable domain according to claim 3.
31. A pharmaceutical composition comprising an immunoglobulin
single variable domain according to claim 3 and optionally a
pharmaceutically acceptable excipient.
32. An immunoglobulin single variable domain according to claim 3
for use in cancer, preferably head or neck cancer, GBM,
inflammatory diseases, rheumatoid arthritis and/or multiple
sclerosis.
33-34. (canceled)
35. Method for producing an immunoglobulin single variable domain,
said method at least comprising the steps of: a) expressing, in a
suitable host cell or host organism or in another suitable
expression system, a nucleic acid or nucleotide sequence according
to claim 30; optionally followed by: b) isolating and/or purifying
the immunoglobulin single variable domain.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to biological materials and
methods related to CXCR7 including polypeptides, nucleic adds
encoding such polypeptides; methods for preparing such
polypeptides; host cells expressing or capable of expressing such
polypeptides; compositions including pharmaceutical compositions
that comprise such polypeptides, such as for prophylactic,
therapeutic or diagnostic purposes.
BACKGROUND OF THE INVENTION
[0002] Although it is suggested in the art i) that the blockage of
CXCR7 employed along with CXCR4 blockage may be useful for the
treatment of SDF-1-dependent tumor progression and metastasis (RB
Maksym et al., 2009, The role of stromal-derived factor-1--CXCR7
axis in development of cancer, European Journal of Pharmacology,
625 (1-3), pages 31-40) and ii) that some small molecular
inhibitors, such as CCX733 or CCX266, siRNA and blocking antibodies
(clones Mab 11G8, Mab 9C4 see e.g., US20070167443; clone 358426
(R&D Systems); Mab 8F11 (Biolegend)), may be useful for
therapeutic interference with CXCR4-mediated activation of
integrins (TN Hartmann et al., 2008, A crosstalk between
intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered
integrin activation but not in chemokine-triggered motility of
human T lymphocytes and CD34+ cells, Journal of Leukocyte Biology,
84, pages 11301140), the biology of CXCR7 is still poorly
understood as the mechanism(s) of action through which CXCR7 acts
is unclear because i) it may act as a kind of decoy or signalling
receptor depending on cell type--RM Maksym et al., supra and since
ii) the interplay between I-TAC and SDF-1 binding to CXCR7 is
unclear.
[0003] The identification of selective therapeutically effective
anti-CXCR7 agents is not only challenging because of its poorly
understood biology (such as e.g., mechanism of action, e.g., of the
potential agonists CCX733 or CCX266 versus antagonists, interplay
with CXCR4, recognition of important epitopes, cross-reactivity of
the compounds CCX733 or CCX266 and associated toxicity), it is also
acknowledged in the art (see e.g., Naunyn-Schmied Archives
Pharmacology 379: 385-388) that the generation of an anti-GPCR
therapeutic agent such as an anti-CXCR7 agent is difficult since i)
the native conformation of active CXCR7 in cancer cells is not
exactly known, and ii) it is expected that CXCR7 shows low
immunogenicity (due to a limited number of extracellular surface
exposed amino acid residues that are in addition very conserved,
e.g., mouse-human CXCR7 is 96% homologous).
[0004] Furthermore, compounds (CCX733, CCX754), which can
selectively block binding of CXCL11 and CXCL12 to CXR7, function
like chemokine ligands with respect to homodimerization, i.e., they
enhance CXCR7 homodimerization by 2.5 to 3.5 fold with significant
increases (P<0.05) first detected at 10 and 100 nM (K E Luker et
al., 2009, Imaging chemokine receptor dimerization with firefly
luciferase complementation, FASEB journal, 23, pages 823-834).
[0005] CXCR7 has been attributed a potential role in tumour
development because its expression provides cells with a growth and
survival advantage. It was recently demonstrated that CXCR7
promotes the growth of breast and lung tumours and enhances lung
metastases (Proc. Natl. Acad. Sci. USA 2007 104:15735-15740).
Moreover, CXCR7 expression is correlated with tumour aggressiveness
in prostate cancer (J. Biol. Chem 2008 283:4283-4294).
Administration of a small molecule antagonist to CXCR7 resulted in
impediment of tumour growth in animal models, validating CXCR7 as
target for development of novel cancer therapeutics (J. Exp. Med.
2006 203:2201-2213).
[0006] Head and neck cancers are among the most prevalent tumors in
the world. Despite advances in the treatment of head and neck
tumors, the survival of patients with these cancers has not
markedly improved over the past several decades because of the
inability to control and poor understanding of the regional and
distant spread of this disease. Head and neck cancers consistently
rank among the six most frequently diagnosed cancers in the world.
Cancers of the oral cavity and pharynx alone account for some
300,000 new cases worldwide and little under 200,000 deaths
annually. Over 90% of head and neck cancers are squamous cell
carcinomas of the upper aerodigestive tract, including the oral
cavity, pharynx, larynx, and paranasal sinuses. In addition,
epithelial head and neck tumors can arise in the salivary and
thyroid glands. Despite advances in our understanding and advances
in the prevention and treatment of head and neck cancers, the
survival of patients with head and neck cancers has not
significantly improved over the past several decades.
SUMMARY OF THE INVENTION
[0007] WO2006/116319 and WO2008/048519 both note that the
production of antibodies to G-protein coupled receptors (GPCRs) has
been notoriously difficult. Indeed, the generation of a
conventional anti-CXCR7 antibody has been described only in a
limited number of cases, e.g., in WO2006/116319 for conventional
antibodies 11G8, 6E10 and in Zabel et al. for conventional antibody
8F11 (Zabel et al., 2009, Elucidation of CXCR7 mediated signalling
events and inhibition of CXCR4 mediated tumor cell transendothelial
migration by CXCR7 ligands. J Immunol.; 183 (5):3204-11). However,
despite extensive research, it is unclear at present whether these
or similar antibodies are suitable for a medical application.
[0008] Zheng et al. reports increased CXCR7 expression in
hepatocellular carcinoma tissues. Downregulation of CXCR7
expression leads to a reduction of tumour growth in a xenograft
model of HCC. However, the authors used SMMC-7721 cells, which were
previously transfected in vitro by CXCR7 shRNA (Zheng et al. 2010
"Chemokine receptor CXCR7 regulates the invasion, angiogenesis and
tumour growth of human hepatocellular carcinoma cells" J. Exp.
Clin. Cancer Res, 29:31).
[0009] Small molecules are known for side effects and unwanted
effects. The small molecule CCX771 blocks CXCL12 binding (cf.
Carbajal et al; 2010 "Migration of engrafted neural stem cells is
mediated by CXCL12 signaling through CXCR4 in a viral model of
multiple sclerosis Proc Nati Aced Sci USA. 107:11068-11073), on the
other hand it is described as a synthetic CXCR7 ligand CCX771,
which also potently stimulates .beta.-arrestin2 recruitment to
CXCR7, with greater potency and efficacy than the endogenous
chemokine ligands (Zabel et al. 2009 "Elucidation of CXCR7-Mediated
Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell
Transendothelial Migration by CXCR7 Ligands" J. Immun. 183:
0000-0000). Similarly, the small compound VUF11403 (VU Amsterdam)
behaves as an agonist in the .beta.-arrestin assay.
[0010] Currently, there is no anti-CXCR7 drug on the market or in
the clinic.
[0011] There is a need therefore for potent anti-CXCR7 agents that
can explore and establish the medical potential of this target.
Furthermore, there is a need for diagnostically, preventatively,
and/or therapeutically suitable anti-CXCR7 agents, such as those
provided herein.
[0012] CXCR7 is expressed on many human tumour cells but not on
most healthy cells. In our tumour model systems we found that
reduction or inhibition of CXCR7 by immunoglobulin single variable
domains reduces or abolishes tumour formation in vivo.
[0013] Immunoglobulin sequences, such as antibodies and antigen
binding fragments derived there from (e.g., immunoglobulin single
variable domains) are used to specifically target their respective
antigens in research and therapeutic applications. The generation
of immunoglobulin single variable domains such as e.g., VHHs may
involve the immunization of an experimental animal such as a Llama,
construction of phage libraries from immune tissue, selection of
phage displaying antigen binding immunoglobulin single variable
domains and screening of said domains and engineered constructs
thereof for the desired specificities (WO 94/04678). Alternatively,
immunoglobulin single variable domains such as e.g., dAbs can be
generated by selecting phage displaying antigen binding
immunoglobulin single variable domains directly from naive or
synthetic libraries and subsequent screening of said domains and
engineered constructs thereof for the desired specificities (Ward
et al, Binding activities of a repertoire of single immunoglobulin
variable domains secreted from Escherichia coli, Nature, 1989, Oct.
12; 341 (6242): 544-6); Holt et al., Trends Biotechnol., 2003,
21(11):484-490; as well as for example WO 06/030220, WO 06/003388
and other published patent applications of Domantis Ltd.).
[0014] Targeting serum albumin to extend the half-life of
biological molecules such as e.g., immunoglobulin single variable
domains has been described e.g. in WO2008/028977.
[0015] In one aspect, the present invention relates to polypeptides
that comprise or essentially consist of i) a first building block
consisting essentially of one or more immunoglobulin single
variable domain(s), wherein said immunoglobulin single variable
domain(s) is (are) directed against CXCR7 and in particular against
human CXCR7; and ii) a second building block consisting essentially
of one or more (preferably one) immunoglobulin single variable
domain(s), wherein said immunoglobulin single variable domain(s) is
(are) directed against serum albumin and in particular against
human serum albumin (and even more preferably wherein said
immunoglobulin single variable domain is Alb8 (as herein defined)).
Furthermore, the invention also relates to nucleic acids encoding
such polypeptides; to methods for preparing such polypeptides; to
host cells expressing or capable of expressing such polypeptides;
to compositions, and in particular to pharmaceutical compositions
that comprise such polypeptides, nucleic acids and/or host cells;
and to uses of such polypeptides, nucleic acids, host cells and/or
compositions for prophylactic, therapeutic or diagnostic purposes.
Other aspects, embodiments, advantages and applications of the
invention will become clear from the further description
herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1 shows an SDP-1 competition experiment using FACS.
[0017] FIG. 2 shows an Mab 11G8 competition experiment using
FACS.
[0018] FIG. 3 shows an immunohistochemical analysis of CXCR7
expression in primary tumor sections.
[0019] FIG. 4 shows profiling of CXCR7 mRNA in head and neck cancer
cell lines 11B, 22A, 22B, FaDu, OE and 93-VU-147 by qPCR.
[0020] FIG. 5 shows a [.sup.125I]-CXCL12 competition experiment on
head and neck cancer cell lines 11B, 22A, 22B, FaDu, OE and
93-VU-147 with ligand CXCL11, CXCL12, Nanobody 09404 and negative
controls: no competitor (designated by "-", indicating total
binding (TB)); and CXCL10 (indicating a-specific competition).
[0021] FIG. 6 shows in vivo CXCR7 Nanobody therapy with 22A
transplants in nude mice: "-" negative control (PBS); polypeptide
constructs clone 060, clone 083, clone 085 and clone 093.
[0022] FIG. 7 shows tumour volumes after 50 days of treatment with
in viva CXCR7 Nanobody therapy with 22A transplants in nude mice:
"-" negative control (PBS); polypeptide constructs clone 085 and
clone 093.
[0023] FIG. 8 shows inhibition of SDF-1 binding to HEK293T hCXCR7
in presence of 2 mg/ml HSA.
DESCRIPTION OF THE INVENTION
Definitions
[0024] a) Unless indicated or defined otherwise, all terms used
have their usual meaning in the art, which will be clear to the
skilled person. Reference is for example made to the standard
handbooks mentioned in paragraph a) on page 46 of WO 08/020079.
[0025] b) Unless indicated otherwise, the term "Immunoglobulin
single variable domain" (ISVD) is used as a general term to include
but not limited to antigen-binding domains or fragments such as
V.sub.HH domains or V.sub.H or V.sub.L domains, respectively. The
terms antigen-binding molecules or antigen-binding protein are used
interchangeably and include also the term Nanobodies. The
immunoglobulin single variable domains further are light chain
variable domain sequences (e.g., a V.sub.L-sequence), or heavy
chain variable domain sequences (e.g., a V.sub.H-sequence); more
specifically, they can be heavy chain variable domain sequences
that are derived from a conventional four-chain antibody or heavy
chain variable domain sequences that are derived from a heavy chain
antibody. Accordingly, the immunoglobulin single variable domains
can be domain antibodies, or immunoglobulin sequences that are
suitable for use as domain antibodies, single domain antibodies, or
immunoglobulin sequences that are suitable for use as single domain
antibodies, "dAbs", or immunoglobulin sequences that are suitable
for use as dAbs, or Nanobodies, including but not limited to
V.sub.HH sequences. The invention includes immunoglobulin sequences
of different origin, comprising mouse, rat, rabbit, donkey, human
and camelid immunoglobulin sequences. The immunoglobulin single
variable domain includes fully human, humanized, otherwise sequence
optimized or chimeric immunoglobulin sequences. The immunoglobulin
single variable domain and structure of an immunoglobulin single
variable domain can be considered--without however being limited
thereto--to be comprised of four framework regions or "FR's", which
are referred to in the art and herein as "Framework region 1" or
"FR1"; as "Framework region 2" or "FR2"; as "Framework region 3" or
"FR3"; and as "Framework region 4" or "FR4", respectively; which
framework regions are interrupted by three complementary
determining regions or "CDR's", which are referred to in the art as
"Complementarity Determining Region 1" or "CDR1"; as
"Complementarity Determining Region 2" or "CDR2"; and as
"Complementarity Determining Region 3" or "CDR3", respectively. It
is noted that the terms Nanobody or Nanobodies are registered
trademarks of Ablynx N.V. and thus may also be referred to as
Nanobody.RTM. and/or Nanobodies.RTM.). [0026] c) Unless indicated
otherwise, the terms "immunoglobulin sequence", "sequence",
"nucleotide sequence" and "nucleic acid" are as described in
paragraph b) on page 46 of WO 08/020079. The term Nanobody is also
as defined in WO 08/020079, and as described therein generally
refers to an immunoglobulin heavy chain variable domain that has
the functional and/or structural characteristics of a V.sub.HH;
domain (e.g., a V.sub.H domain from the "heavy-chain only"
antibodies that occur in Camelids), and as such may in particular
be a (native) V.sub.HH, a humanized V.sub.HH or a camelized
V.sub.H, such as a camelized human V.sub.H. [0027] d) Unless
indicated otherwise, all methods, steps, techniques and
manipulations that are not specifically described in detail can be
performed and have been performed in a manner known per se, as will
be clear to the skilled person. Reference is for example again made
to the standard handbooks and the general background art mentioned
herein and to the further references cited therein; as well as to
for example the following reviews Presta, Adv. Drug Deliv. Rev.
2006, 58 (5-6): 640-56; Levin and Weiss, Mol. Biosyst. 2006, 2(1):
49-57; Irving et al., J. Immunol. Methods, 2001, 248(1-2), 31-45;
Schmitz et al., Placenta, 2000, 21 Suppl. A, 5106-12, Gonzales et
al., Tumour Biol., 2005, 26(1), 31-43, which describe techniques
for protein engineering, such as affinity maturation and other
techniques for improving the specificity and other desired
properties of proteins such as immunoglobulins. [0028] e) Amino
acid residues will be indicated according to the standard
three-letter or one-letter amino acid code. Reference is made to
Table A-2 on page 48 of the International application WO 08/020079
of Ablynx N.V. entitled "Immunoglobulin single variable domains
directed against IL-6R and polypeptides comprising the same for the
treatment of diseases and disorders associated with II-6 mediated
signalling". [0029] f) For the purposes of comparing two or more
nucleotide sequences, the percentage of "sequence identity" between
a first nucleotide sequence and a second nucleotide sequence may be
calculated or determined as described in paragraph e) on page 49 of
WO 08/020079 (incorporated herein by reference), such as by
dividing [the number of nucleotides in the first nucleotide
sequence that are identical to the nucleotides at the corresponding
positions in the second nucleotide sequence] by [the total number
of nucleotides in the first nucleotide sequence] and multiplying by
[100%], in which each deletion, insertion, substitution or addition
of a nucleotide in the second nucleotide sequence--compared to the
first nucleotide sequence--is considered as a difference at a
single nucleotide (position); or using a suitable computer
algorithm or technique, again as described in paragraph e) on pages
49 of WO 08/020079 (incorporated herein by reference). [0030] g)
For the purposes of comparing two or more immunoglobulin single
variable domains or other amino acid sequences such e.g., the
polypeptides of the invention etc., the percentage of "sequence
identity" between a first amino acid sequence and a second amino
acid sequence (also referred to herein as "amino acid identity")
may be calculated or determined as described in paragraph f) on
pages 49 and 50 of WO 08/020079 (incorporated herein by reference),
such as by dividing [the number of amino acid residues in the first
amino acid sequence that are identical to the amino acid residues
at the corresponding positions in the second amino acid sequence]
by [the total number of amino acid residues in the first amino acid
sequence] and multiplying by [100%], in which each deletion,
insertion, substitution or addition of an amino acid residue in the
second amino acid sequence--compared to the first amino acid
sequence--is considered as a difference at a single amino acid
residue (position), i.e. as an "amino acid difference" as defined
herein; or using a suitable computer algorithm or technique, again
as described in paragraph f) on pages 49 and 50 of WO 08/020079
(incorporated herein by reference).
[0031] Also, in determining the degree of sequence identity between
two immunoglobulin single variable domains, the skilled person may
take into account so-called "conservative" amino acid
substitutions, as described on page 50 of WO 08/020079.
[0032] Any amino acid substitutions applied to the polypeptides
described herein may also be based on the analysis of the
frequencies of amino acid variations between homologous proteins of
different species developed by Schulz et al., Principles of Protein
Structure, Springer-Verlag, 1978, on the analyses of structure
forming potentials developed by Chou and Fasman, Biochemistry 13:
211, 1974 and Adv. Enzymol., 47: 45-149, 1978, and on the analysis
of hydrophobicity patterns in proteins developed by Eisenberg et
al., Proc. Natl. Acad. Sci. USA 81: 140-144, 1984; Kyte &
Doolittle; J Molec. Biol. 157: 105-132, 1981, and Goldman et al.,
Ann. Rev. Biophys. Chem. 15: 321-353, 1986, all incorporated herein
in their entirety by reference. Information on the primary,
secondary and tertiary structure of Nanobodies is given in the
description herein and in the general background art cited above.
Also, for this purpose, the crystal structure of a V.sub.HH domain
from a llama is for example given by Desrnyter et al., Nature
Structural Biology, Vol. 3, 9, 803 (1996); Spinelli et al., Natural
Structural Biology (1996); 3, 752-757; and Decanniere et al.,
Structure, Vol. 7, 4, 361 (1999). Further information about some of
the amino acid residues that in conventional V.sub.H domains form
the V.sub.H/V.sub.L interface and potential camelizing
substitutions on these positions can be found in the prior art
cited above. [0033] h) Immunoglobulin single variable domains and
nucleic acid sequences are said to be "exactly the same" if they
have 100% sequence identity (as defined herein) over their entire
length. [0034] i) When comparing two immunoglobulin single variable
domains, the term "amino acid difference" refers to an insertion,
deletion or substitution of a single amino acid residue on a
position of the first sequence, compared to the second sequence; it
being understood that two immunoglobulin single variable domains
can contain one, two or more such amino acid differences. [0035] j)
When a nucleotide sequence or amino acid sequence is said to
"comprise" another nucleotide sequence or amino acid sequence,
respectively, or to "essentially consist of" another nucleotide
sequence or amino acid sequence, this has the meaning given in
paragraph i) on pages 51-52 of WO 08/020079. [0036] k) The term "in
essentially isolated form" has the meaning given to it in paragraph
j) on pages 52 and 53 of WO 08/020079. [0037] l) The terms "domain"
and "binding domain" have the meanings given to it in paragraph k)
on page 53 of WO 08/020079. [0038] m) The terms "antigenic
determinant" and "epitope", which may also be used interchangeably
herein, have the meanings given to it in paragraph l) on page 53 of
WO 08/020079. [0039] n) As further described in paragraph m) on
page 53 of WO 08/020079, an amino acid sequence (such as an
antibody, a polypeptide of the invention, or generally an antigen
binding protein or polypeptide or a fragment thereof) that can
(specifically) bind to, that has affinity for and/or that has
specificity for a specific antigenic determinant, epitope, antigen
or protein (or for at least one part, fragment or epitope thereof)
is said to be "against" or "directed against" said antigenic
determinant, epitope, antigen or protein. [0040] o) The term
"specificity" has the meaning given to it in paragraph n) on pages
53-56 of WO 08/020,079; and as mentioned therein refers to the
number of different types of antigens or antigenic determinants to
which a particular antigen-binding molecule or antigen-binding
protein (such as a polypeptide of the invention) molecule can bind.
The specificity of an antigen-binding protein can be determined
based on affinity and/or avidity, as described on pages 53-56 of WO
08/020079 (incorporated herein by reference), which also describes
some preferred techniques for measuring binding between an
antigen-binding molecule (such as a polypeptide of the invention)
and the pertinent antigen. Typically, antigen-binding proteins
(such as the immunoglobulin single variable domains, and/or
polypeptides of the invention) will bind to their antigen with a
dissociation constant (K.sub.D) of 10.sup.-5 to 10.sup.-12
moles/liter or less, and preferably 10.sup.-7 to 10.sup.-12
moles/liter or less and more preferably 10.sup.-8 to 10.sup.-12
moles/liter (i.e., with an association constant (K.sub.A) of
10.sup.5 to 10.sup.12 liter/moles or more, and preferably 10.sup.7
to 10.sup.12 liter/moles or more and more preferably 10.sup.8 to
10.sup.12 liter/moles). Any K.sub.D value greater than 10.sup.4
mol/liter (or any K.sub.A value lower than 10.sup.4 M.sup.-1)
liters/mol is generally considered to indicate non-specific
binding. Preferably, a monovalent immunoglobulin single variable
domain of the invention will bind to the desired antigen with an
affinity less than 500 nM, preferably less than 200 nM, more
preferably less than 10 nM, such as less than 500 pM. Specific
binding of an antigen-binding protein to an antigen or antigenic
determinant can be determined in any suitable manner known per se,
including, for example, Scatchard analysis and/or competitive
binding assays, such as radioimmunoassays (RIA), enzyme
immunoassays (EIA) and sandwich competition assays, and the
different variants thereof known per se in the art; as well as the
other techniques mentioned herein. As will be clear to the skilled
person, and as described on pages 53-56 of WO 08/020079, the
dissociation constant may be the actual or apparent dissociation
constant. Methods for determining the dissociation constant will be
clear to the skilled person, and for example include the techniques
mentioned on pages 53-56 of WO 08/020079. [0041] p) The half-life
of an amino acid sequence, compound or polypeptide of the invention
can generally be defined as described in paragraph o) on page 57 of
WO 08/020079 and as mentioned therein refers to the time taken for
the serum concentration of the amino acid sequence, compound or
polypeptide to be reduced by 50%, in vivo, for example due to
degradation of the sequence or compound and/or clearance or
sequestration of the sequence or compound by natural mechanisms.
The in vivo half-life of an amino acid sequence, compound or
polypeptide of the invention can be determined in any manner known
per se, such as by pharmacokinetic analysis. Suitable techniques
will be clear to the person skilled in the art, and may for example
generally be as described in paragraph o) on page 57 of WO
08/020079. As also mentioned in paragraph o) on page 57 of WO
08/020079, the half-life can be expressed using parameters such as
the t1/2-alpha, t1/2-beta and the area under the curve (AUC).
Reference is for example made to the Experimental Part below, as
well as to the standard handbooks, such as Kenneth, A et al.
Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists
and Peters et al, Pharmacokinetic analysis: A Practical Approach
(1996). Reference is also made to "Pharmacokinetics", M Gibaldi
& D Perron, published by Marcel Dekker, 2nd Rev. edition
(1982). The terms "increase in half-life" or "increased half-life"
as also as defined in paragraph o) on page 57 of WO 08/020079 and
in particular refer to an increase in the t1/2-beta, either with or
without an increase in the t1/2-alpha and/or the AUC or both.
[0042] q) In respect of a target or antigen, the term "interaction
site" on the target or antigen means a site, epitope, antigenic
determinant, part, domain or stretch of amino acid residues on the
target or antigen that is a site for binding to a ligand, receptor
or other binding partner, a catalytic site, a cleavage site, a site
for allosteric interaction, a site involved in multimerization
(such as homomerization or heterodimerization) of the target or
antigen; or any other site, epitope, antigenic determinant, part,
domain or stretch of amino acid residues on the target or antigen
that is involved in a biological action or mechanism of the target
or antigen. More generally, an "interaction site" can be any site,
epitope, antigenic determinant, part, domain or stretch of amino
acid residues on the target or antigen to which an amino acid
sequence or polypeptide of the invention can bind such that the
target or antigen (and/or any pathway, interaction, signalling,
biological mechanism or biological effect in which the target or
antigen is involved) is modulated (as defined herein). [0043] r) An
immunoglobulin single variable domain or polypeptide is said to be
"specific for" a first target or antigen compared to a second
target or antigen when is binds to the first antigen with an
affinity/avidity (as described above, and suitably expressed as a
K.sub.D value, K.sub.A value, K.sub.off rate and/or K.sub.on rate)
that is at least 10 times, such as at least 100 times, and
preferably at least 1000 times, and up to 10.000 times or more
better than the affinity with which said amino acid sequence or
polypeptide binds to the second target or polypeptide. For example,
the first antigen may bind to the target or antigen with a K.sub.D
value that is at least 10 times less, such as at least 100 times
less, and preferably at least 1000 times less, such as 10.000 times
less or even less than that, than the K.sub.D with which said amino
acid sequence or polypeptide binds to the second target or
polypeptide. Preferably, when an immunoglobulin single variable
domain or polypeptide is "specific for" a first target or antigen
compared to a second target or antigen, it is directed against (as
defined herein) said first target or antigen, but not directed
against said second target or antigen. [0044] s) The terms
"cross-block", "cross-blocked" and "cross-blocking" are used
interchangeably herein to mean the ability of an immunoglobulin
single variable domain or polypeptide to interfere with the binding
directly or indirectly through allosteric modulation of other
immunoglobulin single variable domains or polypeptides of the
invention to a given target. The extent to which an immunoglobulin
single variable domain or polypeptide of the invention is able to
interfere with the binding of another to target, and therefore
whether it can be said to cross-block according to the invention,
can be determined using competition binding assays. One
particularly suitable quantitative cross-blocking assay uses a
FACS- or an ELISA-based approach to measure competition between the
labelled (e.g., His tagged or radioactive labelled) immunoglobulin
single variable domain or polypeptide according to the invention
and the other binding agent in terms of their binding to the
target. The experimental part generally describes suitable FACS-,
ELISA- or radioligand-displacement-based assays for determining
whether a binding molecule cross-blocks or is capable of
cross-blocking an immunoglobulin single variable domain or
polypeptide according to the invention. It will be appreciated that
the assay can be used with any of the immunoglobulin single
variable domains or other binding agents described herein. Thus, in
general, a cross-blocking amino acid sequence or other binding
agent according to the invention is for example one which will bind
to the target in the above cross-blocking assay such that, during
the assay and in the presence of a second amino acid sequence or
other binding agent of the invention, the recorded displacement of
the immunoglobulin single variable domain or polypeptide according
to the invention is between 60% and 100% (e.g., in
ELISA/radioligand based competition assay) or between 80% to 100%
(e.g., in FACS based competition assay) of the maximum theoretical
displacement (e.g., displacement by cold (e.g., unlabeled)
immunoglobulin single variable domain or polypeptide that needs to
be cross-blocked) by the to be tested potentially cross-blocking
agent that is present in an amount of 0.01 mM or less
(cross-blocking agent may be another conventional monoclonal
antibody such as IgG, classic monovalent antibody fragments (Fab,
scFv)) and engineered variants (diabodies, triabodies, minibodies,
VHHs, dAbs, VHs, VLs). [0045] t) An amino acid sequence such as
e.g. an immunoglobulin single variable domain or polypeptide
according to the invention is said to be "cross-reactive" for two
different antigens or antigenic determinants (such as serum albumin
from two different species of mammal, such as human serum albumin
and cyno serum albumin) if it is specific for (as defined herein)
both these different antigens or antigenic determinants. [0046] u)
As further described in paragraph q) on pages 58 and 59 of WO
08/020079 (incorporated herein by reference), the amino acid
residues of an immunoglobulin single variable domain are numbered
according to the general numbering for V.sub.H domains given by
Kabat et al. ("Sequence of proteins of immunological interest", US
Public Health Services, NIH Bethesda, Md., Publication No. 91), as
applied to V.sub.HH domains from Camelids in the article of
Riechmann and Muyldermans, J. Immunol. Methods 2000 Jun. 23; 240
(1-2): 185-195 (see for example FIG. 2 of this publication), and
accordingly FR1 of an immunoglobulin single variable domain
comprises the amino acid residues at positions 1-30, CDR1 of an
immunoglobulin single variable domain comprises the amino acid
residues at positions 31-35, FR2 of an immunoglobulin single
variable domain comprises the amino acids at positions 36-49, CDR2
of an immunoglobulin single variable domain comprises the amino
acid residues at positions 50-65, FR3 of an immunoglobulin single
variable domain comprises the amino acid residues at positions
66-94, CDR3 of an immunoglobulin single variable domain comprises
the amino acid residues at positions 95-102, and FR4 of an
immunoglobulin single variable domain comprises the amino acid
residues at positions 103-113. [0047] v) The Figures, Sequence
Listing and the Experimental Part/Examples are only given to
further illustrate the invention and should not be interpreted or
construed as limiting the scope of the invention and/or of the
appended claims in any way, unless explicitly indicated otherwise
herein.
1. Polypeptides of the Invention and Uses Thereof
1.1. Anti-CXCR7 Building Blocks
[0048] The polypeptides of the present invention can generally be
used to modulate, and in particular inhibit and/or prevent, binding
of CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) to CXCL12
(and/or CXCL11) and in particular human CXCL12 (NM.sub.--000609)
and/or in particular human CXCL11 (U66096), and thus to modulate,
and in particular inhibit or prevent, the signalling that is
mediated by CXCR7 and in particular human CXCR7 (SEQ ID NO: 1)
and/or CXCL12 (and/or CXCL11) and in particular human CXCL12
(NM.sub.--000609) and/or in particular human CXCL11 (U66096), to
modulate the biological pathways in which CXCR7 and in particular
human CXCR7 (SEQ ID NO: 1) and/or CXCL12 (and/or CXCL11) and in
particular human CXCL12 (NM.sub.--000609) and/or in particular
human CXCL11 (U66096) are involved, and/or to modulate the
biological mechanisms, responses and effects associated with such
signalling or these pathways.
[0049] As such, the polypeptides and compositions of the present
invention can be used for the diagnosis, prevention and treatment
of diseases and disorders of the present invention (herein also
"diseases and disorders of the present invention") and include, but
are not limited to cancer, e.g., carcinomas, gliomas,
mesotheliomas, melanomas, lymphomas, leukemias, adenocarcinomas,
breast cancer, ovarian cancer, cervical cancer, glioblastoma,
leukemia, lymphoma, prostate cancer, and Burkitt's lymphoma, head
and neck cancer, colon cancer, colorectal cancer, non-small cell
lung cancer, small cell lung cancer, cancer of the esophagus,
stomach cancer, pancreatic cancer, hepatobiliary cancer, cancer of
the gallbladder, cancer of the small intestine, rectal cancer,
kidney cancer, bladder cancer, prostate cancer, penile cancer,
urethral cancer, testicular cancer, cervical cancer, vaginal
cancer, uterine cancer, ovarian cancer, thyroid cancer, parathyroid
cancer, adrenal cancer, pancreatic endocrine cancer, carcinoid
cancer, bone cancer, skin cancer, retinoblastomas, Hodgkin's
lymphoma, non-Hodgkin's lymphoma, Kaposi's sarcoma, multicentric
Castleman's disease or AIDS-associated primary effusion lymphoma,
neuroectodermal tumors, rhabdomyosarcoma (see, Cancer, Principles
and practice (DeVita, V. T. et al. eds 1997) for additional
cancers); preferably head and neck cancer, as well as brain and
neuronal dysfunction, such as Alzheimer's disease and multiple
sclerosis; kidney dysfunction, renal allograft rejection; nasal
polyposis; rheumatoid arthritis; cardiac aliograft rejection;
cardiac dysfunction; atherosclerosis; asthma; glomerulonephritis;
contact dermatitis; inflammatory bowel disease; colitis; psoriasis;
reperfusion injury; as well as other disorders and diseases
described herein. In particular, the polypeptides and compositions
of the present invention can be used for the diagnosis, prevention
and treatment of diseases involving CXCR7 mediated metastasis,
chemotaxis, cell adhesion, trans endothelial migration, cell
proliferation and/or survival.
[0050] Generally, said "diseases and disorders of the present
invention" can be defined as diseases and disorders that can be
diagnosed, prevented and/or treated, respectively, by suitably
administering to a subject in need thereof (i.e., having the
disease or disorder or at least one symptom thereof and/or at risk
of attracting or developing the disease or disorder) of either a
polypeptide or composition of the invention (and in particular, of
a pharmaceutically active amount thereof) and/or of a known active
principle active against CXCR7 and in particular human CXCR7 (SEQ
ID NO: 1) or a biological pathway or mechanism in which CXCR7 and
in particular human CXCR7 (SEQ ID NO: 1) is involved (and in
particular, of a pharmaceutically active amount thereof).
[0051] In particular, the polypeptides of the present invention can
be used for the diagnosis, prevention and treatment of diseases and
disorders of the present invention which are characterized by
excessive and/or unwanted CXCL12 and in particular human CXCL12
signalling mediated by CXCR7 and in particular human CXCR7 (SEQ ID
NO: 1) or by the pathway(s) in which CXCR7 and in particular human
CXCR7 (SEQ ID NO: 1) is involved (e.g., CXCL11/I-TAC-CXCR7 axis).
Examples of such diseases and disorders of the present invention
will again be clear to the skilled person based on the disclosure
herein.
[0052] Thus, without being limited thereto, the immunoglobulin
single variable domains and polypeptides of the invention can for
example be used to diagnose, prevent and/or to treat all diseases
and disorders that are currently being diagnosed, prevented or
treated with active principles that can modulate CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1)-mediated signalling, such as
those mentioned in the prior art cited herein. It is also envisaged
that the polypeptides of the invention can be used to diagnose,
prevent and/or to treat all diseases and disorders for which
treatment with such active principles is currently being developed,
has been proposed, or will be proposed or developed in future. In
addition, it is envisaged that, because of their favourable
properties as further described herein, the polypeptides of the
present invention may be used for the diagnosis, prevention and
treatment of other diseases and disorders than those for which
these known active principles are being used or will be proposed or
developed; and/or that the polypeptides of the present invention
may provide new methods and regimens for treating the diseases and
disorders described herein.
[0053] Other applications and uses of the immunoglobulin single
variable domains and polypeptides of the invention will become
clear to the skilled person from the further disclosure herein.
[0054] Generally, it is an object of the invention to provide
pharmacologically active agents, as well as compositions comprising
the same, that can be used in the diagnosis, prevention and/or
treatment of diseases and/or disorders of the invention; and to
provide methods for the diagnosis, prevention and/or treatment of
such diseases and disorders that involve the administration and/or
use of such agents and compositions.
[0055] In particular, it is an object of the invention to provide
such pharmacologically active agents, compositions and/or methods
that have certain advantages compared to the agents, compositions
and/or methods that are currently used and/or known in the art.
These advantages will become clear from the further description
below.
[0056] More in particular, it is an object of the invention to
provide therapeutic proteins that can be used as pharmacologically
active agents, as well as compositions comprising the same, for the
diagnosis, prevention and/or treatment of diseases and/or disorders
of the invention and of the further diseases and disorders
mentioned herein; and to provide methods for the diagnosis,
prevention and/or treatment of such diseases and disorders that
involve the administration and/or the use of such therapeutic
proteins and compositions.
[0057] Accordingly, it is a specific object of the present
invention to provide immunoglobulin single variable domains that
are directed against CXCR7, in particular against CXCR7 from a
warm-blooded animal, more in particular against CXCR7 from a mammal
such as e.g., mouse, and especially against human CXCR7 (SEQ ID NO:
1); and to provide proteins and polypeptides comprising or
essentially consisting of at least one such immunoglobulin single
variable domain.
[0058] In particular, it is a specific object of the present
invention to provide such immunoglobulin single variable domains
and such proteins and/or polypeptides that are suitable for
prophylactic, therapeutic and/or diagnostic use in a warm-blooded
animal, and in particular in a mammal, and more in particular in a
human being.
[0059] More in particular, it is a specific object of the present
invention to provide such immunoglobulin single variable domains
and such proteins and/or polypeptides that can be used for the
prevention, treatment, alleviation and/or diagnosis of one or more
diseases, disorders or conditions associated with CXCR7 and/or
mediated by CXCR7 (such as the diseases, disorders and conditions
mentioned herein) in a warm-blooded animal, in particular in a
mammal, and more in particular in a human being.
[0060] It is also a specific object of the invention to provide
such immunoglobulin single variable domains and such proteins
and/or polypeptides that can be used in the preparation of
pharmaceutical or veterinary compositions for the prevention and/or
treatment of one or more diseases, disorders or conditions
associated with and/or mediated by CXCR7 (such as the diseases,
disorders and conditions mentioned herein) in a warm-blooded
animal, in particular in a mammal, and more in particular in a
human being.
[0061] In the invention, generally, these objects are achieved by
the use of the immunoglobulin single variable domains, proteins,
polypeptides and compositions that are described herein.
[0062] In general, the invention provides immunoglobulin single
variable domains that are directed against (as defined herein)
and/or can specifically bind (as defined herein) to CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1); as well as compounds and
constructs, and in particular proteins and polypeptides, that
comprise at least one such amino acid sequence.
[0063] More in particular, the invention provides immunoglobulin
single variable domains and polypeptides that can bind to CXCR7 and
in particular human CXCR7 (SEQ ID NO: 1) with an affinity (suitably
measured and/or expressed as a K.sub.D-value (actual or apparent),
a K.sub.A-value (actual or apparent), a k.sub.on-rate and/or a
k.sub.off-rate, or alternatively as an IC.sub.50 value, as further
described herein) that is as defined herein; as well as compounds
and constructs, and in particular proteins and polypeptides, that
comprise at least one such amino acid sequence.
[0064] In a particular aspect, the immunoglobulin single variable
domains and/or polypeptides of the invention are such that they:
[0065] bind to human CXCR7 (SEQ ID NO: 1) with an EC50 of 100 nM or
lower, more preferably of 50 nM or lower, even more preferably of
20 nM or lower, most preferably of 10 nM or lower in a binding FACS
assay as e.g. described in the experimental part (see Example 8),
and wherein the polypeptides comprise only one human CXCR7 binding
immunoglobulin single variable domain unit; and/or such that they:
[0066] fully displace human CXCL12 (SDF-1) from human CXCR7 (SEQ ID
NO: 1) at an average Ki value of 100 nM or less, more preferably at
an average Ki value of 20 nM or less, even more preferably at an
average Ki value of 10 nM or less in an assay as e.g., described in
the experimental part (Examples 9 and 10), and wherein the
polypeptides comprise only one human CXCR7 binding immunoglobulin
single variable domain unit, and wherein full displacement means an
average CXCL12 displacement of about 60% to 80% and more (e.g.,
when measured according to the ligand displacement assay of Example
9) or wherein full displacement means an average CXCL12
displacement of about 80% to 100% and more (when measured according
to the FACS based competition assay of Example 10); and/or such
that they: [0067] fully displace human CXCL11 (I-TAC) from human
CXCR7 (SEQ ID NO: 1) at an average Ki value of 1000 nM or less,
more preferably at an average Ki value 500 nM or less, even more
preferably at an average Ki value 100 nM or less, even more
preferably at an average Ki value of 20 nM or less, even more
preferably at an average Ki value of 10 nM or less in an assay as
e.g. described in the experimental part (Examples 9 and 10), and
wherein the polypeptides comprise only one human CXCR7 binding
immunoglobulin single variable domain unit, and wherein full
displacement means an average CXCL11 displacement of about 60% to
80% and more (e.g., when measured according to the ligand
displacement assay of Example 9) or wherein full displacement means
an average CXCL12 displacement of about 80% to 100% and more (when
measured according to the FACS based competition assay of Example
10) and/or such that they: [0068] partially displace human CXCL12
(SDF-1) from human CXCR7 (SEQ ID NO: 1) at an average Ki value of
100 nM or less, more preferably at an average Ki value of 20 nM or
less, even more preferably at an average Ki value of 10 nM or less
in an assay as e.g. described in the experimental part (Examples 9
and 10), and wherein the polypeptides comprise only one human CXCR7
binding immunoglobulin single variable domain unit, and wherein
partial displacement means an average CXCL12 displacement of about
40% to 60% (e.g. when measured according to the ligand displacement
assay of Example 9) or wherein partial displacement means an
average CXCL12 displacement of about 50% to 80% (when measured
according to the FACS based competition assay of Example 10);
and/or such that they: [0069] partially displace human CXCL11
(I-TAC) from human CXCR7 (SEQ ID NO: 1) at an average Ki value of
1000 nM or less, more preferably at an average Ki value 500 nM or
less, even more preferably at an average Ki value 100 nM or less,
even more preferably at an average Ki value of 20 nM or less, even
more preferably at an average Ki value of 10 nM or less in an assay
as e.g. described in the experimental part (Examples 9 and 10), and
wherein the polypeptides comprise only one human CXCR7 binding
immunoglobulin single variable domain unit, and wherein partial
displacement means an average CXCL11 displacement of about 40% to
60% (e.g., when measured according to the ligand displacement assay
of Example 9) or wherein partial displacement means an average
CXCL12 displacement of about 50% to 80% (when measured according to
the FACS based competition assay of Example 10), and/or such that
they: [0070] bind human CXCR7 (SEQ ID NO: 1) with an average Kd
value of 100 nM or less, more preferably at an average Kd value of
50 nM or less, even more preferably at an average Kd value of 40 nM
or less, such as less than 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3,
3 nM or even less, such as less than 1 nM, or most preferably even
less than 0.1 nM.
[0071] It should be appreciated that binding of the immunoglobulin
single variable domains and/or polypeptides of the invention to
(human) CXCR7 may result in displacing (human) CXCL11 and/or CXCL12
from (human) CXCR7 as described herein. It should further be
appreciated that binding of the immunoglobulin single variable
domains and/or polypeptides of the invention to (human) CXCR7 may
result in inhibiting binding of (human) CXCL11 and/or CXCL12 to its
cognate receptor, such as, (human) CXCR7 as described herein.
[0072] As already mentioned, in some specific, but non-limiting
aspects (described in more detail herein), the invention
provides:
[0073] amino acid sequences that are directed against (as defined
herein) CXCR7 and that are capable of inhibiting or blocking (fully
or partially, as further described herein) ligand binding, and in
particular of inhibiting or blocking (fully or partially, as
further described herein) the binding of SDF-1 to CXCR7 (as further
described herein). These amino acid sequences are also referred to
herein as "CXCR-7 binding amino acid sequences" or "CXCR7 binding
blocks". Preferably, these CXCR7-binding amino acid sequences are
ISVD's (as described herein), in which case they are also referred
to as "CXCR7-binding ISVD's". Preferably, any CXCR7-binding amino
acid sequences, CXCR7-binding building blocks or CXCR7-binding
ISVD's are such that they have blocking activity, i.e. block SDF-1
binding to CXCR7 partially, or completely, which can be determined
by any suitable assay known to the person skilled in the art, such
as, for instance, by an Alphascreen assay or by a FACS competition
assay (e.g. as described herein). Preferably, the blocking activity
is determined by a FACS competition assay as described in Example
9. Preferably, the ISVD has a blocking activity or competition
capacity in NIH3T3-hCXCR7 cells of blocking or competing SDF-1
binding to CXCR7 with an average Ki of less than 600 nMs, but
preferably, 500 nMs, 400 nMs, 300 nMs, 200 nMs, 100 nMs or even
less. [0074] For instance, the 01C10-like ISVD has a blocking
activity or competition capacity in this assay with an average Ki
of less than 100 nMs, more preferably, less than 75 nMs, 50 nMs or
even less, such as less than 40 nMs or 30 nMs, 25 nMs or 24 nMs or
even more preferably of less than 22 nMs. [0075] For instance, the
14G03-like ISVD has a blocking activity or competition capacity in
this assay with an average Ki of less than 150 nMs, more
preferably, less than 100 nMs, 90 nMs, 80 nMs or even less, such as
less than 70 nMs or 60 nMs, 50 nMs or 40 nMs, 30 nMs, 20 nMs, 15
nMs or 10 nMs, 5 nMs or even more preferably of less than 4
nMs.
[0076] In one specific, but non-limiting aspect, (some of the)
"CXCR-7 binding amino acid sequences" or "CXCR7 binding blocks" may
(and preferably also are) be such that they are capable of
inhibiting or blocking .beta.-arrestin recruitment (see Example
15). Preferably, any CXCR7-binding amino acid sequences,
CXCR7-binding building blocks or CXCR7-binding ISVD's are such that
they have blocking activity, i.e. block or inhibit SDF-1 mediated
CXCR7 signalling partially or completely, which can be determined
by any suitable assay known to the person skilled in the art, such
as, for instance, by any suitable .beta.-arrestin recruitment
assay, as described herein.
[0077] Preferably, the blocking activity or inhibiting capacity is
determined by a .beta.-arrestin assay as described in Example 15.
Preferably, the ISVD has a blocking activity or an inhibition
capacity of ligand (e.g.SDF-1) induced .beta.-arrestin in the
PathHunter eXpress .beta.-arrestin assay (DiscoverX) with a %
inhibition of .beta.-arrestin recruitment of more than 25%, more
than 30%, but preferably, 40%, 50%, 60%, 70%, 80% or even more.
[0078] For instance, the 14G03-like ISVD has a blocking activity or
inhibition capacity in this assay with a % inhibition of more than
50%, more preferably, more than 60%, 70% or even more, such as more
than 75% or 80%, 85%, or even more preferably of more than 90%.
[0079] Some preferred technical values for binding, displacing,
migration or other in vivo and/or in vitro potency of the
immunoglobulin single variable domains or polypeptides of the
invention to CXCR7 and in particular human CXCR7 (SEQ ID NO: 1)
will become clear from the further description and examples
herein.
[0080] Also, in the present description and claims, the following
terms are defined as follows: [0081] A) 01C10-like sequences: a
"01C10-like sequence", "01C10-like ISVD", "01C10-like building
block" or "Group 1 ISVDs" is defined as an ISVD (as described
herein) that comprises: [0082] a) a CDR1 which comprises or
essentially consists of either (1) the amino acid sequence NYAMG
(SEQ ID NO: 93) or (ii) an amino acid sequence that has only 3, 2
or 1 amino acid difference(s) (as defined herein) with the amino
acid sequence NYAMG (SEQ ID NO: 93); and/or [0083] b) a CDR2 which
comprises or essentially consists of either (i) the amino acid
sequence AITPRAFTTYYADSVKG (SEQ ID NO: 95) or (ii) an amino acid
sequence that has at least 80%, such as at least 85%, for example
at least 90% or more than 95% sequence identity with the amino acid
sequence AITPRAFTTYYADSVKG (SEQ ID NO: 95); or (iii) an amino acid
sequence that has only 7, 6, 5, 4, 3, 2 or 1 amino acid
difference(s) (as defined herein) with the amino acid sequence
AITPRAFTTYYADSVKG (SEQ ID NO: 95); and/or [0084] c) a CDR3 which
comprises or essentially consists of either (i) the amino acid
sequence QLVGSGSNLGRQESYAY (SEQ ID NO: 97) or (ii) an amino acid
sequence that has at least 80%, such as at least 85%, for example
at least 90% or more than 95% sequence identity with the amino acid
sequence QLVGSGSNLGRQESYAY (SEQ ID NO: 97); or (iii) an amino acid
sequence that has only 7, 6, 5, 4, 3, 2 or 1 amino acid
difference(s) (as defined herein) with the amino acid sequence
QLVGSGSNLGRQESYAY (SEQ ID NO: 97); [0085] in which the framework
sequences present in such an ISVD are as further described herein,
and in which CDR1, CDR2 and CDR3 are preferably such that the
01C10-like ISVD has blocking activity, e.g. block CXCL11 and/or
CXCL12 binding to CXCR7 partially or completely as described above,
and/or reducing and/or inhibiting tumorigenesis in a xenograph
model, and/or binds and/or recognizes amino acid residue W19, and
optionally amino acid residue S23 and/or amino acid residue D25 in
CXCR7 (SEQ ID NO: 1), all as described herein. [0086] As also
mentioned herein, (some of the) 01C10-like sequences may (and
preferably also are) be such that they are capable of inhibiting,
blocking or displacing SDF-1 binding (see Examples 9 and 10), for
example in the displacement assay used in Example 10. Preferably,
in such a 01C10-like sequence, CDR1 and CDR2 are as defined under
a) and b), respectively; or CDR1 and CDR3 are as defined under a)
and c), respectively; or CDR2 and CDR3 are as defined under b) and
c), respectively. More preferably, in such a 01C10-like sequence,
CDR1, CDR2 and CDR3 are all as defined under a), b) and c),
respectively. Again, in such an 01C10-like sequence, CDR1, CDR2 and
CDR3 are preferably such that the 01C10-like ISVD has blocking
activity, e.g. block SDF-1 binding to CXCR7 partially or completely
as described herein, and/or reducing and/or inhibiting
tumorigenesis in a xenograph model, and/or binds and/or recognizes
amino acid residue W19, and optionally amino acid residue S23
and/or amino acid residue D25 in CXCR7 (SEQ ID NO: 1), all as
described herein. [0087] For example, in such an 01C10-like
sequence: CDR1 may comprise or essentially consist of the amino
acid sequence NYAMG (SEQ ID NO: 93) (with CDR2 and CDR3 being as
defined under b) and c), respectively); and/or CDR2 may comprise or
essentially consist of the amino acid sequence AITPRAFTTYYADSVKG
(SEQ ID NO: 95) (with CDR1 and CDR3 being as defined under a) and
c), respectively); and/or CDR3 may comprise or essentially consist
of the amino acid sequence QLVGSGSNLGRQESYAY (SEQ ID NO: 97) (with
CDR1 and CDR2 being as defined under a) and b), respectively).
Particularly, when an 01C10-like sequence is according to this
aspect: CDR1 may comprise or essentially consist of the amino acid
sequence NYAMG (SEQ ID NO: 93) and CDR2 may comprise or essentially
consist of the amino acid sequence AITPRAFTTYYADSVKG (SEQ ID NO:
95) (with CDR3 being as defined under c) above); and/or CDR1 may
comprise or essentially consist of the amino acid sequence NYAMG
(SEQ ID NO: 93) and CDR3 may comprise or essentially consist of the
amino acid sequence QLVGSGSNLGRQESYAY (SEQ ID NO: 97) (with CDR2
being as defined under b) above); and/or CDR2 may comprise or
essentially consist of the amino acid sequence AITPRAFTTYYADSVKG
(SEQ ID NO: 95) and CDR3 may comprise or essentially consist of the
amino acid sequence QLVGSGSNLGRQESYAY (SEQ ID NO: 97) (with CDR1
being as defined under a) above). Again, in such 01C10-like
sequences, CDR1, CDR2 and CDR3 are preferably such that the
01C10-like ISVD has blocking activity, e.g. block SDF-1 binding to
CXCR7 partially or completely as described herein and/or reducing
and/or inhibiting tumorigenesis in a xenograph model, and/or binds
and/or recognizes amino acid residue W19, and optionally amino acid
residue S23 and/or amino acid residue D25 in CXCR7 (SEQ ID NO: 1),
all as described herein. In a specifically preferred aspect, a
"01C10-like sequence", "01C10-like ISVD", "01C10-like building
block" or "Group 1 ISVD" is an ISVD that comprises: [0088] d) a
CDR1 which is either (i) the amino acid sequence NYAMG (SEQ ID NO:
93) or (ii) an amino acid sequence that has only 3, 2 or 1 amino
acid difference(s) (as defined herein) with the amino acid sequence
NYAMG (SEQ ID NO: 93); and/or [0089] e) a CDR2 which is either (i)
the amino acid sequence AITPRAFTTYYADSVKG (SEQ ID NO: 95) or (ii)
an amino acid sequence that has at least 80%, such as at least 85%,
for example at least 90% or more than 95% sequence identity with
the amino acid sequence AITPRAFTTYYADSVKG (SEQ ID NO: 95); or (iii)
an amino acid sequence that has only 7, 6, 5, 4, 3, 2 or 1 amino
acid difference(s) (as defined herein) with the amino acid sequence
AITPRAFTTYYADSVKG (SEQ ID NO: 95); and/or [0090] f) a CDR3 which is
either (i) the amino acid sequence QLVGSGSNLGRQESYAY (SEQ ID NO:
97) or (ii) an amino acid sequence that has at least 80%, such as
at least 85%, for example at least 90% or more than 95% sequence
identity with the amino acid sequence QLVGSGSNLGRQESYAY (SEQ ID NO:
97); or (iii) an amino acid sequence that has only 7, 6, 5, 4, 3, 2
or 1 amino acid difference(s) (as defined herein) with the amino
acid sequence QLVGSGSNLGRQESYAY (SEQ ID NO: 97); [0091] in which
the framework sequences present in such an ISVD are as further
described herein, and in which CDR1, CDR2 and CDR3 are preferably
such that the 01C10-like ISVD has blocking activity, e.g., block
SDF-1 binding to CXCR7 partially or completely as described herein
and/or reducing and/or inhibiting tumorigenesis in a xenograph
model, and/or binds and/or recognizes amino acid residue W19, and
optionally amino acid residue S23 and/or amino acid residue D25 in
CXCR7 (SEQ ID NO: 1), all as described herein. Preferably, in a
01C10-like sequence according to this specifically preferred
aspect, CDR1 and CDR2 are as defined under d) and e), respectively;
or CDR1 and CDR3 are as defined under d) and f), respectively; or
CDR2 and CDR3 are as defined under e) and f), respectively. More
preferably, in such a 01C10-like sequence, CDR1, CDR2 and CDR3 are
all as defined under d), e) and f), respectively. Again, in such an
01C10-like sequence, CDR1, CDR2 and CDR3 are preferably such that
the 01C10-like ISVD has blocking activity, e.g. block SDF-1 binding
to CXCR7 partially or completely as described herein, and/or
reducing and/or inhibiting tumorigenesis in a xenograph model,
and/or binds and/or recognizes amino acid residue W19, and
optionally amino acid residue S23 and/or amino acid residue D25 in
CXCR7 (SEQ ID NO: 1), all as described herein. [0092] For example,
in a 01C10-like sequence according to this specifically preferred
aspect: CDR1 is the amino acid sequence NYAMG (SEQ ID NO: 93) (with
CDR2 and CDR3 being as defined under e) and f), respectively);
and/or CDR2 is the amino acid sequence AITPRAFTTYYADSVKG (SEQ ID
NO: 95) (with CDR1 and CDR3 being as defined under d) and f),
respectively); and/or CDR3 is the amino acid sequence
QLVGSGSNLGRQESYAY (SEQ ID NO: 97) (with CDR1 and CDR2 being as
defined under d) and e), respectively). Particularly, when an
01C10-like sequence is according to this aspect: CDR1 is the amino
acid sequence NYAMG (SEQ ID NO: 93) and CDR2 is the amino acid
sequence AITPRAFTTYYADSVKG (SEQ ID NO: 95) (with CDR3 being as
defined under f) above); and/or CDR1 is the amino acid sequence
NYAMG (SEQ ID NO: 93) and CDR3 is the amino acid sequence
QLVGSGSNLGRQESYAY (SEQ ID NO: 97) (with CDR2 being as defined under
e) above); and/or CDR2 is the amino acid sequence AITPRAFTTYYADSVKG
(SEQ ID NO: 95) and CDR3 is QLVGSGSNLGRQESYAY (SEQ ID NO: 97) (with
CDR1 being as defined under d) above). Again, in such 01C10-like
sequences, CDR1, CDR2 and CDR3 are preferably such that the
01C10-like ISVD has blocking activity, e.g., block SDF-1 binding to
CXCR7 partially or completely as described herein, and/or reducing
and/or inhibiting tumorigenesis in a xenograph model, and/or binds
and/or recognizes amino acid residue W19, and optionally amino acid
residue S23 and/or amino acid residue D25 in CXCR7 (SEQ ID NO: 1),
all as described herein. [0093] In a particularly preferred
01C10-like sequence: CDR1 is the amino acid sequence NYAMG (SEQ ID
NO: 93), CDR2 is the amino acid sequence AITPRAFTTYYADSVKG (SEQ ID
NO: 95); and CDR3 is the amino acid sequence QLVGSGSNLGRQESYAY (SEQ
ID NO: 97). [0094] In all the 01C10-like sequence described in this
paragraph A), the framework sequences may be as further described
herein. Preferably, the framework sequences are such that the
framework sequences have at least 80%, such as at least 85%, for
example at least 90%, such as at least 95% sequence identity with
the framework sequences of 01C10 (which, for example, can be
determined by determining the overall degree of sequence identity
of a given sequence with the sequence of 01C10 while disregarding
the CDR's in the calculation). Again, the combination of CDR's and
frameworks present in a given sequence are preferably such that the
resulting 01C10-like ISVD has blocking activity, e.g., block SDF-1
binding to CXCR7 partially or completely as described herein and/or
reducing and/or inhibiting tumorigenesis in a xenograph model,
and/or binds and/or recognizes amino acid residue W19, and
optionally amino acid residue S23 and/or amino acid residue D25 in
CXCR7 (SEQ ID NO: 1), all as described herein. [0095] In one
specific aspect, a 01C10-like sequence is an ISVD that has at least
70%, such at least 80%, for example at/east 85%, such as at least
90% or more than 95% sequence identity with the amino acid sequence
01C10 (SEQ ID NO: 91). For example, in an 01C10-like sequence
according to this aspect, the CDR's may be according to the
specifically preferred aspect described above, and may in
particularly (but without limitation) be NYAMG (SEQ ID NO: 93)
(CDR1); AITPRAFTTYYADSVKG (SEQ ID NO: 95) (CDR2); and
QLVGSGSNLGRQESYAY (SEQ ID NO: 97) (CDR3). Again, preferably, the
combination of CDR's and frameworks present in such a 01C10-like)
SVD are preferably such that the resulting 01C10-like ISVD has
blocking activity, e.g. block SDF-1 binding to CXCR7 partially or
completely as described herein and/or reducing and/or inhibiting
tumorigenesis in a xenograph model, and/or binds and/or recognizes
amino acid residue W19, and optionally amino acid residue S23
and/or amino acid residue 025 in CXCR7 (SEQ ID NO: 1), all as
described herein. In one particular aspect, any 01C10-like sequence
may be a humanized and/or sequence optimized sequence, as further
described herein. [0096] B) 14G03-like sequences: a "14G03-like
sequence", "14G03-like ISVD", "14G03-like building block" or "Group
2 ISVDs" is defined as an ISVD (as described herein) that
comprises: [0097] a) a CDR1 which comprises or essentially consists
of either (i) the amino acid sequence INYMG (SEQ ID NO: 13) or (ii)
an amino acid sequence that has only 3, 2 or 1 amino acid
difference(s) (as defined herein) with the amino acid sequence
(NYMG (SEQ ID NO: 13); and/or [0098] b) a CDR2 which comprises or
essentially consists of either (i) the amino acid sequence
TLTSGGSTNYAGSVKG (SEQ ID NO: 23) or (ii) an amino acid sequence
that has at least 80%, such as at least 85%, for example at least
90% or more than 95% sequence identity with the amino acid sequence
TLTSGGSTNYAGSVKG (SEQ ID NO: 23); or (iii) an amino acid sequence
that has only 7, 6, 5, 4, 3, 2 or 1 amino acid difference(s) (as
defined herein) with the amino acid sequence TLTSGGSTNYAGSVKG (SEQ
ID NO: 23); and/or [0099] c) a CDR3 which comprises or essentially
consists of either (i) the amino acid sequence GGTLYDRRRFES (SEQ ID
NO: 33) or (ii) an amino acid sequence that has at least 80%, such
as at least 85%, for example at least 90% or more than 95% sequence
identity with the amino acid sequence GGTLYDRRRFES (SEQ ID NO: 33);
or (iii) an amino acid sequence that has only 7, 6, 5, 4, 3, 2 or 1
amino acid difference(s) (as defined herein with the amino acid
sequence GGTLYDRRRFES (SEQ ID NO: 33); [0100] in which the
framework sequences present in such an ISVD are as further
described herein, and in which CDR1, CDR2 and CDR3 are preferably
such that the 14G03-like ISVD has blocking activity, e.g. block
CXCL11 and/or CXCL12 binding to CXCR7 partially or completely as
described above, and/or reducing and/or inhibiting tumorigenesis in
a xenograph model, and/or inhibits .beta.-arrestin recruitment,
and/or binds and/or recognizes amino acid residue M33, and
optionally amino acid residue V32 and/or amino acid residue M37 in
CXCR7 (SEQ ID NO: 1), all as described herein. [0101] As also
mentioned herein, (some of the) 14G03-like sequences may (and
preferably also are) be such that they are capable of inhibiting,
blocking or displacing SDF-1 binding (see Examples 9 and 10), for
example in the displacement assay used in Example 10. Preferably,
in such a 14G03-like sequence, CDR1 and CDR2 are as defined under
a) and b), respectively; or CDR1 and CDR3 are as defined under a)
and c), respectively; or CDR2 and CDR3 are as defined under b) and
c), respectively. More preferably, in such a 14G03-like sequence,
CDR1, CDR2 and CDR3 are all as defined under a), b) and c),
respectively. Again, in such an 14G03-like sequence, CDR1, CDR2 and
CDR3 are preferably such that the 14G03-like ISVD has blocking
activity, e.g. block SDF-1 binding to CXCR7 partially or completely
as described herein, and/or reducing and/or inhibiting
tumorigenesis in a xenograph model, and/or inhibits .beta.-arrestin
recruitment, and/or binds and/or recognizes amino acid residue M33,
and optionally amino acid residue V32 and/or amino acid residue M37
in CXCR7 (SEQ ID NO: 1), all as described herein. [0102] For
example, in such an 14G03-like sequence: CDR1 may comprise or
essentially consist of the amino acid sequence INYMG (SEQ ID NO:
13) (with CDR2 and CDR3 being as defined under b) and c),
respectively); and/or CDR2 may comprise or essentially consist of
the amino acid sequence TLTSGGSTNYAGSVKG (SEQ ID NO: 23) (with CDR1
and CDR3 being as defined under a) and c), respectively); and/or
CDR3 may comprise or essentially consist of the amino acid sequence
GGTLYDRRRFES (SEQ ID NO: 33) (with CDR1 and CDR2 being as defined
under a) and b), respectively). Particularly, when an 14G03-like
sequence is according to this aspect: CDR1 may comprise or
essentially consist of the amino acid sequence INYMG (SEQ ID NO:
13) and CDR2 may comprise or essentially consist of the amino acid
sequence TLTSGGSTNYAGSVKG (SEQ ID NO: 23) (with CDR3 being as
defined under c) above); and/or CDR1 may comprise or essentially
consist of the amino acid sequence INYMG (SEQ ID NO: 13) and CDR3
may comprise or essentially consist of the amino acid sequence
GGTLYDRRRFES (SEQ ID NO: 33) (with CDR2 being as defined under b)
above); and/or CDR2 may comprise or essentially consist of the
amino acid sequence TLTSGGSTNYAGSVKG (SEQ ID NO: 23) and CDR3 may
comprise or essentially consist of the amino acid sequence
GGTLYDRRRFES (SEQ ID NO: 33) (with CDR1 being as defined under a)
above). Again, in such 14G03-like sequences, CDR1, CDR2 and CDR3
are preferably such that the 14G03-like ISVD has blocking activity,
e.g. block SDF-1 binding to CXCR7 partially or completely as
described herein and/or reducing and/or inhibiting tumorigenesis in
a xenograph model, and/or inhibits .beta.-arrestin recruitment,
and/or binds and/or recognizes amino acid residue M33, and
optionally amino acid residue V32 and/or amino acid residue M37 in
CXCR7 (SEQ ID NO: 1), all as described herein.
[0103] In a specifically preferred aspect, a "14G03-like sequence",
"14G03-like ISVD", "14G03-like building block" or "Group 2 ISVD" is
an ISVD that comprises: [0104] d) a CDR1 which is either (i) the
amino acid sequence INYMG (SEQ ID NO: 13) or (ii) an amino acid
sequence that has only 3, 2 or 1 amino acid difference(s) (as
defined herein) with the amino acid sequence INYMG (SEQ ID NO: 13);
and/or [0105] e) a CDR2 which is either (i) the amino acid sequence
TLTSGGSTNYAGSVKG (SEQ ID NO: 23) or (ii) an amino acid sequence
that has at least 80%, such as at least 85%, for example at least
90% or more than 95% sequence identity with the amino acid sequence
TLTSGGSTNYAGSVKG (SEQ ID NO: 23); or (iii) an amino acid sequence
that has only 7, 6, 5, 4, 3, 2 or 1 amino acid difference(s) (as
defined herein with the amino acid sequence TLTSGGSTNYAGSVKG (SEQ
ID NO: 23); and/or [0106] f) a CDR3 which is either (i) the amino
acid sequence GGTLYDRRRFES (SEQ ID NO: 33) or (ii) an amino acid
sequence that has at least 80%, such as at least 85%, for example
at least 90% or more than 95% sequence identity with the amino acid
sequence GGTLYDRRRFES (SEQ ID NO: 33); or (iii) an amino acid
sequence that has only 7, 6, 5, 4, 3, 2 or 1 amino acid
difference(s) (as defined herein) with the amino acid sequence
GGTLYDRRRFES (SEQ ID NO: 33); [0107] in which the framework
sequences present in such an ISVD are as further described herein,
and in which CDR1, CDR2 and CDR3 are preferably such that the
14G03-like ISVD has blocking activity, e.g. block SDF-1 binding to
CXCR7 partially or completely as described herein and/or reducing
and/or inhibiting tumorigenesis in a xenograph model, and/or
inhibits .beta.-arrestin recruitment, and/or binds and/or
recognizes amino acid residue M33, and optionally amino acid
residue V32 and/or amino acid residue M37 in CXCR7 (SEQ ID NO: 1),
all as described herein. Preferably, in a 14G03-like sequence
according to this specifically preferred aspect, CDR1 and CDR2 are
as defined under d) and e), respectively; or CDR1 and CDR3 are as
defined under d) and f), respectively; or CDR2 and CDR3 are as
defined under e) and f), respectively. More preferably, in such a
14G03-like sequence, CDR1, CDR2 and CDR3 are all as defined under
d), e) and f), respectively. Again, in such an 14G03-like sequence,
CDR1, CDR2 and CDR3 are preferably such that the 14G03-like ISVD
has blocking activity, e.g. block SDF-1 binding to CXCR7 partially
or completely as described herein, and/or reducing and/or
inhibiting tumorigenesis in a xenograph model, and/or inhibits
arrestin recruitment, and/or binds and/or recognizes amino acid
residue M33, and optionally amino acid residue V32 and/or amino
acid residue M37 in CXCR7 (SEQ ID NO: 1), all as described herein.
[0108] For example, in a 14G03-like sequence according to this
specifically preferred aspect: CDR1 is the amino acid sequence
INYMG (SEQ ID NO: 13) (with CDR2 and CDR3 being as defined under e)
and f), respectively); and/or CDR2 is the amino acid sequence
TLTSGGSTNYAGSVKG (SEQ ID NO: 23) (with CDR1 and CDR3 being as
defined under d) and f), respectively); and/or CDR3 is the amino
acid sequence GGTLYDRRRFES (SEQ ID NO: 33) (with CDR1 and CDR2
being as defined under d) and e), respectively). Particularly, when
an 14G03-like sequence is according to this aspect: CDR1 is the
amino acid sequence INYMG (SEQ ID NO: 13) and CDR2 is the amino
acid sequence TLTSGGSTNYAGSVKG (SEQ ID NO: 23) (with CDR3 being as
defined under f) above); and/or CDR1 is the amino acid sequence
INYMG (SEQ ID NO: 13) and CDR3 is the amino acid sequence
GGTLYDRRRFES (SEQ ID NO: 33) (with CDR2 being as defined under e)
above); and/or CDR2 is the amino acid sequence TLTSGGSTNYAGSVKG
(SEQ ID NO: 23) and CDR3 is GGTLYDRRRFES (SEQ ID NO: 33) (with CDR1
being as defined under d) above). Again, in such 14G03-like
sequences, CDR1, CDR2 and CDR3 are preferably such that the
14G03-like ISVD has blocking activity, e.g. block SDF-1 binding to
CXCR7 partially or completely as described herein, and/or reducing
and/or inhibiting tumorigenesis in a xenograph model, and/or
inhibits .beta.-arrestin recruitment, and/or binds and/or
recognizes amino acid residue M33, and optionally amino acid
residue V32 and/or amino acid residue M37 in CXCR7 (SEQ ID NO: 1),
all as described herein. [0109] In a particularly preferred
14G03-like sequence: CDR1 is the amino acid sequence INYMG (SEQ ID
NO: 13), CDR2 is the amino acid sequence TLTSGGSTNYAGSVKG (SEQ ID
NO: 23); and CDR3 is the amino acid sequence GGTLYDRRRFES (SEQ ID
NO: 33). [0110] In all the 14G03-like sequence described in this
paragraph A), the framework sequences may be as further described
herein. Preferably, the framework sequences are such that the
framework sequences have at least 80%, such as at least 85%, for
example at least 90%, such as at least 95% sequence identity with
the framework sequences of 14G03 (which, for example, can be
determined by determining the overall degree of sequence identity
of a given sequence with the sequence of 14G03 while disregarding
the CDR's in the calculation). Again, the combination of CDR's and
frameworks present in a given sequence are preferably such that the
resulting 14G03-like ISVD has blocking activity, e.g. block SDF-1
binding to CXCR7 partially or completely as described herein and/or
reducing and/or inhibiting tumorigenesis in a xenograph model,
and/or inhibits .beta.-arrestin recruitment, and/or binds and/or
recognizes amino acid residue M33, and optionally amino acid
residue V32 and/or amino acid residue M37 in CXCR7 (SEQ ID NO: 1),
all as described herein.
[0111] In one specific aspect, a 14G03-like sequence is an ISVD
that has at least 70%, such at least 80%, for example at least 85%,
such as at least 90% or more than 95% sequence identity with the
amino acid sequence 14G03 (SEQ ED NO: 43). For example, in an
14G03-like sequence according to this aspect, the CDR's may be
according to the specifically preferred aspect described above, and
may in particularly (but without limitation) be INYMG (SEQ ID NO:
13) (CDR1); TLTSGGSTNYAGSVKG (SEQ ID NO: 23) (CDR2); and
GGTLYDRRRFES (SEQ ID NO: 33) (CDR3). Again, preferably, the
combination of CDR's and frameworks present in such a 14G03-like
ISVD are preferably such that the resulting 14G03-like ISVD has
blocking activity, e.g., block SDF-1 binding to CXCR7 partially or
completely as described herein and/or reducing and/or inhibiting
tumorigenesis in a xenograph model, and/or inhibits .beta.-arrestin
recruitment, and/or binds and/or recognizes amino acid residue M33,
and optionally amino acid residue V32 and/or amino acid residue M37
in CXCR7 (SEQ ID NO: 1), all as described herein. In one particular
aspect, any 14G03-like sequence may be a humanized and/or sequence
optimized sequence, as further described herein.
[0112] For binding to CXCR7 and in particular human CXCR7 (SEQ ID
NO: 1), an amino acid sequence or polypeptide of the invention will
usually contain within its amino acid sequence one or more amino
acid residues or one or more stretches of amino acid residues
(i.e., with each "stretch" comprising two or amino acid residues
that are adjacent to each other or in close proximity to each
other, i.e., in the primary or tertiary structure of the amino acid
sequence) via which the amino acid sequence of the invention can
bind to CXCR7 and in particular human CXCR7 (SEQ ID NO: 1), which
amino acid residues or stretches of amino acid residues thus form
the "site" for binding to CXCR7 and in particular human CXCR7 (SEQ
ID NO: 1) (also referred to herein as the "antigen binding
site").
[0113] The immunoglobulin single variable domains provided by the
invention are preferably in essentially isolated form (as defined
herein), or form part of a protein or polypeptide of the invention
(as defined herein), which may comprise or essentially consist of
one or more immunoglobulin single variable domains of the invention
and which may optionally further comprise one or more further
immunoglobulin single variable domains (all optionally linked via
one or more suitable linkers), and/or one or more further binding
domains, binding units, amino acid sequences or other (functional)
groups or moieties, that preferably also confer one or more desired
properties to the constructs (some non-limiting examples of the
same will become clear from the further description herein).
[0114] The polypeptides or immunoglobulin single variable domains
provided by the invention preferentially reduce tumorigenesis in
vivo.
[0115] In a further preferred embodiment, the invention provides
constructs comprising at least two immunoglobulin single variable
domains against CXCR7. More preferably, said immunoglobulin single
variable domains against CXCR7 are selected from variants of
polypeptides and immunoglobulin single variable domains against
CXCR7 as defined in section 1.5 in respect of Table B-2 infra
(e.g., Group 2 immunoglobulin single variable domains), wherein
said immunoglobulin single variable domains against CXCR7 may be
the same or different. Preferably, said two immunoglobulin single
variable domains against CXCR7 are chosen from 14G03-like ISVDs,
such as 14G03, 08A05, 08A10, 07C03 and 07B11. In another further
preferred embodiment, the invention provides constructs comprising
at least two immunoglobulin single variable domains against CXCR7
are selected from variants of polypeptides and immunoglobulin
single variable domains against CXCR7 which as defined in section
1.5 in respect of Table B-2 infra (e.g., Group 1 immunoglobulin
single variable domains), wherein said immunoglobulin single
variable domains against CXCR7 may be the same or different.
Preferably, said two immunoglobulin single variable domains against
CXCR7 are chosen from 01C10 (SEQ ID NO: 91), 01B12 (SEQ ID NO:
100), 01F11 (SEQ ID NO: 101) or 01B10 (SEQ ID NO: 102).
[0116] It has unexpectedly been demonstrated that bispecific
constructs comprising at least one Group 1 immunoglobulin single
variable domain and at least one Group 2 ISVD are especially
suitable for reducing tumour growth in vivo. In particular, it has
been shown that these constructs inhibit SDF-1 binding to CXCR7,
inhibit tumour growth in vivo, as well as inhibit .beta.-arrestin
recruitment. Moreover, in view of the binding efficacy of the Group
2 ISVDs, for instance as characterized by SDF-1 displacement, these
constructs comprising at least one Group 1 ISVD and at least one
Group 2 ISVD bind better to the target (see e.g., Example 17). This
would result in a lower dose for inhibiting tumour growth. In
addition, the simultaneous inhibition of .beta.-arrestin
recruitment would result in a prolonged anti-tumorigenic
effect.
[0117] Accordingly, in a further preferred embodiment, the
invention provides constructs comprising at least two
immunoglobulin single variable domains against CXCR7, wherein at
least one of said immunoglobulin single variable domains against
CXCR7 (i.e., a "first" immunoglobulin single variable domains
against CXCR7) is 01C10-like, such as for instance 01C10 (SEQ ID
NO: 91), 01B12 (SEQ ID NO: 100), 01F11 (SEQ ID NO: 101) or 01B10
(SEQ ID NO: 102), or variants thereof as defined in section 1.5 in
respect of Table B-2 infra (e.g., Group 1 immunoglobulin single
variable domains), and wherein at least one immunoglobulin single
variable domains against CXCR7 (i.e., a "second" immunoglobulin
single variable domain against CXCR7) is selected from variants of
polypeptides and immunoglobulin single variable domains against
CXCR7 as defined in section 1.5 infra in respect of Table B-2
different from the "first" immunoglobulin single variable domains
against CXCR7 or variants thereof. Preferably, said "first"
immunoglobulin single variable domains against CXCR7 is 01C10 and
said "second" immunoglobulin single variable domains against CXCR7
is chosen from the group consisting of 14G03-like, such as for
instance, 14G03, 08A05, 08A10, 07C03 and 07B11.
[0118] As described in Example 11, binding to CXCR7 by the Group 1
immunoglobulin single variable domains as represented by 01C10 was
influenced by mutating W19. In contrast, binding of all tested
immunoglobulin single variable domains was affected by a M33
mutation, while Group 1 ISVDs were not. It was further shown that
Group 1 ISVDs preferably recognize and/or bind also S23 and D25
(data not shown).
[0119] Group 1 ISVDs or polypeptides can be characterized by
binding/recognizing "Group 1 epitope". Group 1 ISVDs or
polypeptides bind and/or recognize amino acid residue W19, and
optionally amino acid residue S23 and/or amino acid residue D25 in
CXCR7 (SEQ ID NO: 1). Group 1 epitope comprises amino acid residue
W19, and optionally amino acid residue S23 and/or amino acid
residue D25 in CXCR7 (SEQ ID NO: 1). Group 1 ISVDs is represented
by inter cilia 01C10 (SEQ ID NO: 91), 01B12 (SEQ ID NO: 100), 01F11
(SEQ ID NO: 101) or 01B10 (SEQ ID NO: 102), apparently hitting an
epitope distinct from Group 2 epitope;
[0120] Group 2 ISVDs or polypeptides can be characterized by
binding/recognizing "Group 2 epitope". Group 2 ISVDs or
polypeptides do not bind and/or recognize amino acid residue W19,
amino acid residue S23 and/or amino acid residue D25 in CXCR7 (SEQ
ID NO: 1). Group 2 ISVDs or polypeptides bind and/or recognize
amino acid residue M33, and optionally amino acid residue V32
and/or amino acid residue M37 in CXCR7 (SEQ ID NO: 1). Group 2
epitope comprises amino acid residue M33, and optionally amino acid
residue V32 and/or amino acid residue M37 in CXCR7 (SEQ ID NO: 1).
Group 2 ISVDs are represented by 14G03-like ISVDs, such as for
instance, 14G03 (09A04), 08A05, 08A10 and 07C03, apparently hitting
an epitope distinct from Group 1. Preferably, Group 2 ISVDs inhibit
.beta.-arrestin recruitment, as defined herein; and
[0121] Group 3 ISVDs or polypeptides can be characterized by
binding/recognizing (part of) "Group 1" epitope as well as (part
of) "Group 2" epitope. Group 3 ISVDs or polypeptides is represented
by 07B11, apparently intermediary to Group 1 and Group 2.
[0122] The person skilled in the art is familiar with methods
common in the art for determining epitopes, such as for instance
provided in Example 11: "epitope mapping" of the present
invention.
[0123] Accordingly, the present invention relates to polypeptides
ISVDs, as well as (conventional) antibodies, or parts thereof, such
as Fc, Fab, minibodies, etc., recognizing and/or binding W19, and
optionally S23 and/or D25 in CXCR7.
[0124] The above described anti-CXCR7/CXCR7 bispecific constructs
may be suitably half-life extended (e.g., by pegylation, fusion to
serum albumin, or fusion to a peptide or binding unit that can bind
to a serum protein such as serum albumin, as further described
herein), and thus may for example further comprise a serum-albumin
binding peptide or binding domain (such as those described herein),
optionally linked via one or more suitable spacers or linkers.
[0125] Again, such further binding domains, binding units, amino
acid sequences or other (functional) groups or moieties include one
or more other immunoglobulin single variable domains, such as one
or more (single) domain antibodies, dAb's or Nanobodies (e.g., a
V.sub.HH, humanized V.sub.HH or camelized V.sub.H, such as a
camelized human V.sub.H), so as to provide a "bispecific" protein
or polypeptide of the invention (i.e., a polypeptide of the
invention that contains at least one--such as one or
two--immunoglobulin single variable domain that is directed against
CXCR7 and at least one--such as one or two--immunoglobulin single
variable domain that is directed against another target).
[0126] For example, according to a specific but non-limiting
aspect, the constructs, proteins or polypeptides of the invention
may have been provided with an increased half-life, for example by
functionalisation and/or by including in the construct a moiety or
binding unit that increases the half-life of the construct.
Examples of such functionalisation, moieties or binding units will
be clear to the skilled person and may for example include
pegylation, fusion to serum albumin, or fusion to a peptide or
binding unit that can bind to a serum protein such as serum
albumin.
[0127] In the latter constructs (i.e., fusion constructs comprising
at least one--such as one or two--amino acid sequence of the
invention and at least one--such as one or two--peptide or binding
unit that can bind to a serum protein such as serum albumin), the
serum-albumin binding peptide or binding domain may be any suitable
serum-albumin binding peptide or binding domain capable of
increasing the half-life of the construct (compared to the same
construct without the serum-albumin binding peptide or binding
domain), and may in particular be serum albumin binding peptides as
described in WO 2008/068280 by applicant (and in particular WO
2009/127691 and WO 2011/095545, both by applicant), or a
serum-albumin binding immunoglobulin single variable domain (such
as a serum-albumin binding Nanobody; for example Alb-1 or a
humanized version of Alb-1 such as Alb-8, for which reference is
for example made to WO 06/122787).
[0128] With respect to half-life, it should be noted that in the
invention, and by using the various half-life extending techniques
described herein (for example, by suitably choosing a serum-albumin
binding peptide according to WO 2008/068280, WO 2009/127691 and/or
WO 2011/095545, the half-life of a construct or polypeptide of the
invention can (and preferably is) suitably "tailored" for the
intended (therapeutic and/or diagnostic) application and/or to
obtain the best balance between the desired therapeutic and/or
pharmacological effect and possible undesired side-effects.
[0129] Thus, for example, and without limitation, a preferred
aspect of the invention provides a "bispecific" polypeptide
consisting essentially of one immunoglobulin single variable domain
directed against human CXCR7 (or, alternatively, of two
immunoglobulin single variable domains directed against human
CXCR7, which may be the same or different, so as to provide--when
they are the same or different--a "bivalent" polypeptide of the
invention, or--when they are different--"biparatopic" polypeptide
of the invention) and one immunoglobulin single variable domain
directed against human serum albumin linked by a peptide linker (as
defined herein), so as to provide a bispecific polypeptide of the
invention, respectively, all as described herein. Such a protein or
polypeptide may also be in essentially isolated form (as defined
herein).
[0130] In another specific, but non-limiting aspect, an amino acid
sequence (such as a Nanobody) of the invention or a polypeptide of
the invention (such as a bivalent, biparatopic or bispecific
polypeptide of the invention) may be suitably linked (again,
chemically or via one or more suitable linkers or spacers) to a
toxin or to a (cyto)toxic residue, moiety or payload. Examples of
suitable (cyto)toxic moieties, compounds, payloads or residues
which can be linked to amino acids sequences or polypeptides of the
invention to provide--for example--a cytotoxic compound (i.e., an
antibody-drug conjugate or "ADC" based upon an amino acid sequence
or polypeptide of the invention) will be clear to the skilled
person. Reference is for example made to the review by Ducry and
Stump, Bioconjugate Chem., 2010, 21 (1), pp. 5-13. Such cytotoxic
amino acid sequences or polypeptides of the invention may in
particular be useful/suitable for those applications in which it is
intended to kill a cell that expresses the target against which the
amino acid sequences or polypeptides of the invention are directed
(e.g. in the treatment of cancer), or to reduce or slow the growth
and/or proliferation such a cell. Usually, but without limitation,
(cyto)toxic polypeptides of the invention will either not be
half-life extended or will have only a limited and/or tightly
controlled half-life extension.
[0131] In another aspect, at least one amino acid sequence of the
invention (i.e., immunoglobulin single variable domain against
CXCR7) may be suitably linked to at least one immunoglobulin single
variable domain that is directed against CXCR4, so as to provide a
bispecific polypeptide of the invention that is directed against
both CXCR7 and CXCR4.
[0132] For example, in this aspect, at least one--such as one or
two--amino acid sequences of the invention may be suitably linked
to at least one such as one or two--immunoglobulin single variable
domains against CXCR4.
[0133] Some preferred but non-limiting examples of immunoglobulin
single variable domains against CXCR4 that can be used in such
constructs are (or may be suitably chosen from) [0134] the
immunoglobulin single variable domains (and in particular one of
the Na nobodies) against CXCR4 from the international application
WO 09/138519 by Ablynx N.V. (for example and without limitation,
238D2/SEQ ID NO: 238 and 238D4/SEQ ID NO: 239 in Table B-1.1 of WO
09/138,519); and/or [0135] the sequence-optimized/improved variants
of the amino acid sequences 238D2 and 238D4 described in the
non-prepublished U.S. application 61/358,495 by Ablynx N. V. (filed
on Jun. 25, 2010; and/or [0136] the immunoglobulin single variable
domains that are capable of binding to the same epitope as 238D2
and/or 238D4 as described in the PCT application PCT/EP2010/064766
by Ablynx N.V. filed on Oct. 4, 2010; and/or [0137] the 10E9-type
sequences, 281E10-type sequences, 10E12-type sequences, 10A10-type
sequences, 10G10-type sequences, 14A2-type sequences, 15A1-type
sequences, 15H3-type sequences and/or 283B6-type sequences
described on pages 7-13 of the PCT application PCT/EP2011/050156 by
Ablynx N.V. filed on Jan. 7, 2011; and/or [0138] the 10E9-type
sequences, 281E10-type sequences, 10E12-type sequences, 10A10-type
sequences, 10G10-type sequences, 14A2-type sequences, 15A1-type
sequences, 15H3-type sequences and/or 283B6-type sequences
described on pages 15-47 of the PCT application PCT/EP2011/050156
by Ablynx N.V. filed on Jan. 7, 2011.
[0139] The above described anti-CXCR7/CXCR4 bispecific constructs
(as well as other bispecific constructs comprising at least one
amino acid sequence of the invention) may be suitably half-life
extended (e.g., by pegylation, fusion to serum albumin, or fusion
to a peptide or binding unit that can bind to a serum protein such
as serum albumin, as further described herein), and thus may for
example further comprise a serum-albumin binding peptide or binding
domain (such as those described herein), optionally linked via one
or more suitable spacers or linkers.
[0140] Thus, one specific but non-limiting aspect of the invention
is a polypeptide that comprises one or two (and preferably one)
immunoglobulin single variable domains (as defined herein, and
preferably one or two Nanobodies) against CXCR7, one or two (and
preferably one) immunoglobulin single variable domains (as defined
herein, and preferably one or two Na nobodies) against CXCR4, and a
peptide or immunoglobulin single variable domain against (human)
serum albumin, optionally suitably linked via one or more spacers
or linkers.
[0141] The above anti-CXCR7/CXCR4 bispecific constructs (as well as
other bispecific constructs comprising at least one amino acid
sequence of the invention) may also be suitably linked (again,
chemically or via one or more suitable linkers or spacers) to a
toxin or to a (cyto)toxic residue, moiety or payload (as further
described herein). Again, such (cyto)toxic bispecfic polypeptides
of the invention will either not be half-life extended or will have
only a limited and/or tightly controlled half-life extension.
[0142] The invention in its broadest sense also comprises
derivatives of the amino acid sequences (e.g., Nanobodies) of the
invention and of the polypeptides of the invention. Such
derivatives can generally be obtained by modification, and in
particular by chemical and/or biological (e.g. enzymatical)
modification, of the amino acid sequences (e.g., Nanobodies) of the
invention and polypeptides of the invention and/or of one or more
of the amino acid residues that form the Nanobodies of the
invention.
[0143] Examples of such modifications, as well as examples of amino
acid residues within the amino acid sequences (e.g., Nanobodies) of
the invention and polypeptides that can be modified in such a
manner (i.e., either on the protein backbone but preferably on a
side chain), methods and techniques that can be used to introduce
such modifications and the potential uses and advantages of such
modifications will be clear to the skilled person.
[0144] For example, such a modification may involve the
introduction (e.g., by covalent linking or in another suitable
manner) of one or more functional groups, residues or moieties into
or onto the amino acid sequences (e.g., Nanobodies) of the
invention and polypeptides of the invention, and in particular of
one or more functional groups, residues or moieties that confer one
or more desired properties or functionalities to the Nanobody of
the invention. Example of such functional groups will be clear to
the skilled person.
[0145] For example, such modification may comprise the introduction
(e.g., by covalent binding or in any other suitable manner) of one
or more functional groups that increase the half-life, the
solubility and/or the absorption of the Nanobody of the invention,
that reduce the immunogenicity and/or the toxicity of the Nanobody
of the invention, that eliminate or attenuate any undesirable side
effects of the Nanobody of the invention, and/or that confer other
advantageous properties to and/or reduce the undesired properties
of the Nanobodies and/or polypeptides of the invention; or any
combination of two or more of the foregoing. Examples of such
functional groups and of techniques for introducing them will be
clear to the skilled person, and can generally comprise all
functional groups and techniques mentioned in the general
background art cited hereinabove as well as the functional groups
and techniques known per se for the modification of pharmaceutical
proteins, and in particular for the modification of antibodies or
antibody fragments (including ScFv's and single domain antibodies),
for which reference is for example made to Remington's
Pharmaceutical Sciences, 16th ed., Mack Publishing Co., Easton, Pa.
(1980). Such functional groups may for example be linked directly
(for example covalently) to a Nanobody of the invention, or
optionally via a suitable linker, or spacer, as will again be clear
to the skilled person.
[0146] One of the most widely used techniques for increasing the
half-life and/or reducing the immunogenicity of pharmaceutical
proteins comprises attachment of a suitable pharmacologically
acceptable polymer, such as poly(ethyleneglycol) (PEG) or
derivatives thereof (such as methoxypoly(ethyleneglycol) or mPEG).
Generally, any suitable form of pegylation can be used, such as the
pegylation used in the art for antibodies and antibody fragments
(including but not limited to (single) domain antibodies and
ScFv's); reference is made to for example Chapman, Nat.
Biotechnol., 54, 531-545 (2002); by Veronese and Harris, Adv. Drug
Deliv. Rev. 54, 453-456 (2003), by Harris and Chess, Nat. Rev.
Drug. Discov, 2, (2003) and in WO 04/060965. Various reagents for
pegylation of proteins are also commercially available, for example
from Nektar Therapeutics, USA.
[0147] Preferably, site-directed pegylation is used, in particular
via a cysteine-residue (see for example Yang et al., Protein
Engineering, 16, 10, 761-770 (2003). For example, for this purpose,
PEG may be attached to a cysteine residue that naturally occurs in
a Nanobody of the invention, a Nanobody of the invention may be
modified so as to suitably introduce one or more cysteine residues
for attachment of PEG, or an amino acid sequence comprising one or
more cysteine residues for attachment of PEG may be fused to the N-
and/or C-terminus of a Na nobody of the invention, all using
techniques of protein engineering known per se to the skilled
person.
[0148] Preferably, for the Nanobodies and proteins of the
invention, a PEG is used with a molecular weight of more than 5000,
such as more than 10,000 and less than 200,000, such as less than
100,000; for example in the range of 20,000-80,000.
[0149] Another, usually less preferred modification comprises
N-linked or O-linked glycosylation, usually as part of
co-translational and/or post-translational modification, depending
on the host cell used for expressing the Nanobody or polypeptide of
the invention.
[0150] Yet another modification may comprise the introduction of
one or more detectable labels or other signal-generating groups or
moieties, depending on the intended use of the labelled Nanobody.
Suitable labels and techniques for attaching, using and detecting
them will be clear to the skilled person, and for example include,
but are not limited to, the fluorescent labels, phosphorescent
labels, chemiluminescent labels, bioluminescent labels,
radio-isotopes, metals, metal chelates, metallic cations,
chromophores and enzymes, such as those mentioned on page 109 of WO
08/020,079. Other suitable labels will be clear to the skilled
person, and for example include moieties that can be detected using
NMR or ESR spectroscopy.
[0151] Such labelled Nanobodies and polypeptides of the invention
may for example be used for in vitro, in viva or in situ assays
(including immunoassays known per se such as ELISA, RIA, EIA and
other "sandwich assays", etc.) as well as in vivo diagnostic and
imaging purposes, depending on the choice of the specific
label.
[0152] As will be clear to the skilled person, another modification
may involve the introduction of a chelating group, for example to
chelate one of the metals or metallic cations referred to above.
Suitable chelating groups for example include, without limitation,
diethyl-enetriaminepentaacetic acid (DTPA) or
ethylenediaminetetraacetic acid (EDTA).
[0153] Yet another modification may comprise the introduction of a
functional group that is one part of a specific binding pair, such
as the biotin-(strept)avidin binding pair. Such a functional group
may be used to link the Nanobody of the invention to another
protein, polypeptide or chemical compound that is bound to the
other half of the binding pair, i.e., through formation of the
binding pair. For example, a Nanobody of the invention may be
conjugated to biotin, and linked to another protein, polypeptide,
compound or carrier conjugated to avidin or streptavidin. For
example, such a conjugated Nanobody may be used as a reporter, for
example in a diagnostic system where a detectable signal-producing
agent is conjugated to avidin or streptavidin. Such binding pairs
may for example also be used to bind the Nanobody of the invention
to a carrier, including carriers suitable for pharmaceutical
purposes. One non-limiting example are the liposomal formulations
described by Cao and Suresh, Journal of Drug Targetting, 8, 4, 257
(2000). Such binding pairs may also be used to link a
therapeutically active agent to the Nanobody of the invention.
[0154] Other potential chemical and enzymatical modifications will
be clear to the skilled person. Such modifications may also be
introduced for research purposes (e.g., to study function-activity
relationships). Reference is for example made to Lundblad and
Bradshaw, Biotechnol. Appl. Biochem., 26, 143451 (1997).
[0155] The immunoglobulin single variable domains and polypeptides
of the invention as such preferably essentially consist of a single
amino acid chain that is not linked via disulphide bridges to any
other amino acid sequence or chain (but that may or may not contain
one or more intramolecular disulphide bridges. For example, it is
known that agent of the invention--as described herein--may
sometimes contain a disulphide bridge between CDR3 and CDR1 or
FR2). However, it should be noted that one or more immunoglobulin
single variable domains of the invention may be linked to each
other and/or to other immunoglobulin single variable domains (e.g.,
via disulphide bridges) to provide peptide constructs that may also
be useful in the invention (for example Fab' fragments,
F(ab').sub.2 fragments, ScFv constructs, "diabodies" and other
multispecific constructs. Reference is for example made to the
review by Holliger and Hudson, Nat. Biotechnol. 2005 September;
23(9):1126-36).
[0156] Generally, when an amino acid sequence of the invention (or
a compound, construct or polypeptide comprising the same) is
intended for administration to a subject (for example for
therapeutic and/or diagnostic purposes as described herein), it is
preferably either an amino acid sequence that does not occur
naturally in said subject; or, when it does occur naturally in said
subject, is in essentially isolated form (as defined herein).
[0157] It will also be clear to the skilled person that for
pharmaceutical use, the immunoglobulin single variable domains of
the invention (as well as compounds, constructs and polypeptides
comprising the same) are preferably directed against human CXCR7
and in particular human CXCR7 (SEQ ID NO: 1); whereas for
veterinary purposes, the immunoglobulin single variable domains and
polypeptides of the invention are preferably directed against CXCR7
from the species to be treated, or at least cross-reactive with
CXCR7 from the species to be treated.
[0158] Furthermore, an amino acid sequence of the invention may
optionally, and in addition to the at least one binding site for
binding against CXCR7 and in particular human CXCR7 (SEQ ID NO: 1),
contain one or more further binding sites for binding against other
antigens, proteins or targets.
[0159] The efficacy of the immunoglobulin single variable domains
and polypeptides of the invention, and of compositions comprising
the same, can be tested using any suitable in vitro assay,
cell-based assay, in vivo assay and/or animal model known per se,
or any combination thereof, depending on the specific disease or
disorder involved. Suitable assays and animal models will be clear
to the skilled person, and for example include ligand displacement
assays (Burns et al, J. Exp. Med. 2006 4; 203(9):2201-13), beta
arrestin recruitment assays (Zabel et al., J. Immunol. 2009 1;
183(5):3204-11), dimerization assays (Luker et al, Faseb J. 2009
23(3):823-34), signaling assays (Wang et al, J Immunol. 2009 Sep.
1; 183(5):3204-11) proliferation assays (Wang et al, J Immunol.
2009 Sep. 1; 183(5):3204-11; Odemis et al., J Cell Sign. 2010 Apr.
1; 123(Pt 7): 1081-8), survival assays (Burns et al, J. Exp. Med.
2006 4; 203(9):2201-13), cell adhesion assays (Burns et al, J. Exp.
Med. 2006 4; 203(9):2201-13) and transendothelial migration assays
(Mazzinghi et al, J. Exp. Med. 2008 Feb. 18; 205(2):479-90),
endothelial cell sprouting assays (Wang et al, J. Immunol. 2009
Sep. 1; 183(5):3204-11), myogenic differentiation (Melchionna et
al., Muscle Nerve, 2010 Feb. 11) and in vivo xenograft models
(Burns et al, J. Exp. Med. 2006 4; 203(9):2201-13), collagen
induced arthritis models (Hegen et al, Ann Rheum Dis. 2008
November; 67(11):1505-15) and experimental autoimmune
encephalomyelitis models (Wekerle, Ann Rheum Dis. 2008 December; 67
Suppl 3:iii56-60) as well as the assays and animal models used in
the experimental part below and in the prior art cited herein.
[0160] Also, according to the invention, immunoglobulin single
variable domains and polypeptides that are directed against CXCR7
from a first species of warm-blooded animal may or may not show
cross-reactivity with CXCR7 from one or more other species of
warm-blooded animal. For example, immunoglobulin single variable
domains and polypeptides directed against human CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1) may or may not show cross
reactivity with CXCR7 from one or more other species of primates
(such as, without limitation, monkeys from the genus Macaca (such
as, and in particular, cynomolgus monkeys (Macaca fascicularis)
and/or rhesus monkeys (Maraca mulatta)) and baboon (Papio ursinus))
and/or with CXCR7 from one or more species of animals that are
often used in animal models for diseases (for example mouse, rat,
rabbit, pig or dog), and in particular in animal models for
diseases and disorders associated with CXCR7 and in particular
human CXCR7 (SEQ ID NO: 1) (such as the species and animal models
mentioned herein). In this respect, it will be clear to the skilled
person that such cross-reactivity, when present, may have
advantages from a drug development point of view, since it allows
the immunoglobulin single variable domains and polypeptides against
human CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) to be
tested in such disease models (see e.g., Example 12).
[0161] More generally, immunoglobulin single variable domains and
polypeptides of the invention that are cross-reactive with CXCR7
from multiple species of mammal will usually be advantageous for
use in veterinary applications, since it will allow the same amino
acid sequence or polypeptide to be used across multiple species.
Thus, it is also encompassed within the scope of the invention that
immunoglobulin single variable domains and polypeptides directed
against CXCR7 from one species of animal (such as immunoglobulin
single variable domains and polypeptides against human CXCR7 (SEQ
ID NO: 1)) can be used in the treatment of another species of
animal, as long as the use of the immunoglobulin single variable
domains and/or polypeptides provide the desired effects in the
species to be treated.
[0162] The present invention is in its broadest sense also not
particularly limited to or defined by a specific antigenic
determinant, epitope, part, domain, subunit or confirmation (where
applicable) of CXCR7 and in particular human CXCR7 (SEQ ID NO: 1)
against which the immunoglobulin single variable domains and
polypeptides of the invention are directed. For example, the
immunoglobulin single variable domains and polypeptides may or may
not be directed against the CXCL11/CXCL12 interaction site and/or
CXCR7/CXCR7 homodimerization site and/or CXCR4/CXCR7
heterodimerization site (or heterodimerization of CXCR7 to other
chemokine receptor such as e.g. CXCR3), and are as further defined
herein.
[0163] As further described herein, a polypeptide of the invention
may contain two or more immunoglobulin single variable domains of
the invention that are directed against CXCR7 and in particular
human CXCR7 (SEQ ID NO: 1). Generally, such polypeptides will bind
to CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) with
increased avidity compared to a single amino acid sequence of the
invention. Such a polypeptide may for example comprise two
immunoglobulin single variable domains of the invention that are
directed against the same antigenic determinant, epitope, part,
domain, subunit or confirmation (where applicable) of CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1) (which may or may not be an
interaction site); or comprise at least one "first" amino acid
sequence of the invention that is directed against a first same
antigenic determinant, epitope, part, domain, subunit or
confirmation (where applicable) of CXCR7 and in particular human
CXCR7 (SEQ ID NO: 1) (which may or may not be an interaction site),
such as for instance Group 1 epitopes; and at least one "second"
amino acid sequence of the invention that is directed against a
second antigenic determinant, epitope, part, domain, subunit or
confirmation (where applicable) different from the first (and which
again may or may not be an interaction site), such as for instance
Group 2 epitopes. Preferably, in such "biparatopic" polypeptides of
the invention, at least one amino acid sequence of the invention is
directed against an interaction site (as defined herein), although
the invention in its broadest sense is not limited thereto. For
instance, polypeptides of the invention may be formatted e.g., in a
biparatopic way such as to combine monovalent building blocks
directed against different epitopes as characterized in the
experimental part (see Examples 9 to 17). Although the binding
constants, e.g., association and dissociation constants, of
individual immunoglobulin single variable domains of a "bivalent"
polypeptide are wholly favourable over the binding constants of the
individual immunoglobulin single variable domains of a
"biparatopic" polypeptide, the present invention demonstrates
completely unexpectedly that a "biparatopic" polypeptide of the
invention is more effective in biological assays, e.g.,
.beta.-arrestin assay, than "bivalent" polypeptides.
[0164] Also, when the target is part of a binding pair (for
example, a receptor-ligand binding pair), the immunoglobulin single
variable domains and polypeptides may be such that they compete
with the cognate binding partners, e.g., CXCL11 (also referred to
as I-TAC) and/or CXCL12 (also referred to as SDF-1), for binding to
CXCR7, and/or such that they (fully or partially) neutralize
binding of the binding partner to the target.
[0165] It is also expected that the immunoglobulin single variable
domains and polypeptides of the invention will generally bind to
all naturally occurring or synthetic analogs, variants, mutants,
alleles, parts and fragments of CXCR7 and in particular human CXCR7
(SEQ ID NO: 1); or at least to those analogs, variants, mutants,
alleles, parts and fragments of CXCR7 and in particular human CXCR7
(SEQ ID NO: 1) that contain one or more antigenic determinants or
epitopes that are essentially the same as the antigenic
determinant(s) or epitope(s) to which the immunoglobulin single
variable domains and polypeptides of the invention bind to CXCR7
and in particular to human CXCR7 (SEQ ID NO: 1). Again, in such a
case, the immunoglobulin single variable domains and polypeptides
of the invention may bind to such analogs, variants, mutants,
alleles, parts and fragments with an affinity and/or specificity
that are the same as, or that are different from (i.e., higher than
or lower than), the affinity and specificity with which the
immunoglobulin single variable domains of the invention bind to
(wild-type) CXCR7.
[0166] As CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) exists
in a monomeric form and in one or more multimeric forms, e.g., in
homodimeric as well in heterodimeric form with CXCR4, e.g., human
CXCR4 (R M Maksym et al., supra; KE Luker et al. supra), it is
within the scope of the invention that the immunoglobulin single
variable domains and polypeptides of the invention i) only bind to
CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) in monomeric
form, ii) only bind to CXCR7 and in particular human CXCR7 (SEQ ID
NO: 1) in multimeric/dimeric (homo- and/or heterodimeric) form, or
iii) bind to both the monomeric and the multimeric form. In a
preferred aspect of the invention, the polypeptides of the
invention prevent formation of homodimeric human CXCR7 complexes
and/or heterodimeric human CXCR4/CXCR7 complexes. In another
preferred aspect of the invention, the polypeptides of the
invention do not induce (even at higher concentration such as 10 nM
or less, 50 nM or less, 100 nM or less, or 500 nM or less)
formation of homodimeric human CXCR7 complexes and/or heterodimeric
human CXCR4/CXCR7 complexes. Again, in such a case, the
polypeptides of the invention may bind to the monomeric form with
an affinity and/or specificity that are the same as, or that are
different from (i.e., higher than or lower than), the affinity and
specificity with which the immunoglobulin single variable domains
of the invention bind to the multimeric form.
[0167] Also, when CXCR7 and in particular human CXCR7 (SEQ ID NO:
1) can associate with other proteins or polypeptides to form
protein complexes (e.g., with CXCL12/SDF-1 or CXCL11/I-TAC), it is
within the scope of the invention that the immunoglobulin single
variable domains and polypeptides of the invention bind to CXCR7
and in particular human CXCR7 (SEQ ID NO: 1) in its non-associated
state (and e.g. prevent the ligand binding), bind to CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1) in its associated state, or
bind to both (preferably to the non-associated state). In all these
cases, the immunoglobulin single variable domains and polypeptides
of the invention may bind to such associated protein complexes with
an affinity and/or specificity that may be the same as or different
from (i.e., higher than or lower than) the affinity and/or
specificity with which the immunoglobulin single variable domains
and polypeptides of the invention bind to CXCR7 and in particular
human CXCR7 (SEQ ID NO: 1) in its non-associated state.
[0168] Also, as will be clear to the skilled person, proteins or
polypeptides that contain two or more immunoglobulin single
variable domains directed against CXCR7 and in particular human
CXCR7 (SEQ ID NO: 1) may bind with higher avidity to CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1) than the corresponding
monomeric amino acid sequence(s). For example, and without
limitation, proteins or polypeptides that contain two or more
immunoglobulin single variable domains directed against different
epitopes of CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) may
(and usually will) bind with higher avidity than each of the
different monomers, and proteins or polypeptides that contain two
or more immunoglobulin single variable domains directed against
CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) may (and usually
will) bind also with higher avidity to a multimer (e.g. homodimer,
heterodimer with CXCR4) of CXCR7 and in particular to a multimer
(e.g. homodimer, heterodimer with human CXCR4) of human CXCR7 (SEQ
ID NO: 1).
[0169] Generally, immunoglobulin single variable domains and
polypeptides of the invention will at least bind to those forms of
CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) (including
monomeric, multimeric, associated and different conformational
forms) that are the most relevant from a biological and/or
therapeutic point of view, as will be clear to the skilled
person.
[0170] It is also within the scope of the invention to use parts,
fragments, analogs, mutants, variants, alleles and/or derivatives
of the immunoglobulin single variable domains and polypeptides of
the invention, and/or to use proteins or polypeptides comprising or
essentially consisting of one or more of such parts, fragments,
analogs, mutants, variants, alleles and/or derivatives, as long as
these are suitable for the uses envisaged herein. Such parts,
fragments, analogs, mutants, variants, alleles and/or derivatives
will usually contain (at least part of) a functional
antigen-binding site for binding against CXCR7 and in particular
human CXCR7 (SEQ ID NO: 1); and more preferably will be capable of
specific binding to CXCR7 and in particular human CXCR7 (SEQ ID NO:
1), and even more preferably capable of binding to CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1) with an EC50 value, average
Ki, IC.sub.50 value concerning binding, migration, displacing
and/or proliferation blocking and/or other measures for potency, as
further described herein, e.g., in the experimental part) that is
as defined herein and such parts, fragments, analogs, mutants,
variants, alleles and/or derivatives may be more potent, more
stable, more soluble and may have the same epitope. Some
non-limiting examples of such parts, fragments, analogs, mutants,
variants, alleles, derivatives, proteins and/or polypeptides will
become clear from the further description herein. Additional
fragments or polypeptides of the invention may also be provided by
suitably combining (i.e. by linking or genetic fusion) one or more
(smaller) parts or fragments as described herein.
[0171] For a general description of immunoglobulin single variable
domains, reference is made to the further description below, as
well as to the prior art cited herein. In this respect, it should
however be noted that this description and the prior art mainly
describes immunoglobulin single variable domains of the so-called
"V.sub.H3 class" (i.e., immunoglobulin single variable domains with
a high degree of sequence homology to human germline sequences of
the V.sub.H3 class, such as DP-47, DP-51 or DP-29), which form a
preferred aspect of this invention. It should however be noted that
the invention in its broadest sense generally covers any type of
immunoglobulin single variable domains directed against CXCR7 and
in particular human CXCR7 (SEQ ID NO: 1), and for example also
covers the immunoglobulin single variable domains belonging to the
so-called "V.sub.H4 class" (i.e., immunoglobulin single variable
domains with a high degree of sequence homology to human germline
sequences of the V.sub.H4 class such as DP-78), as for example
described in WO 07/118670.
[0172] Generally, immunoglobulin single variable domains (in
particular V.sub.HH sequences and sequence optimized immunoglobulin
single variable domains) can in particular be characterized by the
presence of one or more "Hallmark residues" (as described herein)
in one or more of the framework sequences (again as further
described herein).
[0173] Thus, generally, an immunoglobulin single variable domain
can be defined as an amino acid sequence with the (general)
structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
in which FR1 to FR4 refer to framework regions 1 to 4,
respectively, and in which CDR1 to CDR3 refer to the
complementarity determining regions 1 to 3, respectively.
[0174] In a preferred aspect, the invention provides polypeptides
comprising at least an immunoglobulin single variable domain that
is an amino acid sequence with the (general) structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
in which FR1 to FR4 refer to framework regions 1 to 4,
respectively, and in which CDR1 to CDR3 refer to the
complementarity determining regions 1 to 3, respectively, and in
which: [0175] i) at least one of the amino acid residues at
positions 11, 37, 44, 45, 47, 83, 84, 103, 104 and 108 according to
the Kabat numbering are chosen from the Hallmark residues mentioned
in Table A-1 below; and/or in which: [0176] ii) said amino acid
sequence has at least 80%, more preferably 90%, even more
preferably 95% amino acid identity with at least one of the
immunoglobulin single variable domains as shown in WO 2009/138519
(see SEQ ID NOs: 1 to 125 in WO 2009/138519), in which for the
purposes of determining the degree of amino acid identity, the
amino acid residues that form the CDR sequences (indicated with X
in the sequences) are disregarded; and/or in which: [0177] iii) the
CDR sequences are generally as further defined herein (e.g. the
CDR1, CDR2 and CDR3 in a combination as provided in Table B-2, note
that the CDR definitions are calculated according to the Kabat
numbering system); and/or in which: [0178] iv) the FR sequences are
generally as further defined herein, such as, for instance, the
FR1, FR2, FR3 and FR4 in a combination as provided in Table B-2,
and/or FR1, FR2, FR3 and FR4 has at least 80%, more preferably 90%,
even more preferably 95% amino acid identity with at least one of
FR1, FR2, FR3 and FR4, respectively, of the FRs as provided in
Table B-2 (wherein the FR definitions are calculated according to
the Kabat numbering system).
TABLE-US-00001 [0178] TABLE A-1 Hallmark Residues in VHHs Position
Human V.sub.H3 Hallmark Residues 11 L, V; predominantly L L, S, V,
M, W, F, T, Q, E, A, R, G, K, Y, N, P, I; preferably L 37 V, I, F;
usually V F.sup.(1), Y, V, L, A, H, S, I, W, C, N, G, D, T, P,
preferably F.sup.(1) or Y 44.sup.(8) G E.sup.(3), Q.sup.(3),
G.sup.(2), D, A, K, R, L, P, S, V, H, T, N, W, M, I; preferably
G.sup.(2), E.sup.(3) or Q.sup.(3); most preferably G.sup.(2) or
Q.sup.(3). 45.sup.(8) L L.sup.(2), R.sup.(3), P, H, F, G, Q, S, E,
T, Y, C, I, D, V; preferably L.sup.(2) or R.sup.(3) 47.sup.(8) W, Y
F.sup.(1), L.sup.(1) or W.sup.(2) G, I, S, A, V, M, R, Y, E, P, T,
C, H, K, Q, N, D; preferably W.sup.(2), L.sup.(1) or F.sup.(1) 83 R
or K; usually R R, K.sup.(5), T, E.sup.(5), Q, N, S, I, V, G, M, L,
A, D, Y, H; preferably K or R; most preferably K 84 A, T, D;
P.sup.(5), S, H, L, A, V, I, T, F, D, R, Y, N, Q, G, E; preferably
P predominantly A 103 W W.sup.(4), R.sup.(6), G, S, K, A, M, Y, L,
F, T, N, V, Q, P.sup.(6), E, C; preferably W 104 G G, A, S, T, D,
P, N, E, C, L; preferably G 108 L, M or T; Q, L.sup.(7), R, P, E,
K, S, T, M, A, H; preferably Q or L.sup.(7) predominantly L
.sup.(1)In particular, but not exclusively, in combination with
KERE or KQRE at positions 43-46. .sup.(2)Usually as GLEW at
positions 44-47. .sup.(3)Usually as KERE or KQRE at positions
43-46, e.g. as KEREL, KEREF, KQREL, KQREF, KEREG, KQREW or KQREG at
positions 43-47. Alternatively, also sequences such as TERE (for
example TEREL), TQRE (for example TQREL), KECE (for example KECEL
or KECER), KQCE (for example KQCEL), RERE (for example REREG), RQRE
(for example RQREL, RQREF or RQREW), QERE (for example QEREG),
QQRE, (for example QQREW, QQREL or QQREF), KGRE (for example
KGREG), KDRE (for example KDREV) are possible. Some other possible,
but less preferred sequences include for example DECKL and NVCEL.
.sup.(4)With both GLEW at positions 44-47 and KERE or KQRE at
positions 43-46. .sup.(5)Often as KP or EP at positions 83-84 of
naturally occurring V.sub.HH domains. .sup.(6)In particular, but
not exclusively, in combination with GLEW at positions 44-47.
.sup.(7)With the proviso that when positions 44-47 are GLEW,
position 108 is always Q in (non-humanized) V.sub.HH sequences that
also contain a W at 103. .sup.(8)The GLEW group also contains
GLEW-like sequences at positions 44-47, such as for example GVEW,
EPEW, GLER, DQEW, DLEW, GIEW, ELEW, GPEW, EWLP, GPER, GLER and
ELEW.
[0179] Again, such immunoglobulin single variable domains may be
derived in any suitable manner and from any suitable source, and
may for example be naturally occurring V.sub.HH sequences (i.e.,
from a suitable species of Camelid, e.g., llama) or synthetic or
semi-synthetic VHs or VLs (e.g., from human), Such immunoglobulin
single variable domains may include "humanized" or otherwise
"sequence optimized" VHHs, "camelized" immunoglobulin sequences
(and in particular camelized heavy chain variable domain sequences,
i.e., camelized VHs), as well as human VHs, human VLs, camelid VHHs
that have been altered by techniques such as affinity maturation
(for example, starting from synthetic, random or naturally
occurring immunoglobulin sequences), CDR grafting, veneering,
combining fragments derived from different immunoglobulin
sequences, PCR assembly using overlapping primers, and similar
techniques for engineering immunoglobulin sequences well known to
the skilled person; or any suitable combination of any of the
foregoing as further described herein.
[0180] In a further preferred aspect, the invention provides
polypeptides comprising one immunoglobulin single variable domain
with amino acid sequence selected from the group consisting of
amino acid sequences with SEQ ID NOs: 39 to 43 and 91 as well as
99-102 (see Table B-3) and one immunoglobulin single variable
domain with amino acid sequence selected from the group consisting
of moieties providing an increased half-life (see below).
[0181] In a further preferred aspect, the invention provides
polypeptides comprising at least one immunoglobulin single variable
domain with amino acid sequence selected from the group consisting
of amino acid sequences that essentially consist of 4 framework
regions (FR1 to FR4, respectively) and 3 complementarity
determining regions (CDR1 to CDR3, respectively), in which the CDR
sequences of said amino acid sequences have at least 70% amino acid
identity, preferably at least 80% amino acid identity, more
preferably at least 90% amino acid identity, such as 95% amino acid
identity or more or even essentially 100% amino acid identity with
the CDR sequences of at least one of the immunoglobulin single
variable domains of SEQ ID NOs: 39 to 43 and 91 as well as 99-102
(see Tables B-2 and 8-3). This degree of amino acid identity can
for example be determined by determining the degree of amino acid
identity (in a manner described herein) between said amino acid
sequence and one or more of the sequences of SEQ ID NOs: 39 to 43
and 91 as well as 99-102 (see Tables 8-2 and 8-3), in which the
amino acid residues that form the framework regions are
disregarded. Such polypeptides and/or immunoglobulin single
variable domains of the invention may further provide the
following: [0182] 1. polypeptides comprising at least one
immunoglobulin single variable domain that is directed against (as
defined herein) CXCR7 and in particular human CXCR7 (SEQ ID NO: 1)
and that has at least 80%, preferably at least 85%, such as 90% or
95% or more sequence identity with at least one of the
immunoglobulin single variable domains of SEQ ID NOs: 39 to 43 and
91 as well as 99-102 (see Table B-3); [0183] 2. polypeptides
comprising at least one immunoglobulin single variable domain that
is directed against (as defined herein) CXCR7 and in particular
human CXCR7 (SEQ ID NO: 1) and that cross-block (as defined herein)
the binding of at least one of the immunoglobulin single variable
domains of SEQ ID NOs: 39 to 43 and 91 as well as 99-102 (see Table
B-3) to CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) and/or
that compete with at least one of the immunoglobulin single
variable domains of SEQ ID NOs: 39 to 43 and 91 as well as 99-102
(see Table B-3) for binding to CXCR7 and in particular human CXCR7
(SEQ ID NO: 1); and [0184] 3. which immunoglobulin single variable
domains may be as further described herein; as well as polypeptides
of the invention that comprise one or more of such immunoglobulin
single variable domains (which may be as further described herein,
and may for example be bispecific (e.g., also bind to serum
albumin) and/or biparatopic polypeptides as described herein), and
nucleic acid sequences that encode such immunoglobulin single
variable domains and polypeptides. Such immunoglobulin single
variable domains and polypeptides do not include any naturally
occurring ligands.
[0185] The polypeptides of the invention comprise or essentially
consist of at least one immunoglobulin single variable domain of
the invention. Some preferred, but non-limiting examples of
immunoglobulin single variable domains of the invention are given
in SEQ ID NOs: 39 to 43 and 91 as well as 99-102 (see Table
B-3).
1.2. Serum Albumin Binding Building Blocks or Other Building Blocks
Increasing Half-Life
[0186] In another aspect, the invention relates to a compound or
construct, and in particular to a protein or polypeptide (also
referred to herein as a "compound of the invention" or "polypeptide
of the invention", respectively) that comprises or essentially
consists of one or more (preferably one) immunoglobulin single
variable domains directed to human CXCR7 (or suitable fragments
thereof), and optionally further comprises one or more other
groups, residues, moieties or binding units. As will become clear
to the skilled person from the further disclosure herein, such
further groups, residues, moieties, binding units or immunoglobulin
single variable domains may or may not provide further
functionality to the amino acid sequence of the invention (and/or
to the compound or construct in which it is present) and may or may
not modify the properties of the amino acid sequence of the
invention.
[0187] As will be clear from the further description above and
herein, this means that the immunoglobulin single variable domains
of the invention can be used as "building blocks" to form
polypeptides of the invention, i.e. by suitably combining them with
other groups, residues, moieties or binding units, in order to form
compounds or constructs as described herein (such as, without
limitations, the biparatopic, bi/multivalent and bi/multispecific
polypeptides of the invention described herein) which combine
within one molecule one or more desired properties or biological
functions.
[0188] The compounds or polypeptides of the invention can generally
be prepared by a method which comprises at least one step of
suitably linking the one or more immunoglobulin single variable
domains of the invention to the one or more further groups,
residues, moieties or binding units, optionally via the one or more
suitable linkers, so as to provide the compound or polypeptide of
the invention. Polypeptides of the invention can also be prepared
by a method which generally comprises at least the steps of
providing a nucleic acid that encodes a polypeptide of the
invention, expressing said nucleic acid in a suitable manner, and
recovering the expressed polypeptide of the invention. Such methods
can be performed in a manner known per se, which will be clear to
the skilled person, for example on the basis of the methods and
techniques further described herein.
[0189] The process of designing/selecting and/or preparing a
compound or polypeptide of the invention, starting from an amino
acid sequence of the invention, is also referred to herein as
"formatting" said amino acid sequence of the invention; and an
amino acid of the invention that is made part of a compound or
polypeptide of the invention is said to be "formatted" or to be "in
the format of" said compound or polypeptide of the invention.
Examples of ways in which an amino acid sequence of the invention
can be formatted and examples of such formats will be clear to the
skilled person based on the disclosure herein; and such formatted
immunoglobulin single variable domains form a further aspect of the
invention.
[0190] For example, such further groups, residues, moieties or
binding units may be one or more additional immunoglobulin single
variable domains, such that the compound or construct is a (fusion)
protein or (fusion) polypeptide. In a preferred but non-limiting
aspect, said one or more other groups, residues, moieties or
binding units are immunoglobulin sequences. Even more preferably,
said one or more other groups, residues, moieties or binding units
are chosen from the group consisting of domain antibodies,
immunoglobulin single variable domains that are suitable for use as
a domain antibody, single domain antibodies, immunoglobulin single
variable domains that are suitable for use as a single domain
antibody, "dAb's", immunoglobulin single variable domains that are
suitable for use as a dAb, or Nanobodies. Alternatively, such
groups, residues, moieties or binding units may for example be
chemical groups, residues, moieties, which may or may not by
themselves be biologically and/or pharmacologically active. For
example, and without limitation, such groups may be linked to the
one or more immunoglobulin single variable domains of the invention
so as to provide a "derivative" of an amino acid sequence or
polypeptide of the invention, as further described herein.
[0191] Also within the scope of the present invention are compounds
or constructs, that comprises or essentially consists of one or
more derivatives as described herein, and optionally further
comprises one or more other groups, residues, moieties or binding
units, optionally linked via one or more linkers. Preferably, said
one or more other groups, residues, moieties or binding units are
immunoglobulin single variable domains. In the compounds or
constructs described above, the one or more immunoglobulin single
variable domains of the invention and the one or more groups,
residues, moieties or binding units may be linked directly to each
other and/or via one or more suitable linkers or spacers. For
example, when the one or more groups, residues, moieties or binding
units are immunoglobulin single variable domains, the linkers may
also be immunoglobulin single variable domains, so that the
resulting compound or construct is a fusion (protein) or fusion
(polypeptide).
[0192] In one specific, but non-limiting aspect of the invention,
which will be further described herein, the polypeptides of the
invention have an increased half-life in serum (as further
described herein) compared to the immunoglobulin single variable
domain from which they have been derived. For example, an
immunoglobulin single variable domain of the invention may be
linked (chemically or otherwise) to one or more groups or moieties
that extend the half-life (such as PEG), so as to provide a
derivative of an amino acid sequence of the invention with
increased half-life.
[0193] In one specific aspect of the invention, a compound of the
invention or a polypeptide of the invention may have an increased
half-life, compared to the corresponding amino acid sequence of the
invention. Some preferred, but non-limiting examples of such
compounds and polypeptides will become clear to the skilled person
based on the further disclosure herein, and for example comprise
immunoglobulin single variable domains or polypeptides of the
invention that have been chemically modified to increase the
half-life thereof (for example, by means of pegylation);
immunoglobulin single variable domains of the invention that
comprise at least one additional binding site for binding to a
serum protein (such as serum albumin); or polypeptides of the
invention that comprise at least one amino acid sequence of the
invention that is linked to at least one moiety (and in particular
at feast one amino acid sequence) that increases the half-life of
the amino acid sequence of the invention. Examples of polypeptides
of the invention that comprise such half-life extending moieties or
immunoglobulin single variable domains will become clear to the
skilled person based on the further disclosure herein; and for
example include, without limitation, polypeptides in which the one
or more immunoglobulin single variable domains of the invention are
suitably linked to one or more serum proteins or fragments thereof
(such as (human) serum albumin or suitable fragments thereof) or to
one or more binding units that can bind to serum proteins (such as,
for example, domain antibodies, immunoglobulin single variable
domains that are suitable for use as a domain antibody, single
domain antibodies, immunoglobulin single variable domains that are
suitable for use as a single domain antibody, "dAb's",
immunoglobulin single variable domains that are suitable for use as
a dAb, or Nanobodies that can bind to serum proteins such as serum
albumin (such as human serum albumin), serum immunoglobulins such
as IgG, or transferrin; reference is made to the further
description and references mentioned herein); polypeptides in which
an amino acid sequence of the invention is linked to an Fc portion
(such as a human Fc) or a suitable part or fragment thereof; or
polypeptides in which the one or more immunoglobulin single
variable domains of the invention are suitable linked to one or
more small proteins or peptides that can bind to serum proteins
(such as, without limitation, the proteins and peptides described
in WO 91/01743, WO 01/45746, WO 02/076489, WO2008/068280,
WO2009/127691).
[0194] Generally, the compounds or polypeptides of the invention
with increased half-life preferably have a half-life that is at
least 1.5 times, preferably at least 2 times, such as at least 5
times, for example at least 10 times or more than 20 times, greater
than the half-life of the corresponding amino acid sequence of the
invention per se. For example, the compounds or polypeptides of the
invention with increased half-life may have a half-life e.g., in
humans that is increased with more than 1 hours, preferably more
than 2 hours, more preferably more than 6 hours, such as more than
12 hours, or even more than 24, 48 or 72 hours, compared to the
corresponding amino acid sequence of the invention per se.
[0195] In a preferred, but non-limiting aspect of the invention,
such compounds or polypeptides of the invention have a serum
half-life e.g., in humans that is increased with more than 1 hours,
preferably more than 2 hours, more preferably more than 6 hours,
such as more than 12 hours, or even more than 24, 48 or 72 hours,
compared to the corresponding amino acid sequence of the invention
per se.
[0196] In another preferred, but non-limiting aspect of the
invention, such compounds or polypeptides of the invention exhibit
a serum half-life in human of at least about 12 hours, preferably
at least 24 hours, more preferably at least 48 hours, even more
preferably at least 72 hours or more. For example, compounds or
polypeptides of the invention may have a half-life of at least 5
days (such as about 5 to 10 days), preferably at least 9 days (such
as about 9 to 14 days), more preferably at least about 10 days
(such as about 10 to 15 days), or at least about 11 days (such as
about 11 to 16 days), more preferably at least about 12 days (such
as about 12 to 18 days or more), or more than 14 days (such as
about 14 to 19 days).
[0197] In a particular preferred but non-limiting aspect of the
invention, the invention provides a polypeptide of the invention
comprising i) one CXCR7 binding immunoglobulin single variable
domain as described herein; and ii) one or more (preferably one)
serum albumin binding immunoglobulin single variable domain as
described herein.
[0198] In a further preferred aspect, the invention provides a
polypeptide of the invention comprising i) one or more CXCR7
binding immunoglobulin single variable domain as described herein;
and ii) one or more (preferably one) serum albumin binding
immunoglobulin single variable domain of SEQ ID NO: 2 (Table
B-1).
[0199] In a further preferred aspect, the invention provides a
polypeptide of the invention comprising i) one or more CXCR7
binding immunoglobulin single variable domain as described herein;
and ii) one or more (preferably one) serum albumin binding
immunoglobulin single variable domain with CDRs (defined according
to the Kabat numbering) of SEQ ID NO: 2 (Table B-2, B-1).
[0200] Thus, for example, further reference (and thus incorporated
by reference) is made in particular to the experimental part and
further description of WO2008/068280, wherein further details on
SEQ ID NO: 2 is made and e.g., the half-life of a immunoglobulin
single variable domain construct containing said sequence in rhesus
monkeys is disclosed.
[0201] Generally, proteins or polypeptides that comprise or
essentially consist of a single immunoglobulin single variable
domain will be referred to herein as "monovalent" proteins or
polypeptides or as "monovalent constructs". Proteins and
polypeptides that comprise or essentially consist of two or more
immunoglobulin single variable domains (such as at least two
immunoglobulin single variable domains of the invention or at least
one immunoglobulin single variable domain of the invention and at
least one other immunoglobulin single variable domain) will be
referred to herein as "multivalent" proteins or polypeptides or as
"multivalent constructs", and these may provide certain advantages
compared to the corresponding monovalent immunoglobulin single
variable domains of the invention. Some non-limiting examples of
such multivalent constructs will become clear from the further
description herein.
[0202] According to another specific, but non-limiting aspect, a
polypeptide of the invention comprises or essentially consists of
at least one immunoglobulin single variable domain of the invention
and at least one other binding unit (i.e. directed against another
epitope, antigen, target, protein or polypeptide), which is
preferably also a immunoglobulin single variable domain. Such
proteins or polypeptides are also referred to herein as
"multispecific" proteins or polypeptides or as "multispecific
constructs", and these may comprise of two immunoglobulin single
variable domains of the invention, such as one immunoglobulin
single variable domain directed against CXCR7 and one
immunoglobulin single variable domain against serum albumin. Such
multispecific constructs will be clear to the skilled person based
on the disclosure herein; some preferred, but non-limiting examples
of such multispecific immunoglobulin single variable domains are
the constructs of SEQ NOs: 44 to 48, 80-81, 83-85 and 88-89 as well
as 131-140 (see Table B-4), as well as clones 009, 013, 018-029,
031-038, 044, 046, 048-053, 055-058, 060, 061, 063, 065, 068, 069,
072, 081-086 and 093 (Tables B-12 to 8-14).
[0203] According to yet another specific, but non-limiting aspect,
a polypeptide of the invention comprises or essentially consists of
at least one immunoglobulin single variable domain of the
invention, optionally one or more further immunoglobulin single
variable domains, and at least one other amino acid sequence (such
as a protein or polypeptide) that confers at least one desired
property to the immunoglobulin single variable domain of the
invention and/or to the resulting fusion protein. Again, such
fusion proteins may provide certain advantages compared to the
corresponding monovalent immunoglobulin single variable domains of
the invention such as e.g. may provide an increased half-life.
[0204] In the above constructs, the one or more immunoglobulin
single variable domains and/or other immunoglobulin single variable
domains may be directly linked to each other and/or suitably linked
to each other via one or more linker sequences. Some suitable but
non-limiting examples of such linkers will become clear from the
further description herein.
[0205] In one embodiment, the linker sequence joining the
immunoglobulin single variable domains are SEQ ID NOs: 49 to
58--see Table B-5, or a combination of both, or as known in the
art.
[0206] According to yet another specific, but non-limiting aspect,
a polypeptide of the invention may for example be chosen from the
group consisting of immunoglobulin single variable domains that
have more than 80%, preferably more than 90%, more preferably more
than 95%, such as 99% or more "sequence identity" (as defined
herein) with one or more of the immunoglobulin single variable
domains of SEQ ID NOs: 39 to 43 and 91 as well as 99-102 (see Table
B-3), in which the polypeptides are preferably as further defined
herein, i.e., in the preferred format of one immunoglobulin single
variable domain directed against CXCR7 and one immunoglobulin singe
variable domain directed against serum albumin.
[0207] According to yet another specific, but non-limiting aspect,
a polypeptide of the invention may for example be chosen from the
group consisting of polypeptides that have more than 80%,
preferably more than 90%, more preferably more than 95%, such as
99% or more "sequence identity" (as defined herein) with one or
more of the polypeptides of SEQ ID NOs: 44 to 48 (see Table B-4).
Some illustrative non-limiting examples of biparatopic and
bispecific polypeptides of the invention are given in SEQ ID NOs:
78 to 89 as well as SEQ ID NOs: 131-140, or clones 009, 013,
018-029, 031-038, 044, 046, 048-053, 055-058, 060, 061, 063, 065,
068, 069, 072, 081-086 and 093 (Tables B-12 to B-14).
13. Compositions of the Invention
[0208] Generally, for pharmaceutical use, the polypeptides of the
invention may be formulated as a pharmaceutical preparation or
composition comprising at least one polypeptide of the invention
and at least one pharmaceutically acceptable carrier, diluent or
excipient and/or adjuvant, and optionally one or more further
pharmaceutically active polypeptides and/or compounds. By means of
non-limiting examples, such a formulation may be in a form suitable
for oral administration, for parenteral administration (such as by
intravenous, intramuscular or subcutaneous injection or intravenous
infusion), for topical administration, for administration by
inhalation, by a skin patch, by an implant, by a suppository, etc.
wherein which the parenteral administration is preferred. Such
suitable administration forms--which may be solid, semi-solid or
liquid, depending on the manner of administration--as well as
methods and carriers for use in the preparation thereof, will be
clear to the skilled person, and are further described herein. Such
a pharmaceutical preparation or composition will generally be
referred to herein as a "pharmaceutical composition". A
pharmaceutical preparation or composition for use in a non-human
organism will generally be referred to herein as a "veterinary
composition".
[0209] Thus, in a further aspect, the invention relates to a
pharmaceutical composition that contains at least one amino acid of
the invention, at least one polypeptide of the invention or at
least one polypeptide of the invention and at least one suitable
carrier, diluent or excipient (i.e., suitable for pharmaceutical
use), and optionally one or more further active substances.
[0210] Generally, the polypeptides of the invention can be
formulated and administered in any suitable manner known per se.
Reference is for example made to the general background an cited
above (and in particular to WO 04/041862, WO 04/041863, WO
04/041865, WO 04/041867 and WO 08/020,079) as well as to the
standard handbooks, such as Remington's Pharmaceutical Sciences,
18.sup.th Ed., Mack Publishing Company, USA (1990), Remington, the
Science and Practice of Pharmacy, 21th Edition, Lippincott Williams
and Wilkins (2005); or the Handbook of Therapeutic Antibodies (S.
Dubel, Ed.), Wiley, Weinheim, 2007 (see for example pages
252-255).
[0211] The polypeptides of the invention may be formulated and
administered in any manner known per se for conventional antibodies
and antibody fragments (including ScFv's and diabodies) and other
pharmaceutically active proteins. Such formulations and methods for
preparing the same will be clear to the skilled person, and for
example include preparations suitable for parenteral administration
(for example intravenous, intraperitoneal, subcutaneous,
intramuscular, intraluminal, intra-arterial or intrathecal
administration) or for topical transdermal or intradermal)
administration.
[0212] Preparations for parenteral administration may for example
be sterile solutions, suspensions, dispersions or emulsions that
are suitable for infusion or injection. Suitable carriers or
diluents for such preparations for example include, without
limitation, those mentioned on page 143 of WO 08/020079. In one
embodiment, the preparation is an aqueous solution or
suspension.
[0213] The polypeptides of the invention can be administered using
gene therapy methods of delivery. See, e.g., U.S. Pat. No.
5,399,346, which is incorporated by reference for its gene therapy
delivery methods. Using a gene therapy method of delivery, primary
cells transfected with the gene encoding an amino acid sequence,
polypeptide of the invention can additionally be transfected with
tissue specific promoters to target specific organs, tissue,
grafts, tumors, or cells and can additionally be transfected with
signal and stabilization sequences for subcellularly localized
expression.
[0214] Thus, the polypeptides of the invention may be systemically
administered, e.g., orally, in combination with a pharmaceutically
acceptable vehicle such as an inert diluent or an assimilable
edible carrier. They may be enclosed in hard or soft shell gelatin
capsules, may be compressed into tablets, or may be incorporated
directly with the food of the patient's diet. For oral therapeutic
administration, the polypeptides of the invention may be combined
with one or more excipients and used in the form of ingestible
tablets, buccal tablets, troches, capsules, elixirs, suspensions,
syrups, wafers, and the like. Such compositions and preparations
should contain at least 0.1% of the polypeptide of the invention.
Their percentage in the compositions and preparations may, of
course, be varied and may conveniently be between about 2 to about
60% of the weight of a given unit dosage form. The amount of the
polypeptide of the invention in such therapeutically useful
compositions is such that an effective dosage level will be
obtained.
[0215] For local administration at the site of tumor resection, the
polypeptides of the invention may be used in biodegradable
polymeric drug delivery systems, slow release
poly(lactic-co-glycolic acid formulations and the like (Hart et
al., Cochrane Database Syst Rev. 2008 Jul. 16; (3): CD007294).
[0216] In a further preferred aspect of the invention, the
polypeptides of the invention, such as a polypeptide consisting
essentially of one monovalent anti-human CXCR7 immunoglobulin
single variable domain and of one monovalent anti-human serum
albumin immunoglobulin single variable domain linked by a GS
linker, may have a beneficial distribution and kinetics profile in
solid tumors compared to conventional antibodies such as e.g.,
IgG.
[0217] The tablets, troches, pills, capsules, and the like may also
contain binders, excipients, disintegrating agents, lubricants and
sweetening or flavoring agents, for example those mentioned on
pages 143-144 of WO 08/020079. When the unit dosage form is a
capsule, it may contain, in addition to materials of the above
type, a liquid carrier, such as a vegetable oil or a polyethylene
glycol. Various other materials may be present as coatings or to
otherwise modify the physical form of the solid unit dosage form.
For instance, tablets, pills, or capsules may be coated with
gelatin, wax, shellac or sugar and the like. A syrup or elixir may
contain the polypeptides of the invention, sucrose or fructose as a
sweetening agent, methyl and propylparabens as preservatives, a dye
and flavoring such as cherry or orange flavor. Of course, any
material used in preparing any unit dosage form should be
pharmaceutically acceptable and substantially non-toxic in the
amounts employed. In addition, the polypeptides of the invention
may be incorporated into sustained-release preparations and
devices.
[0218] Preparations and formulations for oral administration may
also be provided with an enteric coating that will allow the
constructs of the invention to resist the gastric environment and
pass into the intestines. More generally, preparations and
formulations for oral administration may be suitably formulated for
delivery into any desired part of the gastrointestinal tract. In
addition, suitable suppositories may be used for delivery into the
gastrointestinal tract.
[0219] The polypeptides of the invention may also be administered
intravenously or intraperitoneally by infusion or injection.
Particular examples are as further described on pages 144 and 145
of WO 08/020079.
[0220] For topical administration, the polypeptides of the
invention may be applied in pure form, i.e., when they are liquids.
However, it will generally be desirable to administer them to the
skin as compositions or formulations, in combination with a
dermatologically acceptable carrier, which may be a solid or a
liquid. Particular examples are as further described on page 145 of
WO 08/020079.
[0221] Generally, the concentration of the polypeptides of the
invention in a liquid composition, such as a lotion, will be from
about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The
concentration in a semi-solid or solid composition such as a gel or
a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5
wt-%.
[0222] The amount of the polypeptides of the invention required for
use in treatment will vary not only with the particular polypeptide
selected but also with the route of administration, the nature of
the condition being treated and the age and condition of the
patient and will be ultimately at the discretion of the attendant
physician or clinician. Also the dosage of the polypeptides of the
invention varies depending on the target cell, tumor, tissue,
graft, or organ.
[0223] The desired dose may conveniently be presented in a single
dose or as divided doses administered at appropriate intervals, for
example, as two, three, four or more sub-doses per day. The
sub-dose itself may be further divided, e.g., into a number of
discrete loosely spaced administrations.
[0224] An administration regimen could include long-term, daily
treatment. By "long-term" is meant at least two weeks and
preferably, several weeks, months, or years of duration. Necessary
modifications in this dosage range may be determined by one of
ordinary skill in the art using only routine experimentation given
the teachings herein. See Remington's Pharmaceutical Sciences
(Martin, E. W., ed. 4), Mack Publishing Co., Easton, Pa. The dosage
can also be adjusted by the individual physician in the event of
any complication.
[0225] In another aspect, the invention relates to a method for the
prevention and/or treatment of at least one diseases and disorders
associated with CXCR7, said method comprising administering, to a
subject in need thereof, a pharmaceutically active amount of a
polypeptide of the invention, and/or of a pharmaceutical
composition comprising the same.
[0226] In the context of the present invention, the term
"prevention and/or treatment" not only comprises preventing and/or
treating the disease, but also generally comprises preventing the
onset of the disease, slowing or reversing the progress of disease,
preventing or slowing the onset of one or more symptoms associated
with the disease, reducing and/or alleviating one or more symptoms
associated with the disease, reducing the severity and/or the
duration of the disease and/or of any symptoms associated therewith
and/or preventing a further increase in the severity of the disease
and/or of any symptoms associated therewith, preventing, reducing
or reversing any physiological damage caused by the disease, and
generally any pharmacological action that is beneficial to the
patient being treated.
[0227] The subject to be treated may be any warm-blooded animal,
but is in particular a mammal, and more in particular a human
being. As will be clear to the skilled person, the subject to be
treated will in particular be a person suffering from, or at risk
of, the diseases and disorders mentioned herein.
[0228] The invention relates to a method for the prevention and/or
treatment of at least one disease or disorder that is associated
with CXCR7, with its biological or pharmacological activity, and/or
with the biological pathways or signaling in which CXCR7 is
involved, said method comprising administering, to a subject in
need thereof, a pharmaceutically active amount of an amino acid
sequence of the invention, of a Polypeptide of the invention, of a
polypeptide of the invention, and/or of a pharmaceutical
composition comprising the same. In one embodiment, the invention
relates to a method for the prevention and/or treatment of at least
one disease or disorder that can be treated by modulating CXCR7,
its biological or pharmacological activity, and/or the biological
pathways or signaling in which CXCR7 is involved, said method
comprising administering, to a subject in need thereof, a
pharmaceutically active amount of a polypeptide of the invention,
and/or of a pharmaceutical composition comprising the same. In one
embodiment, said pharmaceutically effective amount may be an amount
that is sufficient to modulate CXCR7, its biological or
pharmacological activity, and/or the biological pathways or
signaling in which CXCR7 is involved; and/or an amount that
provides a level of the polypeptide of the invention in the
circulation that is sufficient to modulate CXCR7, its biological or
pharmacological activity, and/or the biological pathways or
signaling in which CXCR7 is involved.
[0229] In one embodiment the invention relates to a method for the
prevention and/or treatment of at least one disease or disorder
that can be prevented and/or treated by administering a polypeptide
of the invention, or a nucleotide construct of the invention
encoding the same, and/or of a pharmaceutical composition
comprising the same, to a patient. In one embodiment, the method
comprises administering a pharmaceutically active amount of a
polypeptide of the invention, or a nucleotide construct of the
invention encoding the same, and/or of a pharmaceutical composition
comprising the same to a subject in need thereof.
[0230] In one embodiment the invention relates to a method for the
prevention and/or treatment of at least one disease or disorder
that can be prevented and/or treated by inhibiting binding of
CXCL12 and/or CXCL11 to CXCR7 in specific cells or in a specific
tissue of a subject to be treated (and in particular, by inhibiting
binding of CXCL12 and/or CXCL11 to CXCR7 in cancer cells or in a
tumor present in the subject to be treated), said method comprising
administering a pharmaceutically active amount of a polypeptide of
the invention, or a nucleotide construct of the invention encoding
the same, and/or of a pharmaceutical composition comprising the
same, to a subject in need thereof.
[0231] In one embodiment, the invention relates to a method for the
prevention and/or treatment of at least one disease or disorder
chosen from the group consisting of the diseases and disorders
listed herein, said method comprising administering, to a subject
in need thereof, a polypeptide of the invention, or a nucleotide
construct of the invention encoding the same, and/or of a
pharmaceutical composition comprising the same.
[0232] In one embodiment, the invention relates to a method for
immunotherapy, and in particular for passive immunotherapy, which
method comprises administering, to a subject suffering from or at
risk of the diseases and disorders mentioned herein, a
pharmaceutically active amount of a polypeptide of the invention,
or a nucleotide construct of the invention encoding the same,
and/or of a pharmaceutical composition comprising the same.
[0233] In the above methods, the amino acid sequences, polypeptides
of the invention and/or the compositions comprising the same can be
administered in any suitable manner, depending on the specific
pharmaceutical formulation or composition to be used. Thus, the
polypeptides of the invention and/or the compositions comprising
the same can for example be administered orally, intraperitoneally
(e.g. intravenously, subcutaneously, intramuscularly, or via any
other route of administration that circumvents the gastrointestinal
tract), intranasally, transdermally, topically, by means of a
suppository, by inhalation, again depending on the specific
pharmaceutical formulation or composition to be used. The clinician
will be able to select a suitable route of administration and a
suitable pharmaceutical formulation or composition to be used in
such administration, depending on the disease or disorder to be
prevented or treated and other factors well known to the
clinician.
[0234] The polypeptides of the invention and/or the compositions
comprising the same are administered according to a regime of
treatment that is suitable for preventing and/or treating the
disease or disorder to be prevented or treated. The clinician will
generally be able to determine a suitable treatment regimen,
depending on factors such as the disease or disorder to be
prevented or treated, the severity of the disease to be treated
and/or the severity of the symptoms thereof, the polypeptide of the
invention to be used, the specific route of administration and
pharmaceutical formulation or composition to be used, the age,
gender, weight, diet, general condition of the patient, and similar
factors well known to the clinician.
[0235] Generally, the treatment regimen will comprise the
administration of one or more polypeptides of the invention, or of
one or more compositions comprising the same, in one or more
pharmaceutically effective amounts or doses. The specific amount(s)
or doses to be administered can be determined by the clinician,
again based on the factors cited above.
[0236] Generally, for the prevention and/or treatment of the
diseases and disorders mentioned herein and depending on the
specific disease or disorder to be treated, the potency of the
specific polypeptide of the invention to be used, the specific
route of administration and the specific pharmaceutical formulation
or composition used, the polypeptides of the invention will
generally be administered in an amount between 1 gram and 0.01
microgram per kg body, weight per day, preferably between 0.1 gram
and 0.1 microgram per kg body weight per day, such as about 1, 10,
100 or 1000 microgram per kg body weight per day, either
continuously (e.g., by infusion), as a single daily dose or as
multiple divided doses during the day. The clinician will generally
be able to determine a suitable daily dose, depending on the
factors mentioned herein. It will also be clear that in specific
cases, the clinician may choose to deviate from these amounts, for
example on the basis of the factors cited above and his expert
judgment. Generally, some guidance on the amounts to be
administered can be obtained from the amounts usually administered
for comparable conventional antibodies or antibody fragments
against the same target administered via essentially the same
route, taking into account however differences in affinity/avidity,
efficacy, biodistribution, half-life and similar factors well known
to the skilled person.
[0237] In one embodiment, a single contiguous polypeptide of the
invention will be used. In one embodiment two or more polypeptides
of the invention are provided in combination.
[0238] The polypeptides of the invention may be used in combination
with one or more further pharmaceutically active compounds or
principles, i.e., as a combined treatment regimen, which may or may
not lead to a synergistic effect. Again, the clinician will be able
to select such further compounds or principles, as well as a
suitable combined treatment regimen, based on the factors cited
above and his expert judgment.
[0239] In particular, the polypeptides of the invention may be used
in combination with other pharmaceutically active compounds or
principles that are or can be used for the prevention and/or
treatment of the diseases and disorders cited herein, as a result
of which a synergistic effect may or may not be obtained. Examples
of such compounds and principles, as well as routes, methods and
pharmaceutical formulations or compositions for administering them
will be clear to the clinician, and generally include the
cytostatic active principles usually applied for the treatment of
the tumor to be treated.
[0240] Specific contemplated combinations for use with the
polypeptides of the invention for oncology include, but are not
limited to, e.g., CXCR4 antagonists such as e.g., AMD3100, other
chemokine receptor antagonists, taxol; gemcitobine; cisplatin; clAP
inhibitors (such as inhibitors to cIAP1, cIAP2 and/or XIAP); MEK
inhibitors including but not limited to, e.g., U0126, PD0325901;
bRaf inhibitors including but not limited to, e.g., RAF265; and
mTOR inhibitors including but not limited to, e.g., RAD001; VEGF
inhibitors including but not limited to e.g. bevacizumab, sutinib
and sorafenib; Her 2 inhibitors including but not limited to e.g.,
trastuzumab and lapatinib; PDGFR, FGFR, src, JAK, STAT and/or GSK3
inhibitors; selective estrogen receptor modulators including but
not limited to tamoxifen; estrogen receptor downregulators
including but not limited to fulvestrant. Specific contemplated
combinations for use with the polypeptides of the invention for
inflammatory conditions include, but are not limited to, e.g.,
interferon beta 1 alpha and beta, natalizumab; TNF alpha
antagonists including but not limited to e.g., infliximab,
adalimumab, certolizumab pegol, etanercept; disease-modifying
antirheumatic drugs such as e.g., methotrexate (MTX);
glucocortioids including but not limited to e.g. hydrocortisone;
Nonsteroidal anti-inflammatory drugs including but not limited to
e.g., ibuprofen, sulindac.
[0241] Other specific compounds/polypeptides that could be used in
combination (therapy) with the compounds/polypeptides of the
invention are the amino acid sequences and polypeptides directed
against CXCR4 that are described in the international application
WO 09/138,519 by Ablynx N.V., the non-prepublished U.S. application
61/358,495 by Ablynx N.V. filed on Jun. 25, 2010; the PCT
application PCT/EP210/064766 by Ablynx N.V. filed on Oct. 4, 2010;
and/or the PCT application PCT/EP2011/050156 by Ablynx N.V. filed
on Jan. 7, 2011.
[0242] When two or more substances or principles are to be used as
part of a combined treatment regimen, they can be administered via
the same route of administration or via different routes of
administration, at essentially the same time or at different times
(e.g., essentially simultaneously, consecutively, or according to
an alternating regime). When the substances or principles are to be
administered simultaneously via the same route of administration,
they may be administered as different pharmaceutical formulations
or compositions or part of a combined pharmaceutical formulation or
composition, as will be clear to the skilled person.
[0243] Also, when two or more active substances or principles are
to be used as part of a combined treatment regimen, each of the
substances or principles may be administered in the same amount and
according to the same regimen as used when the compound or
principle is used on its own, and such combined use may or may not
lead to a synergistic effect. However, when the combined use of the
two or more active substances or principles leads to a synergistic
effect, it may also be possible to reduce the amount of one, more
or all of the substances or principles to be administered, while
still achieving the desired therapeutic action. This may for
example be useful for avoiding, limiting or reducing any unwanted
side-effects that are associated with the use of one or more of the
substances or principles when they are used in their usual amounts,
while still obtaining the desired pharmaceutical or therapeutic
effect.
[0244] The effectiveness of the treatment regimen used according to
the invention may be determined and/or followed in any manner known
per se for the disease or disorder involved, as will be clear to
the clinician. The clinician will also be able, where appropriate
and on a case-by-case basis, to change or modify a particular
treatment regimen, so as to achieve the desired therapeutic effect,
to avoid, limit or reduce unwanted side-effects, and/or to achieve
an appropriate balance between achieving the desired therapeutic
effect on the one hand and avoiding, limiting or reducing undesired
side effects on the other hand.
[0245] Generally, the treatment regimen will be followed until the
desired therapeutic effect is achieved and/or for as long as the
desired therapeutic effect is to be maintained. Again, this can be
determined by the clinician.
[0246] In another aspect, the invention relates to the use of
polypeptide of the invention in the preparation of a pharmaceutical
composition for prevention and/or treatment of at least one of the
diseases and disorders associated with CXCR7; and/or for use in one
or more of the methods of treatment mentioned herein.
[0247] The subject to be treated may be any warm-blooded animal,
but is in particular a mammal, and more in particular a human
being. In veterinary applications, the subject to be treated
includes any animal raised for commercial purposes or kept as a
pet. As will be clear to the skilled person, the subject to be
treated will in particular be a person suffering from, or at risk
of, the diseases and disorders mentioned herein.
[0248] The invention relates to the use of a polypeptide of the
invention, or a nucleotide encoding the same, in the preparation of
a pharmaceutical composition for the prevention and/or treatment of
at least one disease or disorder that can be prevented and/or
treated by administering a polypeptide of the invention, or a
nucleotide encoding the same, and/or a pharmaceutical composition
of the same to a patient.
[0249] More in particular, the invention relates to the use of a
polypeptide of the invention, or a nucleotide encoding the same, in
the preparation of a pharmaceutical composition for the prevention
and/or treatment of diseases and disorders associated with CXCR7,
and in particular for the prevention and treatment of one or more
of the diseases and disorders listed herein.
[0250] Again, in such a pharmaceutical composition, the one or more
polypeptide of the invention, or nucleotide encoding the same,
and/or a pharmaceutical composition of the same, may also be
suitably combined with one or more other active principles, such as
those mentioned herein.
[0251] The invention also relates to a composition (such as,
without limitation, a pharmaceutical composition or preparation as
further described herein) for use, either in vitro (e.g., in an in
vitro or cellular assay) or in vivo (e.g., in an a single cell or
multicellular organism, and in particular in a mammal, and more in
particular in a human being, such as in a human being that is at
risk of or suffers from a disease or disorder of the
invention).
[0252] In the context of the present invention, "modulating" or "to
modulate" generally means reducing or inhibiting the activity of
CXCR7 and in particular human CXCR7 (SEQ ID NO: 1), as measured
using a suitable in vitro, cellular or in vivo assay (such as those
mentioned herein). In particular, reducing or inhibiting the
activity of CXCR7 and in particular human CXCR7 (SEQ ID NO: 1), as
measured using a suitable in vitro, cellular or in vivo assay (such
as those mentioned herein), by at least 1%, preferably at least 5%,
such as at least 10% or at least 25%, for example by at least 50%,
at least 60%, at least 70%, at least 80%, or 90% or more, compared
to activity of CXCR7 and in particular human CXCR7 (SEQ ID NO: 1)
in the same assay under the same conditions but without the
presence of the polypeptide of the invention.
[0253] Modulating may for example involve reducing or inhibiting
the binding CXCR7 to one of its substrates or ligands and/or
competing with natural ligands (CXCL11 and/or CXCL12), substrate
for binding to CXCR7.
1.4, Generation of the Polypeptides of the Invention
[0254] The invention further relates to methods for preparing or
generating the immunoglobulin single variable domains,
polypeptides, nucleic acids, host cells, products and compositions
described herein. Some preferred but non-limiting examples of such
methods will become clear from the further description herein.
[0255] Generally, these methods may comprise the steps of: [0256]
a) providing a set, collection or library of immunoglobulin single
variable domains; and [0257] b) screening said set, collection or
library of immunoglobulin single variable domains for
immunoglobulin single variable domains that can bind to and/or have
affinity for CXCR7 and in particular human CXCR7 (SEQ ID NO: 1);
and [0258] c) isolating the amino acid sequence(s) that can bind to
and/or have affinity for CXCR7 and in particular human CXCR7 (SEQ
ID NO: 1).
[0259] In such a method, the set, collection or library of
immunoglobulin single variable domains may be any suitable set,
collection or library of immunoglobulin single variable domains.
For example, the set, collection or library of immunoglobulin
single variable domains may be a set, collection or library of
immunoglobulin sequences (as described herein), such as a naive
set, collection or library of immunoglobulin sequences; a synthetic
or semi-synthetic set, collection or library of immunoglobulin
sequences; and/or a set, collection or library of immunoglobulin
sequences that have been subjected to affinity maturation.
[0260] Also, in such a method, the set, collection or library of
immunoglobulin single variable domains may be a set, collection or
library of heavy or light chain variable domains (such as VL-, VH-
or VHH domains). For example, the set, collection or library of
immunoglobulin single variable domains may be a set, collection or
library of domain antibodies or single domain antibodies, or may be
a set, collection or library of immunoglobulin single variable
domains that are capable of functioning as a domain antibody or
single domain antibody.
[0261] In a preferred aspect of this method, the set, collection or
library of immunoglobulin single variable domains may be an immune
set, collection or library of immunoglobulin sequences, for example
derived from a mammal that has been suitably immunized with CXCR7
and in particular human CXCR7 (SEQ ID NO: 1) or with a suitable
antigenic determinant based thereon or derived therefrom, such as
an antigenic part, fragment, region, domain, loop or other epitope
thereof. In one particular aspect, said antigenic determinant may
be an extracellular part, region, domain, loop or other
extracellular epitope(s).
[0262] In the above methods, the set, collection or library of
immunoglobulin single variable domains may be displayed on a phage,
phagemid, ribosome or suitable micro-organism (such as yeast), such
as to facilitate screening. Suitable methods, techniques and host
organisms for displaying and screening (a set, collection or
library of) immunoglobulin single variable domains will be clear to
the person skilled in the art, for example on the basis of the
further disclosure herein. Reference is also made to the review by
Hoogenboom in Nature Biotechnology, 23, 9, 1105-1116 (2005).
[0263] In another aspect, the method for generating immunoglobulin
single variable domains comprises at least the steps of: [0264] a)
providing a collection or sample of cells expressing immunoglobulin
single variable domains; [0265] b) screening said collection or
sample of cells for cells that express an amino acid sequence that
can bind to and/or have affinity for CXCR7 and in particular human
CXCR7 (SEQ ID NO: 1); and [0266] c) either (i) isolating said amino
acid sequence; or (ii) isolating from said cell a nucleic acid
sequence that encodes said amino acid sequence, followed by
expressing said amino acid sequence.
[0267] In another aspect, the method for generating an amino acid
sequence directed against CXCR7 and in particular human CXCR7 (SEQ
ID NO: 1) may comprise at least the steps of: [0268] a) providing a
set, collection or library of nucleic acid sequences encoding
immunoglobulin single variable domains; [0269] b) screening said
set, collection or library of nucleic acid sequences for nucleic
acid sequences that encode an amino acid sequence that can bind to
and/or has affinity for CXCR7 and in particular human CXCR7 (SEQ ID
NO: 1); and [0270] c) isolating said nucleic acid sequence,
followed by expressing said amino acid sequence.
[0271] In such a method, the set, collection or library of nucleic
acid sequences encoding immunoglobulin single variable domains may
for example be a set, collection or library of nucleic acid
sequences encoding a naive set, collection or library of
immunoglobulin sequences; a set, collection or library of nucleic
acid sequences encoding a synthetic or semi-synthetic set,
collection or library of immunoglobulin sequences; and/or a set,
collection or library of nucleic acid sequences encoding a set,
collection or library of immunoglobulin sequences that have been
subjected to affinity maturation.
[0272] In another aspect, the method for generating an amino acid
sequence directed against CXCR7 and in particular human CXCR7 (SEQ
ID NO: 1) may comprise at least the steps of: [0273] a) providing a
set, collection or library of nucleic acid sequences encoding
immunoglobulin single variable domains; [0274] b) screening said
set, collection or library of nucleic acid sequences for nucleic
acid sequences that encode an amino acid sequence that can bind to
and/or has affinity for CXCR7 and in particular human CXCR7 (SEQ ID
NO: 1) and that is cross-blocked or is cross blocking a
immunoglobulin single variable domain or polypeptide of the
invention, e.g., SEQ ID NOs: 39 to 43, 91 or 99-102 (Table B-3);
and [0275] c) isolating said nucleic acid sequence, followed by
expressing said amino acid sequence.
[0276] The invention also relates to immunoglobulin single variable
domains that are obtained by the above methods, or alternatively by
a method that comprises the one of the above methods and in
addition at least the steps of determining the nucleotide sequence
or amino acid sequence of said immunoglobulin sequence; and of
expressing or synthesizing said amino acid sequence in a manner
known per se, such as by expression in a suitable host cell or host
organism or by chemical synthesis.
[0277] Also, following the steps above, one or more immunoglobulin
single variable domains of the invention may be suitably humanized,
camelized or otherwise sequence optimized (e.g. sequence optimized
for manufacturability, stability and/or solubility); and/or the
amino acid sequence(s) thus obtained may be linked to each other or
to one or more other suitable immunoglobulin single variable
domains (optionally via one or more suitable linkers) so as to
provide a polypeptide of the invention. Also, a nucleic acid
sequence encoding an amino acid sequence of the invention may be
suitably humanized, camelized or otherwise sequence optimized
(e.g., sequence optimized for manufacturability, stability and/or
solubility) and suitably expressed; and/or one or more nucleic acid
sequences encoding an amino acid sequence of the invention may be
linked to each other or to one or more nucleic acid sequences that
encode other suitable immunoglobulin single variable domains
(optionally via nucleotide sequences that encode one or more
suitable linkers), after which the nucleotide sequence thus
obtained may be suitably expressed so as to provide a polypeptide
of the invention.
[0278] The invention further relates to applications and uses of
the immunoglobulin single variable domains, compounds, constructs,
polypeptides, nucleic acids, host cells, products and compositions
described herein, as well as to methods for the diagnosis,
prevention and/or treatment for diseases and disorders associated
with CXCR7 and in particular human CXCR7 (SEQ ID NO: 1). Some
preferred but non-limiting applications and uses will become clear
from the further description herein.
[0279] The invention also relates to the immunoglobulin single
variable domains, compounds, constructs, polypeptides, nucleic
acids, host cells, products and compositions described herein for
use in therapy.
[0280] In particular, the invention also relates to the
immunoglobulin single variable domains, compounds, constructs,
polypeptides, nucleic acids, host cells, products and compositions
described herein for use in therapy of a disease or disorder that
can be prevented or treated by administering, to a subject in need
thereof, of (a pharmaceutically effective amount of) an amino acid
sequence, compound, construct or polypeptide as described
herein.
[0281] More in particular, the invention relates to the
immunoglobulin single variable domains, compounds, constructs,
polypeptides, nucleic acids, host cells, products and compositions
described herein for use in therapy of cancer.
1.5. Variants of Polypeptides and Immunoglobulin Single Variable
Domains of the Invention
[0282] Polypeptides of the invention and immunoglobulin single
variable domains (that form part of the polypeptides of the
invention) may be altered in order to further improve potency or
other desired properties.
[0283] Generally, an immunoglobulin single variable domain can be
defined as a polypeptide with the formula 1:
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
in which FR1 to FR4 refer to framework regions 1 to 4,
respectively, and in which CDR1 to CDR3 refer to the
complementarity determining regions 1 to 3, respectively.
[0284] Some particularly preferred, but non-limiting combinations
of CDR sequences, as well as preferred combinations of CDR
sequences and framework sequences, are mentioned in Table B-2,
which lists the CDR sequences and framework sequences that are
present in a number of preferred (but non-limiting) Immunoglobulin
single variable domains of the invention. As will be clear to the
skilled person, a combination of CDR1, CDR2 and CDR3 sequences that
occur in the same clone (i.e. CDR1, CDR2 and CDR3 sequences that
are mentioned on the same line or row in Table B-2) will usually be
preferred (although the invention in its broadest sense is not
limited thereto, and also comprises other suitable combinations of
the CDR sequences mentioned in Table B-2). Also, a combination of
CDR sequences and framework sequences that occur in the same clone
(i.e., CDR sequences and framework sequences that are mentioned on
the same line or row in Table B-2) will usually be preferred
(although the invention in its broadest sense is not limited
thereto, and also comprises other suitable combinations of the CDR
sequences and framework sequences mentioned in Table B-2, as well
as combinations of such CDR sequences and other suitable framework
sequences, e.g., as further described herein).
[0285] Also, in the immunoglobulin single variable domains of the
invention that comprise the combinations of CDR's mentioned in
Table B-2, each CDR can be replaced by a CDR chosen from the group
consisting of immunoglobulin single variable domains that have at
least 80%, preferably at least 90%, more preferably at least 95%,
even more preferably at least 99% sequence identity (as defined
herein) with the mentioned CDR's; in which: [0286] i) any amino
acid substitution in such a CDR is preferably, and compared to the
corresponding CDR sequence mentioned in Table 13-2, a conservative
amino acid substitution (as defined herein); and/or [0287] ii) any
such CDR sequence preferably only contains amino acid
substitutions, and no amino acid deletions or insertions, compared
to the corresponding CDR sequence mentioned in Table B-2; and/or
[0288] iii) any such CDR sequence is a CDR that is derived by means
of a technique for affinity maturation known per se, and in
particular starting from the corresponding CDR sequence mentioned
in Table B-2.
[0289] However, as will be clear to the skilled person, the
(combinations of) CDR sequences, as well as (the combinations of)
CDR sequences and framework sequences mentioned in Table B-2 will
generally be preferred.
[0290] Thus, in the immunoglobulin single variable domains of the
invention, at least one of the CDR1, CDR2 and CDR3 sequences
present is suitably chosen from the group consisting of the CDR1,
CDR2 and CDR3 sequences, respectively, listed in Table B-2; or from
the group of CDR1, CDR2 and CDR3 sequences, respectively, that have
at least 80%, preferably at least 90%, more preferably at least
95%, even more preferably at least 99% "sequence identity" (as
defined herein) with at least one of the CDR1, CDR2 and CDR3
sequences, respectively, listed in Table B-2; and/or from the group
consisting of the CDR1, CDR2 and CDR3 sequences, respectively, that
have 3, 2 or only 1 "amino acid difference(s)" (as defined herein)
with at least one of the CDR1, CDR2 and CDR3 sequences,
respectively, listed in Table B-2.
[0291] In this context, by "suitably chosen" is meant that, as
applicable, a CDR1 sequence is chosen from suitable CDR1 sequences
(i.e. as defined herein), a CDR2 sequence is chosen from suitable
CDR2 sequences (i.e. as defined herein), and a CDR3 sequence is
chosen from suitable CDR3 sequence (i.e. as defined herein),
respectively. More in particular, the CDR sequences are preferably
chosen such that the Nanobodies of the invention bind to CXCR7 and
in particular human CXCR7 (SEQ ID NO: 1) with an affinity (suitably
measured and/or expressed as a EC50 value, or alternatively as an
IC.sub.50 value, as further described herein in various in vitro
and/or in vivo potency or other assays) that is as defined
herein.
[0292] In particular, in the immunoglobulin single variable domains
of the invention, at least the CDR3 sequence present is suitably
chosen from the group consisting of the CDR3 sequences listed in
Table B-2 or from the group of CDR3 sequences that have at least
80%, preferably at least 90%, more preferably at least 95%, even
more preferably at least 99% sequence identity with at least one of
the CDR3 sequences listed in Table B-2; and/or from the group
consisting of the CDR3 sequences that have 3, 2 or only 1 amino
acid difference(s) with at least one of the CDR3 sequences listed
in Table B-2.
[0293] Preferably, in the immunoglobulin single variable domains of
the invention, at least two of the CDR1, CDR2 and CDR3 sequences
present are suitably chosen from the group consisting of the CDR1,
CDR2 and CDR3 sequences, respectively, listed in Table B-2 or from
the group consisting of CDR1, CDR2 and CDR3 sequences,
respectively, that have at least 80%, preferably at least 90%, more
preferably at least 95%, even more preferably at least 99% sequence
identity with at least one of the CDR1, CDR2 and CDR3 sequences,
respectively, listed in Table B-2; and/or from the group consisting
of the CDR1, CDR2 and CDR3 sequences, respectively, that have 3, 2
or only 1 "amino acid difference(s)" with at least one of the CDR1,
CDR2 and CDR3 sequences, respectively, listed in Table B-2.
[0294] In particular, in the immunoglobulin single variable domains
of the invention, at least the CDR3 sequence present is suitably
chosen from the group consisting of the CDR3 sequences listed in
Table B-2 or from the group of CDR3 sequences that have at least
80%, preferably at least 90%, more preferably at least 95%, even
more preferably at least 99% sequence identity with at least one of
the CDR3 sequences listed in Table B-2, respectively; and at least
one of the CDR1 and CDR2 sequences present is suitably chosen from
the group consisting of the CDR1 and CDR2 sequences, respectively,
listed in Table B-2 or from the group of CDR1 and CDR2 sequences,
respectively, that have at least 80%, preferably at least 90%, more
preferably at least 95%, even more preferably at least 99% sequence
identity with at least one of the CDR1 and CDR2 sequences,
respectively, listed in Table B-2; and/or from the group consisting
of the CDR1 and CDR2 sequences, respectively, that have 3, 2 or
only 1 amino acid difference(s) with at least one of the CDR1 and
CDR2 sequences, respectively, listed in Table B-2.
[0295] Most preferably, in the immunoglobulin single variable
domains of the invention, all three CDR1, CDR2 and CDR3 sequences
present are suitably chosen from the group consisting of the CDR1,
CDR2 and CDR3 sequences, respectively, listed in Table B-2 or from
the group of CDR1, CDR2 and CDR3 sequences, respectively, that have
at least 80%, preferably at least 90%, more preferably at least
95%, even more preferably at least 99% sequence identity with at
least one of the CDR1, CDR2 and CDR3 sequences, respectively,
listed in Table B-2; and/or from the group consisting of the CDR1,
CDR2 and CDR3 sequences, respectively, that have 3, 2 or only 1
amino acid difference(s) with at least one of the CDR1, CDR2 and
CDR3 sequences, respectively, listed in Table B-2.
[0296] Even more preferably, in the immunoglobulin single variable
domains of the invention, at least one of the CDR1, CDR2 and CDR3
sequences present is suitably chosen from the group consisting of
the CDR1, CDR2 and CDR3 sequences, respectively, listed in Table
B-2. Preferably, in this aspect, at least one or preferably both of
the other two CDR sequences present are suitably chosen from CDR
sequences that have at least 80%, preferably at least 90%, more
preferably at least 95%, even more preferably at least 99% sequence
identity with at least one of the corresponding CDR sequences,
respectively, listed in Table B-2; and/or from the group consisting
of the CDR sequences that have 3, 2 or only 1 amino acid
difference(s) with at least one of the corresponding sequences,
respectively, listed in Table B-2.
[0297] In particular, in the immunoglobulin single variable domains
of the invention, at least the CDR3 sequence present is suitably
chosen from the group consisting of the CDR3 listed in Table B-2.
Preferably, in this aspect, at least one and preferably both of the
CDR1 and CDR2 sequences present are suitably chosen from the groups
of CDR1 and CDR2 sequences, respectively, that have at least 80%,
preferably at least 90%, more preferably at least 95%, even more
preferably at least 99% sequence identity with the CDR1 and CDR2
sequences, respectively, listed in Table B-2; and/or from the group
consisting of the CDR1 and CDR2 sequences, respectively, that have
3, 2 or only 1 amino acid difference(s) with at least one of the
CDR1 and CDR2 sequences, respectively, listed in Table B-2.
[0298] Even more preferably, in the immunoglobulin single variable
domains of the invention, at least two of the CDR1, CDR2 and CDR3
sequences present are suitably chosen from the group consisting of
the CDR1, CDR2 and CDR3 sequences, respectively, listed in Table
B-2. Preferably, in this aspect, the remaining CDR sequence present
is suitably chosen from the group of CDR sequences that have at
least 80%, preferably at least 90%, more preferably at least 95%,
even more preferably at least 99% sequence identity with at least
one of the corresponding CDR sequences listed in Table B-2; and/or
from the group consisting of CDR sequences that have 3, 2 or only 1
amino acid difference(s) with at least one of the corresponding
sequences listed in Table B-2.
[0299] In particular, in the immunoglobulin single variable domains
of the invention, at least the CDR3 sequence is suitably chosen
from the group consisting of the CDR3 sequences listed in Table
B-2, and either the CDR1 sequence or the CDR2 sequence is suitably
chosen from the group consisting of the CDR1 and CDR2 sequences,
respectively, listed in Table B-2. Preferably, in this aspect, the
remaining CDR sequence present is suitably chosen from the group of
CDR sequences that have at least 80%, preferably at least 90%, more
preferably at least 95%, even more preferably at least 99% sequence
identity with at least one of the corresponding CDR sequences
listed in Table B-2; and/or from the group consisting of CDR
sequences that have 3, 2 or only 1 amino acid difference(s) with
the corresponding CDR sequences listed in Table B-2.
[0300] Even more preferably, in the immunoglobulin single variable
domains of the invention, all three CDR1, CDR2 and CDR3 sequences
present are suitably chosen from the group consisting of the CDR1,
CDR2 and CDR3 sequences, respectively, listed in Table B-2.
[0301] Also, generally, the combinations of CDR's listed in Table
B-2 (i.e., those mentioned on the same line or row in Table B-2)
are preferred. Thus, it is generally preferred that, when a CDR in
a immunoglobulin single variable domain of the invention is a CDR
sequence mentioned in Table B-2 or is suitably chosen from the
group of CDR sequences that have at least 80%, preferably at least
90%, more preferably at least 95%, even more preferably at least
99% sequence identity with a CDR sequence listed in Table B-2;
and/or from the group consisting of CDR sequences that have 3, 2 or
only 1 amino acid difference(s) with a CDR sequence listed in Table
B-2, that at least one and preferably both of the other CDR's are
suitably chosen from the CDR sequences that belong to the same
combination in Table B-2 (i.e., mentioned on the same line or row
in Table B-2) or are suitably chosen from the group of CDR
sequences that have at least 80%, preferably at least 90%, more
preferably at least 95%, even more preferably at least 99% sequence
identity with the CDR sequence(s) belonging to the same combination
and/or from the group consisting of CDR sequences that have 3, 2 or
only 1 amino acid difference(s) with the CDR sequence(s) belonging
to the same combination. The other preferences indicated in the
above paragraphs also apply to the combinations of CDR's mentioned
in Table 13-2.
[0302] Thus, by means of non-limiting examples, a polypeptide of
the invention can for example comprise a CDR1 sequence that has
more than 80% sequence identity with one of the CDR1 sequences
mentioned in Table B-2, a CDR2 sequence that has 3, 2 or 1 amino
acid difference with one of the CDR2 sequences mentioned in Table
B-2 (but belonging to a different combination), and a CDR3
sequence.
[0303] Some preferred immunoglobulin single variable domains of the
invention may for example comprise: (1) a CDR1 sequence that has
more than 80% sequence identity with one of the CDR1 sequences
mentioned in Table B-2; a CDR2 sequence that has 3, 2 or 1 amino
acid difference with one of the CDR2 sequences mentioned in Table
B-2 (but belonging to a different combination); and a CDR3 sequence
that has more than 80% sequence identity with one of the CDR3
sequences mentioned in Table B-2 (but belonging to a different
combination); or (2) a CDR1 sequence that has more than 80%
sequence identity with one of the CDR1 sequences mentioned in Table
6-2; a CDR2 sequence, and one of the CDR3 sequences listed in Table
B-2; or (3) a CDR1 sequence; a CDR2 sequence that has more than 80%
sequence identity with one of the CDR2 sequence listed in Table
B-2; and a CDR3 sequence that has 3, 2 or 1 amino acid differences
with the CDR3 sequence mentioned in Table B-2 that belongs to the
same combination as the CDR2 sequence.
[0304] Some particularly preferred immunoglobulin single variable
domains of the invention may for example comprise: (1) a CDR1
sequence that has more than 80% sequence identity with one of the
CDR1 sequences mentioned in Table B-2; a CDR2 sequence that has 3,
2 or 1 amino acid difference with the CDR2 sequence mentioned in
Table B-2 that belongs to the same combination; and a CDR3 sequence
that has more than 80% sequence identity with the CDR3 sequence
mentioned in Table B-2 that belongs to the same combination; (2) a
CDR1 sequence; a CDR2 listed in Table B-2 and a CDR3 sequence
listed in Table B-2 (in which the CDR2 sequence and CDR3 sequence
may belong to different combinations).
[0305] Some even more preferred immunoglobulin single variable
domains of the invention may for example comprise: (1) a CDR1
sequence that has more than 80% sequence identity with one of the
CDR1 sequences mentioned in Table B-2; the CDR2 sequence listed in
Table B-2 that belongs to the same combination; and a CDR3 sequence
mentioned in Table B-2 that belongs to a different combination; or
(2) a CDR1 sequence mentioned in Table B-2; a CDR2 sequence that
has 3, 2 or 1 amino acid differences with the CDR2 sequence
mentioned in Table B-2 that belongs to the same combination; and a
CDR3 sequence that has more than 80% sequence identity with the
CDR3 sequence listed in Table B-2 that belongs to the same or a
different combination.
[0306] Particularly preferred immunoglobulin single variable
domains of the invention may for example comprise a CDR1 sequence
mentioned in Table 6-2, a CDR2 sequence that has more than 80%
sequence identity with the CDR2 sequence mentioned in Table B-2
that belongs to the same combination; and the CDR3 sequence
mentioned in Table B-2 that belongs to the same combination.
[0307] In the most preferred immunoglobulin single variable domains
of the invention, the CDR1, CDR2 and CDR3 sequences present are
suitably chosen from one of the combinations of CDR1, CDR2 and CDR3
sequences, respectively, listed in Table B-2.
[0308] According to another preferred, but non-limiting aspect of
the invention (a) CDR1 has a length of between 1 and 12 amino acid
residues, and usually between 2 and 9 amino acid residues, such as
5, 6 or 7 amino acid residues; and/or (b) CDR2 has a length of
between 13 and 24 amino acid residues, and usually between 15 and
21 amino acid residues, such as 16 and 17 amino acid residues;
and/or (c) CDR3 has a length of between 2 and 35 amino acid
residues, and usually between 3 and 30 amino acid residues, such as
between 6 and 23 amino acid residues.
[0309] In another preferred, but non-limiting aspect, the invention
relates to a immunoglobulin single variable domain in which the CDR
sequences (as defined herein) have more than 80%, preferably more
than 90%, more preferably more than 95%, such as 99% or more
sequence identity (as defined herein) with the CDR sequences of at
least one of the immunoglobulin single variable domains of SEQ ID
NOs: 39 to 43 or 91 as well as 99-102 (see Table B-3).
[0310] Another preferred, but non-limiting aspect of the invention
relates to humanized variants of the immunoglobulin single variable
domains of SEQ ID NOs: 39 to 43 and 91 as well as 99-102 (see Table
B-3), that comprise, compared to the corresponding native V.sub.HH
sequence, at least one humanizing substitution (as defined herein),
and in particular at least one humanizing substitution in at least
one of its framework sequences (as defined herein).
[0311] It will be clear to the skilled person that the
immunoglobulin single variable domains that are mentioned herein as
"preferred" (or "more preferred", "even more preferred", etc.) are
also preferred (or more preferred, or even more preferred, etc.)
for use in the polypeptides described herein. Thus, polypeptides
that comprise or essentially consist of one or more "preferred"
immunoglobulin single variable domains of the invention will
generally be preferred, and polypeptides that comprise or
essentially consist of one or more "more preferred" immunoglobulin
single variable domains of the invention will generally be more
preferred, etc.
1.6. Nucleotides, Host Cells of the Invention
[0312] Another aspect of this invention relates to a nucleic acid
that encodes an amino acid sequence of the invention (such as an
immunoglobulin single variable domain of the invention) or a
polypeptide of the invention comprising the same. Again, as
generally described herein for the nucleic acids of the invention,
such a nucleic acid may be in the form of a genetic construct, as
defined herein. Specific embodiments of this aspect of the
invention are provided in Table B-6, SEQ ID NOs: 59 to 63 and 73 to
77.
[0313] In another preferred, but non-limiting aspect, the invention
relates to nucleic acid sequences of immunoglobulin single variable
domain in which the sequences (as defined herein) have more than
80%, preferably more than 90%, more preferably more than 95%, such
as 99% or more sequence identity (as defined herein) with the
sequences of at least one of nucleic acid sequence of the
immunoglobulin single variable domains of SEQ ID NOs: 59 to 63 and
73 to 77 (see Table B-6).
[0314] In another aspect, the invention relates to nucleic acid
sequences that comprise the nucleic acid sequences of
immunoglobulin single variable domain in which the sequences (as
defined herein) have more than 80%, preferably more than 90%, more
preferably more than 95%, such as 99% or more sequence identity (as
defined herein) with the sequences of at least one of nucleic acid
sequence of the immunoglobulin single variable domains of SEQ ID
NOs: 59 to 63 and 73 to 77 (see Table B-6).
[0315] In another aspect, the invention relates to host or host
cell that expresses or that is capable of expressing an amino acid
sequence (such as an immunoglobulin single variable domain) of the
invention and/or a polypeptide of the invention comprising the
same; and/or that contains a nucleic acid of the invention. Some
preferred but non-limiting examples of such hosts or host cells
will become clear from the further description herein.
[0316] As will be clear to the skilled person, one particularly
useful method for preparing a polypeptide of the invention
generally comprises the steps of: [0317] i) the expression, in a
suitable host cell or host organism (also referred to herein as a
"host of the invention") or in another suitable expression system
of a nucleic acid that encodes said amino acid sequence,
polypeptide of the invention (also referred to herein as a "nucleic
acid of the invention"), optionally followed by: [0318] ii)
isolating and/or purifying the polypeptide of the invention thus
obtained.
[0319] In particular, such a method may comprise the steps of:
[0320] i) cultivating and/or maintaining a host of the invention
under conditions that are such that said host of the invention
expresses and/or produces at least one polypeptide of the
invention; optionally followed by: [0321] ii) isolating and/or
purifying the polypeptide of the invention thus obtained.
[0322] A nucleic acid of the invention can be in the form of single
or double stranded DNA or RNA, and is preferably in the form of
double stranded DNA. For example, the nucleotide sequences of the
invention may be genomic DNA, cDNA or synthetic DNA (such as DNA
with a codon usage that has been specifically adapted for
expression in the intended host cell or host organism).
[0323] According to one aspect of the invention, the nucleic acid
of the invention is in essentially isolated from, as defined
herein.
[0324] The nucleic acid of the invention may also be in the form
of, be present in and/or be part of a vector, such as for example a
plasmid, cosmid or YAC, which again may be in essentially isolated
form.
[0325] The nucleic acids of the invention can be prepared or
obtained in a manner known per se, based on the information on the
immunoglobulin single variable domains for the polypeptides of the
invention given herein, and/or can be isolated from a suitable
natural source. To provide analogs, nucleotide sequences encoding
naturally occurring V.sub.HH domains can for example be subjected
to site-directed mutagenesis, so at to provide a nucleic acid of
the invention encoding said analog. Also, as will be clear to the
skilled person, to prepare a nucleic acid of the invention, also
several nucleotide sequences, such as at least one nucleotide
sequence encoding a polypeptide of the invention and for example
nucleic acids encoding one or more linkers can be linked together
in a suitable manner.
[0326] Techniques for generating the nucleic acids of the invention
will be clear to the skilled person and may for instance include,
but are not limited to, automated DNA synthesis; site-directed
mutagenesis; combining two or more naturally occurring and/or
synthetic sequences (or two or more parts thereof), introduction of
mutations that lead to the expression of a truncated expression
product; introduction of one or more restriction sites (e.g. to
create cassettes and/or regions that may easily be digested and/or
ligated using suitable restriction enzymes), and/or the
introduction of mutations by means of a PCR reaction using one or
more "mismatched" primers, using for example a sequence of a
naturally occurring form of CXCR7 and in particular human CXCR7
(SEQ ID NO: 1) as a template. These and other techniques will be
clear to the skilled person, and reference is again made to the
standard handbooks, such as Sambrook et al. and Ausubel et al.,
mentioned above, as well as the Examples below.
[0327] The nucleic acid of the invention may also be in the form
of, be present in and/or be part of a genetic construct, as will be
clear to the person skilled in the art and as described on pages
131-134 of WO 08/020079 (incorporated herein by reference). Such
genetic constructs generally comprise at least one nucleic acid of
the invention that is optionally linked to one or more elements of
genetic constructs known per se, such as for example one or more
suitable regulatory elements (such as a suitable promoter(s),
enhancer(s), terminator(s), etc.) and the further elements of
genetic constructs referred to herein. Such genetic constructs
comprising at least one nucleic acid of the invention will also be
referred to herein as "genetic constructs of the invention".
[0328] The genetic constructs of the invention may be DNA or RNA,
and are preferably double-stranded DNA. The genetic constructs of
the invention may also be in a form suitable for transformation of
the intended host cell or host organism, in a form suitable for
integration into the genomic DNA of the intended host cell or in a
form suitable for independent replication, maintenance and/or
inheritance in the intended host organism. For instance, the
genetic constructs of the invention may be in the form of a vector,
such as for example a plasmid, cosmid, YAC, a viral vector or
transposon. particular, the vector may be an expression vector,
i.e., a vector that can provide for expression in vitro and/or in
vivo (e.g., in a suitable host cell, host organism and/or
expression system).
[0329] In a preferred but non-limiting aspect, a genetic construct
of the invention comprises [0330] i) at least one nucleic acid of
the invention; operably connected to [0331] ii) one or more
regulatory elements, such as a promoter and optionally a suitable
terminator; and, optionally, [0332] iii) one or more further
elements of genetic constructs known per se; in which the terms
"operably connected" and "operably linked" have the meaning given
on pages 131-134 of WO 08/020079; and in which the "regulatory
elements", "promoter", "terminator" and "further elements" are as
described on pages 131-134 of WO 08/020079; and in which the
genetic constructs may further be as described on pages 131-134 of
WO 08/020079.
[0333] The nucleic acids of the invention and/or the genetic
constructs of the invention may be used to transform a host cell or
host organism, i.e., for expression and/or production of the
polypeptide of the invention. Suitable hosts or host cells will be
clear to the skilled person, and may for example be any suitable
fungal, prokaryotic or eukaryotic cell or cell line or any suitable
fungal, prokaryotic or eukaryotic organism, for example those
described on pages 134 and 135 of WO 08/020079.; as well as all
other hosts or host cells known per se for the expression and
production of antibodies and antibody fragments (including but not
limited to (single) domain antibodies and ScFv fragments), which
will be clear to the skilled person. Reference is also made to the
general background art cited hereinabove, as well as to for example
WO 94/29457; WO 96/34103; WO 99/42077.
[0334] The immunoglobulin single variable domains, and polypeptides
of the invention can for example also be produced in the milk of
transgenic mammals, for example in the milk of rabbits, cows, goats
or sheep (see for example U.S. Pat. No. 6,741,957, U.S. Pat. No.
6,304,489 and U.S. Pat. No. 6,849,992 for general techniques for
introducing transgenes into mammals), in plants or parts of plants
including but not limited to their leaves, flowers, fruits, seed,
roots or turbers (for example in tobacco, maize, soybean or
alfalfa) or in for example pupae of the silkworm Bombix mori.
[0335] Furthermore, the immunoglobulin single variable domains, and
polypeptides of the invention can also be expressed and/or produced
in cell-free expression systems, and suitable examples of such
systems will be clear to the skilled person. Some preferred, but
non-limiting examples include expression in the wheat germ system;
in rabbit reticulocyte lysates; or in the E. coli Zubay system.
[0336] As mentioned above, one of the advantages of the use of
immunoglobulin single variable domains is that the polypeptides
based thereon can be prepared through expression in a suitable
bacterial system, and suitable bacterial expression systems,
vectors, host cells, regulatory elements, etc., will be clear to
the skilled person, for example from the references cited above. It
should however be noted that the invention in its broadest sense is
not limited to expression in bacterial systems.
[0337] Preferably, in the invention, an (in vivo or in vitro)
expression system, such as a bacterial expression system, is used
that provides the polypeptides of the invention in a form that is
suitable for pharmaceutical use, and such expression systems will
again be clear to the skilled person. As also will be clear to the
skilled person, polypeptides of the invention suitable for
pharmaceutical use can be prepared using techniques for peptide
synthesis.
[0338] For production on industrial scale, preferred heterologous
hosts for the (industrial) production of immunoglobulin single
variable domains or immunoglobulin single variable
domain-containing protein therapeutics include strains of E. coli,
Pichia pastoris, S. cerevisiae that are suitable for large scale
expression/production/fermentation, and in particular for large
scale pharmaceutical GMP grade) expression/production/fermentation.
Suitable examples of such strains will be clear to the skilled
person. Such strains and production/expression systems are also
made available by companies such as Richter Helm (Hamburg, Germany)
or CMC Biologics (Soeborg, Denmark).
[0339] Alternatively, mammalian cell lines, in particular Chinese
hamster ovary (CHO) cells, can be used for large scale
expression/production/fermentation, and in particular for large
scale pharmaceutical expression/production/fermentation. Again,
such expression/production systems are also made available by some
of the companies mentioned above.
[0340] The choice of the specific expression system would depend in
part on the requirement for certain post-translational
modifications, more specifically glycosylation. The production of a
immunoglobulin single variable domain-containing recombinant
protein for which glycosylation is desired or required would
necessitate the use of mammalian expression hosts that have the
ability to glycosylate the expressed protein. In this respect, it
will be clear to the skilled person that the glycosylation pattern
obtained (i.e., the nature of the saccharide, number and position
of residues attached) will depend on the cell or cell line that is
used for the expression. Preferably, either a human cell or cell
line is used (i.e., leading to a protein that essentially has a
human glycosylation pattern) or another mammalian cell line is used
that can provide a glycosylation pattern that is essentially and/or
functionally the same as human glycosylation or at least mimics
human glycosylation. Generally, prokaryotic hosts such as E. coli
do not have the ability to glycosylate proteins, and the use of
lower eukaryotes such as yeast usually leads to a glycosylation
pattern that differs from human glycosylation. Nevertheless, it
should be understood that all the foregoing host cells and
expression systems can be used in the invention, depending on the
desired polypeptide to be obtained.
[0341] Thus, according to one non-limiting aspect of the invention,
the polypeptide of the invention is glycosylated. According to
another non-limiting aspect of the invention, the polypeptide of
the invention is non-glycosylated.
[0342] According to one preferred, but non-limiting aspect of the
invention, the polypeptide of the invention is produced in a
bacterial cell, in particular a bacterial cell suitable for large
scale pharmaceutical production, such as cells of the strains
mentioned above.
[0343] According to another preferred, but non-limiting aspect of
the invention, the polypeptide of the invention is produced in a
yeast cell, in particular a yeast cell suitable for large scale
pharmaceutical production, such as cells of the species mentioned
above.
[0344] According to yet another preferred, but non-limiting aspect
of the invention, the polypeptide of the invention is produced in a
mammalian cell, in particular in a human cell or in a cell of a
human cell line, and more in particular in a human cell or in a
cell of a human cell line that is suitable for large scale
pharmaceutical production, such as the cell lines mentioned
hereinabove.
[0345] As further described on pages 138 and 139 of WO 08/020079,
when expression in a host cell is used to produce the
immunoglobulin single variable domains, and the polypeptides of the
invention, the immunoglobulin single variable domains, and
polypeptides of the invention can be produced either
intracellullarly (e.g., in the cytosol, in the periplasma or in
inclusion bodies) and then isolated from the host cells and
optionally further purified; or can be produced extracellularly
(e.g., in the medium in which the host cells are cultured) and then
isolated from the culture medium and optionally further purified.
Thus, according to one non-limiting aspect of the invention, the
polypeptide of the invention is an amino acid sequence, polypeptide
that has been produced intracellularly and that has been isolated
from the host cell, and in particular from a bacterial cell or from
an inclusion body in a bacterial cell. According to another
non-limiting aspect of the invention, the amino acid sequence, or
polypeptide of the invention is an amino acid sequence, or
polypeptide that has been produced extracellularly, and that has
been isolated from the medium in which the host cell is
cultivated.
[0346] Some preferred, but non-limiting promoters for use with
these host cells include those mentioned on pages 139 and 140 of WO
08/020079.
[0347] Some preferred, but non-limiting secretory sequences for use
with these host cells include those mentioned on page 140 of WO
08/020079.
[0348] Suitable techniques for transforming a host or host cell of
the invention will be clear to the skilled person and may depend on
the intended host cell/host organism and the genetic construct to
be used. Reference is again made to the handbooks and patent
applications mentioned above.
[0349] After transformation, a step for detecting and selecting
those host cells or host organisms that have been successfully
transformed with the nucleotide sequence/genetic construct of the
invention may be performed. This may for instance be a selection
step based on a selectable marker present in the genetic construct
of the invention or a step involving the detection of the amino
acid sequence of the invention, e.g., using specific
antibodies.
[0350] The transformed host cell (which may be in the form or a
stable cell line) or host organisms (which may be in the form of a
stable mutant line or strain) form further aspects of the present
invention.
[0351] Preferably, these host cells or host organisms are such that
they express, or are (at least) capable of expressing (e.g., under
suitable conditions), a polypeptide of the invention (and in case
of a host organism: in at least one cell, part, tissue or organ
thereof). The invention also includes further generations, progeny
and/or offspring of the host cell or host organism of the invention
that may for instance be obtained by cell division or by sexual or
asexual reproduction.
[0352] To produce/obtain expression of the immunoglobulin single
variable domains of the invention, the transformed host cell or
transformed host organism may generally be kept, maintained and/or
cultured under conditions such that the (desired) amino acid
sequence, or polypeptide of the invention is expressed/produced.
Suitable conditions will be clear to the skilled person and will
usually depend upon the host cell/host organism used, as well as on
the regulatory elements that control the expression of the
(relevant) nucleotide sequence of the invention. Again, reference
is made to the handbooks and patent applications mentioned above in
the paragraphs on the genetic constructs of the invention.
[0353] Generally, suitable conditions may include the use of a
suitable medium, the presence of a suitable source of food and/or
suitable nutrients, the use of a suitable temperature, and
optionally the presence of a suitable inducing factor or compound
(e.g., when the nucleotide sequences of the invention are under the
control of an inducible promoter); all of which may be selected by
the skilled person. Again, under such conditions, the
immunoglobulin single variable domains of the invention may be
expressed in a constitutive manner, in a transient manner, or only
when suitably induced.
[0354] It will also be clear to the skilled person that the amino
acid sequence, or polypeptide of the invention may (first) be
generated in an immature form (as mentioned above), which may then
be subjected to post-translational modification, depending on the
host cell/host organism used. Also, the amino acid sequence, or
polypeptide of the invention may be glycosylated, again depending
on the host cell/host organism used.
[0355] The amino acid sequence, or polypeptide of the invention may
then be isolated from the host cell/host organism and/or from the
medium in which said host cell or host organism was cultivated,
using protein isolation and/or purification techniques known per
se, such as (preparative) chromatography and/or electrophoresis
techniques, differential precipitation techniques, affinity
techniques (e.g., using a specific, cleavable amino acid sequence
fused with the amino acid sequence, or polypeptide of the
invention) and/or preparative immunological techniques (i.e. using
antibodies against the amino acid sequence to be isolated).
[0356] The entire contents of all of the references (including
literature references, issued patents, published patent
applications, and co-pending patent applications) cited throughout
this application are hereby expressly incorporated by reference, in
particular for the teaching that is referenced hereinabove.
1.7 Modulators of CXCR7
[0357] A number of different screening protocols can be utilized to
identify agents that modulate the level of activity or function of
CXCR7 in cells, particularly in mammalian cells, and especially in
human cells. In general terms, the screening methods involve
screening an agent or a plurality of agents to identify one or more
agents that interacts with (human) CXCR7 (SEQ ID NO:1), for
example, by binding to a CXCR7 or a fragment thereof and preventing
the polypeptides or ISVDs of the invention, such as, for instance,
comprising any one of SEQ ID NOs: 39-48, 78-89, 91, 99-102 or
132-140, from binding to CXCR7 (SEQ ID NO: 1). In some embodiments,
an agent binds CXCR7 with at least about 1.5, 2, 3, 4, 5, 10, 20,
50, 100, 300, 500, or 1000 times the affinity of the agent for
another protein. In some embodiments, the fragment of CXCR7
comprising the epitopes described herein (and optionally comprising
further non-CXCR7 amino acids at the N and/or C termini) is no more
than, e.g., 300, 250, 200, 150, 100, 50, 40, 30, 20 or fewer amino
acids. In some embodiments, the CXCR7 fragment is any fragment
having less than all of the amino acids in the full length_CXCR7
polypeptide.
[0358] In some embodiments, CXCR7 modulators are identified by
screening for molecules that compete with the polypeptide or ISVD
of the invention from binding to a CXCR7 polypeptide, or fragment
thereof. Those of skill in the art will recognize that there are a
number of ways to perform competition analyses, for instance, such
as disclosed herein. In some embodiments, samples with CXCR7 are
pre-incubated with a labeled polypeptides or ISVDs of the
invention, such as, for instance, comprising any one of SEQ ID NOs:
39-48, 78-89, 91, 99-102 or 132-140 and then contacted with a
potential competitor molecule. Alteration (e.g., a decrease) of the
quantity of polypeptide or ISVD bound to CXCR7 in the presence of a
test compound indicates that the test compound is a potential CXCR7
modulator.
1.8 Kits for Use in Diagnostic and/or Prognostic Applications
[0359] For use in the diagnostic, research, and therapeutic
applications suggested above, kits are also provided by the
invention. In the diagnostic and research applications such kits
may include any or all of the following: assay reagents, buffers,
and the anti-CXCR7 polypeptides or ISVDs of the invention. A
therapeutic product may include sterile saline or another
pharmaceutically acceptable emulsion and suspension base.
[0360] In addition, the kits may include instructional materials
containing directions (i.e., protocols) for the practice of the
methods of this invention. While the instructional materials
typically comprise written or printed materials they are not
limited to such. Any medium capable of storing such instructions
and communicating them to an end user is contemplated by this
invention. Such media include, but are not limited to electronic
storage media (e.g., magnetic discs, tapes, cartridges, chips),
optical media (e.g., CD ROM), and the like. Such media may include
addresses to internet sites that provide such instructional
materials.
[0361] The invention will now be further described by means of the
following non-limiting preferred aspects, figures and examples:
Preferred Non-limiting Aspects:
[0362] Aspect A-1: An immunoglobulin single variable domain that is
directed against and/or that can specifically bind to CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1). [0363] Aspect A-2: An
immunoglobulin single variable domain according to aspect A-1, that
is in essentially isolated form. [0364] Aspect A-3: An
immunoglobulin single variable domain according to aspect A-1 or
A-2, for administration to a subject, wherein said immunoglobulin
single variable domain does not naturally occur in said subject.
[0365] Aspect A-4: An immunoglobulin single variable domain that
can specifically bind to CXCR7 and in particular human CXCR7 (SEQ
ID NO: 1) with a dissociation constant (K.sub.D) of 10.sup.-5 to
10.sup.-12 moles/litre or less, and preferably 10.sup.-7 to
10.sup.-12 moles/litre or less and more preferably 10.sup.-8 to
10.sup.-12 moles/litre. Such an immunoglobulin single variable
domain may in particular be an immunoglobulin single variable
domain according to any of the preceding aspects. [0366] Aspect
A-5: An immunoglobulin single variable domain that can specifically
bind to CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) with a
rate of association (k.sub.on-rate) of between 10.sup.2 M.sup.-1
s.sup.-1 to about 10.sup.7 M.sup.-1 s.sup.-1, preferably between
10.sup.3 M.sup.-1 s.sup.-1 and 10.sup.7 M.sup.-1 s.sup.-1, more
preferably between 10.sup.4 M.sup.-1 s.sup.-1 and 10.sup.7 M.sup.-1
s.sup.-1, such as between 10.sup.5 M.sup.-1 s.sup.-1 and 10.sup.7
M.sup.-1 s.sup.-1. Such an immunoglobulin single variable domain
may in particular be an immunoglobulin single variable domain
according to any of the preceding aspects. [0367] Aspect A-6: An
immunoglobulin single variable domain that can specifically bind to
CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) with a rate of
dissociation (k.sub.off rate) between 1 s.sup.-1 and 10.sup.-6
s.sup.-1, preferably between 10.sup.-2 s.sup.-1 and 10.sup.-6
s.sup.-1, more preferably between 10.sup.-3 s.sup.-1 and 10.sup.-6
s.sup.-1, such as between 10.sup.-4 s.sup.-1 and 10.sup.-6
s.sup.-1. Such an immunoglobulin single variable domain may in
particular be an immunoglobulin single variable domain according to
any of the preceding aspects. [0368] Aspect A-7: An immunoglobulin
single variable domain that can specifically bind to CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1) with an affinity less than
500 nM, preferably less than 200 nM, more preferably less than 10
nM, such as less than 500 .mu.M. Such an immunoglobulin single
variable domain may in particular be an immunoglobulin single
variable domain according to any of the preceding aspects. [0369]
Aspect A-8: An immunoglobulin single variable domain that can
specifically displace SDF-1 and/or I-TAC(CXCL11 and/or CXCL12) on
CXCR7 and in particular on human CXCR7 (SEQ ID NO: 1) with an
average Ki of less than 500 nM, preferably less than 200 nM, more
preferably less than 10 nM, such as less than 1 nM and an average
SDF-1 and/or I-TAC displacement of 50% or more, more preferably of
75% or more, even more preferably of 80% or more. Such an average
Ki and/or average displacement value may be determined e.g. in an
assay as described in Example 9 or 10. [0370] Aspect A-9: An
immunoglobulin single variable domain that can specifically
displace SDF-1 and/or I-TAC (CXCL11 and/or CXCL12) on CXCR7 and in
particular on human CXCR7 (SEQ ID NO: 1) with an average Ki of less
than 20 nM and an average SDF-1 and/or I-TAC displacement of 70% or
more. Such an average Ki and/or average displacement value may be
determined e.g. in an assay as described in Example 9 or 10, [0371]
Aspect A-10: An immunoglobulin single variable domain according to
any of the preceding aspects, that essentially consists of 4
framework regions (FR1 to FR4 respectively) and 3 complementarity
determining regions (CDR1 to CDR3 respectively). [0372] Aspect
A-11: An immunoglobulin single variable domain according to any of
the preceding aspects, that is an immunoglobulin sequence. [0373]
Aspect A-12: An immunoglobulin single variable domain according to
any of the preceding aspects, that is a naturally occurring
immunoglobulin sequence (from any suitable species) or a synthetic
or semi-synthetic immunoglobulin sequence. [0374] Aspect A-13: An
immunoglobulin single variable domain according to any of the
preceding aspects that is a humanized immunoglobulin sequence, a
camelized immunoglobulin sequence or an immunoglobulin sequence
that has been obtained by techniques such as affinity maturation.
[0375] Aspect A-14: An immunoglobulin single variable domain
according to any of the preceding aspects, that essentially
consists of a light chain variable domain sequence (e.g., a
VL-sequence); or of a heavy chain variable domain sequence (e.g., a
VH-sequence). [0376] Aspect A-15: An immunoglobulin single variable
domain according to any of the preceding aspects, that essentially
consists of a heavy chain variable domain sequence that is derived
from a conventional four-chain antibody or that essentially consist
of a heavy chain variable domain sequence that is derived from
heavy chain antibody. [0377] Aspect A-16: An immunoglobulin single
variable domain according to any of the preceding aspects, that
essentially consists of a domain antibody (or an immunoglobulin
single variable domain that is suitable for use as a domain
antibody), of a single domain antibody (or an immunoglobulin single
variable domain that is suitable for use as a single domain
antibody), of a "dAb" (or an immunoglobulin single variable domain
that is suitable for use as a dAb) or of a Nanobody (including but
not limited to a VHH sequence). [0378] Aspect A-17: An
immunoglobulin single variable domain according to any of the
preceding aspects, that essentially consists of a Nanobody. [0379]
Aspect A-18: An immunoglobulin single variable domain according to
any of the preceding aspects, that essentially consists of a
Nanobody that [0380] i) has at least 80% amino acid identity with
at least one of the immunoglobulin single variable domains of SEQ
ID NOs: 1 to 22 of WO 2009/138519, in which for the purposes of
determining the degree of amino acid identity, the amino acid
residues that form the CDR sequences are disregarded; [0381] and in
which: [0382] ii) preferably one or more of the amino acid residues
at positions 11, 37, 44, 45, 47, 83, 84, 103, 104 and 108 according
to the Kabat numbering are chosen from the Hallmark residues
mentioned in Table A-1. [0383] Aspect A-19: An immunoglobulin
single variable domain according to any of the preceding aspects,
that essentially consists of an immunoglobulin single variable
domain that [0384] i) has at least 80% amino acid identity with at
least one of the immunoglobulin single variable domains of SEQ ID
NOs: 39 to 43, 91 or 99-102, in which for the purposes of
determining the degree of amino acid identity, the amino acid
residues that form the CDR sequences are disregarded; [0385] and in
which: [0386] ii) preferably one or more of the amino acid residues
at positions 11, 37, 44, 45, 47, 83, 84, 103, 104 and 108 according
to the Kabat numbering are chosen from the Hallmark residues
mentioned in Table A-1. [0387] Aspect A-20: An immunoglobulin
single variable domain according to any of the preceding aspects,
that essentially consists of a polypeptide that comprises of [0388]
i) a first immunoglobulin single variable domain that has at least
80% amino acid identity with an immunoglobulin single variable
domain selected from the group of immunoglobulin single variable
domain having SEQ ID NOs: 39 to 43 91 or 99-102, in which for the
purposes of determining the degree of amino acid identity, the
amino acid residues that form the CDR sequences are disregarded;
and that comprises of [0389] ii) a second immunoglobulin single
variable domain that has at least 80% amino acid identity with the
immunoglobulin single variable domain having SEQ ID NO: 2, in which
for the purposes of determining the degree of amino acid identity,
the amino acid residues that form the CDR sequences are
disregarded; and, optionally, comprises [0390] iii) a linker.
[0391] Aspect A-21: An immunoglobulin single variable domain
according to any of the preceding aspects, that essentially
consists of a humanized or otherwise sequence optimized
immunoglobulin single variable domain. [0392] Aspect A-22: An
immunoglobulin single variable domain according to any of the
preceding aspects, that, in addition to the at least one binding
site for binding against CXCR7 and in particular human CXCR7 (SEQ
ID NO: 1), contains one or more further binding sites for binding
against other antigens, proteins or targets.
CDR-Based Aspects
[0392] [0393] Aspect B-1: An immunoglobulin single variable domain
that is directed against and/or that can specifically bind CXCR7
and in particular human CXCR7 (SEQ ID NO: 1), and that comprises
one or more (preferably one) stretches of amino acid residues
chosen from the group consisting of: [0394] a) the immunoglobulin
single variable domains of SEQ ID NOs: 9 to 13, 93 or 107-110;
[0395] b) immunoglobulin single variable domains that have at least
80% amino acid identity with at least one of the immunoglobulin
single variable domains of SEQ ID NOs 9 to 13, 93 or 107410; [0396]
c) immunoglobulin single variable domains that have 3, 2, or 1
amino acid difference with at least one of the immunoglobulin
single variable domains of SEQ ID NOs: 9 to 13, 93 or 107-110;
[0397] d) the immunoglobulin single variable domains of SEQ ID NOs:
19 to 23, 95, or 115-118; [0398] e) immunoglobulin single variable
domains that have at least 80% amino acid identity with at least
one of the immunoglobulin single variable domains of SEQ ID NOs: 19
to 23, 95, or 115-118; [0399] f) immunoglobulin single variable
domains that have 3, 2, or 1 amino acid difference with at least
one of the immunoglobulin single variable domains of SEQ ID NOs: 19
to 23, 95, or 115-118; [0400] g) the immunoglobulin single variable
domains of SEQ ID NOs: 29 to 33, 97 or 123-126; [0401] h)
immunoglobulin single variable domains that have at least 80% amino
acid identity with at least one of the immunoglobulin single
variable domains of SEQ ID NOs: 29 to 33, 97 or 123-126; [0402] i)
immunoglobulin single variable domains that have 3, 2, or 1 amino
acid difference with at least one of the immunoglobulin single
variable domains of SEQ ID NOs: 29 to 33, 97 or 123-126; [0403] or
any suitable combination thereof. [0404] Such an immunoglobulin
single variable domain may in particular be VHH or sequence
optimized VHH such as humanized, stabilized and/or solubilized
VI-1H. [0405] Aspect B-2: An immunoglobulin single variable domain
according to aspect B-1, in which at least one of said stretches of
amino acid residues forms part of the antigen binding site for
binding against CXCR7 and in particular human CXCR7 (SEQ ID NO: 1).
[0406] Aspect B-3: An immunoglobulin single variable domain
sequence that is directed against and/or that can specifically bind
CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) and that
comprises two or more stretches of amino acid residues chosen from
the group consisting of: [0407] a) the immunoglobulin single
variable domains of SEQ ID NOs: 9 to 13, 93 or 107-110; [0408] b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with at least one of the immunoglobulin single
variable domains of SEQ ID NOs: 9 to 13, 93 or 107-110; [0409] c)
immunoglobulin single variable domains that have 3, 2, or 1 amino
acid difference with at least one of the immunoglobulin single
variable domains of SEQ ID NOs: 9 to 13, 93 or 107-110; [0410] d)
the immunoglobulin single variable domains of SEQ ID NOs: 19 to 23,
95, or 115-118; [0411] e) immunoglobulin single variable domains
that have at least 80% amino acid identity with at least one of the
immunoglobulin single variable domains of SEQ ID NOs: 19 to 23, 95,
or 115-118; [0412] f) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with at least one of the
immunoglobulin single variable domains of SEQ ID NOs: 19 to 23, 95,
or 115-118; [0413] g) the immunoglobulin single variable domains of
SEQ ID NOs: 29 to 33, 97 or 123-126; [0414] h) immunoglobulin
single variable domains that have at least 80% amino acid identity
with at least one of the immunoglobulin single variable domains of
SEQ ID NOs: 29 to 33, 97 or 123-126; [0415] i) immunoglobulin
single variable domains that have 3, 2, or 1 amino acid difference
with at least one of the immunoglobulin single variable domains of
SEQ ID NOs: 29 to 33, 97 or 123-126; [0416] such that (i) when the
first stretch of amino acid residues corresponds to one of the
immunoglobulin single variable domains according to a), b) or c),
the second stretch of amino acid residues corresponds to one of the
immunoglobulin single variable domains according to d), e), f), g),
h) or i); (ii) when the first stretch of amino acid residues
corresponds to one of the immunoglobulin single variable domains
according to d), e) or f), the second stretch of amino acid
residues corresponds to one of the immunoglobulin single variable
domains according to a), b), c), g), h) or i); or (iii) when the
first stretch of amino acid residues corresponds to one of the
immunoglobulin single variable domains according to g), h) or 1),
the second stretch of amino acid residues corresponds to one of the
immunoglobulin single variable domains according to a), b), c), d),
e) or f). [0417] Such an immunoglobulin single variable domain may
in particular be VHH or sequence optimized VHH such as humanized,
stabilized and/or solubilized VHH. [0418] Aspect B-4: An
immunoglobulin single variable domain according to aspect B-3, in
which the at least two stretches of amino acid residues forms part
of the antigen binding site for binding against CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1). [0419] Aspect B-5: An
immunoglobulin single variable domain sequence that is directed
against and/or that can specifically bind CXCR7 and in particular
human CXCR7 (SEQ ID NO: 1) and that comprises three or more
stretches of amino acid residues, in which the first stretch of
amino acid residues is chosen from the group consisting of: [0420]
a) the immunoglobulin single variable domains of SEQ ID NOs: 9 to
13, 93 or 107-110; [0421] b) immunoglobulin single variable domains
that have at least 80% amino acid identity with at least one of the
immunoglobulin single variable domains of SEQ ID NOs: 9 to 13, 93
or 107-110; [0422] c) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with at least one of the
immunoglobulin single variable domains of SEQ ID NOs: 9 to 13, 93
or 107-110; [0423] the second stretch of amino acid residues is
chosen from the group consisting of: [0424] d) the immunoglobulin
single variable domain of SEQ ID NOs: 19 to 23, 95, or 115-118;
[0425] e) immunoglobulin single variable domains that have at least
80% amino acid identity with at least one of the immunoglobulin
single variable domains of SEQ ID NOs: 19 to 23, 95, or 115-118;
[0426] f) immunoglobulin single variable domains that have 3, 2, or
1 amino acid difference with at least one of the immunoglobulin
single variable domains of SEQ ID NOs: 19 to 23, 95, or 115-118;
[0427] and the third stretch of amino acid residues is chosen from
the group consisting of: [0428] g) the immunoglobulin single
variable domains of SEQ ID NOs: 29 to 33, 97 or 123-126; [0429] h)
immunoglobulin single variable domains that have at least 80% amino
acid identity with at least one of the immunoglobulin single
variable domains of SEQ ID NOs: 29 to 33, 97 or 123-126; [0430] i)
immunoglobulin single variable domains that have 3, 2, or 1 amino
acid difference with at least one of the immunoglobulin single
variable domains of SEQ ID NOs: 29 to 33, 97 or 123-126. [0431]
Such an immunoglobulin single variable domain may in particular be
VHH or sequence optimized VHH such as humanized, stabilized and/or
solubilized VHH. [0432] Aspect B-6: An immunoglobulin single
variable domain according to aspect B-5, in which the at least
three stretches of amino acid residues forms part of the antigen
binding site for binding against CXCR7 and in particular human
CXCR7 (SEQ ID NO: 1). [0433] Aspect B-7: An immunoglobulin single
variable domain that is directed against and/or that can
specifically bind CXCR7 and in particular human CXCR7 (SEQ ID NO:
1) in which the CDR sequences of said immunoglobulin single
variable domain have at least 70% amino acid identity, preferably
at least 80% amino acid identity, more preferably at least 90%
amino acid identity, such as 95% amino acid identity or more or
even essentially 100% amino acid identity with the CDR sequences of
at least one of the immunoglobulin single variable domains of SEQ
ID NOs: 39 to 43, 91 or 99-102. The CDR sequences are
preferentially determined via Kabat as defined herein. Such an
immunoglobulin single variable domain may in particular be VHH or
sequence optimized VHH such as humanized, stabilized and/or
solubilized VHH. [0434] Aspect C-1: An immunoglobulin single
variable domain or polypeptide that is directed against CXCR7 and
in particular human CXCR7 (SEQ ID NO: 1) and that cross-blocks the
binding of at least one of the immunoglobulin single variable
domains of SEQ ID NOs: 39 to 43, 91 or 99-102, or polypeptides of
SEQ ID NOs: 44 to 48, 78-89 or 131-140 to CXCR7 and in particular
human CXCR7 (SEQ ID NO: 1). Such an immunoglobulin single variable
domain may in particular be an immunoglobulin single variable
domain according to any of the aspects A-1 to A-22 and/or according
to aspects B-1 to 13-7. Also, preferably, such an immunoglobulin
single variable domain is able to specifically bind to CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1). [0435] Aspect C-2: An
immunoglobulin single variable domain or polypeptide, such as an
antibody or fragment thereof, that is directed against CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1) and that is cross-blocked
from binding to CXCR7 and in particular human CXCR7 (SEQ ID NO: 1)
by at least one of the immunoglobulin single variable domains of
SEQ ID NOs: 39 to 43, 91 or 99-102, or polypeptides of SEQ ID NOs:
44 to 48, 78-89 or 131-140. Such an immunoglobulin single variable
domain may in particular be an immunoglobulin single variable
domain according to any of the aspects A-1 to A-22 and/or according
to aspects B-1 to 8-7. Also, preferably, such an immunoglobulin
single variable domain is able to specifically bind to CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1). [0436] Aspect C-3: An
immunoglobulin single variable domain or polypeptide according to
any of aspects C-1 or C-2, wherein the ability of said
immunoglobulin single variable domain to cross-block or to be
cross-blocked is detected in a displacement assay (e.g., as
described in Examples 9 and/or 10 below). [0437] Aspect C-4: An
immunoglobulin single variable domain or polypeptide according to
any of aspects C-1 to C-3 wherein the ability of said
immunoglobulin single variable domain to cross-block or to be
cross-blocked is detected in an ELISA assay. [0438] Aspect D-1: An
immunoglobulin single variable domain according to any of aspects
B-1 to 8-7 or C-1 to C-7, that is in essentially isolated form.
[0439] Aspect D-2: An immunoglobuiin single variable domain
according to any of aspects B-1 to B-7, C-1 to C-7, and/or 01 for
administration to a subject, wherein said immunoglobulin single
variable domain does not naturally occur in said subject. [0440]
Aspect D-3: An immunoglobulin single variable domain according to
any of aspects B-1 to B-7, C-1 to C-7, and/or D1 to 0-2 that can
specifically bind to CXCR7 and in particular human CXCR7 (SEQ ID
NO: 1) with a dissociation constant (K.sub.D) of 10.sup.-5 to
10.sup.-12 moles/litre or less, and preferably 10.sup.-7 to
10.sup.-12 moles/litre or less and more preferably 10.sup.-8 to
10.sup.-12 moles/litre. [0441] Aspect D-4: An immunoglobulin single
variable domain according to any of aspects B-1 to 8-7, C-1 to C-7,
and/or D-1 to 0-3 that can specifically bind to CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1) with a rate of association
(k.sub.on-rate) of between 10.sup.2 M.sup.-1 s.sup.-1 to about
10.sup.7 M.sup.-1 s.sup.-1, preferably between 10.sup.3 M.sup.-1
s.sup.-1 and 10.sup.7 M.sup.-1 s.sup.-1, more preferably between
10.sup.4 M.sup.-1 s.sup.-1 and 10.sup.7 M.sup.-1 s.sup.-1, such as
between 10.sup.5 M.sup.-1 s.sup.-1 and 10.sup.7 M.sup.-1 s.sup.-1.
[0442] Aspect D-5: An immunoglobulin single variable domain
according to any of aspects B-1 to B-7, C-1 to C-7, and/or D-1 to
D-4 that can specifically bind to CXCR7 and in particular human
CXCR7 (SEQ ID NO: 1) with a rate of dissociation (k.sub.off rate)
between 1 s.sup.-1 and 10.sup.-6 s.sup.-1 preferably between
10.sup.-2 and 10.sup.-5 s.sup.-1, more preferably between 10.sup.-3
s.sup.-1 and 10.sup.-6 s.sup.-1, such as between 10.sup.-4 s.sup.-1
and 10.sup.-5 s.sup.-1. [0443] Aspect D-6: An immunoglobulin single
variable domain according to any of aspects B-1 to B-7, C-1 to C-7,
and/or D-1 to D-5 that can specifically bind to CXCR7 and in
particular human CXCR7 (SEQ ID NO: 1) with an affinity less than
500 nM, preferably less than 200 nM, more preferably less than 10
nM, such as less than 500 pM. [0444] The immunoglobulin single
variable domains according to aspects D-1 to D-6 may in particular
be an immunoglobulin single variable domain according to any of the
aspects A-1 to A-22. [0445] Aspect E-1: An immunoglobulin single
variable domain according to any of aspects B-1 to B-7, C-1 to C-7
and/or D1 to D-6, that is a naturally occurring immunoglobulin
single variable domain (from any suitable species) or a synthetic
or semi-synthetic immunoglobulin single variable domain. [0446]
Aspect E-2: An immunoglobulin single variable domain according to
any of aspects B-1 to B-7, C-1 to C-7, D1 to D-6, and/or E-1 that
is sequence optimized [0447] Aspect E-3: An immunoglobulin single
variable domain according to any of aspects B-1 to 8-7, C-1 to C-7,
D1 to D-6, and/or D-1 or D-2 that is stabilized. [0448] Aspect E-4:
An immunoglobulin single variable domain according to any of
aspects B-1 to B-7, C-1 to C-7, D1 to D-6, and/or E-1 to E-3, that
is a naturally occurring immunoglobulin sequence (from any suitable
species) or a synthetic or semi-synthetic immunoglobulin sequence.
[0449] Aspect E-5: An immunoglobulin single variable domain
according to any of aspects B-1 to B-7, C-1 to C-7, D1 to D-6,
and/or E-1 to E-4 that is a humanized immunoglobulin sequence, a
camelized immunoglobulin sequence or an immunoglobulin sequence
that has been obtained by techniques such as affinity maturation.
[0450] Aspect E-6: An immunoglobulin single variable domain
according to any of aspects B-1 to 8-7, C-1 to C-7, D1 to D-6,
and/or E-1 to E-5 that essentially consists of a light chain
variable domain sequence (e.g., a V.sub.L-sequence); or of a heavy
chain variable domain sequence (e.g., a V.sub.H-sequence). [0451]
Aspect E-7: An immunoglobulin single variable domain according to
any of aspects B-1 to B-7, C-1 to C-7, D1 to D-6, and/or E-1 to
E-6, that essentially consists of a heavy chain variable domain
sequence that is derived from a conventional four-chain antibody or
that essentially consist of a heavy chain variable domain sequence
that is derived from heavy. chain antibody. [0452] Aspect E-8: An
immunoglobulin single variable domain according to any of aspects
B-1 to 8-7, C-1 to C-7, D1 to D-6, and/or E-1 to E-7, that
essentially consists of a domain antibody (or an immunoglobulin
single variable domain that is suitable for use as a domain
antibody), of a single domain antibody (or an immunoglobulin single
variable domain that is suitable for use as a single domain
antibody), of a
"dAb" (or an immunoglobulin single variable domain that is suitable
for use as a dAb) or of a Nanobody (including but not limited to a
V.sub.HH sequence). [0453] Aspect E-9: An immunoglobulin single
variable domain according to any of aspects B-1 to B-7, C-1 to C-7,
D1 to D-6, and/or E-1 to E-8 that essentially consists of a
Nanobody. [0454] Aspect E-10: An immunoglobulin single variable
domain according to any of aspects B-1 to B-7, C-1 to C-7, D1 to
D-6, and/or E-1 to E-9 that essentially consists of a
immunoglobulin single variable domain that [0455] i) has at least
80% amino acid identity with at least one of the immunoglobulin
single variable domains described herein, in which for the purposes
of determining the degree of amino acid identity, the amino acid
residues that form the CDR sequences are disregarded; [0456] and in
which: [0457] ii) preferably one or more of the amino acid residues
at positions 11, 37, 44, 45, 47, 83, 84, 103, 104 and 108 according
to the Kabat numbering are chosen from the Hallmark residues
mentioned in Table B-2. [0458] Aspect E-11: An immunoglobulin
single variable domain according to any of aspects B-1 to B-7, C-1
to C-7, D1 to D-6, and/or E-1 to E-10, that essentially consists of
an immunoglobulin single variable domain that [0459] i) has at
least 80% amino acid identity with at least one of the An
immunoglobulin single variable domains of SEQ ID NOs: 39 to 43, 91
or 99-102, in which for the purposes of determining the degree of
amino acid identity, the amino acid residues that form the CDR
sequences are disregarded; [0460] and in which: [0461] ii)
preferably one or more of the amino acid residues at positions 11,
37, 44, 45, 47, 83, 84, 103, 104 and 108 according to the Kabat
numbering are chosen from the Hallmark residues mentioned in Table
B-2. [0462] Aspect E-12: An immunoglobulin single variable domain
according to any of aspects B-1 to 8-7, C-1 to C-7, D1 to D-6,
and/or E-1 to E-11 that essentially consists of a humanized
immunoglobulin single variable domain. [0463] Aspect E-13: An
immunoglobulin single variable domain according to any of the
aspects B-1 to B-7, C-1 to C-7, D1 to D-6, and/or E-1 to E-11, that
in addition to the at least one binding site for binding formed by
the CDR sequences, contains one or more further binding sites for
binding against other antigens, proteins or targets. [0464] The
immunoglobulin single variable domains according to aspects E-1 to
E-13 may in particular be an immunoglobulin single variable domain
according to any of the aspects A-1 to A-22.
Polypeptides
[0464] [0465] Aspect K-1: Polypeptide that comprises of one or more
immunoglobulin single variable domains according to any of aspects
A-1 to A-22, B-1 to B-7, C-1 to C-4, D-1 to D-6, and/or E-1 to
E-13, and optionally further comprises one or more peptidic
linkers. [0466] Aspect K-2: Polypeptide according to aspect K-1,
which additionally comprises one or more (preferably one)
immunoglobulin single variable domain directed against serum
albumin. [0467] Aspect K-3: Polypeptide according to any of aspects
K-1 or K-2, in which said immunoglobulin single variable domain
directed against serum albumin is directed against human serum
albumin. [0468] Aspect K-4: Polypeptide according to any of aspects
K-1 to K-3, in which said one or more immunoglobulin single
variable domain directed against serum albumin is an immunoglobulin
single variable domain with SEQ ID NO: 2. [0469] Aspect K-5:
Polypeptide that comprises of one or more immunoglobulin single
variable domains according to any of aspects A-1 to A-22, B-1 to
B-7, C-1 to C-4, D-1 to D-6, and/or E-1 to E-13, one or more
cytotoxic payloads, and optionally further comprises one or more
peptidic linkers. [0470] Aspect K-6: Polypeptide that comprises or
essentially consists of one or more immunoglobulin single variable
domains according to any of aspects A-1 to A-22, B-1 to B-7, C-1 to
C-4, D-1 to D-6, and/or E-1 to E-13, one or more (and preferably
one) immunoglobulin single variable domains (preferably Nanobody)
directed against CXCR4 and optionally further comprises one or more
peptidic linkers. [0471] Aspect K-7: Polypeptide that comprises or
essentially consists of at least one (preferably one)
immunoglobulin single variable domain (preferably Nanobody)
directed against (human) CXCR7 and at least one (cyto)toxic group,
moiety or payload (optionally linked chemically or via one or more
suitable linkers or spacers). [0472] Aspect K-8: Polypeptide that
comprises or essentially consists of at least one (preferably one)
immunoglobulin single variable domain (preferably Nanobody)
directed against (human) CXCR7, at least one (preferably one)
immunoglobulin single variable domain (preferably Nanobody)
directed against (human) CXCR4 and at least one (cyto)toxic group,
moiety or payload (optionally linked chemically or via one or more
suitable linkers or spacers). [0473] Aspect K-9: Polypeptide that
comprises or essentially consists of at least one (preferably one)
immunoglobulin single variable domain (preferably Nanobody)
directed against (human) CXCR7 and at least one (preferably one)
immunoglobulin single variable domain (preferably Nanobody)
directed against (human) CXCR4 (optionally linked chemically or via
one or more suitable linkers or spacers). [0474] Aspect K-10:
Polypeptide that comprises or essentially consists of at least one
(preferably one) immunoglobulin single variable domain (preferably
Nanobody) directed against (human) CXCR7, at least one (preferably
one) immunoglobulin single variable domain (preferably Nanobody)
directed against (human) CXCR4, and a peptide or immunoglobulin
single variable domain (preferably Nanobody) directed against
(human) serum albumin (optionally linked chemically or via one or
more suitable linkers or spacers). [0475] Aspect K-11: Polypeptide
that comprises or essentially consists of two immunoglobulin single
variable domains (preferably Nanobody) directed against (human)
CXCR7, which are the same (optionally linked chemically or via one
or more suitable linkers or spacers). [0476] Aspect K-12:
Polypeptide that comprises or essentially consists of two
immunoglobulin single variable domains (preferably Nanobody)
directed against (human) CXCR7, which are different from each other
(optionally linked chemically or via one or more suitable linkers
or spacers). [0477] Aspect K-13: Polypeptide that comprises or
essentially consists of two immunoglobulin single variable domains
(preferably Nanobody) directed against (human) CXCR7, which are the
same, and a peptide or immunoglobulin single variable domain
(preferably Nanobody) directed against (human) serum albumin
(optionally linked chemically or via one or more suitable linkers
or spacers). [0478] Aspect K-14: Polypeptide that comprises or
essentially consists of two immunoglobulin single variable domains
(preferably Nanobody) directed against (human) CXCR7, which are
different from each other, and a peptide or immunoglobulin single
variable domain (preferably Nanobody) directed against (human)
serum albumin (optionally linked chemically or via one or more
suitable linkers or spacers).
Nucleic Acids
[0478] [0479] Aspect M-1: Nucleic acid or nucleotide sequence, that
encodes an immunoglobulin single variable domain according to any
of aspects A-1 to A-22, B-1 to B-7, C-1 to C-4, D-1 to D-6, E-1 to
E-13, a polypeptide according to any of aspects K-1 to K-4. [0480]
Aspect M-2: Nucleic acid or nucleotide sequence with SEQ ID NOs:
59-63, 73-77 or 99 (Table B-6).
Host Cells
[0480] [0481] Aspect N-1: Host or host cell that expresses, or that
under suitable circumstances is capable of expressing, an
immunoglobulin single variable domain according to any of aspects
A-1 to A-22, B-1 to B-7, C-1 to C-4, D-1 to D-6, E-1 to E-13, a
polypeptide according to any of aspects K-1 to K-4; and/or that
comprises a nucleic acid or nucleotide sequence according to aspect
M-1 or M-2.
Compositions
[0482] Aspect O-1: Composition comprising at least one
immunoglobulin single variable domain according to any of aspects
A-1 to A-22, B-1 to B-7, C-1 to C-4, D-1 to D-6, E-1 to E-13, or at
least one polypeptide according to any of aspects K-1 to K-4, or
nucleic acid or nucleotide sequence according to aspects M-1 or
M-2. [0483] Aspect O-2: Composition according to aspect O-1, which
is a pharmaceutical composition. [0484] Aspect O-3: Composition
according to aspect O-2, which is a pharmaceutical composition,
that further comprises at least one pharmaceutically acceptable
carrier, diluent or excipient and/or adjuvant, and that optionally
comprises one or more further pharmaceutically active polypeptides
and/or compounds.
Making of an Agent and Composition of the Invention
[0484] [0485] Aspect P-1: Method for producing an immunoglobulin
single variable domain according to any of aspects A-1 to A-22, B-1
to B-7, C-1 to C-4, D-1 to D-6, E-1 to E-13, a polypeptide
according to any of aspects K-1 to K-4, said method at least
comprising the steps of: [0486] a) expressing, in a suitable host
cell or host organism or in another suitable expression system, a
nucleic acid or nucleotide sequence according to aspect M-1, or
aspect M-2; [0487] optionally followed by: [0488] b) isolating
and/or purifying the immunoglobulin single variable domain
according to any of aspects A-1 to A-22, B-1 to B-7, C-1 to C-4,
D-1 to D-6, E-1 to E-13, a polypeptide according to any of aspects
K-1 to K-4. [0489] Aspect P-2: Method for producing an
immunoglobulin single variable domain according to any of aspects
A-1 to A-22, B-1 to B-7, C-1 to C-4, D-1 to D-6, E-1 to E-13, a
polypeptide according to any of aspects K-1 to K-4, said method at
least comprising the steps of: [0490] a) cultivating and/or
maintaining a host or host cell according to aspect N-1 under
conditions that are such that said host or host cell expresses
and/or produces at least one immunoglobulin single variable domain
according to any of aspects A-1 to A-22, B-1 to B-7, C-1 to C-4,
D-1 to D-6, E-1 to E-13, a polypeptide according to any of aspects
K-1 to K-4; [0491] optionally followed by: [0492] b) isolating
and/or purifying the immunoglobulin single variable domain
according to any of aspects A-1 to A-22, B-1 to B-7, C-1 to C-4,
D-1 to D-6, E-1 to E-13, a polypeptide according to any of aspects
K-1 to K-4.
Method of Screening
[0492] [0493] Aspect Q-1: Method for screening immunoglobulin
single variable domains directed against CXCR7 and in particular
human CXCR7 (SEQ ID NO: 1) that comprises at least the steps of:
[0494] a) providing a set, collection or library of nucleic acid
sequences encoding immunoglobulin single variable domains; [0495]
b) screening said set, collection or library of nucleic acid
sequences for nucleic acid sequences that encode an immunoglobulin
single variable domain that can bind to and/or has affinity for
CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) and that is
cross-blocked or is cross blocking a Nanobody of the invention,
e.g., SEQ ID NO: 39 to 43, 91 or 99-102 (Table-B-3), or a
polypeptide or construct of the invention, e.g., SEQ ID NO: 44 to
48, 78-89 or 131-140 (see Table B-4); and [0496] c) isolating said
nucleic acid sequence, followed by expressing said immunoglobulin
single variable domain.
Use of Agents of the Invention
[0496] [0497] Aspect R-1: Method for the prevention and/or
treatment of cancer and of inflammatory diseases (such as e.g.,
mentioned herein), said method comprising administering, to a
subject in need thereof, a pharmaceutically active amount of at
least one immunoglobulin single variable domain according to any of
aspects A-1 to A-22, B-1 to B-7, C-1 to C-4, D-1 to D-6, E-1 to
E-13, a polypeptide according to any of aspects K-1 to K-4; or
composition according to aspect O-2 or O-3. [0498] Aspect R-2:
Method for the prevention and/or treatment of at least one disease
or disorder that is associated with CXCR7 and in particular human
CXCR7 (SEQ ID NO: 1), with its biological or pharmacological
activity, and/or with the biological pathways or signalling in
which CXCR7 and in particular human CXCR7 (SEQ ID NO: 1) is
involved, said method comprising administering, to a subject in
need thereof, a pharmaceutically active amount of at least one
immunoglobulin single variable domain according to any of aspects
A-1 to A-22, B-1 to B-7, C-1 to C-4, D-1 to D-6, E-1 to E-13, a
polypeptide according to any of aspects K-1 to K-4; or composition
according to aspect O-2 or O-3. [0499] Aspect R-3: Method for the
prevention and/or treatment of at least one disease or disorder
that can be prevented and/or treated by administering, to a subject
in need thereof, at least one immunoglobulin single variable domain
according to any of aspects A-1 to A-22, B-1 to B-7, C-1 to C-4,
D-1 to D-6, E-1 to E-13, a polypeptide according to any of aspects
K-1 to K-4; or composition according to aspect O-2 or O-3, said
method comprising administering, to a subject in need thereof, a
pharmaceutically active amount of at least one at least one
immunoglobulin single variable domain according to any of aspects
A-1 to A-22, B-1 to B-7, C-1 to C-4, D-1 to D-6, E-1 to E-13, a
polypeptide according to any of aspects K-1 to K-4; or composition
according to aspect O-2 or O-3. [0500] Aspect R-4: Method for
immunotherapy, said method comprising administering, to a subject
in need thereof, a pharmaceutically active amount of at least one
immunoglobulin single variable domain according to any of aspects
A-1 to A-22, B-1 to B-7, C-1 to C-4, D-1 to D-6, E-1 to E-13, a
polypeptide according to any of aspects K-1 to K-4; or composition
according to aspect O-2 or O-3. [0501] Aspect R-5: An
immunoglobulin single variable domain according to any of aspects
A-1 to A-22, B-1 to 8-7, C-1 to C-4, D-1 to D-6, E-1 to E-13, a
polypeptide according to any of aspects K-1 to K-4, a
pharmaceutical composition according to aspect O-2 or O-3 for use
in one or more of the methods according to aspects R-1 to R-3.
[0502] Aspect R-6: A polypeptide according to any of aspects K-1 to
K-4, for the diagnosis, prevention and/or treatment of cancer.
Further Aspects:
[0502] [0503] 1. A construct comprising at least one immunoglobulin
single variable domain (ISVD) that binds to and/or recognizes amino
acid residue M33, and optionally amino acid residue V32 and/or
amino acid residue M37 in CXCR7 (SEQ ID NO: 1) and at least one
ISVD that binds to and/or recognizes amino acid residue WF19, and
optionally S23 and/or D25 of CXCR7 (SEQ ID NO: 1). [0504] 2. The
construct according to aspect 1 for use as a medicament to reduce
tumour growth and/or to treat cancer, preferably head and neck
cancer or GEM. [0505] 3. An immunoglobulin single variable domain
that can specifically displace SDF-1 and I-TAC on human CXCR7 (SEQ
ID NO: 1) with an average Ki of less than 100 nM and an average
SDF-1 and I-TAC displacement of 50% or more. [0506] 4. An
immunoglobulin single variable domain that can specifically
displace SDF-1 on human CXCR7 (SEQ ID NO: 1) with an average Ki of
less than 100 nM and an average SDF-1 displacement of 50% or more.
[0507] 5. An immunoglobulin single variable domain that can
specifically displace I-TAC on human CXCR7 (SEQ ID NO: 1) with an
average Ki of less than 100 nM and an average I-TAC displacement of
50% or more. [0508] 6. The immunoglobulin single variable domain of
any of aspects 3-5, wherein the average Ki is 50 nM or less. [0509]
7. The immunoglobulin single variable domain of any of aspects 3-5,
wherein the average Ki is 10 nM or less. [0510] 8. The
immunoglobulin single variable domain of any of aspects 3-7,
wherein the average SDF-1 or I-TAC displacement is 80% or more.
[0511] 9. An immunoglobulin single variable domain that can bind
human CXCR7 (SEQ ID NO: 1) with a Kd of less than 50 nM. [0512] 10.
An immunoglobulin single variable domain that binds to and/or
recognizes amino acid residue M33, and optionally amino acid
residue V32 and/or amino acid residue M37 in CXCR7 (SEQ ID NO:1).
[0513] 11 An immunoglobulin single variable domain that binds to
and/or recognizes amino acid residue WF19, and optionally S23
and/or D25 of CXCR7 (SEQ ID NO: 1). [0514] 12. The immunoglobulin
single variable domain according to aspect 10 or 11 for use as a
medicament to reduce tumour growth and/or to treat cancer,
preferably head and neck cancer or GBM. [0515] 13. The
immunoglobulin single variable domain of any of aspects 3-12,
wherein the immunoglobulin single variable domain comprises an
amino acid sequence with the formula 1
[0515] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0516] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; and [0517] wherein CDR1
is chosen from the group consisting of: [0518] a) the
immunoglobulin single variable domain of SEQ ID NO: 9, [0519] b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 9, [0520] c) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 9, [0521] and wherein CDR2 is
chosen from the group consisting of: [0522] d) the immunoglobulin
single variable domain of SEQ ID NO: 19; [0523] e) immunoglobulin
single variable domains that have at least 80% amino acid identity
with the immunoglobulin single variable domain of SEQ ID NO: 19;
[0524] f) immunoglobulin single variable domains that have 3, 2, or
1 amino acid difference with the immunoglobulin single variable
domain of SEQ ID NO: 19; [0525] and wherein CDR3 is chosen from the
group consisting of: [0526] g) the immunoglobulin single variable
domain of SEQ ID NO: 29; [0527] h) immunoglobulin single variable
domains that have at least 80% amino acid identity with the
immunoglobulin single variable domain of SEQ ID NO: 29; [0528] i)
immunoglobulin single variable domains that have 3, 2, or 1 amino
acid difference with the immunoglobulin single variable domain of
SEQ ID NO: 29. [0529] 14. The immunoglobulin single variable domain
of any of aspects 3-12, wherein the immunoglobulin single variable
domain comprises an amino acid sequence with the formula 1
[0529] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0530] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; and [0531] wherein CDR1
is chosen from the group consisting of: [0532] a) the
immunoglobulin single variable domain of SEQ ID NO: 10, [0533] b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 10, [0534] c) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 10, [0535] and wherein CDR2 is
chosen from the group consisting of: [0536] d) the immunoglobulin
single variable domain of SEQ ID NO: 20; [0537] e) immunoglobulin
single variable domains that have at least 80% amino acid identity
with the immunoglobulin single variable domain of SEQ ID NO: 20;
[0538] f) immunoglobulin single variable domains that have 3, 2, or
1 amino acid difference with the immunoglobulin single variable
domain of SEQ ID NO: 20; [0539] and wherein CDR3 is chosen from the
group consisting of: [0540] g) the immunoglobulin single variable
domain of SEQ ID NO: 30; [0541] h) immunoglobulin single variable
domains that have at least 80% amino acid identity with the
immunoglobulin single variable domain of SEQ ID NO: 30; [0542] i)
immunoglobulin single variable domains that have 3, 2, or 1 amino
acid difference with the immunoglobulin single variable domain of
SEQ ID NO: 30. [0543] 15. The immunoglobulin single variable domain
of any of aspects 3-12, wherein the immunoglobulin single variable
domain comprises an amino acid sequence with the formula 1
[0543] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0544] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; and [0545] wherein CDR1
is chosen from the group consisting of: [0546] a) the
immunoglobulin single variable domain of SEQ ID NO: 11, [0547] b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 11, [0548] c) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 11, [0549] and wherein CDR2 is
chosen from the group consisting of: [0550] d) the immunoglobulin
single variable domain of SEQ ID NO: 21; [0551] e) immunoglobulin
single variable domains that have at least 80% amino acid identity
with the immunoglobulin single variable domain of SEQ ID NO: 21;
[0552] f) immunoglobulin single variable domains that have 3, 2, or
1 amino acid difference with the immunoglobulin single variable
domain of SEQ ID NO: 21; [0553] and wherein CDR3 is chosen from the
group consisting of: [0554] g) the immunoglobulin single variable
domain of SEQ ID NO: 31; [0555] h) immunoglobulin single variable
domains that have at least 80% amino acid identity with the
immunoglobulin single variable domain of SEQ ID NO: 31; [0556] i)
immunoglobulin single variable domains that have 3, 2, or 1 amino
acid difference with the immunoglobulin single variable domain of
SEQ ID NO: 31. [0557] 16. The immunoglobulin single variable domain
of any of aspects 3-12, wherein the immunoglobulin single variable
domain comprises an amino acid sequence with the formula 1
[0557] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0558] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; and [0559] wherein CDR1
is chosen from the group consisting of: [0560] a) the
immunoglobulin single variable domain of SEQ ID NO: 12, [0561] b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 12, [0562] c) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 12, [0563] and wherein CDR2 is
chosen from the group consisting of: [0564] d) the immunoglobulin
single variable domain of SEQ ID NO: 22; [0565] e) immunoglobulin
single variable domains that have at least 80% amino acid identity
with the immunoglobulin single variable domain of SEQ ID NO: 22;
[0566] f) immunoglobulin single variable domains that have 3, 2, or
1 amino acid difference with the immunoglobulin single variable
domain of SEQ ID NO: 22; [0567] and wherein CDR3 is chosen from the
group consisting of: [0568] g) the immunoglobulin single variable
domain of SEQ ID NO: 32; [0569] h) immunoglobulin single variable
domains that have at least 80% amino acid identity with the
immunoglobulin single variable domain of SEQ ID NO: 32; [0570] i)
immunoglobulin single variable domains that have 3, 2, or 1 amino
acid difference with the immunoglobulin single variable domain of
SEQ ID NO: 32. [0571] 17. The immunoglobulin single variable domain
of any of aspects 3-12, wherein the immunoglobulin single variable
domain comprises an amino acid sequence with the formula 1
[0571] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0572] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; and [0573] wherein CDR1
is chosen from the group consisting of: [0574] a) the
immunoglobulin single variable domain of SEQ ID NO: 13, [0575] b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 13, [0576] c) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 13, [0577] and wherein CDR2 is
chosen from the group consisting of: [0578] d) the immunoglobulin
single variable domain of SEQ ID NO: 23; [0579] e) immunoglobulin
single variable domains that have at least 80% amino acid identity
with the immunoglobulin single variable domain of SEQ ID NO: 23;
[0580] f) immunoglobulin single variable domains that have 3, 2, or
1 amino acid difference with the immunoglobulin single variable
domain of SEQ ID NO: 23; [0581] and wherein CDR3 is chosen from the
group consisting of: [0582] g) the immunoglobulin single variable
domain of SEQ ID NO: 33; [0583] h) immunoglobulin single variable
domains that have at least 80% amino acid identity with the
immunoglobulin single variable domain of SEQ ID NO: 33; [0584] i)
immunoglobulin single variable domains that have 3, 2, or 1 amino
acid difference with the immunoglobulin single variable domain of
SEQ ID NO: 33. [0585] 18. The immunoglobulin single variable domain
of any of aspects 3-12, wherein the immunoglobulin single variable
domain comprises an amino acid sequence with the formula 1
[0585] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0586] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; and wherein CDR1 is
chosen from the group consisting of: [0587] a) the immunoglobulin
single variable domain of SEQ ID NO: 93, [0588] b) immunoglobulin
single variable domains that have at least 80% amino acid identity
with the immunoglobulin single variable domain of SEQ ID NO: 93,
[0589] c) immunoglobulin single variable domains that have 3, 2, or
1 amino acid difference with the immunoglobulin single variable
domain of SEQ ID NO: 93; [0590] and wherein CDR2 is chosen from the
group consisting of: [0591] d) the immunoglobulin single variable
domain of SEQ ID NO: 95; [0592] e) immunoglobulin single variable
domains that have at least 80% amino acid identity with the
immunoglobulin single variable domain of SEQ ID NO: 95; [0593] f)
immunoglobulin single variable domains that have 3, 2, or 1 amino
acid difference with the immunoglobulin single variable domain of
SEQ ID NO: 95; [0594] and wherein CDR3 is chosen from the group
consisting of: [0595] g) the immunoglobulin single variable domain
of SEQ ID NO: 97; [0596] h) immunoglobulin single variable domains
that have at least 80% amino acid identity with the immunoglobulin
single variable domain of SEQ ID NO: 97; [0597] i) immunoglobulin
single variable domains that have 3, 2, or 1 amino acid difference
with the immunoglobulin single variable domain of SEQ ID NO: 97.
[0598] 19. The immunoglobulin single variable domain of any of
aspects 3-12, wherein the immunoglobulin single variable domain
comprises an amino acid sequence with the formula 1
[0598] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0599] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; and [0600] wherein CDR1
is chosen from the group consisting of: [0601] a) the
immunoglobulin single variable domain of SEQ ID NO: 107, [0602] b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 107, [0603] c) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 107, [0604] and wherein CDR2
is chosen from the group consisting of: [0605] d) the
immunoglobulin single variable domain of SEQ ID NO: 115; [0606] e)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 115; [0607] f) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 115; [0608] and wherein CDR3
is chosen from the group consisting of: [0609] g) the
immunoglobulin single variable domain of SEQ ID NO: 123; [0610] h)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 123; [0611] i) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 123. [0612] 20. The
immunoglobulin single variable domain of any of aspects 3-12,
wherein the immunoglobulin single variable domain comprises an
amino acid sequence with the formula 1
[0612] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0613] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; and [0614] wherein CDR1
is chosen from the group consisting of: [0615] a) the
immunoglobulin single variable domain of SEQ ID NO: 108, [0616] b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 108, [0617] c) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 108, [0618] and wherein CDR2
is chosen from the group consisting of: [0619] d) the
immunoglobulin single variable domain of SEQ ID NO: 116; [0620] e)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 116; [0621] f) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 116; [0622] and wherein CDR3
is chosen from the group consisting of: [0623] g) the
immunoglobulin single variable domain of SEQ ID NO: 124; [0624] h)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 124; [0625] i) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 124. [0626] 21. The
immunoglobulin single variable domain of any of aspects 3-12,
wherein the immunoglobulin single variable domain comprises an
amino acid sequence with the formula 1
[0626] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0627] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; and [0628] wherein CDR1
is chosen from the group consisting of: [0629] a) the
immunoglobulin single variable domain of SEQ ID NO: 110, [0630] b)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 110, [0631] c) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 110, [0632] and wherein CDR2
is chosen from the group consisting of: [0633] d) the
immunoglobulin single variable domain of SEQ ID NO: 118; [0634] e)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 118; [0635] f) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 118; [0636] and wherein CDR3
is chosen from the group consisting of: [0637] g) the
immunoglobulin single variable domain of SEQ ID NO: 126; [0638] h)
immunoglobulin single variable domains that have at least 80% amino
acid identity with the immunoglobulin single variable domain of SEQ
ID NO: 126; [0639] i) immunoglobulin single variable domains that
have 3, 2, or 1 amino acid difference with the immunoglobulin
single variable domain of SEQ ID NO: 126. [0640] 22. The
immunoglobulin single variable domain according to any of aspects
1-21, wherein the framework regions (FRs) have a sequence identity
of more than 80% with the FRs of SEQ ID NOs: 4 to 8, 92, 103, 104
or 106 (FR1), 14 to 18, 94, 111, 112 or 114 (FR2), 24 to 28, 96,
119, 120 or 122 (FR3), and/or 34 to 38, 98, 127, 128 or 130 (FR4).
[0641] 23. A polypeptide comprising an immunoglobulin single
variable domain of any of aspects 3-22. [0642] 24. The polypeptide
according to aspect 23, wherein the immunoglobulin single variable
domain is selected from the group consisting of immunoglobulin
single variable domains that have an amino acid sequence with a
sequence identity of more than 80% with the immunoglobulin single
variable domains of SEQ ID NOs: 39 to 43, 91 or 99-102. [0643] 25.
The polypeptide according to any of aspects 23-24 and additionally
comprising at least one human serum albumin binding immunoglobulin
single variable domain and optionally comprising a linker selected
from the group of linkers with SEQ ID NOs: 49 to 58. [0644] 26. The
polypeptide according to any of aspects 23-25 and additionally
comprising ALB8 (SEQ ID NO: 2), and optionally comprising a linker
selected from the group of linkers with SEQ ID NOs: 49 to 58.
[0645] 27. The polypeptides according to any of aspects 23-26,
wherein the polypeptide is selected from the group consisting of
polypeptides that have an amino acid sequence with a sequence
identity of more than 80% with the polypeptides of SEQ ID NOs: 44
to 48, 78 to 89 and 131 to 140. [0646] 28. A construct chosen from
the group consisting of: [0647] constructs comprising at least two
ISVDs that bind to and/or recognize amino acid residue WF19, and
optionally S23 and/or D25 of CXCR7 (SEQ ID NO: 1), wherein said at
least two ISVDs can be the same or different; [0648] constructs
comprising at least two ISVDs that bind to and/or recognize amino
acid residue M33, and optionally amino acid residue V32 and/or
amino acid residue M37 in CXCR7 (SEQ ID NO: 1), wherein said at
least two ISVDs can be the same or different; [0649] constructs
comprising at least one group 1 ISVD and at least one group 2 ISVD;
[0650] constructs comprising at least one group 1 ISVD and at least
one group 3 ISVD; [0651] constructs comprising at least one group 2
ISVD and at least one group 3 ISVD; and [0652] constructs
comprising at least one 01C10-like sequence and at least one
14G03-like sequence. [0653] 29. The construct according to aspect
28 for use as a medicament to reduce tumour growth and/or to treat
cancer, preferably head and neck cancer or GBM. [0654] 30. A
nucleic acid sequence encoding [0655] i) for an immunoglobulin
single variable domain according to any of aspects 3-22; [0656] ii)
for a polypeptide according to any of aspects 23-27, or [0657] iii)
for a construct according to any of aspects 1, 2, 28 or 29. [0658]
31. A pharmaceutical composition comprising [0659] i) an
immunoglobulin single variable domain according to any of aspects
3-22; [0660] ii) a polypeptide according to any of aspects 23-27;
or [0661] iii) a construct according to any of aspects 1, 2, 28 or
29; and optionally a pharmaceutically acceptable excipient. [0662]
32. An immunoglobulin single variable domain according to any of
aspects 3-22, a polypeptide according to any of aspects 23-27, or a
construct according to any of aspects 1, 2, 28 or 29 for use in
cancer, preferably head or, neck cancer, GBM and/or inflammatory
diseases. [0663] 33. An immunoglobulin single variable domain
according to any of aspects 3-22, a polypeptide according to any of
aspects 23-27, or a construct according to any of aspects 1, 2, 28
or 29 for use in rheumatoid arthritis. [0664] 34. An immunoglobulin
single variable domain according to any of aspects 3-22, a
polypeptide according to any of aspects 23-27, or a construct
according to any of aspects 1, 2, 28 or 29 for use in multiple
sclerosis. [0665] 35. Method for producing an immunoglobulin single
variable domain according to any of aspects 3-22, a polypeptide
according to any of aspects 23-27, or a construct according to any
of aspects 1, 2, 28 or 29, said method at least comprising the
steps of: [0666] a) expressing, in a suitable host cell or host
organism or in another suitable expression system, a nucleic acid
or nucleotide sequence according to aspect 30; optionally followed
by: [0667] b) isolating and/or purifying the immunoglobulin single
variable domain according to any of aspects 3-22, a polypeptide
according to any of aspects 23-27, or a construct according to any
of aspects 1, 2, 28 or 29. [0668] 36. An immunoglobulin single
variable comprising an amino acid sequence with the formula 1
[0668] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0669] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; [0670] wherein CDR1 is
the immunoglobulin single variable domain of SEQ ID NO: 9; [0671]
wherein CDR2 is the immunoglobulin single variable domain of SEQ ID
NO: 19; and [0672] wherein CDR3 is the immunoglobulin single
variable domain of SEQ ID NO: 29. [0673] 37. An immunoglobulin
single variable comprising an amino acid sequence with the formula
1 variable domain comprises an amino acid sequence with the formula
1
[0673] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0674] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; [0675] wherein CDR1 is
the immunoglobulin single variable domain of SEQ ID NO: 10; [0676]
wherein CDR2 is the immunoglobulin single variable domain of SEQ ID
NO: 20; and [0677] wherein CDR3 is the immunoglobulin single
variable domain of SEQ ID NO: 30. [0678] 38. An immunoglobulin
single variable comprising an amino acid sequence with the formula
1 variable domain comprises an amino acid sequence with the formula
1
[0678] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0679] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; [0680] wherein CDR1 is
the immunoglobulin single variable domain of SEQ ID NO: 11; [0681]
wherein CDR2 is the immunoglobulin single variable domain of SEQ ID
NO: 21; and [0682] wherein CDR3 is the immunoglobulin single
variable domain of SEQ ID NO: 31. [0683] 39. An immunoglobulin
single variable comprising an amino acid sequence with the formula
I variable domain comprises an amino acid sequence with the formula
1
[0683] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0684] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; [0685] wherein CDR1 is
the immunoglobulin single variable domain of SEQ ID NO: 12; [0686]
wherein CDR2 is the immunoglobulin single variable domain of SEQ ID
NO: 22; and [0687] wherein CDR3 is the immunoglobulin single
variable domain of SEQ ID NO: 32. [0688] 40. An immunoglobulin
single variable comprising an amino acid sequence with the formula
I variable domain comprises an amino acid sequence with the formula
1
[0688] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0689] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; [0690] wherein CDR1 is
the immunoglobulin single variable domain of SEQ ID NO: 13; [0691]
wherein CDR2 is the immunoglobulin single variable domain of SEQ ID
NO: 23; and [0692] wherein CDR3 is the immunoglobulin single
variable domains of SEQ ID NO: 33. [0693] 41. An immunoglobulin
single variable comprising an amino acid sequence with the formula
1 variable domain comprises an amino acid sequence with the formula
1
[0693] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0694] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; [0695] wherein CDR1 is
the immunoglobulin single variable domain of SEQ ID NO: 93; [0696]
wherein CDR2 is the immunoglobulin single variable domain of SEQ ID
NO: 95; and [0697] wherein CDR3 is the immunoglobulin single
variable domain of SEQ ID NO: 97. [0698] 42. An immunoglobulin
single variable comprising an amino acid sequence with the formula
1 variable domain comprises an amino acid sequence with the formula
1
[0698] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0699] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; [0700] wherein CDR1 is
the immunoglobulin single variable domain of SEQ ID NO: 107; [0701]
wherein CDR2 is the immunoglobulin single variable domain of SEQ ID
NO: 115; and [0702] wherein CDR3 is the immunoglobulin single
variable domain of SEQ ID NO: 123. [0703] 43. An immunoglobulin
single variable comprising an amino acid sequence with the formula
1 variable domain comprises an amino acid sequence with the formula
1
[0703] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0704] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; [0705] wherein CDR1 is
the immunoglobulin single variable domain of SEQ ID NO: 108; [0706]
wherein CDR2 is the immunoglobulin single variable domain of SEQ ID
NO: 116; and [0707] wherein CDR3 is the immunoglobulin single
variable domains of SEQ ID NO: 124. [0708] 44. An immunoglobulin
single variable comprising an amino acid sequence with the formula
1 variable domain comprises an amino acid sequence with the formula
1
[0708] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (1); [0709] wherein FR1 to
FR4 refer to framework regions 1 to 4 and are framework regions of
an immunoglobulin single variable domain; [0710] wherein CDR1 is
the immunoglobulin single variable domain of SEQ ED NO: 110; [0711]
wherein CDR2 is the immunoglobulin single variable domain of SEQ ID
NO: 118; and [0712] wherein CDR3 is the immunoglobulin single
variable domain of SEQ ID NO: 126.
Experimental Part:
Sequences:
TABLE-US-00002 [0713] TABLE B-1 Prior art sequences SEQ ID Name NO
Amino acid sequences Human 1
MDLHLFDYSEPGNFSDISWPCNSSDCIVVDTVMCPNMPN CXCR7
KSVLLYTLSFIYIFIFVIGMIANSVVVWVNIQAKTTGYD or
THCYILNLAIADLWVVLTIPVWVVSLVQHNQWPMGELTC hCXCR7
KVTHLIFSINLFGSIFFLTCMSVDRYLSITYFTNTPSSR
KKMVRRVVCILVWLLAFCVSLPDTYYLKTVTSASNNETY
CRSFYPEHSIKEWLIGMELVSVVLGFAVPFSIIAVFYFL
LARAISASSDQEKHSSRKIIFSYVVVFLVCWLPYHVAVL
LDIFSILHYIPFTCRLEHALFTALHVTQCLSLVHCCVNP
VLYSFINRNYRYELMKAFIFKYSAKTGLTKLIDASRVSE TEYSALEQSTK Alb8 2
EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQ
APGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTT
LYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS Mouse 3
MDVHLFDYAEPGNYSDINWPCNSSDCIVVDTVQCPTMPN CXCR7
KNVLLYTLSFIYIFIFVIGMIANSVVVWVNIQAKTTGYD or
THCYILNLAIADLWVVITIPVWVVSLVQHNQWPMGELTC mCXCR7
KITHLIFSINLFGSIFFLACMSVDRYLSITYFTGTSSYK
KKMVRRVVCILVWLLAFFVSLPDTYYLKTVTSASNNETY
CRSFYPEHSIKEWLIGMELVSVILGFAVPFTIIAIFYFL
LARAMSASGDQEKHSSRKIIFSYVVVFLVCWLPYHFVVL
LDIFSILHYIPFTCQLENVLFTALHVTQCLSLVHCCVNP
VLYSFINRNYRYELMKAFIFKYSAKTGLTKLIDASRVSE TEYSALEQNTK Tag-1 71
AAAHHHHHHGAAEQKLISEEDLNGAA Tag-2 72 AAAEQKLISEEDLNGAAHHHHHH Tag-3
105 GAAEQKLISEEDLNGAAHHHHHH Cyno- 90
MDLHVFDYSEPGNFSDISWPCNSSDCIVVDTVMCPNMPN molgus
KSVLLYTLAFIYIFIFVIGMIANSVVVWVNIQAKTTGYD CXCR7
THCYILNLAIADLWVVLTIPVWVVSLVQHNQWPMGELTC or
KVTHLIFSINLFGSIFFLTCMSVDRYLSITYFTNTSSSR cCXCR7
KKMVRRVVCVLVWLLAFCVSLPDTYYLKTVTSASNNETY
CRSFYPEHSIKEWLIGMELVSVVLGFAVPFSVIAVFYFL
LARAISASGDQEKHSSRKIIFSYVVVFLVCWLPYHVAYL
LDIFSILHYIPFTCRLEHALFTALHVTQCLSLVHCCVNP
VLYSFINRNYRYELMKAFIFKYSAKTGLTKLIDASRVSE TEYSALEQSTK
TABLE-US-00003 TABLE B-2 Sequences for CDRs and frameworks, plus
preferred combinations as provided in for formula I, namely
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (Terms: "ID" refers to the given SEQ
ID NO. Preferred combination of FR and CDR sequences for each NB
construct are used inter- changeably through-out the application)
Clone ID FR1 ID CDR1 ID FR2 07B11 4 EVQLVESGGNLVQAGGSLGLSCAAS 9
IHIMG 14 WYRQAPGKQRDLVA VSISS 07C03 5 EVQLVESGGGLVQAGESLTLSCAAS 10
AYIMG 15 WFRQAPGKEREFVA GRTLS 08A05 6 EVQLVESGGGLVQAGDSLRLSCAAS 11
NYDMG 16 WFRQAPGKEREFVG GLTFS 08A10 7 EVQLVESGGGLVQAGGSLRLSCAAS 12
IAAMG 17 WYRQATGKQRELVA GSIFS 14G03 8 EVQLVESGGGLVQPGGSLRISCAAS 13
INYMG 18 WYRQAPGKQRELVA (09A04) GSIYL Alb8 64
EVQLVESGGGLVQPGNSLRLSCAAS 65 SFGMS 66 WVRQAPGKGLEWVS GFTFS 01C10 92
EVQLVESGGGLVQTGASLRLSCAAS 93 NYAMG 94 WFRQAPGKERERVA GRTFS 01C12
103 EVQLVESGGGLVQAGASLRLSCAAS 107 NYAMG 111 WFRQAPGKERERVA GRTFS
01B12 104 EVQLVESGGGLVQAGASLRLSCAAS 108 NYAMG 112 WFRQAPGKEREPVA
GRTFS 01F11 105 EVQLVESGGGLVQAGASLRLSCAAS 109 NYAMG 113
WFRQAPGKEREPVA GRTFS 01B10 106 EVQLVESGGGLVQAGASLRLSCAAS 110 NYAMG
114 WFRQAPGKEREPVA GRTFG Clone ID CDR2 ID FR3 07B11 19
TITSGGSTAYADSVKG 24 RFTVSKDNAKNTVYLQMDSLKPEDTSVYYCAA 07C03 20
GIWSGGYTHLADSAKG 25 RFSISRDNAKNTVYLQMNGLKPEDTAVYYCAA 08A05 21
ASWWSGGAPYYSDSVKG 26 RFTISRDNAKNTVYLQANSLRPEDTAVYYCAA 08A10 22
TITDGGTTTYADSVKG 27 RVTISRDRSANTVYLAMNNLKPDDTAVYYCYA 14G03 23
TLTSGGSTNYAGSVKG 28 RFAISRDNAKNTVYLQNNSLKPEDTAVYYCNI (09A04) Alb8
67 SISGSGSDTLYADSVKG 68 RFTISRDNAKTTLYLQMNSLRPEDTAVYYCTI 01C10 95
AITPRAFTTYYADSVKG 96 RFTISRDNAKNTAYLQMVSLKPEDTAVYYCAA 01C12 115
AISPSAVTTYYADSVKG 119 RFTISRDNAKNTAYLQMVSLKPEDTAVYYCAA 01B12 116
AISPAALTTYYADFVKG 120 RFTISRDNAKNTAYLQMVSLKPEDTAVYYCAA 01F11 117
AISPAALTTYYADFVKG 121 RFTISRDNAKNTAYLQMVSLKPEDTAVYYCAA 01B10 118
AISPAAVTTYYADFVKG 122 RFTISRDNAKNTAYLQMVSLKPEDTAVYYCAA Clone ID
CDR3 ID FR4 07B11 29 EVRNGVFGKWNHY 34 WGQGTQVTVSS 07C03 30
GLRGRQYSN 35 WGQGTQVTVSS O8A05 31 KRLRSFASGGSYDY 36 WGQGTQVTVSS
08A10 32 YLRYTSRVPGDNY 37 WGQGTQVTVSS 14G03 33 GGTLYDRRRFES 38
WGQGTQVTVSS (09A04) Alb8 69 GGSLSR 70 SSQGTLVTVSS 01C10 97
QLVGSGSNLGRQESYAY 98 WGQGTQVTVSS 01C12 123 QLPGRGSNLGRQASYAY 127
WGQGTQVTVSS 01B12 124 QLVGSGSNLGRQQSYAY 128 WGQGTQVTVSS 01F11 125
QLVGSGSNLGRQQSYAY 129 WGQGTQVTVSS 01B10 126 QLVGSGSNLGRQQSYAY 130
WGQGTQVTVSS
TABLE-US-00004 TABLE B-3 Amino acid sequences of immunoglobulin
single variable sequences of the invention SEQ Name of ID clone NO:
Amino acid sequences 07B11 39
EVQLVESGGNLVQAGGSLGLSCAASVSISSIHIMGWYRQ
APGKQRDLVATITSGGSTAYADSVKGRFTVSKDNAKNTV
YLQMDSLKPEDTSVYYCAAEVRNGVEGKWNHYWGQGTQV TVSS 07C03 40
EVQLVESGGOLVQAGESLTLSCAASGRTLSAYIMGWFRQ
APGKEREFVAGIWSGGYTHLADSAKGRFSISRDNAKNTV
YLQMNGLKPEDTAVYYCAAGLRGRQYSNWGQGTQVTVSS 08A05 41
EVQLVESGGGLVQAGDSLRLSCAASGLTFSNYDMGWFRQ
APGKEREFVGASWWSGGAPYYSDSVKGRFTISRDNAKNT
VYLQANSLRPEDTAVYYCAAKRLRSFASGGSYDYWGQGT QVTVSS 08A10 42
EVQLVESGGGLVQAGGSLRLSCAASGSIFSIAAMGWYRQ
ATGKQRELVATITDGGTTTYADSVKGRVTISRDRSANTV
YLAMNNLKPDDTAVYYCYAYLRYTSRVPGDNYWGQGTQV TVSS 14G03 43
EVQLVESGGGLVQPGGSLRISCAASGSIYLINYMGWYRQ (09A04)*
APGKQRELVATLTSGGSTNYAGSVKGRFAISRDNAKNTV
YLQMNSLKPEDTAVYYCNIGGTLYDRRRFESWGQGTQVT VSS 01C10 91
EVQLVESGGGLVQTGASLRLSCAASGRTFSNYAMGWFRQ
APGKERERVAAITPRAFTTYYADSVKGRFTISRDNAKNT
AYLQMVSLKPEDTAVYYCAAQLVGSGSNLGRQESYAYWG QGTQVTVSS 01C12 99
EVQLVESGGGLVQAGASLRLSCAASGRTFSNYAMGWFRQ
APGKERERVAAISPSAVTTYYADSVKGRFTISRDNAKNT
AYLQMVSLKPEDTAVYYCAAQLPGRGSNLGRQASYAYWG QGTQVTVSS 01B12 100
EVQLVESGGGLVQAGASLRLSCAASGRTFSNYAMGWFRQ
APGKEREPVAAISPAALTTYYADFVKGRFTISRDNAKNT
AYLQMVSLKPEDTAVYYCAAQLVGSGSNLGRQQSYAYWG QGTQVTVSS 01F11 101
EVQLVESGGGLVQAGASLRLSCAASGRTFSNYAMGWFRQ
APGKEREPVAAISPAALTTYYADFVKGRFTISRDNAKNT
AYLQMVSLKPEDTAVYYCAAQLVGSGSNLGRQQSYAYWG QGTQVTVSS 01B10 102
EVQLVESGGGLVQAGASLRLSCAASGRTFGNYAMGWFRQ
APGKEREPVAAISPAAVTTYYADFVKGRFTISRDNAKNT
AYLQMVSLKPEDTAVYYCAAQLVGSGSNLGRQQSYAYWG QGTQVTVSS *The sequences of
14G03 is identical to the sequence of 09A04; 14G03 is used
interchangeably with 09A04.
TABLE-US-00005 TABLE B-4 Polypeptide sequences of the invention
Name SEQ of ID clone NO Amino acid sequences 07B11- 44
EVQLVESGGNLVQAGGSLGLSCAASVSISSIHIMGWYRQ 9GS-
APGKQRDLVATITSGGSTAYADSVKGRFTVSKDNAKNTV Alb8
YLQMDSLKPEDTSVYYCAAEVRNGVEGKWNHYWGQGTQV
TVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLSCAASG
FTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVK
GRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSR SSQGTLVTVSS 07C03- 45
EVQLVESGGGLVQAGESLTLSCAASGRTLSAYIMGWFRQ 9GS-
APGKEREFVAGIWSGGYTHLADSAKGRFSISRDNAKNTV Alb8
YLQMNGLKPEDTAVYYCAAGLRGRQYSNWGQGTQVTVSS
GGGGSGGGSEVQLVESGGGLVQPGNSLRLSCAASGFTFS
SFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFT
ISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQG TLVTVSS 08A05- 46
EVQLVESGGGLVQAGDSLRLSCAASGLTFSNYDMGWFRQ 9GS-
APGKEREFVGASWWSGGAPYYSDSVKGRFTISRDNAKNT Alb8
VYLQANSLRPEDTAVYYCAAKRLRSFASGGSYDYWGQGT
QVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLSCAA
SGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADS
VKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSL SRSSQGTLVTVSS 08A10- 47
EVQLVESGGGLVQAGGSLRLSCAASGSIFSIAAMGWYRQ 9GS-
ATGKQRELVATITDGGTTTYADSVKGRVTISRDRSANTV Alb8
YLAMNNLKPDDTAVYYCYAYLRYTSRVPGDNYWGQGTQV
TVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLSCAASG
FTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVK
GRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSR SSQGTLVTVSS 14G03- 48
EVQLVESGGGLVQPGGSLRISCAASGSIYLINYMGWYRQ 9GS-
APGKQRELVATLTSGGSTNYAGSVKGRFAISRDNAKNTV Alb8
YLQMNSLKPEDTAVYYCNIGGTLYDRRRFESWGQGTQVT
VSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLSCAASGF
TFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKG
RFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRS SQGTLVTVSS 07B11- 78
EVQLVESGGNLVQAGGSLGLSCAASVSISSIHIMGWYRQ 9GS-
APGKQRDLVATITSGGSTAYADSVKGRFTVSKDNAKNTV 07C03
YLQMDSLKPEDTSVYYCAAEVRNGVFGKWNHYWGQGTQV
TVSSGGGGSGGGSEVQLVESGGGLVQAGESLTLSCAASG
RTLSAYIMGWFRQAPGKEREFVAGIWSGGYTHLADSAKG
RFSISRDNAKNTVYLQMNGLKPEDTAVYYCAAGLRGRQY SNWGQGTQVTVSS 07C03- 79
EVQLVESGGGLVQAGESLTLSCAASGRTLSAYIMGWFRQ 9GS-
APGKEREFVAGIWSGGYTHLADSAKGRFSISRDNAKNTV 07B11
YLQMNGLKPEDTAVYYCAAGLRGRQYSNWGQGTQVTVSS
GGGGSGGGSEVQLVESGGNLVQAGGSLGLSCAASVSISS
IHIMGWYRQAPGKQRDLVATITSGGSTAYADSVKGRFTV
SKDNAKNTVYLQMDSLKPEDTSVYYCAAEVRNGVFGKWN HYWGQGTQVTVSS 07B11- 80
EVQLVESGGNLVQAGGSLGLSCAASVSISSIHIMGWYRQ 9GS-
APGKQRDLVATITSGGSTAYADSVKGRFTVSKDNAKNTV Alb8-
YLQMDSLKPEDTSVYYCAAEVRNGVFGKWNHYWGQGTQV 9GS-
TVSSCGGGSGGGSEVQLVESGGGLVQPGNSLRLSCAASG 07C03
FTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVK
GRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSR
SSQGTLVTVSSGGGGSGGGSEVQLVESGGGLVQAGESLT
LSCAASGRTLSAYIMGWFRQAPGKEREFVAGIWSGGYTH
LADSAKGRFSISRDNAKNTVYLQMNGLKPEDTAVYYCAA GLRGRQYSNWGQGTQVTVSS 07B11-
81 EVQLVESGGNLVQAGGSLGLSCAASVSISSIHIMGWYRQ 9GS-
APGKQRDLVATITSGGSTAYADSVKGRFTVSKDNAKNTV 07C03-
YLQMDSLKPEDTSVYYCAAEVRNGVFGKWNHYWGQGTQV 9GS-
TVSSGGGGSGGGSEVQLVESGGGLVQAGESLTLSCAASG Alb8
RTLSAYIMGWFRQAPGKEREFVAGIWSGGYTHLADSAKG
RFSISRDNAKNTVYLQMNGLKREDTAVYYCAAGLRGRQY
SNWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGNS
LRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGS
DTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYY CTIGGSLSRSSQGTLVTVSS 08A05-
82 EVQLVESGGGLVQAGDSLRLSCAASGLTFSNYDMGWFRQ 9GS-
APGKEREFVGASWWSGGAPYYSDSVKGRFTISRDNAKNT 08A10
VYLQANSLRPEDTAVYYCAAKRLRSFASGGSYDYWGQGT
QVTVSSGGGGSGGGSEVQLVESGGGLVQAGGSLRLSCAA
SGSIFSIAAMGWYRQATGKQRELVATITDGGTTTYADSV
KGRVTISRDRSANTVYLAMNNLKPDDTAVYYCYAYLRYT SRVPGDNYWGQGTQVTVSS 08A10-
83 EVQLVESGGGLVQAGGSLRLSCAASGSIFSIAAMGWYRQ 9GS-
ATGKQRELVATITDGGTTTYADSVKGRVTISRDRSANTV Alb8-
YLAMNNLKPDDTAVYYCYAYLRYTSRVPGDNYWGQGTQV 9GS-
TVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLSCAASG 08A10
FTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVK
GRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSR
SSQGTLVTVSSGGGGSGGGSEVQLVESGGGLVQAGGSLR
LSCAASGSIFSIAAMGWYRQATGKQRELVATITDGGTTT
YADSVKGRVTISRDRSANTVYLAMNNLKPDDTAVYYCYA YLRYTSRVPGDNYWGQGTQVTVSS
08A10- 84 EVQLVESGGGLVQAGGSLRLSCAASGSIFSIAAMGWYRQ 9GS-
ATGKQRELVATITDGGTTTYADSVKGRVTISRDRSANTV 08A10-
YLAMNNLKPDDTAVYYCYAYLRYTSRVPGDNYWGQGTQV 9GS-
TVSSGGGGSGGGSEVQLVESGGGLVQAGGSLRLSCAASG Alb8
SIFSIAAMGWYRQATGKQRELVATITDGGTTTYADSVKG
RVTISRDRSANTVYLAMNNLKPDDTAVYYCYAYLRYTSR
VPGDNYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQ
PGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSIS
GSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDT AVYYCTIGGSLSRSSQGTLVTVSS
08A05- 85 EVQLVESGGGLVQAGDSLRLSCAASGLTFSNYDMGWFRQ 9GS-
APGKEREFVGASWWSGGAPYYSDSVKGRFTISRDNAKNT 08A10-
VYLQANSLRPEDTAVYYCAAKRLRSFASGGSYDYWGQGT 9GS-
QVTVSSGGGGSGGGSEVQLVESGGGLVQAGGSLRLSCAA Alb8
SGSIFSIAAMGWYRQATGKQRELVATITDGGTTTYADSV
KGRVTISRDRSANTVYLAMNNLKPDDTAVYYCYAYLRYT
SRVPGDNYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGL
VQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSS
ISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPE DTAVYYCTIGGSLSRSSQGTLVTVSS
07B11- 86 EVQLVESGGNLVQAGGSLGLSCAASVSISSIHIMGWYRQ 9GS-
APGKQRDLVATITSGGSTAYADSVKGRFTVSKDNAKNTV 238D2
YLQMDSLKPEDTSVYYCAAEVRNGVFGKWNHYWGQGTQV (238D2
TVSSGGGGSGGGSEVQLVESGGGLVQTGGSLRLSCAASG is
FTFSSYAMSWVRQAPGKGLEWVSGIKSSGDSTRYAGSVK directed
GRFTISRDNAKNMLYLQMYSLKPEDTAVYYCAKSRVSRT against GLYTYDNRGQGTQVTVSS
CXCR4) 07C03- 87 EVQLVESGGGLVQAGESLTLSCAASGRTLSAYIMGWFRQ 9GS-
APGKEREFVAGIWSGGYTHLADSAKGRFSISRDNAKNTV 238D4
YLQMNGLKPEDTAVYYCAAGLRGRQYSNWGQGTQVTVSS (238D4
GGGGSGGGSEVQLMESGGGLVQAGGSLRLSCAASGRTFN is
NYAMGWFRRAPGKEREFVAAITRSGVRSGVSAIYGDSVK directed
DRFTISRDNAKNTLYLQMNSLKPEDTAVYTCAASAIGSG against
ALRRFEYDYSGQGTQVTVSS CXCR4) 08A10- 88
EVQLVESGGGLVQAGGSLRLSCAASGSIFSIAAMGWYRQ 9GS-
ATGKQRELVATITDGGTTTYADSVKGRVTISRDRSANTV Alb8-
YLAMNNLKPDDTAVYYCYAYLRYTSRVPGDNYWGQGTQV 9GS-
TVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLSCAASG 238D2
FTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVK (238D2
GRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSR is
SSQGTLVTVSSGGGGSGGGSEVQLVESGGGLVQTGGSLR directed
LSCAASGFTFSSYAMSWVRQAPGKGLEWVSGIKSSGDST against
RYAGSVKGRFTISRDNAKNMLYLQMYSLKPEDTAVYYCA CXCR4)
KSRVSRTGLYTYDNRGQGTQVTVSS 08A05- 89
EVQLVESGGGLVQAGDSLRLSCAASGLTFSNYDMGWFRQ 9GS-
APGKEREFVGASWWSGGAPYYSDSVKGRFTISRDNAKNT 238D4-
VYLQANSLRPEDTAVYYCAAKRLRSFASGGSYDYWGQGT 9GS-
QVTVSSGGGGSGGGSEVQLMESGGGLVQAGGSLRLSCAA Alb8
SGRTFNNYAMGWFRRAPGKEREFVAAITRSGVRSGVSAI (238D4
YGDSVKDRFTISRDNAKNTLYLQMNSLKPEDTAVYTCAA is
SAIGSGALRRFEYDYSGQGTQVTVSSGGGGSGGGSEVQL directed
VESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGK against
GLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQ CXCR4)
MNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS clone 131
EVQLVESGGGLVQAGDSLRLSCAASGLTFSNYDMGWFRQ 060
APGKEREFVGASWWSGGAPYYSDSVKGRFTISRDNAKNT
VYLQANSLRPEDTAVYYCAAKRLRSFASGGSYDYWGQGT
LVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGG
GSEVQLVESGGGLVQAGDSLRLSCAASGLTFSNYDMGWF
RQAPGKEREFVGASWWSGGAPYYSDSVKGRFTISRDNAK
NTVYLQANSLRPEDTAVYYCAAKRLRSFASGGSYDYWGQ
GTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLSC
AASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYA
DSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSRS clone 132
EVQLVESGGGLVQAGDSLRLSCAASGLTFSNYDMGWFRQ 083
APGKEREFVGASWWSGGAPYYSDSVKGRFTISRDNAKNT
VYLQANSLRPEDTAVYYCAAKRLRSFASGGSYDYWGQGT
LVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQ
LVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPG
KGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYL
QMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS clone 133
EVQLVESGGGLVQPGGSLRISCAASGSIYLINYMGWYRQ 085
APGKQRELVATLTSGGSTNYAGSVKGRFAISRDNAKNTV
YLQMNSLKPEDTAVYYCNIGGTLYDRRRFESWGQGTLVT
VSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSE
VQLVESGGGLVQTGASLRLSCAASGRTFSNYAMGWFRQA
PGKERERVAAITPRAFTTYYADSVKGRFTISRDNAKNTA
YLQMVSLKPEDTAVYYCAAQLVGSGSNLGRQESYAYWGQ
GTLVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSG
GGGSEVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMS
WVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDN
AKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTV SS clone 134
EVQLVESGGGLVQTGASLRLSCAASGRTFSNYAMGWFRQ 093
APGKERERVAAITPRAFTTYYADSVKGRFTISRDNAKNT
AYLQMVSLKPEDTAVYYCAAQLVGSGSNLGRQESYAYWG
QGTLVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
GGGGSEVQLVESGGGLVQTGASLRLSCAASGRTFSNYAM
GWFRQAPGKERERVAAITPRAFTTYYADSVKGRFTISRD
NAKNTAYLQMVSLKPEDTAVYYCAAQLVGSGSNLGRQES
YAYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSGGGGS
GGGGSGGGGSEVQLVESGGGLVQPGNSLRLSCAASGFTF
SSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRF
TISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQ GTLVTVSS clone 135
EVQLVESGGGLVQAGGSLRLSCAASGSIFSIAAMGWYRQ 021
ATGKQRELVATITDGGTTTYADSVKGRVTISRDRSANTV
YLAMNNLKPDDTAVYYCYAYLRYTSRVPGDNYWGQGTLV
TVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
EVQLVESGGGLVQTGASLRLSCAASGRTFSNYAMGWFRQ
APGKERERVAAITPRAFTTYYADSVKGRFTISRDNAKNT
AYLQMVSLKPEDTAVYYCAAQLVGSGSNLGRQESYAYWG
QGTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLS
CAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLY
ADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIG GSLSRSSQGTLVTVSS clone 136
EVQLVESGGGLVQAGDSLRLSCAASGLTFSNYDMGWFRQ 023
APGKEREFVGASWWSGGAPYYSDSVKGRFTISRDNAKNT
VYLQANSLRPEDTAVYYCAAKRLRSFASGGSYDYWGQGT
LVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGG
GSEVQLVESGGGLVQTGASLRLSCAASGRTFSNYAMGWF
RQAPGKERERVAAITPRAFTTYYADSVKGRFTISRDNAK
NTAYLQMVSLKPEDTAVYYCAAQLVGSGSNLGRQESYAY
WGQGTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLR
LSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDT
LYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCT IGGSLSRSSQGTLVTVSS clone
137 EVQLVESGGGLVQPGGSLRISCAASGSIYLINYMGWYRQ 038
APGKQRELVATLTSGGSTNYAGSVKGRFAISRDNAKNTV
YLQMNSLKPEDTAVYYCNIGGTLYDRRRFESWGQGTLVT
VSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSE
VQLVESGGGLVQTGASLRLSCAASGRTFSNYAMGWFRQA
PGKERERVAAITPRAFTTYYADSVKGRFTISRDNAKNTA
YLQMVSLKPEDTAVYYCAAQINGSGSNLGRQESYAYWGQ
GTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLSC
AASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYA
DSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSRSSQGTLVTVSS clone 138
EVQLVESGGGLVQTGASLRLSCAASGRTFSNYAMGWFRQ 049
APGKERERVAAITPRAFTTYYADSVKGRFTISRDNAKNT
AYLQMVSLKPEDTAVYYCAAQLVGSGSNLGRQESYAYWG
QGTLVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
GGGGSEVQLVESGGGLVQAGDSLRLSCAASGLTFSNYDM
GWFRQAPGKEREFVGASWWSGGAPYYSDSVKGRFTISRD
NAKNTVYLQANSLRPEDTAVYYCAAKRLRSFASGGSYDY
WGQGTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLR
LSCAASGFTFSSFGMSWVRQAPGKOLEWVSSISGSGSDT
LYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCT IGGSLSRSSQGTLVTVSS clone
139 EVQLVESGGGLVQTGASLRLSCAASGRTFSNYAMGWFRQ 052
APGKERERVAAITPRAFTTYYADSVKGRFTISRDNAKNT
AYLQMVSLKPEDTAVYYCAAQLVGSGSNLGRQESYAYWG
QGTLVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
GGGGSEVQLVESGGGLVQPGGSLRISCAASGSIYLINYM
GWYRQAPGKQRELVATLTSGGSTNYAGSVKGRFAISRDN
AKNTVYLQMNSLKPEDTAVYYCNIGGTLYDRRRFESWGQ
GTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLSC
AASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYA
DSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYGTIGG SLSRSSQGTLVTVSS clone 140
EVQLVESGGGLVQPGGSLRISCAASGSIYLINYMGWYRQ 086
APGKQRELVATLTSGGSTNYAGSVKGRFAISRDNAKNTV
YLQMNSLKPEDTAVYYCNIGGTLYDRRRFESWGQGTLVT
VSSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSE
VQLVESGGGLVQAGESLTLSCAASGRTLSAYIMGWFRQA
PGKEREFVAGIWSGGYTHLADSAKGRFSISRDNAKNTVY
LQMNGLKPEDTAVYYCAAGLRGRQYSNWGQGTLVTVSSG
GGGSGGGSEVQLVESGGGLVQPGNSLRLSCAASGFTFSS
FGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTI
SRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGT LVTVSS
TABLE-US-00006 TABLE B-5 Linker sequences of the invention SEQ Name
of ID linker NO: Amino acid sequences 5GS 49 GGGGS 6GS 50 SGGSGGS
9GS 51 GGGGSGGGS 10GS 52 GGGGSGGGGS 15GS 53 GGGGSGGGGSGGGGS 18GS 54
GGGGSGGGGSGGGGGGGS 20GS 55 GGGGSGGGGSGGGGSGGGGS 25GS 56
GGGGSGGGGSGGGGSGGGGSGGGGS 30GS 57 GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
35GS 58 GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
TABLE-US-00007 TABLE B-6 Nucleic acid sequences of the invention
Name SEQ of ID clone NO: Nucleic acid sequences 07B11 59
GAGGTGCAATTGGTGGAGTCTGGGGGAAACTTGGTGCAG
GCTGGGGGGTCTCTGGGACTCTCCTGTGCAGCCTCTGTA
AGCATCTCCAGTATCCATATCATGGGCTGGTACCGGCAG
GCTCCAGGCAAACAGCGCGACTTGGTCGCTACTATTACT
AGTGGTGGTAGCACAGCATATGCAGACTCCGTGAAGGGA
CGATTCACCGTCTCCAAAGACAACGCCAAGAACACGGTG
TATCTGCAAATGGACAGCCTGAAACCTGAGGACACATCC
GTCTATTACTGTGCAGCCGAGGTCAGAAATGGGGTGTTT
GGAAAATGGAATCACTACTGGGGCCAGGGGACCCAGGTC ACCGTCTCCTCA 07C03 60
GAGGTGCAATTGGTGGAGTCTGGGGGAGGATTGGTGCAG
GCTGGGGAGTCTCTGACTCCTTCCTGTGCAGCCTCTGGA
CGCACCTTAAGTGCCTATATCATGGGCTGGTTCCGCCAG
GCTCCAGGGAAGGAGCGGGAGTTTGTAGCCGGTATCTGG
AGTGGTGGTTACACACACCTTGCAGACTCCGCGAAGGGC
CGATTCAGCATCTCTAGAGACAACGCCAAGAACACTGTA
TATCTGCAAATGAACGGCCTGAAACCTGAGGACACGGCC
GTCTATTACTGTGCAGCAGGTCTGAGAGGCCGCCAGTAT
AGTAACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA 08A05 61
GAGGTGCAATTGGTGGAGTCTGGGGGAGGATTGGTGCAG
GCTGGGGACTCTCTGAGACTCTCCTGTGCAGCCTCTGGA
CTCACTTTCAGTAACTATGACATGGGCTGGTTCCGCCAG
GCTCCAGGGAAGGAGCGTGAATTTGTAGGGGCTAGTTGG
TGGAGTGGTGGTGCCCCATACTATTCAGACTCCGTGAAG
GGCCGATTCACCATCTCCAGAGACAACGCCAAGAACACG
GTGTATCTGCAAGCGAACAGCCTGAGACCTGAGGACACG
GCCGTTTATTACTGTGCAGCCAAAAGGCTGCGTAGTTTC
GCCTCCGGTGGGTCGTATGATTACTGGGGTCAGGGGACC CAGGTCACCGTCTCCTCA 08A10 62
GAGTCTGGGGGAGGCTTGGTGCAGGCTGGAGGGTCTCTG
AGACTCTCCTGTGCAGCTTCTGGAAGCATCTTCAGTATC
GCTGCCATGGGCTGGTACCGCCAGGCTACAGGGAAGCAG
CGCGAGTTGGTCGCAACTATCACTGATGGCGGTACGACA
ACCTATGCAGACTCCGTGAAGGGCCGAGTCACCATCTCC
AGGGACAGGTCTGCGAACACGGTGTATCTGGCAATGAAC
AATTTGAAACCTGATGACACAGCCGTCTATTATTGTTAT
GCGTATCTGCGCTATACAAGCAGAGTACCTGGCGATAAC
TACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA 14G03 63
GAGGTGCAATTGGTGGAGTCTGGGGGAGGCTTGGTGCAG
CCTGGGGGGTCTCTGAGAATTTCCTGTGCAGCCTCTGGA
AGCATCTACCTTATCAATTACATGGGCTGGTACCGCCAG
GCTCCAGGGAAGCAGCGCGAGTTGGTCGCAACGCTTACT
AGTGGTGGTAGTACCAACTATGCAGGCTCCGTGAAGGGC
CGATTCGCCATCTCCAGAGACAACGCCAAGAACACGGTT
TATCTGCAAATGAACAGCCTGAAACCTGAGGACACGGCC
GTCTATTACTGTAATATAGGAGGAACGCTATACGACAGA
AGGCGGTTTGAATCCTGGGGCCAGGGGACCCAGGTCACC GTCTCCTCAG 01C10 99
GAGGTGCAATTGGTGGAGTCTGGGGGAGGGTTGGTGCAG
ACTGGAGCCTCTCTGAGACTCTCCTGTGCAGCCTCTGGA
CGCACCTTCAGTAACTATGCCATGGGCTGGTTCCGCCAG
GCTCCAGGGAAGGAGCGTGAGCGTGTAGCAGCTATTACA
CCGAGAGCATTTACCACATATTATGCAGACTCCGTGAAG
GGCCGATTCACCATCTCCAGAGACAACGCCAAGAACACG
GCGTATCTACAAATGGTGAGCCTGAAACCTGAGGACACG
GCCGTTTATTACTGTGCAGCTCAACTGGTTGGCAGCGGT
AGTAATTTAGGACGTCAGGAGTCCTATGCCTACTGGGGC CAGGGGACCCAGGTCACCGTCTCCTC
07B11- 73 GAGGTGCAATTGGTGGAGTCTGGGGGAAACTTGGTGCAG 9GS-
GCTGGGGGGTCTCTGGGACTCTCCTGTGCAGCCTCTGTA Alb8
AGCATCTCCAGTATCCATATCATGGGCTGGTACCGGCAG
GCTCCAGGCAAACAGCGCGACTTGGTCGCTACTATTACT
AGTGGTGGTAGCACAGCATATGCAGACTCCGTGAAGGGA
CGATTCACCGTCTCCAAAGACAACGCCAAGAACACGGTG
TATCTGCAAATGGACAGCCTGAAACCTGAGGACACATCC
GTCTATTACTGTGCAGCCGAGGTCAGAAATGGGGTGTTT
GGAAAATGGAATCACTACTGGGGCCAGGGGACCCAGGTC
ACGGTCTCCTCAGGAGGTGGCGGGTCCGGAGGCGGATCC
GAGGTACAGCTGGTGGAGTCTGGGGGTGGCTTGGTGCAA
CCGGGTAACAGTCTGCGCCTTAGCTGCGCAGCGTCTGGC
TTTACCTTCAGCTCCTTTGGCATGAGCTGGGTTCGCCAG
GCTCCGGGAAAAGGACTGGAATGGGTTTCGTCTATTAGC
GGCAGTGGTAGCGATACGCTCTACGCGGACTCCGTGAAG
GGCCGTTTCACCATCTCCCGCGATAACGCCAAAACTACA
CTGTATCTGCAAATGAATAGCCTGCGTCCTGAAGACACG
GCCGTTTATTACTGTACTATTGGTGGCTCGTTAAGCCGT
TCTTCACAGGGTACCCTGGTCACCGTCTCCTCA 07C03- 74
GAGGTGCAATTGGTGGAGTCTGGGGGAGGATTGGTGCAG 9GS-
GCTGGGGAGTCTCTGACTCTCTCCTGTGCAGCCTCTGGA Alb8
CGCACCTTAAGTGCCTATATCATGGGCTGGTTCCGCCAG
GCTCCAGGGAAGGAGCGGGAGTTTGTAGCCGGTATCTGG
AGTGGTGGTTACACACACCTTGCAGACTCCGCGAAGGGC
CGATTCAGCATCTCTAGAGACAACGCCAAGAACACTGTA
TATCTGCAAATGAACGGCCTGAAACCTGAGGACACGGCC
GTCTATTACTGTGCAGCAGGTCTGAGAGGCCGCCAGTAT
AGTAACTGGGGCCAGGGGACCCAGGTCACGGTCTCCTCA
GGAGGTGGCGGGTCCGGAGGCGGATCCGAGGTACAGCTG
GTGGAGTCTGGGGGTGGCTTGGTGCAACCGGGTAACAGT
CTGCGCCTTAGCTGCGCAGCGTCTGGCTTTACCTTCAGC
TCCTTTGGCATGAGCTGGGTTCGCCAGGCTCCGGGAAAA
GGACTGGAATGGGTTTCGTCTATTAGCGGCAGTGGTAGC
GATACGCTCTACGCGGACTCCGTGAAGGGCCGTTTCACC
ATCTCCCGCGATAACGCCAAAACTACACTGTATCTGCAA
ATGAATAGCCTGCGTCCTGAAGACACGGCCGTTTATTAC
TGTACTATTGGTGGCTCGTTAAGCCGTTCTTCACAGGGT ACCCTGGTCACCGTCTCCTCA
08A05- 75 GAGGTGCAATTGGTGGAGTCTGGGGGAGGATTGGTGCAG 9GS-
GCTGGGGACTCTCTGAGACTCTCCTGTGCAGCCTCTGGA Alb8
CTCACTTTCAGTAACTATGACATGGGCTGGTTCCGCCAG
GCTCCAGGGAAGGAGCGTGAATTTGTAGGGGCTAGTTGG
TGGAGTGGTGGTGCCCCATACTATTCAGACTCCGTGAAG
GGCCGATTCACCATCTCCAGAGACAACGCCAAGAACACG
GTGTATCTGCAAGCGAACAGCCTGAGACCTGAGGACACG
GCCGTTTATTACTGTGCAGCCAAAAGGCTGCGTAGTTTC
GCCTCCGGTGGGTCGTATGATTACTGGGGTCAGGGGACC
CAGGTCACGGTCTCCTCAGGAGGTGGCGGGTCCGGAGGC
GGATCCGAGGTACAGCTGGTGGAGTCTGGGGGTGGCTTG
GTGCAACCGGGTAACAGTCTGCGCCTTAGCTGCGCAGCG
TCTGGCTTTACCTTCAGCTCCTTTGGCATGAGCTGGGTT
CGCCAGGCTCCGGGAAAAGGACTGGAATGGGTTTCGTCT
ATTAGCGGCAGTGGTAGCGATACGCTCTACGCGGACTCC
GTGAAGGGCCGTTTCACCATCTCCCGCGATAACGCCAAA
ACTACACTGTATCTGCAAATGAATAGCCTGCGTCCTGAA
GACACGGCCGTTTATTACTGTACTATTGGTGGCTCGTTA
AGCCGTTCTTCACAGGGTACCCTGGTCACCGTCTCCTCA C8A10- 76
GAGGTGCAATTGGTGGAGTCTGGGGGAGGCTTGGTGCAG 9GS-
GCTGGAGGGTCTCTGAGACTCTCCTGTGCAGCTTCTGGA Alb8
AGCATCTTCAGTATCGCTGCCATGGGCTGGTACCGCCAG
GCTACAGGGAAGCAGCGCGAGTTGGTCGCAACTATCACT
GATGGCGGTACGACAACCTATGCAGACTCCGTGAAGGGC
CGAGTCACCATCTCCAGGGACAGGTCTGCGAACACGGTG
TATCTGGCAATGAACAATTTGAAACCTGATGACACAGCC
GTCTATTATTGTTATGCGTATCTGCGCTATACAAGCAGA
GTACCTGGCGATAACTACTGGGGCCAGGGGACCCAGGTC
ACGGTCTCCTCAGGAGGTGGCGGGTCCGGAGGCGGATCC
GAGGTACAGCTGGTGGAGTCTGGGGGTGGCTTGGTGCAA
CCGGGTAACAGTCTGCGCCTTAGCTGCGCAGCGTCTGGC
TTTACCTTCAGCTCCTTTGGCATGAGCTGGGTTCGCCAG
GCTCCGGGAAAAGGACTGGAATGGGTTTCGTCTATTAGC
GGCAGTGGTAGCGATACCCTCTACGCGGACTCCGTGAAG
GGCCGTTTCACCATCTCCCGCGATAACGCCAAAACTACA
CTGTATCTGCAAATGAATAGCCTGCGTCCTGAAGACACG
GCCGTTTATTACTGTACTATTGGTGGCTCGTTAAGCCGT
TCTTCACAGGGTACCCTGGTCACCGTCTCCTCA 14G03- 77
GAGGTGCAATTGGTGGAGTCTGGGGGAGGCTTGGTGCAG 9GS-
CCTGGGGGGTCTCTGAGAATTTCCTGTGCAGCCTCTGGA Alb8
AGCATCTACCTTATCAATTACATGGGCTGGTACCGCCAG
GCTCCAGGGAAGCAGCGCGAGTTGGTCGCAACGCTTACT
AGTGGTGGTAGTACCAACTATGCAGGCTCCGTGAAGGGC
CGATTCGCCATCTCCAGAGACAACGCCAAGAACACGGTT
TATCTGCAAATGAACAGCCTGAAACCTGAGGACACGGCC
GTCTATTACTGTAATATAGGAGGAACGCTATACGACAGA
AGGCGGTTTGAATCCTGGGGCCAGGGGACCCAGGTCACG
GTCTCCTCAGGAGGTGGCGGGTCCGGAGGCGGATCCGAG
GTACAGCTGGTGGAGTCTGGGGGTGGCTTGGTGCAACCG
GGTAACAGTCTGCGCCTTAGCTGCGCAGCGTCTGGCTTT
ACCTTCAGCTCCTTTGGCATGAGCTGGGTTCGCCAGGCT
CCGGGAAAAGGACTGGAATGGGTTTCGTCTATTAGCGGC
AGTGGTAGCGATACGCTCTACGCGGACTCCGTGAAGGGC
CGTTTCACCATCTCCCGCGATAACGCCAAAACTACACTG
TATCTGCAAATGAATAGCCTGCGTCCTGAAGACACGGCC
GTTTATTACTGTACTATTGGTGGCTCGTTAAGCCGTTCT
TCACAGGGTACCCTGGTCACCGTCTCCTCA
Example 1
Cloning
[0714] Human CXCR7 (hCXCR7), mouse CXCR7 (Open Biosystems) and
cynomolgus encoding cDNA (Table B-1) were cloned into pVAX-1
(Invitrogen) and/or pcDNA3.1 (Invitrogen). Transfection of
pVAX1-hCXCR7 and pcDNA3.1-human(mouse)(cyno)CXCR7 constructs in
Hek293 cells resulted in CXCR7 cell surface expression as shown by
FACS analysis using the human CXCR7 specific monoclonal antibody
(Mab) 11G8 (R&D Systems) and a PE-labeled goat anti-mouse IgG
detecting antibody (Jackson ImmunoResearch Inc.).
Example 2
Immunizations
[0715] For genetic immunization, endotoxin-free pVAX1-CXCR7 plasmid
was produced, dissolved to a concentration of 2 mg/mL in 0.9%
saline and stored at -20.degree. C. Four llamas (391, 395, 396 and
397) were immunized with 2 mg pVAX1-hCXCR7 via intradermal Jet
injection (Akra DermoJet France) for four times with two weeks
intervals. Three weeks after the final DNA immunization, the 4
animals received a boost with camel kidney (CAKE) cells (Nguyen et
al. 2001. Adv. Immunol. 79: 261-296) (2.times.10.sup.7 cells)
stably expressing hCXCR7.
[0716] Three llamas (385, 387 and 404) were immunized with four
injections of 2.times.10.sup.7 HEK293 cells transfected with
pcDNA3.1-hCXCR7 with two weeks intervals. From llamas 391, 395, 396
and 397, peripheral blood lymphocytes were collected 4 days and 10
days after the last DNA immunization and 3 days and 9 days after
the cell boost. From llamas 385, 387 and 404, peripheral blood
lymphocytes were collected 4 and 8 days after the final cell
injection. Additionally, a biopsy of the palpable bow lymph node
(LN) was collected from each llama via local surgery 3 days after
the last cell boost. From all lymphocyte harboring immune tissues
total RNA was extracted and used as template to prepare cDNA.
Example 3
Library Construction
[0717] Libraries were constructed from immune tissues collected
from all llamas. In short, cDNA was prepared from the extracted
total RNA samples (example 2) and used to amplify the cDNA
repertoire via nested PCR as previously described (WO 02/085945 and
WO 04/049794). The PCR products were digested with SfiI (introduced
via nested PCR in the FR1 primer region) and BstEII (restriction
site naturally occurring in FR4) and following gel electrophoresis,
the DNA fragment of approximately 400 bps was purified from gel.
The amplified cDNA repertoire was ligated into the corresponding
restriction sites of SfiI-BstEII digested phage display vector
(pAX50) to obtain a library after electroporation of Escherichia
coli TG1. This display vector allows the production of phage
particles, expressing the individual VHHs (hereinforth also
referred to as Nanobodies) as a fusion protein with a C-terminal
Myc-His6-tag (hereinforth also TAG-1 or SEQ ID NO: 71) and with the
geneIII product.
[0718] Libraries were rescued by growing the bacteria to
logarithmic phase (OD.sub.600=0.5), followed by infection with
helper phage to obtain recombinant phage expressing the cloned
Nanobodies on tip of the phage as a pill fusion protein. Phage was
stored after filter sterilization at 4.degree. C. for further
use.
Example 4
Selections of Phage Displaying Human CXCR7 Binding Nanobodies
[0719] Phage from the above libraries were used for selections on
hCXCR7 virus-like particles (VLP; Integral Molecular), intact CXCR7
expressing cells, membrane extracts from CXCR7 expressing cells and
peptides.
[0720] In a first selection round, 10 units of VLPs derived from
hCXCR7 transfected HEK293 cells were coated in 96-well Maxisorp
plate (Nunc) and blocked with low-fat milk powder (Marvell 4% in
PBS). After 2 hours of incubation with rescued phage, trypsin
elution (1 mg/ml) was allowed for 15 minutes at room temperature
subsequent to 20 PBS washes. Protease activity was immediately
neutralized by applying 16 mM protease inhibitor ABSF. The round 1
phage outputs were rescued and a second selection round was
performed on 10 or 1 units of plate-immobilized hCXCR7 VLPs. The
round 2 phage outputs selected on 10 or 1 units plate immobilized
hCXCR7 VLPs were infected into TG1 cells and plated on agar plates
(LB+Amp+2% glucose).
[0721] Individual colonies of E. coli TG1 infected with the eluted
phage pools obtained after selections were picked up and grown in
96-deep-well plates to produce monoclonal phage after addition of
helper phage. The production of monoclonal Nanobodies was induced
by the addition of isopropyl-b-D-thiogalactopyranoside (IPTG). The
perisplasmic fraction containing Nanobodies was then prepared by
freezing-thawing of the bacterial pellet in PBS and subsequent
centrifugation to remove cell fragments.
Example 5
Identification of CXCR7 Specific Nanobodies by Phage ELISA
[0722] From all round 2 selection outputs clones were screened in
phage ELISA on 2 units of immobilized CXCR7 VLPs applying 10-fold
dilutions of phage supernatant. After incubation with
HRP-conjugated monoclonal-anti-M13 antibody (GE, Cat#363761) and
several washings, phage binding was revealed using TMB substrate
(Pierce). The reaction was stopped with H.sub.2SO.sub.4 and the
absorbance was measured at 450 nm using Sunrise TECAN
spectrophotometer (TECAN). Nanobodies, showing a minimally 2-fold
increased ELISA signal on hCXCR7 VLPs over non-transfected control
VLPs, were considered to be CXCR7 specific. CXCR7 specific
Nanobodies were sequenced and redundant Nanobodies (identical AA
sequence) were removed. This resulted in the identification of 78
unique sequences, belonging to 45 distinct Nanobody B-cell
lineages. Phage ELISA data for representative clones from distinct
Nanobody B-cell lineages are represented in Table B-7 and indicate
that the Nanobodies do bind to human CXCR7 on VIP. Notably, all
Nanobodies were derived from PBLs after cell boost, except for
Nanobody 01C10 (see Example 2). Evaluated against the other CXCR7
specific Nanobodies, Nanobody 01C10 was a notorious weak binder,
which in first instance was used for comparative reasons (data not
shown).
TABLE-US-00008 TABLE B-7 CXCR7 screening results-ELISA. CXCR7-LP LP
Null-LP Fold CXCR7- Clones with Tag-1 2U/well [OD] [OD] LP/Null-LP
08A05 0.019 0.008 2.4 08A10 0.104 0.006 17.3 14G03 0.316 0.043 7.3
07B11 0.041 0.010 4.1 07C03 0.053 0.012 4.4 01C10 0.145 0.034
4.2
Example 6
Identification of CXCR7 Specific Nanobodies by FACS Analysis
[0723] Clones representing distinct Nanobody B-cell lineages were
tested as periplasmic extracts for their binding to cell surface
exposed CXCR7. In this assay, 5-fold dilutions of periplasmic
extract were incubated with Hek293 hCXCR7 and Hek293 wt cells.
Binding of the Nanobodies was detected using mouse anti-myc
(Serotec), followed by anti-mouse IgG-PE (Jackson
Immununoresearch). Binding signals of selected Nanobody clones (mcf
values and ratios of binding) are represented in Table B-8 and
indicate that the Nanobodies do bind to cellular human CXCR7.
TABLE-US-00009 TABLE B-8 CXCR7 screening results-FACS analysis.
Clones with Hek-CXCR7 Hek wt Fold Hek Tag-1 Family Llama [MCF]
[MCF] CXCR7/CXCR4 08A05 14 396 18621 310 60.1 08A10 20 397 27411
322 85.1 14G03 23 385 45811 381 120.2 07B11 34 395 42877 389 110.2
07C03 37 391 23359 319 73.2 01C10 1 395 No data
Example 7
Expression of CXCR7 Specific Nanobodies
[0724] Selected Nanobodies were recloned in E. coli expression
vector pAX100 and expressed as C-terminal linked myc, His6
(hereforth also Tag-2 or SEQ ID NO: 72)-tagged proteins. Various
Nanobodies were also expressed as fusion proteins comprising Alb8
(Nanobody-linker-Alb8-myc-His6) (see sequences SEQ ID NOs: 44 to
48--Table B-4) or as tagless Nanobodies. Expression was induced by
IPTG and allowed to continue for 4 h at 37.degree. C. After
spinning the cell cultures, periplasmic extracts were prepared by
freeze-thawing the pellets. Nanobodies were purified from these
extracts using immobilized metal affinity chromatography (IMAC) and
a buffer exchange to D-PBS.
Example 8
Binding FACS Analysis of CXCR7 Specific Nanobodies
[0725] Serial dilutions of purified proteins (concentration range:
400 nM-180 .mu.M) were incubated with stable HEK-CXCR7 cells for 30
min at 4.degree. C. and binding was detected using anti-mouse
anti-myc (Serotec) and anti-mouse IgG-PE (Jackson Immunoresearch).
The half maximal effective concentration (EC50) values and upper
plateau levels of selected clones are depicted in Table B-9. These
data confirm the screening data and underscore that the indicated
Nanobodies bind to cellular human CXCR7.
TABLE-US-00010 TABLE B-9 Binding FACS analysis Clones with Tag-2
EC50 Plateau [mcf] 08A05 8.9 28474 08A10 11.9 34896 14G03 10.2
23807 07B11 30.5 24898 07C03 3.3 33113 01C10 No data No data
Example 9
Nanobodies Compete with SDF-1 for CXCR7 Binding (Displacement
Assay)
[0726] In order to assess the competition capacity, Nanobodies were
evaluated in SDF-1 ligand displacement assays using stable
NIH3T3-hCXCR7 cells. 24 h after seeding the cells, the cells were
pre-incubated for 1 h at 4'C with a dilution series of purified
monovalent Nanobodies and the corresponding C-terminal Tag-2 tagged
fusion proteins to the human serum albumin binding Nanobody Alb8
(see Table B-4: SEQ ID NOs 44 to 48 wherein the polypeptides are
all C-terminal tagged with Tag-2). Also reference molecules Mab
8F11 (Biolegend), Mab 11G8 (R&D) and unlabelled SDF-1 were
included in the assay. Radiolabeled [.sup.125I]-CXCL12 was diluted
and added to the cells to reach a final concentration of 75 .mu.M
and cells were incubated for 3 h at 4.degree. C. After incubation,
cells were washed twice, lysed with RIPA buffer and the .sup.125I
signal was measured. Average Ki values and the percentage of
displacement relative to the displacement of cold SDF-1, are shown
in Table B-10. The competition of tested Nanobodies of Group 1 and
Mab 8F11 is between 73 and 83%, relative to competition with
unlabelled SDF-1. This level of displacement correspond to a 100%
blocking of the CXCR7 protein, as the remaining SDF-1 binding is
believed not to be CXCR7 mediated, but due to the SDF-1 interaction
with heparin sulfate proteoglycans. Fusion to the human serum
albumin-binding Nanobody Alb8 has no significant effect on Ki
values.
TABLE-US-00011 TABLE B-10 Displacement assay Average Average Ki
SDF-1 SEM SDF-1 Clones with whole 3T3 displacement displacement
Tag-2 [nMs] (%) n SEM Ki (%) 08A05 13.6 77 8 2.5 6.4 08A05-9GS-Alb8
17.9 1 08A10 12.1 75 8 1.8 3.3 08A10-9GS-Alb8 14.1 1 14G03 3.0 73 6
0.6 3.3 14G03-9GS-Alb8 3.5 1 07B11 96.1 75 2 1.3 1.5 07B11-9GS-Alb8
82.4 1 07C03 12.2 78 2 6.6 15.0 07C03-9GS-Alb8 10.2 1 01C10 20.7 31
3 10.7 15.5 SDF-1 0.121 100 15 0.019 0.0 Mab 11G8 4.4 24 3 2.7 2.0
Mab 8F11 5.9 73 6 2.4 4.1
Example 10
Nanobodies Compete with SDF-1 for CXCR7 Binding (FACS Assay)
[0727] The potency of Nanobody 07C03 and Mab 8F11 (Biolegend) to
compete with SDF-1 was evaluated in competition FACS with
HEK-hCXCR7 cells. Cells were incubated simultaneously with 4 nM
biotinylated SDF-1 (R&D) and with diluted test molecules, for 2
h at 4.degree. C. Binding of biotinylated SDF-1 was detected using
streptavidin-PE. Competition curves are depicted in FIG. 1. In this
assay, Mab 8F11 and 07C03 competition is complete (>95%),
relative to competition with unlabelled SDF-1, underscoring the
complete inhibition of the SDF-1-CXCR7 interaction.
Example 11
Epitope Mapping
[0728] The minimal epitope of Mab 11G8 is known to be F14SDISWP20
located at the CXCR7 N-terminus (see e.g., WO2008/048519). Cells
were incubated simultaneously with 20 nM Mab 11G8 APC(R&D) and
with diluted test molecules for 2 h at 4.degree. C. Competition
curves are depicted at FIG. 2. The level of competition with Mab
11G8 APC ranges from .about.20 to 100%, suggesting that the
respective Nanobody epitopes match to a high degree (high % of
competition) with the Mab 11G8 epitope or to a low degree (low % of
competition) or induce allosteric changes affecting the Mab 11G8
binding. These data indicate that the selected Nanobodies bind to
divergent, but probably overlapping epitopes.
[0729] Nanobodies 08A05, 08A10, 07C03, 07B11, 01C10 and 14G03, Mab
8F11 (Biolegend), Mab 11G8 (R&D) and Mab 9C4 (MBL) were further
tested for competition with Alexa647-labelled 14603 in FACS
analysis. Nanobodies 08A05, 08A10, 07C03, 07B11, Mab 8F11, Mab 11G8
and Mab 9C4 compete with 14G03 binding to CXCR7, while 01C10 does
not, suggesting that 01C10 hits an epitope distinct from the
epitope(s) hit by the other selected Nanobodies.
[0730] In a third approach, Nanobodies were tested for their
binding to a set of 10 point mutants of CXCR7 (S9A, F14Y, I17L,
S18N, W19A, 523G, D25A, V32A, M33Q, N36T), which yielded
information on the individual Nanobody epitopes. For Nanobodies
08A05, 08A10, 07C03, 07B11 and 14G03, the epitope included residue
M33, while that of 01C10 did not. The binding of 01C10 (and 07B11)
was affected by the W19A mutation, while this mutation did not
affect the binding of 08A05, 08A10, 07C03 and 14G03. Again, these
data indicate that 01C10 hits a distinct epitope.
Example 12
Mouse/Cyno Cross-Reactivity
[0731] HEK293 cells transfected respectively with pcDNA3.1-hCXCR7
and pcDNA3.1-mCXCR7 were used to test cross-reactive binding of
Nanobodies to mouse CXCR7 in FACS analysis. Cells were incubated
with 32 nM Mab 11G8 (R&D), Mab 9C4 (MBL), Mab 8F11 (Biolegend)
or with 800 nM Nanobody for 2 h at 4.degree. C. Nanobody binding
was detected using mouse anti-myc (Serotec) and anti-mouse IgG-PE
(Jackson Immunoresearch) and Mab binding by goat anti-mouse IgG-PE
(Jackson Immunoresearchy Nanobodies 08A10, 14G03, 07B11 and Mab9C4
are not cross-reactive to mouse CXCR7, Nanobodies 08A05 and 07C03
are partially cross-reactive with mouse CXCR7 and Mab 8F11, Mab
11G8 and 01C10 are cross-reactive with mouse CXCR7 (Table
B-11).
[0732] Cross-reactive binding to cynomolgus CXCR7 was assessed in
the same way. Nanobodies 08A10, 14G03, 07B11, 08A05, 07CO.sub.3,
01C10 and Mab 9C4, Mab 8F11 and Mab 11G8 are all cross-reactive to
cynomolgus CXCR7 (Table B-11).
TABLE-US-00012 TABLE B-11 Cross-reactivity to mouse CXCR7 Clones
Mouse with Tag-2 Family Llama crossreactivity Cyno crossreactivity
01C10 1 395 Yes Yes 08A05 14 396 Partial Yes 08A10 20 397 No Yes
14G03 23 385 No Yes 07B11 34 395 No Yes 07C03 37 391 Partial Yes
Mab 8F11 Yes Yes Mab 11G8 Yes Yes Mab 9C4 No Yes
Example 13
Construction of Bivalent and Trivalent Nanobodies
[0733] Bivalent Nanobodies were constructed with one N-terminal
CXCR7-specific building block (either 01C10, 14G03, 08A05, 08A10 or
07CO.sub.3 but also even less potent building blocks like 08C02,
01C07, 01D04, which were not listed in the examples above) and a
C-terminal human serum albumin (HSA)-specific building block
(ALB8), providing the Nanobodies with an extended half-life in
vivo. Trivalent Nanobodies consisted of one more CXCR7-specific
building block in order to improve the potency and efficacy of the
Na nobody to displace SDF-1 from the receptor. Bivalent and
trivalent Na nobodies were expressed with Tag-2 extension in
Pichia.
Example 14
Competition with SDF-1 Binding to CXCR7 of Bivalent and Trivalent
Nanobodies
[0734] Bivalent and trivalent Nanobodies were screened in the SDF-1
displacement assay as described in Example 9. Samples were
incubated in the presence or absence of HSA to estimate the effect
of HSA binding to the Nanobodies during the assay. While potencies
of bivalent Nanobodies were dramatically lowered in the presence of
HSA, they are much better conserved for trivalent Nanobodies (Table
B-12).
TABLE-US-00013 TABLE B-12 competition with SDF-1 binding to CXCR7
of bivalent and trivalent Nanobodies SDF-1 SDF-1 Dis- Dis-
placement placement Clones in in with absence of presence of Tag-3
construct HSA[Ki] HSA[Ki] 033 14G03-35GS-07C03-9GS-ALB8 0.82 1.74
035 14G03-35GS-14G03-9GS-ALB8 0.95 4.7 036
14G03-35GS-08C02-9GS-ALB8 1.34 6.19 032 14G03-35GS-08A05-9GS-ALB8
1.51 5.93 026 07C03-35GS-14G03-9GS-ALB8 1.75 33.03 034
14G03-35GS-07B11-9GS-ALB8 1.90 6.93 028 07C03-35GS-01C10-9GS-ALB8
2.2 ND 037 14G03-35GS-01C07-9GS-ALB8 2.28 4.48 013* 14G03-9GS-ALB8
3.1 311 055 01C10-35GS-01C10-9GS-ALB8 3.42 ND 038
14G03-35GS-01C10-9GS-ALB8 3.47 5.85 052 01C10-35GS-14G03-9GS-ALB8
3.65 6.32 049 01C10-35GS-08A05-9GS-ALB8 3.72 ND 018
08A10-35GS-14G03-9GS-ALB8 4.07 ND 053 01C10-35GS-08C02-9GS-ALB8
4.15 ND 048 01C10-35GS-08A10-9GS-ALB8 4.87 ND 050
01C10-35GS-07C03-9GS-ALB8 6.945 ND 025 07C03-35GS-07C03-9GS-ALB8
7.91 ND 009* 07C03-9GS-ALB8 9.50 66.59 056
01D04-35GS-14G03-9GS-ALB8 ND 182.29 Mab 8F11 10.8 *bears tag-2
Example 15
Inhibition of .beta.-Arrestin Recruitment of Bivalent and Trivalent
Nanobodies
[0735] The PathHunter eXpress .beta.-arrestin assay (DiscoverX) was
used to assess the antagonistic effect of trivalent Nanobodies on
recruitment of .beta.-arrestin. A panel of 37 trivalent Nanobodies
(clones) was screened at a 100 nM concentration in the assay.
Results are ranked in Table B-13 on the basis of efficiency of
inhibition. The most efficient trivalent molecules constitute
combinations with 01C10, the Nanobody that hits a distinct epitope
(cf. Example 11). These Nanobodies (clones) can bind in a double
mode to one CXCR7 monomer
[0736] Based on the foregoing results, the Nanobodies may be
classified into 3 groups: [0737] Group 1: represented by 01C10,
apparently hitting an epitope distinct from Group 2; [0738] Group
2: represented by 14G03, 08A05, 08A10 and 07C03, apparently hitting
an epitope distinct from Group 1; and [0739] Group 3: represented
by 07B11, apparently intermediary to Group 1 and Group 2.
[0740] Although Nanobodies of Group 2 (and Group 3) either
monovalently or bivalently demonstrate superior binding and
competition characteristics than the corresponding Nanobodies of
Group 1, Nanobodies of Group 1 combined with Nanobodies of Group 2
gave wholly unexpectedly the best results in the .beta.-arrestin
recruitment assay.
TABLE-US-00014 TABLE B-13 Inhibition of .beta.-arrestin recruitment
of bivalent and trivalent Nanobodies Clones % inhibition of with
.beta.-arrestin Tag-3 construct recruitment 038
14G03-35GS-01C10-9GS-ALB8 94.1 052 01C10-35GS-14G03-9GS-ALB8 93.7
021 08A10-35GS-01C10-9GS-ALB8 89.5 023 08A05-35GS-01C10-9GS-ALB8
92.8 049 01C10-35GS-08A05-9GS-ALB8 89.3 022
08A05-35GS-07C03-9GS-ALB8 88.9 058 08A10-35GS-08A05-9GS-ALB8 87.8
060 08A05-35GS-08A05-9GS-ALB8 86.5 032 14G03-35GS-08A05-9GS-ALB8
76.9 048 01C10-35GS-08A10-9GS-ALB8 76.6 029
07B11-35GS-08A05-9GS-ALB8 73.8 018 08A10-35GS-14G03-9GS-ALB8 68.1
044 01C07-35GS-08A05-9GS-ALB8 66.1 020 08A10-35GS-02C08-9GS-ALB8
62.1 019 08A10-35GS-08C02-9GS-ALB8 61.6 028
07C03-35GS-01C10-9GS-ALB8 60.6 053 01C10-35GS-08C02-9GS-ALB8 58.8
061 08A05-35GS-02C08-9GS-ALB8 58.6 025 07C03-35GS-07C03-9GS-ALB8
54.5 027 07C03-35GS-02C08-9GS-ALB8 49.3 034
14G03-35GS-07B11-9GS-ALB8 43.5 050 01C10-35GS-07C03-9GS-ALB8 41.8
033 14G03-35GS-07C03-9GS-ALB8 41.2 026 07C03-35GS-14G03-9GS-ALB8
35.2 037 14G03-35GS-01C07-9GS-ALB8 34.0 065
02C08-35GS-08C02-9GS-ALB8 31.3 046 02C08-35GS-07B11-9GS-ALB8 29.6
051 01C10-35GS-07B11-9GS-ALB8 28.3 057 07B11-35GS-14G03-9GS-ALB8
26.0 063 01C07-35GS-08C02-9GS-ALB8 25.8 035
14G03-35GS-14G03-9GS-ALB8 24.9 036 14G03-35GS-08C02-9GS-ALB8 22.0
031 07B11-35GS-01C10-9GS-ALB8 4.3 055 01C10-35GS-01C10-9GS-ALB8
-8.5 056 01D04-35GS-14G03-9GS-ALB8 -51.3
Example 16
Optimization of Bivalent and Trivalent Nanobodies
[0741] Selected bivalent and trivalent Nanobodies were further
characterized in the .beta.-arrestin recruitment assay and
potencies were assessed. The assay was run in the presence and
absence of HSA to estimate the effect of HSA binding to the
Nanobody during the assay. Longer linkers preceding the ALB8
building block were evaluated to minimize sterical interference of
HSA binding to the Nanobody (Table B-14).
TABLE-US-00015 TABLE B-14 Optimization of bivalent and trivalent
Nanobodies .beta.-arrestin .beta.-arrestin recruitment in
recruitment in Clones with absence of HSA presence of HSA Tag-3
construct [IC50] [IC50] 038 14G03-35GS-01C10-9GS-ALB8 3.28 19.38
052 01C10-35GS-14G03-9GS-ALB8 18.3 86.8 055
01C10-35GS-01C10-9GS-ALB8 no antagonism no antagonism 056
01D04-35GS-14G03-9GS-ALB8 no antagonism no antagonism 068
07C03-9GS-ALB8 279.6 inefficient antagonism 069 08A05-9GS-ALB8
120.2 inefficient antagonism 072 14G03-9GS-ALB8 inefficient
inefficient antagonism antagonism 081 07C03-30GS-ALB8 296.9
inefficient antagonism 082 14G03-30GS-ALB8 578 inefficient
antagonism 083 08A05-30GS-ALB8 45.46 179.1 084
14G03-35GS-01C10-35GS-ALB8 6.3 10.0
Example 17
Characterization of Tagless Nanobodies
[0742] To exclude any influence of Tag-3 on Nanobody potencies,
selected Nanobodies were expressed without Tag-3 and characterized
in both the .beta.-arrestin recruitment assay and in the SDF-1
competition FACS in the presence of 2 mg/ml HSA (further
essentially as described in Example 10) and potencies were assessed
(Table B-15 and FIG. 8). Constructs comprising "Group 2
ISVD"-"Group 2 ISVD" (represented by e.g. clone 086) and constructs
comprising "Group 2 ISVD"-"Group 1 ISVD" (represented by e.g.,
clone 085) are more efficacious in SDF-1 displacement than
constructs comprising "Group 1 ISVD"-"Group 1 ISVD" (represented by
e.g., clone 093). Competition with constructs comprising "Group 1
ISVD"-"Group 1 ISVD" (represented by e.g., clone 093) is less
effective.
[0743] These data corroborate the radioligand competition assays,
in which the monovalent 01C10 was tested (cf. Table B-10: 31% for
01C10).
[0744] Thus, Group 2 ISVDs are excellent SDF-1 displacers.
TABLE-US-00016 TABLE B-15 Characterization of tagless Nanobodies
.beta.-arrestin .beta.-arrestin recruitment in recruitment in SDF-1
absence of HSA presence of HSA displacement Clones construct [IC50]
[IC50] FACS [IC50] 085 14G03-35GS-01C10-35GS-ALB8 4.36 22.31 7.83
086 14G03-35GS-07C03-9GS-ALB8 weak antagonism no antagonism 5.02
093 01C10-35GS-01C10-35GS-ALB8 no antagonism no antagonism 20.6 Mab
8F11 12.9 34.8 34.2
Example 18
Immunohistochemical Analysis of CXCR7 Expression in Primary Tumor
Sections
[0745] Tumor sections that were analyzed for CXCR7 expression
originated from human primary tumors of variable cancer types that
had been passaged one time in nude mice. Paraffin embedded tumors
were cut into 5 .mu.m sections (with a Leica RM 2135 microtome),
dried, dewaxed and stained with hematoxylin and eosin. Thereafter,
one representative region was marked on these tumor sections so
that a 1 mm diameter cone for assembling the Tissue Micro Array
(TMA) could be punched out. The TMA was then prepared according to
Mirlacher and Storz using a Beecher Instruments Micro Tissuearrayer
(Mirlacher M. and Storz M., 2000, Gewebe-Chips fur die molekulare
Untersuchung von Tumoren, Labmed., 293-297). Array sections were
cut using the Instrumedics Sectioning Aid System and specifically
coated using "Starfrost" slides.
[0746] Immunohistochemical staining of CXCR7-expressing tissue was
performed as follows: (1) paraffin was removed from the tissue,
tissues were dehydrated and washed; (2) endogenous peroxidase was
inactivated by addition of 3% H2O2 in distilled water; (3) the
specimen was dried upon washing; (4) unspecific binding was blocked
by 10% BSA in PBS; (5) the anti-human/mouse CXCR7 monoclonal
antibody (Biolegend, clone Mab 8F11) or an isotype control antibody
(Biolegend, IgG2b) was incubated at a concentration of 25 .mu.g/mL
and subsequently the tissue was washed; (6) the secondary antibody
goat anti-mouse biotinylated IgG (JacksonImmunoResearch) was
incubated at a final concentration of 2.8 .mu.g/mL and the tissue
was washed afterwards; (7) the detection was performed with the ABC
solution and peroxidase substrate of the Vectastain ABC kit
(Vector), each step followed by a washing step; (8) counterstaining
with hematoxylin and (9) dehydration of the tissue.
[0747] The TMA (170 tumor models) was evaluated semi-quantitatively
using a Zeiss Axiovert 35 microscope. Photographs were taken with a
Zeiss AxioCam MRc camera. All tumor samples were evaluated in
duplicate. Staining was interpreted based on the proportion of
positively-stained cells as well as on the signal intensity.
Samples were grouped in the following categories: 0, no staining
(antigen absent); 1, weak staining; 2, moderate staining; 3, strong
staining.
[0748] FIG. 3 gives an overview of the scores assigned to the
different tumor types. A high CXCR7 expression (score=3) in at
least one of the two tissue patches was found in 55 out of the 170
tumors tested (=32.4%). Nine tumors did not show any CXCR7
expression (staining score=0) and for the rest of the xenograft
tissues a weak or intermediate expression (scores 1 and 2) was
found. Notably, the majority of colon cancer tumors (19 out of 23
or 82.6%) and gastric cancer tumors (8 out of 12 or 66.7%)
displayed no or only weak staining with a score of .gtoreq.1,
whereas all of the head and neck cancer tumors (7 out of 7 or 100%)
tested showed a relatively high CXCR7 expression with a score of
.gtoreq.2. In the other histotypes, however, CXCR7 staining was
highly variable between the individual tumor models.
[0749] For some tumor samples, staining intensity was confirmed on
whole tumor sections.
Example 19
CXCR7 Nanobodies Reduce Head and Neck Cancer Xenograft Tumour
Growth In Vivo
19.1 Materials and Methods
19.1.1 Cell Lines.
[0750] Cell line UM-SCC-11B (11B) was cultured from a biopsy of a
primary laryngeal cancer, after the patient got chemotherapy. Cell
line UM-SCC-22A (22A) was derived from a primary squamous cell
carcinoma of the oropharynx. Cell line UM-SCC-22B (22B) was derived
from a metastatic squamous cell carcinoma of the oropharynx. The
human head and neck squamous cell carcinoma (HNSCC) cell lines FaDu
and HNX-OE have been described earlier (Hermsen et al., (1996)
"Centromeric breakage as a major cause of cytogenetic abnormalities
in oral squamous cell carcinoma" Genes Chromosomes Cancer 15:1-9;
Ranger (1972) "A new human cell line (FaDu) from a hypopharyngeal
carcinoma" Cancer 29: 117-121). The HNX-OE and 93-VU-147T cell
lines were established at Vrije Universiteit Amsterdam (Hermsen et
al. ibid), whereas the FaDu line was obtained from Karl-Heinz
Heider (Boehringer Ingelheim Austria).
19.1.2 Quantitative RT-PCR Analysis.
[0751] Total RNA was extracted from head and neck cancer cell lines
with the RNeasy kit from Qiagen according to the manufacturer
protocol. Messenger (m)RNA was converted into cDNA using the BioRad
iScript cDNA synthesis kit. Subsequently, mRNA expression levels
were detected with SyberGreen (BioRad) using CXCR7 and
.beta.-actin-specific primers from Origene. CXCR7 expression levels
were normalized against those of .beta.-actin to allow comparison
of the different cell lines.
19.1.3 Radioligand Binding.
[0752] Head and neck cancer cell lines were seeded on
poly-L-lysine-coated 96-well plates and grown overnight. The
following day, binding buffer (50 mM Hepes pH 7.4, 1 mM CaCl.sub.2,
5 mM MgCl.sub.2, 0.1 M NaCl) supplemented with 0.5% BSA was added
to the cells in the absence or presence of either chemokine
(10.sup.-7 M) or CXCR7-specific Nanobody 9A4 (10.sup.-5 M).
Subsequently, radiolabelled [.sup.125I]-CXCL12 (Perkin-Elmer) was
added to reach a final concentration of 75 .mu.M. Cells were
incubated for 3 h at 4.degree. C., washed twice with binding buffer
containing 0.5 M NaCl. After harvesting the samples with lysis
buffer, the remaining cell-bound radioactivity was counted.
19.1.4 Animal Experiment.
[0753] All animal experiments were conducted according to the NIH
principles of laboratory animal care and Dutch national law ["Wet
op de Dierproeven" (Stb 1985, 336)], approved by the
Dierexperimentencommissie from the VU University Medical Center and
performed in compliance with the protocol FaCh 10-01. Head and neck
cancer cells 22A were injected s.c. in the flanks of 8- to 10-week
old female donor nude mice (Hsd, athymic nu/nu, Harlan
laboratories). Xenograft tumors were grown to a size of 200-500
mm.sup.3, and were subsequently excised, cut in smaller pieces of
equal size and transplanted s.c. in the flanks of recipient nude
mice. When transplanted tumors properly engrafted, mice were
injected i.p. bi-weekly with either PBS, or 1 mg bivalent Nanobody
or 1.5 mg trivalent Nanobody.
19.2 Results
[0754] 19.2.1 mRNA Expression of CXCR7.
[0755] Head and neck cancer cell lines were first tested for CXCR7
mRNA expression. Out of 6 cell lines tested, 4 cell lines showed
mRNA expression of CXCR7, namely 22A, 22B, OE and 93-VU-147 cell
lines (FIG. 4).
19.2.2 Protein Expression of CXCR7.
[0756] CXCR7 mRNA is expressed in a wide range of tissues in
humans. However, mRNA expression does not always correlate with
cell surface expression of the protein. Therefore, in order to
further assess the presence of CXCR7 protein, protein expression of
CXCR7 was confirmed in a [.sup.125I]-CXCL12 radioligand binding
assay. CXCR7-specific expression was determined by displacing the
radioligand with the cold chemokines CXCL12 and CXCL11, but not
CXCL10. Additionally, the monovalent Nanobody 09A04 displaced
[.sup.125I]-CXCL12 to a similar extent than CXCL11 and CXCL12 (FIG.
5).
[0757] These data confirmed that mRNA and protein CXCR7 were
expressed in 4 head and neck cancer cell lines.
19.2.3 CXCR7 Nanobodies are Able to Inhibit Tumour Growth.
[0758] CXCR7-expressing cell lines were used in a xenograft model
in viva where tumour growth was measured. The 22A cell line was
chosen as xenograft tumour model since nude mice s.c. injected with
2.times.10.sup.6 cells per flank allowed for xenograft tumor
formation. Next, to ensure that mice from different groups (treated
vs. non-treated) presented similar initial tumour sizes for the
therapy experiment, we performed tumour transplantation. First,
donor nude mice were initially injected with 2.times.10.sup.6 22A
cells s.c. in their flanks. Tumours were grown to a size of 200-500
mm.sup.3 and subsequently extracted, cut in smaller pieces of equal
size, and transplanted s.c. in recipient nude mice. When engrafted
tumours started growing, mice were randomly distributed into five
groups that were injected bi-weekly with 400 ul PBS without or with
Nanobodies. The constructs tested for therapy were clone 060, clone
083, clone 085 and clone 093. Bivalent and trivalent Nanobodies
were dosed at 1 and 1.5 mg per injection, respectively. Over a
period of 50 days of therapy, the control (PBS) and clone 060 and
clone 083 groups grew tumors to a similar extent (no significant
different sizes)(FIG. 6). Mice treated with clone 085 and clone 093
displayed a slower tumour growth and significant smaller size
compared to PBS-injected mice at the end of the therapy experiment
(tumour volumes PBS 274.+-.47 mm.sup.3, clone 085=119.+-.30
mm.sup.3 and clone 093=114.+-.32 mm.sup.3) (FIG. 7).
[0759] Thus, CXCR7 Nanobodies reduce head and neck cancer cell
growth in viva.
[0760] This study supports not only the anti-tumour efficacy of the
Nanobodies, but also an excellent safety profile, a reflection of
its highly targeted and specific activity profile, which is
fundamentally different from many other cytotoxic drugs in
development or on the market.
Example 20
CXCR7 Nanobodies Reduce Xenograft Tumour Growth In Vivo
[0761] In Example 19, it has been demonstrated that CXCR7
Nanobodies are able to inhibit tumours as exemplified by head and
neck cancers.
[0762] In a first phase to demonstrate in vivo that the Nanobodies
are also effective in other tumours in which CXCR7 is
(over)-expressed than head and neck cancers, further xenograph
models can be used.
[0763] Gliomas are the most common forms of primary human brain
tumors, and they are often classified into four clinical grades.
The most aggressive tumors, grade 4 tumors, also known as
glioblastoma multiforme (GBM), are associated with high mortality
and morbidity. Survival of patients affected by GBM has remained
virtually unchanged during the last decades (i.e., 6-12 months
postdiagnosis) despite advances in surgery, radiation, and
chemotherapy. GBM xenograph models can be used essentially as
described, for instance, by Yi et al. (EGFR Gene Overexpression
Retained in an Invasive Xenograft Model by Solid Orthotopic
Transplantation of Human Glioblastoma Multiforme Into Nude Mice"
Cancer Invest. 2011 29: 229-239).
[0764] Essentially, the xenograph set up as described in Example 19
is employed, but using xenographs derived from primary tumours,
which are obtained from patients who undergo surgical treatment.
Cells derived from these tumours are injected into 4-6 weeks old,
congenitally athymic nude mice, female, on Balb/c nu/nu background.
Mice are maintained under specific pathogen-free barrier
environment. For grafting and imaging, the mice are anesthetized
intraperitoneally with a 0.10 mg ketamine hydrochloride solution
per gram body weight. If necessary, the tumours are excised and
retransplanted into other mice, as described in Example 19.
[0765] Therapy is started with biweekly injections of 1.5 mg of
either PBS, clone 060, clone 083, clone 085 and clone 093. Tumour
size is measured every 4 days. The tumour size is measured by a
caliper, and the tumour volume is calculated using the formula
(length.times.width.sup.2)/2. The development of the tumour volumes
of the mice is followed for 30 days. At 30 days the mice are
sacrificed. The tumours are weighed and fixed in 4%
polyformaldehyde. The tumour sections are excised for
immunohistochemical analysis.
[0766] The tumours listed in FIG. 3 are tested similarly, either by
xenographs of established cell lines or derived from primary
tumours. Tumours having a high percentage of CXCR7 are preferred
for initial testing.
Example 21
Group 1 Immunoglobulin Single Variable Domains
[0767] In view of binding, competition and/or .beta.-arrestin
results, various ISVDs were not further assessed after initial
screening. However, the in vivo results of Examples 19-20 prompted
us to further evaluate the presence of other family members of
Group 1 ISVDs.
[0768] After reassessing the sequences, at least the following 4
Group 1 ISVDs were identified: 01C12 (SEQ ID NO: 99), 01B12 (SEQ ID
NO: 100), 01F11 (SEQ ID NO: 101) and 01B10 (SEQ ID NO: 102) (Table
B-3).
Example 22
CXCR7 Nanobodies Reduce Head and Neck Cancer Xenograft Tumour
Growth In Vivo
[0769] In Example 19 it was demonstrated that CXCR7 Nanobodies
reduce head and neck cancer cell growth in vivo. In Example 19,
mice received 1.5 mg of either clone 085 (Group 1 ISVD-Group 2
ISVD) or clone 093 (Group 1 ISVD-Group 1 ISVD).
[0770] In view of the binding efficacies of Group 2 ISVDs, it is
expected that constructs comprising Group 1 ISVD-Group 2 ISVD (e.g.
clone 085) would be more efficient than Group 1 ISVD-Group 1 ISVD
(e.g. clone 093).
[0771] Accordingly, the in vivo xenograft model of Example 19 is
used to test this hypothesis. Again, the mice are randomly
distributed into 11 groups of 5 mice each that are injected
bi-weekly with 400 ul PBS without or with the constructs. The
constructs tested for therapy are clone 085 and clone 093.
[0772] The dosing is according to the following scheme:
TABLE-US-00017 construct dose/biweekly/5 mice clone 085 1.5 mg 0.75
mg 0.375 mg 0.17 mg 0.085 mg clone 093 1.5 mg 0.75 mg 0.375 mg 0.17
mg 0.085 mg PBS (negative -- -- -- -- -- control)
[0773] Tumour size is measured every 4 days. The tumour size is
measured by a caliper, and the tumour volume is calculated using
the formula (length.times.width.sup.2)/2. The development of the
tumour volumes of the mice is followed for 30 days. At 50 days the
mice are sacrificed. The tumours are weighed and fixed in 4%
polyformaldehyde. The tumour sections are excised for
immunohistochemical analysis.
Sequence CWU 1
1
1401362PRTHomo sapiens 1Met Asp Leu His Leu Phe Asp Tyr Ser Glu Pro
Gly Asn Phe Ser Asp 1 5 10 15 Ile Ser Trp Pro Cys Asn Ser Ser Asp
Cys Ile Val Val Asp Thr Val 20 25 30 Met Cys Pro Asn Met Pro Asn
Lys Ser Val Leu Leu Tyr Thr Leu Ser 35 40 45 Phe Ile Tyr Ile Phe
Ile Phe Val Ile Gly Met Ile Ala Asn Ser Val 50 55 60 Val Val Trp
Val Asn Ile Gln Ala Lys Thr Thr Gly Tyr Asp Thr His 65 70 75 80 Cys
Tyr Ile Leu Asn Leu Ala Ile Ala Asp Leu Trp Val Val Leu Thr 85 90
95 Ile Pro Val Trp Val Val Ser Leu Val Gln His Asn Gln Trp Pro Met
100 105 110 Gly Glu Leu Thr Cys Lys Val Thr His Leu Ile Phe Ser Ile
Asn Leu 115 120 125 Phe Gly Ser Ile Phe Phe Leu Thr Cys Met Ser Val
Asp Arg Tyr Leu 130 135 140 Ser Ile Thr Tyr Phe Thr Asn Thr Pro Ser
Ser Arg Lys Lys Met Val 145 150 155 160 Arg Arg Val Val Cys Ile Leu
Val Trp Leu Leu Ala Phe Cys Val Ser 165 170 175 Leu Pro Asp Thr Tyr
Tyr Leu Lys Thr Val Thr Ser Ala Ser Asn Asn 180 185 190 Glu Thr Tyr
Cys Arg Ser Phe Tyr Pro Glu His Ser Ile Lys Glu Trp 195 200 205 Leu
Ile Gly Met Glu Leu Val Ser Val Val Leu Gly Phe Ala Val Pro 210 215
220 Phe Ser Ile Ile Ala Val Phe Tyr Phe Leu Leu Ala Arg Ala Ile Ser
225 230 235 240 Ala Ser Ser Asp Gln Glu Lys His Ser Ser Arg Lys Ile
Ile Phe Ser 245 250 255 Tyr Val Val Val Phe Leu Val Cys Trp Leu Pro
Tyr His Val Ala Val 260 265 270 Leu Leu Asp Ile Phe Ser Ile Leu His
Tyr Ile Pro Phe Thr Cys Arg 275 280 285 Leu Glu His Ala Leu Phe Thr
Ala Leu His Val Thr Gln Cys Leu Ser 290 295 300 Leu Val His Cys Cys
Val Asn Pro Val Leu Tyr Ser Phe Ile Asn Arg 305 310 315 320 Asn Tyr
Arg Tyr Glu Leu Met Lys Ala Phe Ile Phe Lys Tyr Ser Ala 325 330 335
Lys Thr Gly Leu Thr Lys Leu Ile Asp Ala Ser Arg Val Ser Glu Thr 340
345 350 Glu Tyr Ser Ala Leu Glu Gln Ser Thr Lys 355 360 2
115PRTArtificial SequenceNanobody sequence 2Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln
Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 3 362PRTMus
musculus 3Met Asp Val His Leu Phe Asp Tyr Ala Glu Pro Gly Asn Tyr
Ser Asp 1 5 10 15 Ile Asn Trp Pro Cys Asn Ser Ser Asp Cys Ile Val
Val Asp Thr Val 20 25 30 Gln Cys Pro Thr Met Pro Asn Lys Asn Val
Leu Leu Tyr Thr Leu Ser 35 40 45 Phe Ile Tyr Ile Phe Ile Phe Val
Ile Gly Met Ile Ala Asn Ser Val 50 55 60 Val Val Trp Val Asn Ile
Gln Ala Lys Thr Thr Gly Tyr Asp Thr His 65 70 75 80 Cys Tyr Ile Leu
Asn Leu Ala Ile Ala Asp Leu Trp Val Val Ile Thr 85 90 95 Ile Pro
Val Trp Val Val Ser Leu Val Gln His Asn Gln Trp Pro Met 100 105 110
Gly Glu Leu Thr Cys Lys Ile Thr His Leu Ile Phe Ser Ile Asn Leu 115
120 125 Phe Gly Ser Ile Phe Phe Leu Ala Cys Met Ser Val Asp Arg Tyr
Leu 130 135 140 Ser Ile Thr Tyr Phe Thr Gly Thr Ser Ser Tyr Lys Lys
Lys Met Val 145 150 155 160 Arg Arg Val Val Cys Ile Leu Val Trp Leu
Leu Ala Phe Phe Val Ser 165 170 175 Leu Pro Asp Thr Tyr Tyr Leu Lys
Thr Val Thr Ser Ala Ser Asn Asn 180 185 190 Glu Thr Tyr Cys Arg Ser
Phe Tyr Pro Glu His Ser Ile Lys Glu Trp 195 200 205 Leu Ile Gly Met
Glu Leu Val Ser Val Ile Leu Gly Phe Ala Val Pro 210 215 220 Phe Thr
Ile Ile Ala Ile Phe Tyr Phe Leu Leu Ala Arg Ala Met Ser 225 230 235
240 Ala Ser Gly Asp Gln Glu Lys His Ser Ser Arg Lys Ile Ile Phe Ser
245 250 255 Tyr Val Val Val Phe Leu Val Cys Trp Leu Pro Tyr His Phe
Val Val 260 265 270 Leu Leu Asp Ile Phe Ser Ile Leu His Tyr Ile Pro
Phe Thr Cys Gln 275 280 285 Leu Glu Asn Val Leu Phe Thr Ala Leu His
Val Thr Gln Cys Leu Ser 290 295 300 Leu Val His Cys Cys Val Asn Pro
Val Leu Tyr Ser Phe Ile Asn Arg 305 310 315 320 Asn Tyr Arg Tyr Glu
Leu Met Lys Ala Phe Ile Phe Lys Tyr Ser Ala 325 330 335 Lys Thr Gly
Leu Thr Lys Leu Ile Asp Ala Ser Arg Val Ser Glu Thr 340 345 350 Glu
Tyr Ser Ala Leu Glu Gln Asn Thr Lys 355 360 430PRTArtificial
SequenceNanobody sequence 4Glu Val Gln Leu Val Glu Ser Gly Gly Asn
Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Gly Leu Ser Cys Ala Ala
Ser Val Ser Ile Ser Ser 20 25 30 530PRTArtificial SequenceNanobody
sequence 5Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala
Gly Glu 1 5 10 15 Ser Leu Thr Leu Ser Cys Ala Ala Ser Gly Arg Thr
Leu Ser 20 25 30 630PRTArtificial SequenceNanobody sequence 6Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp 1 5 10
15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser 20 25 30
730PRTArtificial SequenceNanobody sequence 7Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Ser Ile Phe Ser 20 25 30 830PRTArtificial
SequenceNanobody sequence 8Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Ile Ser Cys Ala Ala
Ser Gly Ser Ile Tyr Leu 20 25 30 95PRTArtificial SequenceNanobody
sequence 9Ile His Ile Met Gly 1 5 105PRTArtificial SequenceNanobody
sequence 10Ala Tyr Ile Met Gly 1 5 115PRTArtificial
SequenceNanobody sequence 11Asn Tyr Asp Met Gly 1 5
125PRTArtificial SequenceNanobody sequence 12Ile Ala Ala Met Gly 1
5 135PRTArtificial SequenceNanobody sequence 13Ile Asn Tyr Met Gly
1 5 1414PRTArtificial SequenceNanobody sequence 14Trp Tyr Arg Gln
Ala Pro Gly Lys Gln Arg Asp Leu Val Ala 1 5 10 1514PRTArtificial
SequenceNanobody sequence 15Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg
Glu Phe Val Ala 1 5 10 1614PRTArtificial SequenceNanobody sequence
16Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Gly 1 5 10
1714PRTArtificial SequenceNanobody sequence 17Trp Tyr Arg Gln Ala
Thr Gly Lys Gln Arg Glu Leu Val Ala 1 5 10 1814PRTArtificial
SequenceNanobody sequence 18Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg
Glu Leu Val Ala 1 5 10 1916PRTArtificial SequenceNanobody sequence
19Thr Ile Thr Ser Gly Gly Ser Thr Ala Tyr Ala Asp Ser Val Lys Gly 1
5 10 15 2016PRTArtificial SequenceNanobody sequence 20Gly Ile Trp
Ser Gly Gly Tyr Thr His Leu Ala Asp Ser Ala Lys Gly 1 5 10 15
2117PRTArtificial SequenceNanobody sequence 21Ala Ser Trp Trp Ser
Gly Gly Ala Pro Tyr Tyr Ser Asp Ser Val Lys 1 5 10 15 Gly
2216PRTArtificial SequenceNanobody sequence 22Thr Ile Thr Asp Gly
Gly Thr Thr Thr Tyr Ala Asp Ser Val Lys Gly 1 5 10 15
2316PRTArtificial SequenceNanobody sequence 23Thr Leu Thr Ser Gly
Gly Ser Thr Asn Tyr Ala Gly Ser Val Lys Gly 1 5 10 15
2432PRTArtificial SequenceNanobody sequence 24Arg Phe Thr Val Ser
Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln 1 5 10 15 Met Asp Ser
Leu Lys Pro Glu Asp Thr Ser Val Tyr Tyr Cys Ala Ala 20 25 30
2532PRTArtificial SequenceNanobody sequence 25Arg Phe Ser Ile Ser
Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln 1 5 10 15 Met Asn Gly
Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 30
2632PRTArtificial SequenceNanobody sequence 26Arg Phe Thr Ile Ser
Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln 1 5 10 15 Ala Asn Ser
Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 30
2732PRTArtificial SequenceNanobody sequence 27Arg Val Thr Ile Ser
Arg Asp Arg Ser Ala Asn Thr Val Tyr Leu Ala 1 5 10 15 Met Asn Asn
Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys Tyr Ala 20 25 30
2832PRTArtificial SequenceNanobody sequence 28Arg Phe Ala Ile Ser
Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln 1 5 10 15 Met Asn Ser
Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ile 20 25 30
2913PRTArtificial SequenceNanobody sequence 29Glu Val Arg Asn Gly
Val Phe Gly Lys Trp Asn His Tyr 1 5 10 309PRTArtificial
SequenceNanobody sequence 30Gly Leu Arg Gly Arg Gln Tyr Ser Asn 1 5
3114PRTArtificial SequenceNanobody sequence 31Lys Arg Leu Arg Ser
Phe Ala Ser Gly Gly Ser Tyr Asp Tyr 1 5 10 3213PRTArtificial
SequenceNanobody sequence 32Tyr Leu Arg Tyr Thr Ser Arg Val Pro Gly
Asp Asn Tyr 1 5 10 3312PRTArtificial SequenceNanobody sequence
33Gly Gly Thr Leu Tyr Asp Arg Arg Arg Phe Glu Ser 1 5 10
3411PRTArtificial SequenceNanobody sequence 34Trp Gly Gln Gly Thr
Gln Val Thr Val Ser Ser 1 5 10 3511PRTArtificial SequenceNanobody
sequence 35Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 1 5 10
3611PRTArtificial SequenceNanobody sequence 36Trp Gly Gln Gly Thr
Gln Val Thr Val Ser Ser 1 5 10 3711PRTArtificial SequenceNanobody
sequence 37Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 1 5 10
3811PRTArtificial SequenceNanobody sequence 38Trp Gly Gln Gly Thr
Gln Val Thr Val Ser Ser 1 5 10 39121PRTArtificial SequenceNanobody
sequence 39Glu Val Gln Leu Val Glu Ser Gly Gly Asn Leu Val Gln Ala
Gly Gly 1 5 10 15 Ser Leu Gly Leu Ser Cys Ala Ala Ser Val Ser Ile
Ser Ser Ile His 20 25 30 Ile Met Gly Trp Tyr Arg Gln Ala Pro Gly
Lys Gln Arg Asp Leu Val 35 40 45 Ala Thr Ile Thr Ser Gly Gly Ser
Thr Ala Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Val Ser
Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu 65 70 75 80 Gln Met Asp Ser
Leu Lys Pro Glu Asp Thr Ser Val Tyr Tyr Cys Ala 85 90 95 Ala Glu
Val Arg Asn Gly Val Phe Gly Lys Trp Asn His Tyr Trp Gly 100 105 110
Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 40117PRTArtificial
SequenceNanobody sequence 40Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Ala Gly Glu 1 5 10 15 Ser Leu Thr Leu Ser Cys Ala Ala
Ser Gly Arg Thr Leu Ser Ala Tyr 20 25 30 Ile Met Gly Trp Phe Arg
Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45 Ala Gly Ile Trp
Ser Gly Gly Tyr Thr His Leu Ala Asp Ser Ala Lys 50 55 60 Gly Arg
Phe Ser Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu 65 70 75 80
Gln Met Asn Gly Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85
90 95 Ala Gly Leu Arg Gly Arg Gln Tyr Ser Asn Trp Gly Gln Gly Thr
Gln 100 105 110 Val Thr Val Ser Ser 115 41123PRTArtificial
SequenceNanobody sequence 41Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Ala Gly Asp 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Leu Thr Phe Ser Asn Tyr 20 25 30 Asp Met Gly Trp Phe Arg
Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45 Gly Ala Ser Trp
Trp Ser Gly Gly Ala Pro Tyr Tyr Ser Asp Ser Val 50 55 60 Lys Gly
Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr 65 70 75 80
Leu Gln Ala Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Ala Lys Arg Leu Arg Ser Phe Ala Ser Gly Gly Ser Tyr Asp
Tyr 100 105 110 Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120
42121PRTArtificial SequenceNanobody sequence 42Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Ser Ile Ala 20 25 30 Ala
Met Gly Trp Tyr Arg Gln Ala Thr Gly Lys Gln Arg Glu Leu Val 35 40
45 Ala Thr Ile Thr Asp Gly Gly Thr Thr Thr Tyr Ala Asp Ser Val Lys
50 55 60 Gly Arg Val Thr Ile Ser Arg Asp Arg Ser Ala Asn Thr Val
Tyr Leu 65 70 75 80 Ala Met Asn Asn Leu Lys Pro Asp Asp Thr Ala Val
Tyr Tyr Cys Tyr 85 90 95 Ala Tyr Leu Arg Tyr Thr Ser Arg Val Pro
Gly Asp Asn Tyr Trp Gly 100 105 110 Gln Gly Thr Gln Val Thr Val Ser
Ser 115 120 43120PRTArtificial SequenceNanobody sequence 43Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Ile Ser Cys Ala Ala Ser Gly Ser Ile Tyr Leu Ile Asn 20
25 30 Tyr Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu
Val 35 40 45 Ala Thr Leu Thr Ser Gly Gly Ser Thr Asn Tyr Ala Gly
Ser Val Lys 50 55 60 Gly Arg Phe Ala Ile Ser Arg Asp Asn Ala Lys
Asn Thr Val Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Lys Pro Glu Asp
Thr Ala Val Tyr Tyr Cys Asn 85 90 95 Ile Gly Gly Thr Leu Tyr Asp
Arg Arg Arg Phe Glu Ser Trp Gly Gln 100
105 110 Gly Thr Gln Val Thr Val Ser Ser 115 120 44245PRTArtificial
SequenceNanobody sequence 44Glu Val Gln Leu Val Glu Ser Gly Gly Asn
Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Gly Leu Ser Cys Ala Ala
Ser Val Ser Ile Ser Ser Ile His 20 25 30 Ile Met Gly Trp Tyr Arg
Gln Ala Pro Gly Lys Gln Arg Asp Leu Val 35 40 45 Ala Thr Ile Thr
Ser Gly Gly Ser Thr Ala Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg
Phe Thr Val Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu 65 70 75 80
Gln Met Asp Ser Leu Lys Pro Glu Asp Thr Ser Val Tyr Tyr Cys Ala 85
90 95 Ala Glu Val Arg Asn Gly Val Phe Gly Lys Trp Asn His Tyr Trp
Gly 100 105 110 Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly
Ser Gly Gly 115 120 125 Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro 130 135 140 Gly Asn Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Phe Thr Phe Ser 145 150 155 160 Ser Phe Gly Met Ser Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu 165 170 175 Trp Val Ser Ser
Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp 180 185 190 Ser Val
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr 195 200 205
Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 210
215 220 Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr
Leu 225 230 235 240 Val Thr Val Ser Ser 245 45241PRTArtificial
SequenceNanobody sequence 45Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Ala Gly Glu 1 5 10 15 Ser Leu Thr Leu Ser Cys Ala Ala
Ser Gly Arg Thr Leu Ser Ala Tyr 20 25 30 Ile Met Gly Trp Phe Arg
Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45 Ala Gly Ile Trp
Ser Gly Gly Tyr Thr His Leu Ala Asp Ser Ala Lys 50 55 60 Gly Arg
Phe Ser Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu 65 70 75 80
Gln Met Asn Gly Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85
90 95 Ala Gly Leu Arg Gly Arg Gln Tyr Ser Asn Trp Gly Gln Gly Thr
Gln 100 105 110 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
Ser Glu Val 115 120 125 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Asn Ser Leu 130 135 140 Arg Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser Ser Phe Gly Met 145 150 155 160 Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val Ser Ser 165 170 175 Ile Ser Gly Ser
Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val Lys Gly 180 185 190 Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr Leu Gln 195 200 205
Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ile 210
215 220 Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr Val
Ser 225 230 235 240 Ser 46247PRTArtificial SequenceNanobody
sequence 46Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala
Gly Asp 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr
Phe Ser Asn Tyr 20 25 30 Asp Met Gly Trp Phe Arg Gln Ala Pro Gly
Lys Glu Arg Glu Phe Val 35 40 45 Gly Ala Ser Trp Trp Ser Gly Gly
Ala Pro Tyr Tyr Ser Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Ala Asn
Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala
Lys Arg Leu Arg Ser Phe Ala Ser Gly Gly Ser Tyr Asp Tyr 100 105 110
Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115
120 125 Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val 130 135 140 Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr 145 150 155 160 Phe Ser Ser Phe Gly Met Ser Trp Val Arg
Gln Ala Pro Gly Lys Gly 165 170 175 Leu Glu Trp Val Ser Ser Ile Ser
Gly Ser Gly Ser Asp Thr Leu Tyr 180 185 190 Ala Asp Ser Val Lys Gly
Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys 195 200 205 Thr Thr Leu Tyr
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala 210 215 220 Val Tyr
Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly 225 230 235
240 Thr Leu Val Thr Val Ser Ser 245 47245PRTArtificial
SequenceNanobody sequence 47Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Ser Ile Phe Ser Ile Ala 20 25 30 Ala Met Gly Trp Tyr Arg
Gln Ala Thr Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Thr Ile Thr
Asp Gly Gly Thr Thr Thr Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg
Val Thr Ile Ser Arg Asp Arg Ser Ala Asn Thr Val Tyr Leu 65 70 75 80
Ala Met Asn Asn Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys Tyr 85
90 95 Ala Tyr Leu Arg Tyr Thr Ser Arg Val Pro Gly Asp Asn Tyr Trp
Gly 100 105 110 Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly
Ser Gly Gly 115 120 125 Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro 130 135 140 Gly Asn Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Phe Thr Phe Ser 145 150 155 160 Ser Phe Gly Met Ser Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu 165 170 175 Trp Val Ser Ser
Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp 180 185 190 Ser Val
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr 195 200 205
Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 210
215 220 Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr
Leu 225 230 235 240 Val Thr Val Ser Ser 245 48244PRTArtificial
SequenceNanobody sequence 48Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Ile Ser Cys Ala Ala
Ser Gly Ser Ile Tyr Leu Ile Asn 20 25 30 Tyr Met Gly Trp Tyr Arg
Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Thr Leu Thr
Ser Gly Gly Ser Thr Asn Tyr Ala Gly Ser Val Lys 50 55 60 Gly Arg
Phe Ala Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu 65 70 75 80
Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85
90 95 Ile Gly Gly Thr Leu Tyr Asp Arg Arg Arg Phe Glu Ser Trp Gly
Gln 100 105 110 Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser
Gly Gly Gly 115 120 125 Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly 130 135 140 Asn Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser Ser 145 150 155 160 Phe Gly Met Ser Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 165 170 175 Val Ser Ser Ile
Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser 180 185 190 Val Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu 195 200 205
Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr 210
215 220 Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu
Val 225 230 235 240 Thr Val Ser Ser 495PRTArtificial
SequenceNanobody sequence 49Gly Gly Gly Gly Ser 1 5
507PRTArtificial SequenceNanobody sequence 50Ser Gly Gly Ser Gly
Gly Ser 1 5 519PRTArtificial SequenceNanobody sequence 51Gly Gly
Gly Gly Ser Gly Gly Gly Ser 1 5 5210PRTArtificial SequenceNanobody
sequence 52Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10
5315PRTArtificial SequenceNanobody sequence 53Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 15 5418PRTArtificial
SequenceNanobody sequence 54Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Gly Gly 1 5 10 15 Gly Ser 5520PRTArtificial
SequenceNanobody sequence 55Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser 20
5625PRTArtificial SequenceNanobody sequence 56Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly
Ser Gly Gly Gly Gly Ser 20 25 5730PRTArtificial SequenceNanobody
sequence 57Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser 20 25 30 5835PRTArtificial SequenceNanobody sequence 58Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10
15 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
20 25 30 Gly Gly Ser 35 59363DNAArtificial SequenceNanobody
sequence 59gaggtgcaat tggtggagtc tgggggaaac ttggtgcagg ctggggggtc
tctgggactc 60tcctgtgcag cctctgtaag catctccagt atccatatca tgggctggta
ccggcaggct 120ccaggcaaac agcgcgactt ggtcgctact attactagtg
gtggtagcac agcatatgca 180gactccgtga agggacgatt caccgtctcc
aaagacaacg ccaagaacac ggtgtatctg 240caaatggaca gcctgaaacc
tgaggacaca tccgtctatt actgtgcagc cgaggtcaga 300aatggggtgt
ttggaaaatg gaatcactac tggggccagg ggacccaggt caccgtctcc 360tca
36360351DNAArtificial SequenceNanobody sequence 60gaggtgcaat
tggtggagtc tgggggagga ttggtgcagg ctggggagtc tctgactctc 60tcctgtgcag
cctctggacg caccttaagt gcctatatca tgggctggtt ccgccaggct
120ccagggaagg agcgggagtt tgtagccggt atctggagtg gtggttacac
acaccttgca 180gactccgcga agggccgatt cagcatctct agagacaacg
ccaagaacac tgtatatctg 240caaatgaacg gcctgaaacc tgaggacacg
gccgtctatt actgtgcagc aggtctgaga 300ggccgccagt atagtaactg
gggccagggg acccaggtca ccgtctcctc a 35161369DNAArtificial
SequenceNanobody sequence 61gaggtgcaat tggtggagtc tgggggagga
ttggtgcagg ctggggactc tctgagactc 60tcctgtgcag cctctggact cactttcagt
aactatgaca tgggctggtt ccgccaggct 120ccagggaagg agcgtgaatt
tgtaggggct agttggtgga gtggtggtgc cccatactat 180tcagactccg
tgaagggccg attcaccatc tccagagaca acgccaagaa cacggtgtat
240ctgcaagcga acagcctgag acctgaggac acggccgttt attactgtgc
agccaaaagg 300ctgcgtagtt tcgcctccgg tgggtcgtat gattactggg
gtcaggggac ccaggtcacc 360gtctcctca 36962348DNAArtificial
SequenceNanobody sequence 62gagtctgggg gaggcttggt gcaggctgga
gggtctctga gactctcctg tgcagcttct 60ggaagcatct tcagtatcgc tgccatgggc
tggtaccgcc aggctacagg gaagcagcgc 120gagttggtcg caactatcac
tgatggcggt acgacaacct atgcagactc cgtgaagggc 180cgagtcacca
tctccaggga caggtctgcg aacacggtgt atctggcaat gaacaatttg
240aaacctgatg acacagccgt ctattattgt tatgcgtatc tgcgctatac
aagcagagta 300cctggcgata actactgggg ccaggggacc caggtcaccg tctcctca
34863361DNAArtificial SequenceNanobody sequence 63gaggtgcaat
tggtggagtc tgggggaggc ttggtgcagc ctggggggtc tctgagaatt 60tcctgtgcag
cctctggaag catctacctt atcaattaca tgggctggta ccgccaggct
120ccagggaagc agcgcgagtt ggtcgcaacg cttactagtg gtggtagtac
caactatgca 180ggctccgtga agggccgatt cgccatctcc agagacaacg
ccaagaacac ggtttatctg 240caaatgaaca gcctgaaacc tgaggacacg
gccgtctatt actgtaatat aggaggaacg 300ctatacgaca gaaggcggtt
tgaatcctgg ggccagggga cccaggtcac cgtctcctca 360g
3616430PRTArtificial SequenceNanobody sequence 64Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 1 5 10 15 Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 20 25 30
655PRTArtificial SequenceNanobody sequence 65Ser Phe Gly Met Ser 1
5 6614PRTArtificial SequenceNanobody sequence 66Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val Ser 1 5 10 6717PRTArtificial
SequenceNanobody sequence 67Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu
Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly 6832PRTArtificial
SequenceNanobody sequence 68Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys
Thr Thr Leu Tyr Leu Gln 1 5 10 15 Met Asn Ser Leu Arg Pro Glu Asp
Thr Ala Val Tyr Tyr Cys Thr Ile 20 25 30 696PRTArtificial
SequenceNanobody sequence 69Gly Gly Ser Leu Ser Arg 1 5
7011PRTArtificial SequenceNanobody sequence 70Ser Ser Gln Gly Thr
Leu Val Thr Val Ser Ser 1 5 10 7126PRTArtificial SequenceNanobody
sequence 71Ala Ala Ala His His His His His His Gly Ala Ala Glu Gln
Lys Leu 1 5 10 15 Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala 20 25
7223PRTArtificial SequenceNanobody sequence 72Ala Ala Ala Glu Gln
Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala 1 5 10 15 Ala His His
His His His His 20 73735DNAArtificial SequenceNanobody sequence
73gaggtgcaat tggtggagtc tgggggaaac ttggtgcagg ctggggggtc tctgggactc
60tcctgtgcag cctctgtaag catctccagt atccatatca tgggctggta ccggcaggct
120ccaggcaaac agcgcgactt ggtcgctact attactagtg gtggtagcac
agcatatgca 180gactccgtga agggacgatt caccgtctcc aaagacaacg
ccaagaacac ggtgtatctg 240caaatggaca gcctgaaacc tgaggacaca
tccgtctatt actgtgcagc cgaggtcaga 300aatggggtgt ttggaaaatg
gaatcactac tggggccagg ggacccaggt cacggtctcc 360tcaggaggtg
gcgggtccgg aggcggatcc gaggtacagc tggtggagtc tgggggtggc
420ttggtgcaac cgggtaacag tctgcgcctt agctgcgcag cgtctggctt
taccttcagc 480tcctttggca tgagctgggt tcgccaggct ccgggaaaag
gactggaatg ggtttcgtct 540attagcggca gtggtagcga tacgctctac
gcggactccg tgaagggccg tttcaccatc 600tcccgcgata acgccaaaac
tacactgtat ctgcaaatga atagcctgcg tcctgaagac 660acggccgttt
attactgtac tattggtggc tcgttaagcc gttcttcaca gggtaccctg
720gtcaccgtct cctca 73574723DNAArtificial SequenceNanobody sequence
74gaggtgcaat tggtggagtc tgggggagga ttggtgcagg ctggggagtc tctgactctc
60tcctgtgcag cctctggacg caccttaagt gcctatatca tgggctggtt ccgccaggct
120ccagggaagg agcgggagtt tgtagccggt atctggagtg gtggttacac
acaccttgca 180gactccgcga agggccgatt cagcatctct agagacaacg
ccaagaacac tgtatatctg 240caaatgaacg gcctgaaacc tgaggacacg
gccgtctatt actgtgcagc aggtctgaga 300ggccgccagt atagtaactg
gggccagggg acccaggtca cggtctcctc aggaggtggc 360gggtccggag
gcggatccga ggtacagctg gtggagtctg ggggtggctt ggtgcaaccg
420ggtaacagtc tgcgccttag ctgcgcagcg tctggcttta ccttcagctc
ctttggcatg 480agctgggttc gccaggctcc gggaaaagga ctggaatggg
tttcgtctat tagcggcagt 540ggtagcgata cgctctacgc ggactccgtg
aagggccgtt tcaccatctc ccgcgataac 600gccaaaacta cactgtatct
gcaaatgaat agcctgcgtc ctgaagacac ggccgtttat 660tactgtacta
ttggtggctc gttaagccgt tcttcacagg gtaccctggt caccgtctcc 720tca
72375741DNAArtificial SequenceNanobody sequence 75gaggtgcaat
tggtggagtc tgggggagga ttggtgcagg ctggggactc tctgagactc 60tcctgtgcag
cctctggact cactttcagt aactatgaca tgggctggtt ccgccaggct
120ccagggaagg agcgtgaatt tgtaggggct agttggtgga gtggtggtgc
cccatactat 180tcagactccg tgaagggccg attcaccatc tccagagaca
acgccaagaa cacggtgtat 240ctgcaagcga acagcctgag acctgaggac
acggccgttt attactgtgc agccaaaagg 300ctgcgtagtt tcgcctccgg
tgggtcgtat gattactggg gtcaggggac ccaggtcacg 360gtctcctcag
gaggtggcgg gtccggaggc ggatccgagg tacagctggt ggagtctggg
420ggtggcttgg tgcaaccggg taacagtctg cgccttagct gcgcagcgtc
tggctttacc 480ttcagctcct ttggcatgag ctgggttcgc caggctccgg
gaaaaggact ggaatgggtt 540tcgtctatta gcggcagtgg tagcgatacg
ctctacgcgg actccgtgaa gggccgtttc 600accatctccc gcgataacgc
caaaactaca ctgtatctgc aaatgaatag cctgcgtcct 660gaagacacgg
ccgtttatta ctgtactatt ggtggctcgt taagccgttc ttcacagggt
720accctggtca ccgtctcctc a 74176735DNAArtificial SequenceNanobody
sequence 76gaggtgcaat tggtggagtc tgggggaggc ttggtgcagg ctggagggtc
tctgagactc 60tcctgtgcag cttctggaag catcttcagt atcgctgcca tgggctggta
ccgccaggct 120acagggaagc agcgcgagtt ggtcgcaact atcactgatg
gcggtacgac aacctatgca 180gactccgtga agggccgagt caccatctcc
agggacaggt ctgcgaacac ggtgtatctg 240gcaatgaaca atttgaaacc
tgatgacaca gccgtctatt attgttatgc gtatctgcgc 300tatacaagca
gagtacctgg cgataactac tggggccagg ggacccaggt cacggtctcc
360tcaggaggtg gcgggtccgg aggcggatcc gaggtacagc tggtggagtc
tgggggtggc 420ttggtgcaac cgggtaacag tctgcgcctt agctgcgcag
cgtctggctt taccttcagc 480tcctttggca tgagctgggt tcgccaggct
ccgggaaaag gactggaatg ggtttcgtct 540attagcggca gtggtagcga
tacgctctac gcggactccg tgaagggccg tttcaccatc 600tcccgcgata
acgccaaaac tacactgtat ctgcaaatga atagcctgcg tcctgaagac
660acggccgttt attactgtac tattggtggc tcgttaagcc gttcttcaca
gggtaccctg 720gtcaccgtct cctca 73577732DNAArtificial
SequenceNanobody sequence 77gaggtgcaat tggtggagtc tgggggaggc
ttggtgcagc ctggggggtc tctgagaatt 60tcctgtgcag cctctggaag catctacctt
atcaattaca tgggctggta ccgccaggct 120ccagggaagc agcgcgagtt
ggtcgcaacg cttactagtg gtggtagtac caactatgca 180ggctccgtga
agggccgatt cgccatctcc agagacaacg ccaagaacac ggtttatctg
240caaatgaaca gcctgaaacc tgaggacacg gccgtctatt actgtaatat
aggaggaacg 300ctatacgaca gaaggcggtt tgaatcctgg ggccagggga
cccaggtcac ggtctcctca 360ggaggtggcg ggtccggagg cggatccgag
gtacagctgg tggagtctgg gggtggcttg 420gtgcaaccgg gtaacagtct
gcgccttagc tgcgcagcgt ctggctttac cttcagctcc 480tttggcatga
gctgggttcg ccaggctccg ggaaaaggac tggaatgggt ttcgtctatt
540agcggcagtg gtagcgatac gctctacgcg gactccgtga agggccgttt
caccatctcc 600cgcgataacg ccaaaactac actgtatctg caaatgaata
gcctgcgtcc tgaagacacg 660gccgtttatt actgtactat tggtggctcg
ttaagccgtt cttcacaggg taccctggtc 720accgtctcct ca
73278247PRTArtificial SequenceNanobody sequence 78Glu Val Gln Leu
Val Glu Ser Gly Gly Asn Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu
Gly Leu Ser Cys Ala Ala Ser Val Ser Ile Ser Ser Ile His 20 25 30
Ile Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Asp Leu Val 35
40 45 Ala Thr Ile Thr Ser Gly Gly Ser Thr Ala Tyr Ala Asp Ser Val
Lys 50 55 60 Gly Arg Phe Thr Val Ser Lys Asp Asn Ala Lys Asn Thr
Val Tyr Leu 65 70 75 80 Gln Met Asp Ser Leu Lys Pro Glu Asp Thr Ser
Val Tyr Tyr Cys Ala 85 90 95 Ala Glu Val Arg Asn Gly Val Phe Gly
Lys Trp Asn His Tyr Trp Gly 100 105 110 Gln Gly Thr Gln Val Thr Val
Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Ser Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala 130 135 140 Gly Glu Ser
Leu Thr Leu Ser Cys Ala Ala Ser Gly Arg Thr Leu Ser 145 150 155 160
Ala Tyr Ile Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 165
170 175 Phe Val Ala Gly Ile Trp Ser Gly Gly Tyr Thr His Leu Ala Asp
Ser 180 185 190 Ala Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys
Asn Thr Val 195 200 205 Tyr Leu Gln Met Asn Gly Leu Lys Pro Glu Asp
Thr Ala Val Tyr Tyr 210 215 220 Cys Ala Ala Gly Leu Arg Gly Arg Gln
Tyr Ser Asn Trp Gly Gln Gly 225 230 235 240 Thr Gln Val Thr Val Ser
Ser 245 79247PRTArtificial SequenceNanobody sequence 79Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu 1 5 10 15 Ser
Leu Thr Leu Ser Cys Ala Ala Ser Gly Arg Thr Leu Ser Ala Tyr 20 25
30 Ile Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
35 40 45 Ala Gly Ile Trp Ser Gly Gly Tyr Thr His Leu Ala Asp Ser
Ala Lys 50 55 60 Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Asn
Thr Val Tyr Leu 65 70 75 80 Gln Met Asn Gly Leu Lys Pro Glu Asp Thr
Ala Val Tyr Tyr Cys Ala 85 90 95 Ala Gly Leu Arg Gly Arg Gln Tyr
Ser Asn Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser Gly
Gly Gly Gly Ser Gly Gly Gly Ser Glu Val 115 120 125 Gln Leu Val Glu
Ser Gly Gly Asn Leu Val Gln Ala Gly Gly Ser Leu 130 135 140 Gly Leu
Ser Cys Ala Ala Ser Val Ser Ile Ser Ser Ile His Ile Met 145 150 155
160 Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Asp Leu Val Ala Thr
165 170 175 Ile Thr Ser Gly Gly Ser Thr Ala Tyr Ala Asp Ser Val Lys
Gly Arg 180 185 190 Phe Thr Val Ser Lys Asp Asn Ala Lys Asn Thr Val
Tyr Leu Gln Met 195 200 205 Asp Ser Leu Lys Pro Glu Asp Thr Ser Val
Tyr Tyr Cys Ala Ala Glu 210 215 220 Val Arg Asn Gly Val Phe Gly Lys
Trp Asn His Tyr Trp Gly Gln Gly 225 230 235 240 Thr Gln Val Thr Val
Ser Ser 245 80371PRTArtificial SequenceNanobody sequence 80Glu Val
Gln Leu Val Glu Ser Gly Gly Asn Leu Val Gln Ala Gly Gly 1 5 10 15
Ser Leu Gly Leu Ser Cys Ala Ala Ser Val Ser Ile Ser Ser Ile His 20
25 30 Ile Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Asp Leu
Val 35 40 45 Ala Thr Ile Thr Ser Gly Gly Ser Thr Ala Tyr Ala Asp
Ser Val Lys 50 55 60 Gly Arg Phe Thr Val Ser Lys Asp Asn Ala Lys
Asn Thr Val Tyr Leu 65 70 75 80 Gln Met Asp Ser Leu Lys Pro Glu Asp
Thr Ser Val Tyr Tyr Cys Ala 85 90 95 Ala Glu Val Arg Asn Gly Val
Phe Gly Lys Trp Asn His Tyr Trp Gly 100 105 110 Gln Gly Thr Gln Val
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Ser Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 130 135 140 Gly
Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 145 150
155 160 Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu 165 170 175 Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu
Tyr Ala Asp 180 185 190 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Thr Thr 195 200 205 Leu Tyr Leu Gln Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val Tyr 210 215 220 Tyr Cys Thr Ile Gly Gly Ser
Leu Ser Arg Ser Ser Gln Gly Thr Leu 225 230 235 240 Val Thr Val Ser
Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val 245 250 255 Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu Ser Leu 260 265 270
Thr Leu Ser Cys Ala Ala Ser Gly Arg Thr Leu Ser Ala Tyr Ile Met 275
280 285 Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala
Gly 290 295 300 Ile Trp Ser Gly Gly Tyr Thr His Leu Ala Asp Ser Ala
Lys Gly Arg 305 310 315 320 Phe Ser Ile Ser Arg Asp Asn Ala Lys Asn
Thr Val Tyr Leu Gln Met 325 330 335 Asn Gly Leu Lys Pro Glu Asp Thr
Ala Val Tyr Tyr Cys Ala Ala Gly 340 345 350 Leu Arg Gly Arg Gln Tyr
Ser Asn Trp Gly Gln Gly Thr Gln Val Thr 355 360 365 Val Ser Ser 370
81371PRTArtificial SequenceNanobody sequence 81Glu Val Gln Leu Val
Glu Ser Gly Gly Asn Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Gly
Leu Ser Cys Ala Ala Ser Val Ser Ile Ser Ser Ile His 20 25 30 Ile
Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Asp Leu Val 35 40
45 Ala Thr Ile Thr Ser Gly Gly Ser Thr Ala Tyr Ala Asp Ser Val Lys
50 55 60 Gly Arg Phe Thr Val Ser Lys Asp Asn Ala Lys Asn Thr Val
Tyr Leu 65 70 75 80 Gln Met Asp Ser Leu Lys Pro Glu Asp Thr Ser Val
Tyr Tyr Cys Ala 85 90 95 Ala Glu Val Arg Asn Gly Val Phe Gly Lys
Trp Asn His Tyr Trp Gly 100 105 110 Gln Gly Thr Gln Val Thr Val Ser
Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Ser Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Ala 130 135 140 Gly Glu Ser Leu
Thr Leu Ser Cys Ala Ala Ser Gly Arg Thr Leu Ser 145 150 155 160 Ala
Tyr Ile Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 165 170
175 Phe Val Ala Gly Ile Trp Ser Gly Gly Tyr Thr His Leu Ala Asp Ser
180 185 190 Ala Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Asn
Thr Val 195 200 205 Tyr Leu Gln Met Asn Gly Leu Lys Pro Glu Asp Thr
Ala Val Tyr Tyr 210 215 220 Cys Ala Ala Gly Leu Arg Gly Arg Gln Tyr
Ser Asn Trp Gly Gln Gly 225 230 235 240 Thr Gln Val Thr Val Ser Ser
Gly Gly Gly Gly Ser Gly Gly Gly Ser 245 250 255 Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 260 265 270 Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 275 280 285 Gly
Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 290 295
300 Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val
305 310 315 320 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr
Thr Leu Tyr 325 330 335 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr
Ala Val Tyr Tyr Cys 340 345 350 Thr Ile Gly Gly Ser Leu Ser Arg Ser
Ser Gln Gly Thr Leu Val Thr 355 360 365 Val Ser Ser 370
82253PRTArtificial SequenceNanobody sequence 82Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp 1 5 10 15 Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Tyr 20 25 30 Asp
Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40
45 Gly Ala Ser Trp Trp Ser Gly Gly Ala Pro Tyr Tyr Ser Asp Ser Val
50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr
Val Tyr 65 70 75 80 Leu Gln Ala Asn Ser Leu Arg Pro Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Ala Lys Arg Leu Arg Ser Phe Ala Ser
Gly Gly Ser Tyr Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Gln Val Thr
Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Ser Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val 130 135 140 Gln Ala Gly Gly
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile 145 150 155 160 Phe
Ser Ile Ala Ala Met Gly Trp Tyr Arg Gln Ala Thr Gly Lys Gln 165 170
175 Arg Glu Leu Val Ala Thr Ile Thr Asp Gly Gly Thr Thr Thr Tyr Ala
180 185 190 Asp Ser Val Lys Gly Arg Val Thr Ile Ser Arg Asp Arg Ser
Ala Asn 195 200 205 Thr Val Tyr Leu Ala Met Asn Asn Leu Lys Pro Asp
Asp Thr Ala Val 210 215 220 Tyr Tyr Cys Tyr Ala Tyr Leu Arg Tyr Thr
Ser Arg Val Pro Gly Asp 225 230 235 240 Asn Tyr Trp Gly Gln Gly Thr
Gln Val Thr Val Ser Ser 245 250 83375PRTArtificial SequenceNanobody
sequence 83Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala
Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile
Phe Ser Ile Ala 20 25 30 Ala Met Gly Trp Tyr Arg Gln Ala Thr Gly
Lys Gln Arg Glu Leu Val 35 40 45 Ala Thr Ile Thr Asp Gly Gly Thr
Thr Thr Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Val Thr Ile Ser
Arg Asp Arg Ser Ala Asn Thr Val Tyr Leu 65 70 75 80 Ala Met Asn Asn
Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys Tyr 85 90 95 Ala Tyr
Leu Arg Tyr Thr Ser Arg Val Pro Gly Asp Asn Tyr Trp Gly 100 105 110
Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115
120 125 Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro 130 135 140 Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser 145 150 155 160 Ser Phe Gly Met Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu 165 170 175 Trp Val Ser Ser Ile Ser Gly Ser
Gly Ser Asp Thr Leu Tyr Ala Asp 180 185 190 Ser Val Lys Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr 195 200 205 Leu Tyr Leu Gln
Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 210 215 220 Tyr Cys
Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu 225 230 235
240 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val
245 250 255 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
Ser Leu 260 265 270 Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Ser
Ile Ala Ala Met 275 280 285 Gly Trp Tyr Arg Gln Ala Thr Gly Lys Gln
Arg Glu Leu Val Ala Thr 290 295 300 Ile Thr Asp Gly Gly Thr Thr Thr
Tyr Ala Asp Ser Val Lys Gly Arg 305 310 315 320 Val Thr Ile Ser Arg
Asp Arg Ser Ala Asn Thr Val Tyr Leu Ala Met 325 330 335 Asn Asn Leu
Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys Tyr Ala Tyr 340 345 350 Leu
Arg Tyr Thr Ser Arg Val Pro Gly Asp Asn Tyr Trp Gly Gln Gly 355 360
365 Thr Gln Val Thr Val Ser Ser 370 375 84375PRTArtificial
SequenceNanobody sequence 84Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Ala Gly Gly 1 5 10 15 Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Ser Ile Ala 20 25
30 Ala Met Gly Trp Tyr Arg Gln Ala Thr Gly Lys Gln Arg Glu Leu Val
35 40 45 Ala Thr Ile Thr Asp Gly Gly Thr Thr Thr Tyr Ala Asp Ser
Val Lys 50 55 60 Gly Arg Val Thr Ile Ser Arg Asp Arg Ser Ala Asn
Thr Val Tyr Leu 65 70 75 80 Ala Met Asn Asn Leu Lys Pro Asp Asp Thr
Ala Val Tyr Tyr Cys Tyr 85 90 95 Ala Tyr Leu Arg Tyr Thr Ser Arg
Val Pro Gly Asp Asn Tyr Trp Gly 100 105 110 Gln Gly Thr Gln Val Thr
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125 Gly Ser Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala 130 135 140 Gly Gly
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Ser 145 150 155
160 Ile Ala Ala Met Gly Trp Tyr Arg Gln Ala Thr Gly Lys Gln Arg Glu
165 170 175 Leu Val Ala Thr Ile Thr Asp Gly Gly Thr Thr Thr Tyr Ala
Asp Ser 180 185 190 Val Lys Gly Arg Val Thr Ile Ser Arg Asp Arg Ser
Ala Asn Thr Val 195 200 205 Tyr Leu Ala Met Asn Asn Leu Lys Pro Asp
Asp Thr Ala Val Tyr Tyr 210 215 220 Cys Tyr Ala Tyr Leu Arg Tyr Thr
Ser Arg Val Pro Gly Asp Asn Tyr 225 230 235 240 Trp Gly Gln Gly Thr
Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser 245 250 255 Gly Gly Gly
Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 260 265 270 Gln
Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr 275 280
285 Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
290 295 300 Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr
Leu Tyr 305 310 315 320 Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
Arg Asp Asn Ala Lys 325 330 335 Thr Thr Leu Tyr Leu Gln Met Asn Ser
Leu Arg Pro Glu Asp Thr Ala 340 345 350 Val Tyr Tyr Cys Thr Ile Gly
Gly Ser Leu Ser Arg Ser Ser Gln Gly 355 360 365 Thr Leu Val Thr Val
Ser Ser 370 375 85377PRTArtificial SequenceNanobody sequence 85Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp 1 5 10
15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Tyr
20 25 30 Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu
Phe Val 35 40 45 Gly Ala Ser Trp Trp Ser Gly Gly Ala Pro Tyr Tyr
Ser Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ala Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Ala Asn Ser Leu Arg Pro
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Lys Arg Leu Arg
Ser Phe Ala Ser Gly Gly Ser Tyr Asp Tyr 100 105 110 Trp Gly Gln Gly
Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly
Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 130 135 140
Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile 145
150 155 160 Phe Ser Ile Ala Ala Met Gly Trp Tyr Arg Gln Ala Thr Gly
Lys Gln 165 170 175 Arg Glu Leu Val Ala Thr Ile Thr Asp Gly Gly Thr
Thr Thr Tyr Ala 180 185 190 Asp Ser Val Lys Gly Arg Val Thr Ile Ser
Arg Asp Arg Ser Ala Asn 195 200 205 Thr Val Tyr Leu Ala Met Asn Asn
Leu Lys Pro Asp Asp Thr Ala Val 210 215 220 Tyr Tyr Cys Tyr Ala Tyr
Leu Arg Tyr Thr Ser Arg Val Pro Gly Asp 225 230 235 240 Asn Tyr Trp
Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 245 250 255 Gly
Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 260 265
270 Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
275 280 285 Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala
Pro Gly 290 295 300 Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser
Gly Ser Asp Thr 305 310 315 320 Leu Tyr Ala Asp Ser Val Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn 325 330 335 Ala Lys Thr Thr Leu Tyr Leu
Gln Met Asn Ser Leu Arg Pro Glu Asp 340 345 350 Thr Ala Val Tyr Tyr
Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser 355 360 365 Gln Gly Thr
Leu Val Thr Val Ser Ser 370 375 86252PRTArtificial SequenceNanobody
sequence 86Glu Val Gln Leu Val Glu Ser Gly Gly Asn Leu Val Gln Ala
Gly Gly 1 5 10 15 Ser Leu Gly Leu Ser Cys Ala Ala Ser Val Ser Ile
Ser Ser Ile His 20 25 30 Ile Met Gly Trp Tyr Arg Gln Ala Pro Gly
Lys Gln Arg Asp Leu Val 35 40 45 Ala Thr Ile Thr Ser Gly Gly Ser
Thr Ala Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Val Ser
Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu 65 70 75 80 Gln Met Asp Ser
Leu Lys Pro Glu Asp Thr Ser Val Tyr Tyr Cys Ala 85 90 95 Ala Glu
Val Arg Asn Gly Val Phe Gly Lys Trp Asn His Tyr Trp Gly 100 105 110
Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115
120 125 Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Thr 130 135 140 Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser 145 150 155 160 Ser Tyr Ala Met Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu 165 170 175 Trp Val Ser Gly Ile Lys Ser Ser
Gly Asp Ser Thr Arg Tyr Ala Gly 180 185 190 Ser Val Lys Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys Asn Met 195 200 205 Leu Tyr Leu Gln
Met Tyr Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 210 215 220 Tyr Cys
Ala Lys Ser Arg Val Ser Arg Thr Gly Leu Tyr Thr Tyr Asp 225 230 235
240 Asn Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser 245 250
87254PRTArtificial SequenceNanobody sequence 87Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu 1 5 10 15 Ser Leu Thr
Leu Ser Cys Ala Ala Ser Gly Arg Thr Leu Ser Ala Tyr 20 25 30 Ile
Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40
45 Ala Gly Ile Trp Ser Gly Gly Tyr Thr His Leu Ala Asp Ser Ala Lys
50 55 60 Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Lys Asn Thr Val
Tyr Leu 65 70 75 80 Gln Met Asn Gly Leu Lys Pro Glu Asp Thr Ala Val
Tyr Tyr Cys Ala 85 90 95 Ala Gly Leu Arg Gly Arg Gln Tyr Ser Asn
Trp Gly Gln Gly Thr Gln 100 105 110 Val Thr Val Ser Ser Gly Gly Gly
Gly Ser Gly Gly Gly Ser Glu Val 115 120 125 Gln Leu Met Glu Ser Gly
Gly Gly Leu Val Gln Ala Gly Gly Ser Leu 130 135 140 Arg Leu Ser Cys
Ala Ala Ser Gly Arg Thr Phe Asn Asn Tyr Ala Met 145 150 155 160 Gly
Trp Phe Arg Arg Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala 165 170
175 Ile Thr Arg Ser Gly Val Arg Ser Gly Val Ser Ala Ile Tyr Gly Asp
180 185 190 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys
Asn Thr 195 200 205 Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp
Thr Ala Val Tyr 210 215 220 Thr Cys Ala Ala Ser Ala Ile Gly Ser Gly
Ala Leu Arg Arg Phe Glu 225 230 235 240 Tyr Asp Tyr Ser Gly Gln Gly
Thr Gln Val Thr Val Ser Ser 245 250 88376PRTArtificial
SequenceNanobody sequence 88Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Ser Ile Phe Ser Ile Ala 20 25 30 Ala Met Gly Trp Tyr Arg
Gln Ala Thr Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Thr Ile Thr
Asp Gly Gly Thr Thr Thr Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg
Val Thr Ile Ser Arg Asp Arg Ser Ala Asn Thr Val Tyr Leu 65 70 75 80
Ala Met Asn Asn Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys Tyr 85
90 95 Ala Tyr Leu Arg Tyr Thr Ser Arg Val Pro Gly Asp Asn Tyr Trp
Gly 100 105 110 Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly
Ser Gly Gly 115 120 125 Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro 130 135 140 Gly Asn Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Phe Thr Phe Ser 145 150 155 160 Ser Phe Gly Met Ser Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu 165 170 175 Trp Val Ser Ser
Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp 180 185 190 Ser Val
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr 195 200 205
Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 210
215 220 Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr
Leu 225 230 235 240 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
Gly Ser Glu Val 245 250 255 Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Gln Thr Gly Gly Ser Leu 260 265 270 Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser Ser Tyr Ala Met 275 280 285 Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val Ser Gly 290 295 300 Ile Lys Ser Ser
Gly Asp Ser Thr Arg Tyr Ala Gly Ser Val Lys Gly 305 310 315 320 Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Leu Tyr Leu Gln 325 330
335 Met Tyr Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
340 345 350 Ser Arg Val Ser Arg Thr Gly Leu Tyr Thr Tyr Asp Asn Arg
Gly Gln 355 360 365 Gly Thr Gln Val Thr Val Ser Ser 370 375
89384PRTArtificial SequenceNanobody sequence 89Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp 1 5 10 15 Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Tyr 20 25 30 Asp
Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40
45 Gly Ala Ser Trp Trp Ser Gly Gly Ala Pro Tyr Tyr Ser Asp Ser Val
50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr
Val Tyr 65 70 75 80 Leu Gln Ala Asn Ser Leu Arg Pro Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Ala Lys Arg Leu Arg Ser Phe Ala Ser
Gly Gly Ser Tyr Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Gln Val Thr
Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Ser Glu Val
Gln Leu Met Glu Ser Gly Gly Gly Leu Val 130 135 140 Gln Ala Gly Gly
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr 145 150 155 160 Phe
Asn Asn Tyr Ala Met Gly Trp Phe Arg Arg Ala Pro Gly Lys Glu 165 170
175 Arg Glu Phe Val Ala Ala Ile Thr Arg Ser Gly Val Arg Ser Gly Val
180 185 190 Ser Ala Ile Tyr Gly Asp Ser Val Lys Asp Arg Phe Thr Ile
Ser Arg 195 200 205 Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn
Ser Leu Lys Pro 210 215 220 Glu Asp Thr Ala Val Tyr Thr Cys Ala Ala
Ser Ala Ile Gly Ser Gly 225 230 235 240 Ala Leu Arg Arg Phe Glu Tyr
Asp Tyr Ser Gly Gln Gly Thr Gln Val 245 250 255 Thr Val Ser Ser Gly
Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln 260 265 270 Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Asn Ser Leu Arg 275 280 285 Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Gly Met Ser 290 295
300 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile
305 310 315 320 Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val
Lys Gly Arg 325 330 335 Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr
Leu Tyr Leu Gln Met 340 345 350 Asn Ser Leu Arg Pro Glu Asp Thr Ala
Val Tyr Tyr Cys Thr Ile Gly 355 360 365 Gly Ser Leu Ser Arg Ser Ser
Gln Gly Thr Leu Val Thr Val Ser Ser 370 375 380 90362PRTMacaca
fascicularis 90Met Asp Leu His Val Phe Asp Tyr Ser Glu Pro Gly Asn
Phe Ser Asp 1 5 10 15 Ile Ser Trp Pro Cys Asn Ser Ser Asp Cys Ile
Val Val Asp Thr Val 20 25 30 Met Cys Pro Asn Met Pro Asn Lys Ser
Val Leu Leu Tyr Thr Leu Ala 35 40 45 Phe Ile Tyr Ile Phe Ile Phe
Val Ile Gly Met Ile Ala Asn Ser Val 50 55 60 Val Val Trp Val Asn
Ile Gln Ala Lys Thr Thr Gly Tyr Asp Thr His 65 70 75 80 Cys Tyr Ile
Leu Asn Leu Ala Ile Ala Asp Leu Trp Val Val Leu Thr 85 90 95 Ile
Pro Val Trp Val Val Ser Leu Val Gln His Asn Gln Trp Pro Met 100 105
110 Gly Glu Leu Thr Cys Lys Val Thr His Leu Ile Phe Ser Ile Asn Leu
115 120 125 Phe Gly Ser Ile Phe Phe Leu Thr Cys Met Ser Val Asp Arg
Tyr Leu 130 135 140 Ser Ile Thr Tyr Phe Thr Asn Thr Ser Ser Ser Arg
Lys Lys Met Val 145 150 155 160 Arg Arg Val Val Cys Val Leu Val Trp
Leu Leu Ala Phe Cys Val Ser 165 170 175 Leu Pro Asp Thr Tyr Tyr Leu
Lys Thr Val Thr Ser Ala Ser Asn Asn 180 185 190 Glu Thr Tyr Cys Arg
Ser Phe Tyr Pro Glu His Ser Ile Lys Glu Trp 195 200 205 Leu Ile Gly
Met Glu Leu Val Ser Val Val Leu Gly Phe Ala Val Pro 210 215 220 Phe
Ser Val Ile Ala Val Phe Tyr Phe Leu Leu Ala Arg Ala Ile Ser 225 230
235 240 Ala Ser Gly Asp Gln Glu Lys His Ser Ser Arg Lys Ile Ile Phe
Ser 245 250 255 Tyr Val Val Val Phe Leu Val Cys Trp Leu Pro Tyr His
Val Ala Val 260
265 270 Leu Leu Asp Ile Phe Ser Ile Leu His Tyr Ile Pro Phe Thr Cys
Arg 275 280 285 Leu Glu His Ala Leu Phe Thr Ala Leu His Val Thr Gln
Cys Leu Ser 290 295 300 Leu Val His Cys Cys Val Asn Pro Val Leu Tyr
Ser Phe Ile Asn Arg 305 310 315 320 Asn Tyr Arg Tyr Glu Leu Met Lys
Ala Phe Ile Phe Lys Tyr Ser Ala 325 330 335 Lys Thr Gly Leu Thr Lys
Leu Ile Asp Ala Ser Arg Val Ser Glu Thr 340 345 350 Glu Tyr Ser Ala
Leu Glu Gln Ser Thr Lys 355 360 91126PRTArtificial SequenceNanobody
sequence 91Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr
Gly Ala 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr
Phe Ser Asn Tyr 20 25 30 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly
Lys Glu Arg Glu Arg Val 35 40 45 Ala Ala Ile Thr Pro Arg Ala Phe
Thr Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ala Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Val
Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala
Gln Leu Val Gly Ser Gly Ser Asn Leu Gly Arg Gln Glu Ser 100 105 110
Tyr Ala Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125
9230PRTArtificial SequenceNanobody sequence 92Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Ala 1 5 10 15 Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 30
935PRTArtificial SequenceNanobody sequence 93Asn Tyr Ala Met Gly 1
5 9414PRTArtificial SequenceNanobody sequence 94Trp Phe Arg Gln Ala
Pro Gly Lys Glu Arg Glu Arg Val Ala 1 5 10 9517PRTArtificial
SequenceNanobody sequence 95Ala Ile Thr Pro Arg Ala Phe Thr Thr Tyr
Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly 9632PRTArtificial
SequenceNanobody sequence 96Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys
Asn Thr Ala Tyr Leu Gln 1 5 10 15 Met Val Ser Leu Lys Pro Glu Asp
Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 30 9717PRTArtificial
SequenceNanobody sequence 97Gln Leu Val Gly Ser Gly Ser Asn Leu Gly
Arg Gln Glu Ser Tyr Ala 1 5 10 15 Tyr 9811PRTArtificial
SequenceNanobody sequence 98Trp Gly Gln Gly Thr Gln Val Thr Val Ser
Ser 1 5 10 99126PRTArtificial SequenceNanobody sequence 99Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Ala 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asn Tyr 20
25 30 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Arg
Val 35 40 45 Ala Ala Ile Ser Pro Ser Ala Val Thr Thr Tyr Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Val Ser Leu Lys Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Gln Leu Pro Gly Arg
Gly Ser Asn Leu Gly Arg Gln Ala Ser 100 105 110 Tyr Ala Tyr Trp Gly
Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125 100126PRTArtificial
SequenceNanobody sequence 100Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Ala Gly Ala 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Arg Thr Phe Ser Asn Tyr 20 25 30 Ala Met Gly Trp Phe
Arg Gln Ala Pro Gly Lys Glu Arg Glu Pro Val 35 40 45 Ala Ala Ile
Ser Pro Ala Ala Leu Thr Thr Tyr Tyr Ala Asp Phe Val 50 55 60 Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Ala Tyr 65 70
75 80 Leu Gln Met Val Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95 Ala Ala Gln Leu Val Gly Ser Gly Ser Asn Leu Gly Arg
Gln Gln Ser 100 105 110 Tyr Ala Tyr Trp Gly Gln Gly Thr Gln Val Thr
Val Ser Ser 115 120 125 101126PRTArtificial SequenceNanobody
sequence 101Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala
Gly Ala 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr
Phe Ser Asn Tyr 20 25 30 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly
Lys Glu Arg Glu Pro Val 35 40 45 Ala Ala Ile Ser Pro Ala Ala Leu
Thr Thr Tyr Tyr Ala Asp Phe Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ala Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Val
Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala
Gln Leu Val Gly Ser Gly Ser Asn Leu Gly Arg Gln Gln Ser 100 105 110
Tyr Ala Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125
102126PRTArtificial SequenceNanobody sequence 102Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Ala 1 5 10 15 Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Gly Asn Tyr 20 25 30
Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Pro Val 35
40 45 Ala Ala Ile Ser Pro Ala Ala Val Thr Thr Tyr Tyr Ala Asp Phe
Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
Thr Ala Tyr 65 70 75 80 Leu Gln Met Val Ser Leu Lys Pro Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Gln Leu Val Gly Ser Gly Ser
Asn Leu Gly Arg Gln Gln Ser 100 105 110 Tyr Ala Tyr Trp Gly Gln Gly
Thr Gln Val Thr Val Ser Ser 115 120 125 10330PRTArtificial
SequenceNanobody sequence 103Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Ala Gly Ala 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Arg Thr Phe Ser 20 25 30 10430PRTArtificial
SequenceNanobody sequence 104Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Ala Gly Ala 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Arg Thr Phe Ser 20 25 30 10530PRTArtificial
SequenceNanobody sequence 105Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Ala Gly Ala 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Arg Thr Phe Ser 20 25 30 10630PRTArtificial
SequenceNanobody sequence 106Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Ala Gly Ala 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Arg Thr Phe Gly 20 25 30 1075PRTArtificial
SequenceNanobody sequence 107Asn Tyr Ala Met Gly 1 5
1085PRTArtificial SequenceNanobody sequence 108Asn Tyr Ala Met Gly
1 5 1095PRTArtificial SequenceNanobody sequence 109Asn Tyr Ala Met
Gly 1 5 1105PRTArtificial SequenceNanobody sequence 110Asn Tyr Ala
Met Gly 1 5 11114PRTArtificial SequenceNanobody sequence 111Trp Phe
Arg Gln Ala Pro Gly Lys Glu Arg Glu Arg Val Ala 1 5 10
11214PRTArtificial SequenceNanobody sequence 112Trp Phe Arg Gln Ala
Pro Gly Lys Glu Arg Glu Pro Val Ala 1 5 10 11314PRTArtificial
SequenceNanobody sequence 113Trp Phe Arg Gln Ala Pro Gly Lys Glu
Arg Glu Pro Val Ala 1 5 10 11414PRTArtificial SequenceNanobody
sequence 114Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Pro Val Ala
1 5 10 11517PRTArtificial SequenceNanobody sequence 115Ala Ile Ser
Pro Ser Ala Val Thr Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly
11617PRTArtificial SequenceNanobody sequence 116Ala Ile Ser Pro Ala
Ala Leu Thr Thr Tyr Tyr Ala Asp Phe Val Lys 1 5 10 15 Gly
11717PRTArtificial SequenceNanobody sequence 117Ala Ile Ser Pro Ala
Ala Leu Thr Thr Tyr Tyr Ala Asp Phe Val Lys 1 5 10 15 Gly
11817PRTArtificial SequenceNanobody sequence 118Ala Ile Ser Pro Ala
Ala Val Thr Thr Tyr Tyr Ala Asp Phe Val Lys 1 5 10 15 Gly
11932PRTArtificial SequenceNanobody sequence 119Arg Phe Thr Ile Ser
Arg Asp Asn Ala Lys Asn Thr Ala Tyr Leu Gln 1 5 10 15 Met Val Ser
Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 30
12032PRTArtificial SequenceNanobody sequence 120Arg Phe Thr Ile Ser
Arg Asp Asn Ala Lys Asn Thr Ala Tyr Leu Gln 1 5 10 15 Met Val Ser
Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 30
12132PRTArtificial SequenceNanobody sequence 121Arg Phe Thr Ile Ser
Arg Asp Asn Ala Lys Asn Thr Ala Tyr Leu Gln 1 5 10 15 Met Val Ser
Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 30
12232PRTArtificial SequenceNanobody sequence 122Arg Phe Thr Ile Ser
Arg Asp Asn Ala Lys Asn Thr Ala Tyr Leu Gln 1 5 10 15 Met Val Ser
Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 30
12317PRTArtificial SequenceNanobody sequence 123Gln Leu Pro Gly Arg
Gly Ser Asn Leu Gly Arg Gln Ala Ser Tyr Ala 1 5 10 15 Tyr
12417PRTArtificial SequenceNanobody sequence 124Gln Leu Val Gly Ser
Gly Ser Asn Leu Gly Arg Gln Gln Ser Tyr Ala 1 5 10 15 Tyr
12517PRTArtificial SequenceNanobody sequence 125Gln Leu Val Gly Ser
Gly Ser Asn Leu Gly Arg Gln Gln Ser Tyr Ala 1 5 10 15 Tyr
12617PRTArtificial SequenceNanobody sequence 126Gln Leu Val Gly Ser
Gly Ser Asn Leu Gly Arg Gln Gln Ser Tyr Ala 1 5 10 15 Tyr
12711PRTArtificial SequenceNanobody sequence 127Trp Gly Gln Gly Thr
Gln Val Thr Val Ser Ser 1 5 10 12811PRTArtificial SequenceNanobody
sequence 128Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 1 5 10
12911PRTArtificial SequenceNanobody sequence 129Trp Gly Gln Gly Thr
Gln Val Thr Val Ser Ser 1 5 10 13011PRTArtificial SequenceNanobody
sequence 130Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 1 5 10
131405PRTArtificial SequenceNanobody sequence 131Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp 1 5 10 15 Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Tyr 20 25 30
Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35
40 45 Gly Ala Ser Trp Trp Ser Gly Gly Ala Pro Tyr Tyr Ser Asp Ser
Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
Thr Val Tyr 65 70 75 80 Leu Gln Ala Asn Ser Leu Arg Pro Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Lys Arg Leu Arg Ser Phe Ala
Ser Gly Gly Ser Tyr Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 130 135 140 Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val 145 150 155 160
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu 165
170 175 Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Tyr Asp
Met 180 185 190 Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe
Val Gly Ala 195 200 205 Ser Trp Trp Ser Gly Gly Ala Pro Tyr Tyr Ser
Asp Ser Val Lys Gly 210 215 220 Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Asn Thr Val Tyr Leu Gln 225 230 235 240 Ala Asn Ser Leu Arg Pro
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 245 250 255 Lys Arg Leu Arg
Ser Phe Ala Ser Gly Gly Ser Tyr Asp Tyr Trp Gly 260 265 270 Gln Gly
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 275 280 285
Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 290
295 300 Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
Ser 305 310 315 320 Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu 325 330 335 Trp Val Ser Ser Ile Ser Gly Ser Gly Ser
Asp Thr Leu Tyr Ala Asp 340 345 350 Ser Val Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ala Lys Thr Thr 355 360 365 Leu Tyr Leu Gln Met Asn
Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 370 375 380 Tyr Cys Thr Ile
Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu 385 390 395 400 Val
Thr Val Ser Ser 405 132268PRTArtificial SequenceNanobody sequence
132Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp
1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser
Asn Tyr 20 25 30 Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu
Arg Glu Phe Val 35 40 45 Gly Ala Ser Trp Trp Ser Gly Gly Ala Pro
Tyr Tyr Ser Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg
Asp Asn Ala Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Ala Asn Ser Leu
Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Lys Arg
Leu Arg Ser Phe Ala Ser Gly Gly Ser Tyr Asp Tyr 100 105 110 Trp Gly
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 130
135 140 Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu
Ser 145 150 155 160 Gly Gly Gly Leu Val Gln Pro Gly Asn Ser Leu Arg
Leu Ser Cys Ala 165 170 175 Ala Ser Gly Phe Thr Phe Ser Ser Phe Gly
Met Ser Trp Val Arg Gln 180 185 190 Ala Pro Gly Lys Gly Leu Glu Trp
Val Ser Ser Ile Ser Gly Ser Gly 195 200 205 Ser Asp Thr Leu Tyr Ala
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 210 215 220 Arg Asp Asn Ala
Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg 225 230 235 240 Pro
Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser 245 250
255 Arg Ser Ser Gln Gly Thr Leu Val Thr Val Ser Ser 260 265
133431PRTArtificial SequenceNanobody sequence 133Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser
Leu Arg Ile Ser Cys Ala Ala Ser Gly Ser Ile Tyr Leu Ile Asn 20 25
30 Tyr Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
35 40 45 Ala Thr Leu Thr Ser Gly Gly Ser Thr Asn Tyr Ala Gly Ser
Val Lys 50 55 60 Gly Arg Phe Ala Ile Ser Arg Asp Asn Ala Lys Asn
Thr Val Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Lys Pro Glu Asp Thr
Ala Val Tyr Tyr Cys Asn 85 90 95 Ile Gly Gly Thr Leu Tyr Asp Arg
Arg Arg Phe Glu Ser Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140 Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val 145 150 155
160 Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Ala Ser Leu Arg Leu Ser
165 170 175 Cys Ala Ala Ser Gly Arg Thr Phe Ser Asn Tyr Ala Met Gly
Trp Phe 180 185 190 Arg Gln Ala Pro Gly Lys Glu Arg Glu Arg Val Ala
Ala Ile Thr Pro 195 200 205 Arg Ala Phe Thr Thr Tyr Tyr Ala Asp Ser
Val Lys Gly Arg Phe Thr 210 215 220 Ile Ser Arg Asp Asn Ala Lys Asn
Thr Ala Tyr Leu Gln Met Val Ser 225 230 235 240 Leu Lys Pro Glu Asp
Thr Ala Val Tyr Tyr Cys Ala Ala Gln Leu Val 245 250 255 Gly Ser Gly
Ser Asn Leu Gly Arg Gln Glu Ser Tyr Ala Tyr Trp Gly 260 265 270 Gln
Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 275 280
285 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
290 295 300 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val
Gln Leu 305 310 315 320 Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
Asn Ser Leu Arg Leu 325 330 335 Ser Cys Ala Ala Ser Gly Phe Thr Phe
Ser Ser Phe Gly Met Ser Trp 340 345 350 Val Arg Gln Ala Pro Gly Lys
Gly Leu Glu Trp Val Ser Ser Ile Ser 355 360 365 Gly Ser Gly Ser Asp
Thr Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe 370 375 380 Thr Ile Ser
Arg Asp Asn Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn 385 390 395 400
Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly 405
410 415 Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr Val Ser Ser
420 425 430 134437PRTArtificial SequenceNanobody sequence 134Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Ala 1 5 10
15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asn Tyr
20 25 30 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu
Arg Val 35 40 45 Ala Ala Ile Thr Pro Arg Ala Phe Thr Thr Tyr Tyr
Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ala Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Val Ser Leu Lys Pro
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Gln Leu Val Gly
Ser Gly Ser Asn Leu Gly Arg Gln Glu Ser 100 105 110 Tyr Ala Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 115 120 125 Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 130 135 140
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 145
150 155 160 Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Thr Gly 165 170 175 Ala Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg
Thr Phe Ser Asn 180 185 190 Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro
Gly Lys Glu Arg Glu Arg 195 200 205 Val Ala Ala Ile Thr Pro Arg Ala
Phe Thr Thr Tyr Tyr Ala Asp Ser 210 215 220 Val Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ala Lys Asn Thr Ala 225 230 235 240 Tyr Leu Gln
Met Val Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr 245 250 255 Cys
Ala Ala Gln Leu Val Gly Ser Gly Ser Asn Leu Gly Arg Gln Glu 260 265
270 Ser Tyr Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly
275 280 285 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly 290 295 300 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly 305 310 315 320 Gly Ser Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Gln Pro 325 330 335 Gly Asn Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser 340 345 350 Ser Phe Gly Met Ser
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu 355 360 365 Trp Val Ser
Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp 370 375 380 Ser
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr 385 390
395 400 Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val
Tyr 405 410 415 Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln
Gly Thr Leu 420 425 430 Val Thr Val Ser Ser 435 135406PRTArtificial
SequenceNanobody sequence 135Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Ser Ile Phe Ser Ile Ala 20 25 30 Ala Met Gly Trp Tyr
Arg Gln Ala Thr Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Thr Ile
Thr Asp Gly Gly Thr Thr Thr Tyr Ala Asp Ser Val Lys 50 55 60 Gly
Arg Val Thr Ile Ser Arg Asp Arg Ser Ala Asn Thr Val Tyr Leu 65 70
75 80 Ala Met Asn Asn Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys
Tyr 85 90 95 Ala Tyr Leu Arg Tyr Thr Ser Arg Val Pro Gly Asp Asn
Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
Gly Gly Ser Gly Gly 115 120 125 Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly 130 135 140 Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Glu Val Gln Leu 145 150 155 160 Val Glu Ser Gly
Gly Gly Leu Val Gln Thr Gly Ala Ser Leu Arg Leu 165 170 175 Ser Cys
Ala Ala Ser Gly Arg Thr Phe Ser Asn Tyr Ala Met Gly Trp 180 185 190
Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Arg Val Ala Ala Ile Thr 195
200 205 Pro Arg Ala Phe Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg
Phe 210 215 220 Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Ala Tyr Leu
Gln Met Val 225 230 235 240 Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr
Tyr Cys Ala Ala Gln Leu 245 250 255 Val Gly Ser Gly Ser Asn Leu Gly
Arg Gln Glu Ser Tyr Ala Tyr Trp 260 265 270 Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 275 280 285 Gly Gly Ser Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln 290 295 300 Pro Gly
Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 305 310 315
320 Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
325 330 335 Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu
Tyr Ala 340 345 350 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Thr 355 360 365 Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val 370 375 380 Tyr Tyr Cys Thr Ile Gly Gly Ser
Leu Ser Arg Ser Ser Gln Gly Thr 385 390 395 400 Leu Val Thr Val Ser
Ser 405 136408PRTArtificial SequenceNanobody sequence 136Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Tyr 20
25 30 Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe
Val 35 40 45 Gly Ala Ser Trp Trp Ser Gly Gly Ala Pro Tyr Tyr Ser
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Ala Asn Ser Leu Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Lys Arg Leu Arg Ser
Phe Ala Ser Gly Gly Ser Tyr Asp Tyr 100 105 110 Trp Gly Gln Gly Thr
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125 Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 130 135 140 Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val 145 150
155 160 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Ala Ser
Leu 165 170 175 Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asn
Tyr Ala Met 180 185 190 Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg
Glu Arg Val Ala Ala 195 200 205 Ile Thr Pro Arg Ala Phe Thr Thr Tyr
Tyr Ala Asp Ser Val Lys Gly 210 215 220 Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Thr Ala Tyr Leu Gln 225 230 235 240 Met Val Ser Leu
Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 245 250 255 Gln Leu
Val Gly Ser Gly Ser Asn Leu Gly Arg Gln Glu Ser Tyr Ala 260 265 270
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly 275
280 285 Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu 290 295 300 Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe 305 310 315 320 Thr Phe Ser Ser Phe Gly Met Ser Trp Val
Arg Gln Ala Pro Gly Lys 325 330 335 Gly Leu Glu Trp Val Ser Ser Ile
Ser Gly Ser Gly Ser Asp Thr Leu 340 345 350 Tyr Ala Asp Ser Val Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala 355 360 365 Lys Thr Thr Leu
Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr 370 375 380 Ala Val
Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln 385 390 395
400 Gly Thr Leu Val Thr Val Ser Ser 405 137405PRTArtificial
SequenceNanobody sequence 137Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Ile Ser Cys Ala
Ala Ser Gly Ser Ile Tyr Leu Ile Asn 20 25 30 Tyr Met Gly Trp Tyr
Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Thr Leu
Thr Ser Gly Gly Ser Thr Asn Tyr Ala Gly Ser Val Lys 50 55 60 Gly
Arg Phe Ala Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu 65 70
75 80 Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
Asn 85 90 95 Ile Gly Gly Thr Leu Tyr Asp Arg Arg Arg Phe Glu Ser
Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
Gly Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly 130 135 140 Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Glu Val Gln Leu Val 145 150 155 160 Glu Ser Gly Gly
Gly Leu Val Gln Thr Gly Ala Ser Leu Arg Leu Ser 165 170 175 Cys Ala
Ala Ser Gly Arg Thr Phe Ser Asn Tyr Ala Met Gly Trp Phe 180 185 190
Arg Gln Ala Pro Gly Lys Glu Arg Glu Arg Val Ala Ala Ile Thr Pro 195
200 205 Arg Ala Phe Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe
Thr 210 215 220 Ile Ser Arg Asp Asn Ala Lys Asn Thr Ala Tyr Leu Gln
Met Val Ser 225 230 235 240 Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr
Cys Ala Ala Gln Leu Val 245 250 255 Gly Ser Gly Ser Asn Leu Gly Arg
Gln Glu Ser Tyr Ala Tyr Trp Gly 260 265 270 Gln Gly Thr Leu Val Thr
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 275 280 285 Gly Ser Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 290 295 300 Gly Asn
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 305 310 315
320 Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
325 330 335 Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr
Ala Asp 340 345 350 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ala Lys Thr Thr 355 360 365 Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro
Glu Asp Thr Ala Val Tyr 370 375 380 Tyr Cys Thr Ile Gly Gly Ser Leu
Ser Arg Ser Ser Gln Gly Thr Leu 385 390 395 400 Val Thr Val Ser Ser
405 138408PRTArtificial SequenceNanobody sequence 138Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Ala 1 5 10 15 Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asn Tyr 20 25
30 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Arg Val
35 40 45 Ala Ala Ile Thr Pro Arg Ala Phe Thr Thr Tyr Tyr Ala Asp
Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys
Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Val Ser Leu Lys Pro Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Gln Leu Val Gly Ser Gly
Ser Asn Leu Gly Arg Gln Glu Ser 100 105 110 Tyr Ala Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser Gly Gly 115 120 125 Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 130 135 140 Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 145 150 155
160 Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly
165 170 175 Asp Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe
Ser Asn 180 185
190 Tyr Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe
195 200 205 Val Gly Ala Ser Trp Trp Ser Gly Gly Ala Pro Tyr Tyr Ser
Asp Ser 210 215 220 Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Asn Thr Val 225 230 235 240 Tyr Leu Gln Ala Asn Ser Leu Arg Pro
Glu Asp Thr Ala Val Tyr Tyr 245 250 255 Cys Ala Ala Lys Arg Leu Arg
Ser Phe Ala Ser Gly Gly Ser Tyr Asp 260 265 270 Tyr Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly 275 280 285 Ser Gly Gly
Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 290 295 300 Val
Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe 305 310
315 320 Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly
Lys 325 330 335 Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser
Asp Thr Leu 340 345 350 Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ala 355 360 365 Lys Thr Thr Leu Tyr Leu Gln Met Asn
Ser Leu Arg Pro Glu Asp Thr 370 375 380 Ala Val Tyr Tyr Cys Thr Ile
Gly Gly Ser Leu Ser Arg Ser Ser Gln 385 390 395 400 Gly Thr Leu Val
Thr Val Ser Ser 405 139405PRTArtificial SequenceNanobody sequence
139Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Ala
1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser
Asn Tyr 20 25 30 Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu
Arg Glu Arg Val 35 40 45 Ala Ala Ile Thr Pro Arg Ala Phe Thr Thr
Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg
Asp Asn Ala Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Val Ser Leu
Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Gln Leu
Val Gly Ser Gly Ser Asn Leu Gly Arg Gln Glu Ser 100 105 110 Tyr Ala
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 115 120 125
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 130
135 140 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly 145 150 155 160 Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly 165 170 175 Gly Ser Leu Arg Ile Ser Cys Ala Ala Ser
Gly Ser Ile Tyr Leu Ile 180 185 190 Asn Tyr Met Gly Trp Tyr Arg Gln
Ala Pro Gly Lys Gln Arg Glu Leu 195 200 205 Val Ala Thr Leu Thr Ser
Gly Gly Ser Thr Asn Tyr Ala Gly Ser Val 210 215 220 Lys Gly Arg Phe
Ala Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr 225 230 235 240 Leu
Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 245 250
255 Asn Ile Gly Gly Thr Leu Tyr Asp Arg Arg Arg Phe Glu Ser Trp Gly
260 265 270 Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
Gly Gly 275 280 285 Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro 290 295 300 Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser 305 310 315 320 Ser Phe Gly Met Ser Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu 325 330 335 Trp Val Ser Ser Ile
Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp 340 345 350 Ser Val Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr 355 360 365 Leu
Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 370 375
380 Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu
385 390 395 400 Val Thr Val Ser Ser 405 140396PRTArtificial
SequenceNanobody sequence 140Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Ile Ser Cys Ala
Ala Ser Gly Ser Ile Tyr Leu Ile Asn 20 25 30 Tyr Met Gly Trp Tyr
Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45 Ala Thr Leu
Thr Ser Gly Gly Ser Thr Asn Tyr Ala Gly Ser Val Lys 50 55 60 Gly
Arg Phe Ala Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu 65 70
75 80 Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
Asn 85 90 95 Ile Gly Gly Thr Leu Tyr Asp Arg Arg Arg Phe Glu Ser
Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
Gly Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly 130 135 140 Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Glu Val Gln Leu Val 145 150 155 160 Glu Ser Gly Gly
Gly Leu Val Gln Ala Gly Glu Ser Leu Thr Leu Ser 165 170 175 Cys Ala
Ala Ser Gly Arg Thr Leu Ser Ala Tyr Ile Met Gly Trp Phe 180 185 190
Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Trp Ser 195
200 205 Gly Gly Tyr Thr His Leu Ala Asp Ser Ala Lys Gly Arg Phe Ser
Ile 210 215 220 Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met
Asn Gly Leu 225 230 235 240 Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
Ala Ala Gly Leu Arg Gly 245 250 255 Arg Gln Tyr Ser Asn Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser 260 265 270 Gly Gly Gly Gly Ser Gly
Gly Gly Ser Glu Val Gln Leu Val Glu Ser 275 280 285 Gly Gly Gly Leu
Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala 290 295 300 Ala Ser
Gly Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln 305 310 315
320 Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly
325 330 335 Ser Asp Thr Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr
Ile Ser 340 345 350 Arg Asp Asn Ala Lys Thr Thr Leu Tyr Leu Gln Met
Asn Ser Leu Arg 355 360 365 Pro Glu Asp Thr Ala Val Tyr Tyr Cys Thr
Ile Gly Gly Ser Leu Ser 370 375 380 Arg Ser Ser Gln Gly Thr Leu Val
Thr Val Ser Ser 385 390 395
* * * * *